

(19)



(11)

EP 1 028 945 B9

(12)

CORRECTED EUROPEAN PATENT SPECIFICATION

(15) Correction information:

Corrected version no 2 (W2 B1)

Corrections, see

Description Paragraph(s) 25, 26

(51) Int Cl.:

C07D 213/73 ^(2006.01) **C07D 213/75** ^(2006.01)

C07D 213/82 ^(2006.01) **A61K 31/44** ^(2006.01)

C07D 413/12 ^(2006.01) **C07D 401/12** ^(2006.01)

C07D 409/12 ^(2006.01) **C07D 417/12** ^(2006.01)

C07D 471/04 ^(2006.01) **C07D 405/12** ^(2006.01)

(48) Corrigendum issued on:

18.02.2009 Bulletin 2009/08

(86) International application number:

PCT/US1998/023510

(45) Date of publication and mention
of the grant of the patent:

11.07.2007 Bulletin 2007/28

(87) International publication number:

WO 1999/024404 (20.05.1999 Gazette 1999/20)

(21) Application number: **98956570.0**

(22) Date of filing: **04.11.1998**

(54) **SUBSTITUTED PYRIDINE COMPOUNDS AS ANTI-INFLAMMATORY AGENTS**

SUBSTITUIERTE PYRIDIN-DERIVATE ALS ENTZÜNDUNGSHEMMENDE MITTEL

COMPOSES PYRIDINE SUBSTITUES PRESENTANT UNE ACTION ANTI-INFLAMMATOIRE

(84) Designated Contracting States:

**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE**

Designated Extension States:

AL LT LV MK RO SI

• **SCHLACHTER, Steven, T.**

Boulder, CO 80304 (US)

• **JOSEY, John, A.**

Longmont, CO 80503 (US)

(30) Priority: **07.11.1997 US 64953 P**

03.11.1998 US 185119

(74) Representative: **Richardson, Kate**

Forrester & Boehmert,

Pettenkoferstrasse 20-22

80336 München (DE)

(43) Date of publication of application:

23.08.2000 Bulletin 2000/34

(56) References cited:

EP-A- 0 424 848

EP-A- 0 480 258

EP-A- 0 799 825

DE-A- 1 810 162

DE-A- 3 804 346

US-A- 5 380 734

(73) Proprietor: **AMGEN INC.**

Thousand Oaks, CA 91320-1799 (US)

(72) Inventors:

• **MANTLO, Nathan, B.**

Lafayette, CO 80026 (US)

EP 1 028 945 B9

Description

BACKGROUND OF THE INVENTION

[0001] The present invention comprises a new class of compounds useful in treating diseases, such as TNF- α , IL-1 β , IL-6 and/or IL-8 mediated diseases and other maladies, such as pain, cancer, and diabetes. In particular, the compounds of the invention are useful for the prophylaxis and treatment of diseases or conditions involving inflammation. This invention also relates to intermediates and processes useful in the preparation of such compounds.

[0002] (IL-1) and Tumor Necrosis Factor α (TNF- α) are pro-inflammatory cytokines secreted by a variety of cells, including monocytes and macrophages, in response to many inflammatory stimuli (e.g., lipopolysaccharide - LPS) or external cellular stress (e.g., osmotic shock and peroxide).

[0003] Elevated levels of TNF- α and/or IL-1 over basal levels have been implicated in mediating or exacerbating a number of disease states including rheumatoid arthritis; Pagets disease; osteophorosis; multiple myeloma; uveitis; acute and chronic myelogenous leukemia; pancreatic β cell destruction; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; adult respiratory distress syndrome (ARDS); psoriasis; Crohn's disease; allergic rhinitis; ulcerative colitis; anaphylaxis; contact dermatitis; asthma; muscle degeneration; cachexia; Reiter's syndrome; type I and type II diabetes; bone resorption diseases; graft vs. host reaction; ischemia reperfusion injury; atherosclerosis; brain trauma; multiple sclerosis; cerebral malaria; sepsis; septic shock; toxic shock syndrome; fever, and myalgias due to infection. HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses (including HSV-1, HSV-2), and herpes zoster are also exacerbated by TNF- α .

[0004] It has been reported that TNF- α plays a role in head trauma, stroke, and ischemia. For instance, in animal models of head trauma (rat), TNF- α levels increased in the contused hemisphere (Shohami et al., J. Cereb. Blood Flow Metab. 14, 615 (1994)). In a rat model of ischemia wherein the middle cerebral artery was occluded, the levels of TNF- α mRNA of TNF- α increased (Feurstein et al., Neurosci. Lett. 164, 125 (1993)). Administration of TNF- α into the rat cortex has been reported to result in significant neutrophil accumulation in capillaries and adherence in small blood vessels. TNF- α promotes the infiltration of other cytokines (IL-1 β , IL-6) and also chemokines, which promote neutrophil infiltration into the infarct area (Feurstein, Stroke 25, 1481 (1994)). TNF- α has also been implicated to play a role in type II diabetes (Endocrinol. 130, 43-52, 1994; and Endocrinol. 136, 1474-1481, 1995).

[0005] TNF- α appears to play a role in promoting certain viral life cycles and disease states associated with them. For instance, TNF- α secreted by monocytes induced elevated levels of HIV expression in a chronically infected T cell clone (Clouse et al., J. Immunol. 142, 431 (1989)). Lahdevirta et al., (Am. J. Med. 85, 289 (1988)) discussed the role of TNF- α in the HIV associated states of cachexia and muscle degradation.

[0006] TNF- α is upstream in the cytokine cascade of inflammation. As a result, elevated levels of TNF- α may lead to elevated levels of other inflammatory and proinflammatory cytokines, such as IL-1, IL-6, and IL-8.

[0007] Elevated levels of IL-1 over basal levels have been implicated in mediating or exacerbating a number of disease states including rheumatoid arthritis; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; adult respiratory distress syndrome (ARDS); psoriasis; Crohn's disease; ulcerative colitis; anaphylaxis; muscle degeneration; cachexia; Reiter's syndrome; type I and type II diabetes; bone resorption diseases; ischemia reperfusion injury; atherosclerosis; brain trauma; multiple sclerosis; sepsis; septic shock; and toxic shock syndrome. Viruses sensitive to TNF- α inhibition, e.g., HIV-1, HIV-2, HIV-3, are also affected by IL-1.

[0008] TNF- α and IL-1 appear to play a role in pancreatic β cell destruction and diabetes. Pancreatic β cells produce insulin which helps mediate blood glucose homeostasis. Deterioration of pancreatic β cells often accompanies type I diabetes. Pancreatic β cell functional abnormalities may occur in patients with type II diabetes. Type II diabetes is characterized by a functional resistance to insulin. Further, type II diabetes is also often accompanied by elevated levels of plasma glucagon and increased rates of hepatic glucose production. Glucagon is a regulatory hormone that attenuates liver gluconeogenesis inhibition by insulin. Glucagon receptors have been found in the liver, kidney and adipose tissue. Thus glucagon antagonists are useful for attenuating plasma glucose levels (WO 97/16442, incorporated herein by reference in its entirety). By antagonizing the glucagon receptors, it is thought that insulin responsiveness in the liver will improve, thereby decreasing gluconeogenesis and lowering the rate of hepatic glucose production.

[0009] In rheumatoid arthritis models in animals, multiple intra-articular injections of IL-1 have led to an acute and destructive form of arthritis (Chandrasekhar et al., Clinical Immunol Immunopathol. 55, 382 (1990)). In studies using cultured rheumatoid synovial cells, IL-1 is a more potent inducer of stromelysin than is TNF- α (Firestein, Am. J. Pathol. 140, 1309 (1992)). At sites of local injection, neutrophil, lymphocyte, and monocyte emigration has been observed. The emigration is attributed to the induction of chemokines (e.g., IL-8), and the up-regulation of adhesion molecules (Dinarello, Eur. Cytokine Netw. 5, 517-531 (1994)).

[0010] IL-1 also appears to play a role in promoting certain viral life cycles. For example, cytokine-induced increase of HIV expression in a chronically infected macrophage line has been associated with a concomitant and selective increase in IL-1 production (Folks et al., J. Immunol. 136, 40 (1986)). Beutler et al. (J. Immunol. 135, 3969 (1985))

discussed the role of IL-1 in cachexia. Baracos et al. (New Eng. J. Med. 308, 553 (1983)) discussed the role of IL-1 in muscle degeneration.

[0011] In rheumatoid arthritis, both IL-1 and TNF- α induce synoviocytes and chondrocytes to produce collagenase and neutral proteases, which leads to tissue destruction within the arthritic joints. In a model of arthritis (collagen-induced arthritis (CIA) in rats and mice), intra-articular administration of TNF- α either prior to or after the induction of CIA led to an accelerated onset of arthritis and a more severe course of the disease (Brahm et al., Lymphokine Cytokine Res. 11, 253 (1992); and Cooper, Clin. Exp. Immunol. 898, 244 (1992)).

[0012] IL-8 has been implicated in exacerbating and/or causing many disease states in which massive neutrophil infiltration into sites of inflammation or injury (e.g., ischemia) is mediated by the chemotactic nature of IL-8, including, but not limited to, the following: asthma, inflammatory bowel disease, psoriasis, adult respiratory distress syndrome, cardiac and renal reperfusion injury, thrombosis and glomerulonephritis. In addition to the chemotaxis effect on neutrophils, IL-8 also has the ability to activate neutrophils. Thus, reduction in IL-8 levels may lead to diminished neutrophil infiltration.

[0013] Several approaches have been taken to block the effect of TNF- α . One approach involves using soluble receptors for TNF- α (e.g., TNFR-55 or TNFR-75), which have demonstrated efficacy in animal models of TNF- α -mediated disease states. A second approach to neutralizing TNF- α using a monoclonal antibody specific to TNF- α , cA2, has demonstrated improvement in swollen joint count in a Phase II human trial of rheumatoid arthritis (Feldmann et al., Immunological Reviews, pp. 195-223 (1995)). These approaches block the effects of TNF- α and IL-1 by either protein sequestration or receptor antagonism.

[0014] The present invention also relates to a method of treating cancer which is mediated by Raf and Raf-inducible proteins. Raf proteins are kinases activated in response to extracellular mitogenic stimuli such as PDGF, EGF, acidic FGF, thrombin, insulin or endothelin, and also in response to oncoproteins such as v-src, v-sis, and v-fms. Raf functions downstream of ras in signal transduction from the cellular membrane to the nucleus. Compounds in the present invention may be oncolytics through the antagonism of Raf kinase. Antisense constructs which reduce cellular levels of c-Raf and hence Raf activity inhibit the growth of rodent fibroblasts in soft agar, while exhibiting little or no general cytotoxicity. This inhibition of growth in soft agar is highly predictive of tumor responsiveness in whole animals. Moreover Raf antisense constructs have shown efficacy in reducing tumor burden in animals. Examples of cancers where Raf kinase is implicated by overexpression include cancers of the brain, larynx, lung, lymphatic system, urinary tract and stomach, including hystocytic lymphoma, lung adenocarcinoma and small cell lung cancers. Other examples include cancers involving overexpression of upstream activators of Raf or Raf-activating oncogenes, including pancreatic and breast carcinoma.

[0015] Substituted imidazole and pyrrole compounds have been described for use in the treatment of cytokine mediated diseases by inhibition of proinflammatory cytokines, such as IL-1, IL-6, IL-8 and TNF. Substituted imidazoles for use in the treatment of cytokine mediated diseases have been described in US Pat. 5,593,992; WO 93/14081; WO 97/18626; WO 96/21452; WO 96/21654; WO 96/40143; WO 97/05878; WO 97/05878; (each of which is incorporated herein by reference in its entirety). Substituted imidazoles for use in the treatment of inflammation has been described in US Pat. 3,929,807 (which is incorporated herein by reference in its entirety). Substituted pyrrole compounds for use in the treatment of cytokine mediated diseases have been described in WO 97/05877; WO 97/05878; WO 97/16426; WO 97/16441; and WO 97/16442 (each of which is incorporated herein by reference in its entirety).

[0016] Substituted 2-aminopyridine compounds have been described as nitric oxide synthase inhibitors for use in the treatment of inflammation, neurodegenerative disorders and disorders of gastrointestinal motility in WO 96/18616 and WO 96/18617.

[0017] Diaryl substituted pyridine compounds have been described for use in the treatment of inflammation and inflammation related disorders in WO 96/24584 and US 5,596,008.

[0018] US 3,980,652, US 3,991,057 and US 4,002,629 describe piperaziny substituted pyridine compounds for use as anti-inflammatory and cardiovascular agents.

[0019] JP 6135934 describes substituted pyridine compounds as phospholipase A2 inhibitors for use as antiphlogistic and anti-pancreatitis agents. GB 1,189,188 describes pyrimidin-2-ylamino substituted pyridine compounds as therapeutically valuable compounds for use as antiphlogistic agents.


[0020] EP-A-0424848 discloses aminopyridinylaminophenols and related compounds, a process and intermediates for their preparation and their use as medicaments.

BRIEF DESCRIPTION OF THE INVENTION

[0021] The present invention comprises a new class of compounds useful in the prophylaxis and treatment of diseases, such as TNF- α , IL-1 β , IL-6 and/or IL-8 mediated diseases and other maladies, such as pain, cancer, and diabetes. In particular, the compounds of the invention are useful for the prophylaxis and treatment of diseases or conditions involving inflammation. Accordingly, the invention also comprises pharmaceutical compositions comprising the compounds, methods for the prophylaxis and treatment of TNF- α , IL-1 β , IL-6 and/or IL-8 mediated diseases, such as inflammatory, pain

and diabetes diseases, using the compounds and compositions of the invention, and intermediates and processes useful for the preparation of the compounds of the invention.

[0022] The compounds of the invention are represented by the following general structure:




wherein R¹, R⁵, R⁶, R⁷, X and Y are defined below.

[0023] The foregoing merely summarizes certain aspects of the invention and is not intended, nor should it be construed, as limiting the invention in any way.

DETAILED DESCRIPTION OF THE INVENTION

[0024] According to the present invention, there is provided a compound of the formula:




or a pharmaceutically acceptable salt thereof, wherein

X is NR²;


Y is -NR⁴-C(O)-R³;

R¹ is a radical of the formula



R² is a hydrogen or methyl radical;

R³ is a radical of the formula



R⁴ is a radical of hydrogen, methyl or ethyl radical;

R⁵, R⁶ and R⁷ are each independently a hydrogen radical;

R¹¹ and R¹³ are each independently a radical of hydrogen, C₁-C₄ alkyl, halo, trifluoromethyl, cyano, azido, nitro, amidino or R¹⁹-Z¹⁹;

each R¹² is independently a radical of hydrogen, C₁-C₆ alkyl, halo, C₁-C₄ haloalkyl of 1-3 halo radicals, R³¹-Z³¹- or R³¹-Z³¹-C₁-C₄ alkyl; provided that the combined total number of aryl and heteroaryl radicals in R¹¹, R¹² and R¹³ is 0-1;

each R¹⁸ is independently a hydrogen, C₁-C₄ alkyl, trifluoromethyl, aryl, heteroaryl, aryl-C₁-C₂ alkyl or heteroaryl-C₁-C₂ alkyl radical; wherein the aryl and heteroaryl radicals are optionally substituted by 1-2 radicals of hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthiol, amino, C₁-C₄ alkylamino, di(C₁-C₄ alkyl)amino, acetylamino, cyano, halo, azido, C₁-C₄ alkyl, trifluoromethyl or trifluoromethoxy, each R¹⁹ is independently a hydrogen, C₁-C₄ alkyl, trifluoromethyl, aryl, heteroaryl, aryl-C₁-C₄ alkyl or heteroaryl-C₁-C₄ alkyl radical; wherein the aryl and heteroaryl radicals are optionally substituted by 1-2 radicals of hydroxy, methoxy, ethoxy, amino, methylamino, dimethylamino, acetylamino, cyano, halo, methyl, ethyl, trifluoromethyl or trifluoromethoxy;

each R²¹ is independently a hydrogen or methyl radical;

R²², R²³, R²⁴, R²⁵ and R²⁶ are each independently a radical of hydrogen, C₁-C₄ alkyl, halo, trifluoromethyl, cyano, azido, nitro, amidino, R¹⁸-Z¹⁸- or R¹⁸-Z¹⁸-C₁-C₄ alkyl; provided at least one of R²¹, R²², R²³, R²⁴ and R²⁵ is hydrogen; and provided that at least one of R²², R²³, R²⁴, R²⁵ and R²⁶ is other than hydrogen; and provided that the combined total number of aryl and heteroaryl radicals in R²², R²³, R²⁴, R²⁵ and R²⁶ is 0-1 ;

each R³¹ is independently a hydrogen, C₁-C₄ alkyl, trifluoromethyl, aryl, heteroaryl, aryl-C₁-C₄ alkyl or heteroaryl-C₁-C₄ alkyl radical; wherein the aryl and heteroaryl radicals are optionally substituted by 1-2 radicals of hydroxy, methoxy, ethoxy, amino, methylamino, dimethylamino, acetylamino, cyano, halo, methyl, ethyl, trifluoromethyl or trifluoromethoxy; U is C-R¹³ or N;

V and W are each independently C-R¹² or N ;


each Z¹⁸ is independently -O-, -S-, -S(O)₂-, -CO₂-, -NR²¹-, -NR²¹-C(O)-, -C(O)-NR²¹-, -NR²¹-S(O)₂- or -S(O)₂-NR²¹-;

each Z¹⁹ is independently -O-, -S(O)₂-, -CO₂-, -C(O)-, -NR²¹-C(O)-, -C(O)-NR²¹-, -NR²¹-S(O)₂- or -S(O)₂-NR²¹-;

each Z³¹ is independently -O-, -NR²¹-, -NR²¹-C(O)-, -C(O)-NR²¹-, -NR²¹-S(O)₂- or -S(O)₂-NR²¹-; and

wherein aryl is a phenyl, biphenyl or naphthyl radical; and heteroaryl is a monocyclic aromatic heterocyclic ring system having 5-6 ring members per ring, wherein 1-3 ring members are oxygen, sulfur or nitrogen heteroatoms.

[0025] The present invention also provides a compound of the formula:




or a pharmaceutically acceptable salt thereof, wherein

X is NR²;


Y is -NR⁴-C(O)-R³;

R¹ is a radical of the formula



R² is a hydrogen or methyl radical;

R³ is a radical of the formula



R⁴ is a radical of hydrogen, methyl or ethyl radical;

R⁵, R⁶ and R⁷ are each independently a hydrogen radical;

R¹¹ and R¹³ are each independently a radical of hydrogen, C₁-C₄ alkyl, halo, trifluoromethyl, cyano, azido, nitro, amidino or R¹⁹-Z¹⁹;

each R¹² is independently a radical of hydrogen, C₁-C₆ alkyl, halo, C₁-C₄ haloalkyl of 1-3 halo radicals, R³¹-Z³¹- or R³¹-Z³¹-C₁-C₄ alkyl; provided that the combined total number of aryl and heteroaryl radicals in R¹¹, R¹² and R¹³ is 0-1;

each R¹⁸ is independently a hydrogen, C₁-C₄ alkyl, trifluoromethyl, aryl, heteroaryl, aryl-C₁-C₂ alkyl or heteroaryl-C₁-C₂ alkyl radical; wherein the aryl and heteroaryl radicals are optionally substituted by 1-2 radicals of hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthiol, amino, C₁-C₄ alkylamino, di(C₁-C₄ alkyl)amino, acetaminomethyl, cyano, halo, azido, C₁-C₄ alkyl, trifluoromethyl or trifluoromethoxy;

each R¹⁹ is independently a hydrogen, C₁-C₄ alkyl, trifluoromethyl, aryl, heteroaryl, aryl-C₁-C₄ alkyl or heteroaryl-C₁-C₄ alkyl radical; wherein the aryl and heteroaryl radicals are optionally substituted by 1-2 radicals of hydroxy, methoxy, ethoxy, amino, methylamino, dimethylamino, acetaminomethyl, cyano, halo, methyl, ethyl, trifluoromethyl or trifluoromethoxy;

each R²¹ is independently a hydrogen or methyl radical;

R²², R²³, R²⁴, R²⁵ and R²⁶ are each independently a radical of hydrogen, C₁-C₄ alkyl, halo, trifluoromethyl, cyano, azido, nitro, amidino, R¹⁸-Z¹⁸- or R¹⁸-Z¹⁸-C₁-C₄ alkyl; provided at least one of R²¹, R²², R²³, R²⁴ and R²⁵ is hydrogen; and provided that the combined total number of aryl and heteroaryl radicals in R²², R²³, R²⁴, R²⁵ and R²⁶ is 0-1;

each R³¹ is independently a hydrogen, C₁-C₄ alkyl, trifluoromethyl, aryl, heteroaryl, aryl-C₁-C₄ alkyl or heteroaryl-C₁-C₄ alkyl radical; wherein the aryl and heteroaryl radicals are optionally substituted by 1-2 radicals of hydroxy, methoxy, ethoxy, amino, methylamino, dimethylamino, acetaminomethyl, cyano, halo, methyl, ethyl, trifluoromethyl or trifluoromethoxy, U is C-R¹³ or N;

V is N;

W is C-R¹² or N;

each Z¹⁸ is independently -O-, -S-, -S(O)₂-, -CO₂-, -NR²¹-, -NR²¹-C(O)-, -C(O)-NR²¹-, -NR²¹-S(O)₂- or -S(O)₂-NR²¹;


each Z¹⁹ is independently -O-, -S(O)₂-, -CO₂-, -C(O)-, -NR²¹-C(O)-, -C(O)-NR²¹-, -NR²¹-S(O)₂- or -S(O)₂-NR²¹;

each Z³¹ is independently -O-, -NR²¹-, -NR²¹-C(O)-, -C(O)-NR²¹-, -NR²¹-S(O)₂- or -S(O)₂-NR²¹; and

wherein aryl is a phenyl, biphenyl or naphthyl radical; and heteroaryl is a monocyclic aromatic heterocyclic ring system having 5-6 ring members per ring,

wherein 1-3 ring members are oxygen, sulfur or nitrogen heteroatoms.

[0026] According to the present invention, there is also provided a compound of the formula:




or a pharmaceutically acceptable salt thereof, wherein

X is NR^2 ;


Y is $-\text{NR}^4-\text{C}(\text{O})-\text{R}^3$;

R^1 is a radical of the formula



R^2 is a hydrogen or methyl radical;

R^3 is a radical of the formula



R^4 is a radical of hydrogen, methyl or ethyl radical;

R^5 , R^6 and R^7 are each independently a hydrogen radical;

R^1 and R^{13} are each independently a radical of hydrogen, $\text{C}_1\text{-C}_4$ alkyl, halo, trifluoromethyl, cyano, azido, nitro, amidino or $\text{R}^{19}\text{-Z}^{19}$;

each R^{12} is independently a radical of hydrogen, $\text{C}_1\text{-C}_6$ alkyl, halo, $\text{C}_1\text{-C}_4$ haloalkyl of 1-3 halo radicals, $\text{R}^{31}\text{-Z}^{31}$ - or $\text{R}^{31}\text{-Z}^{31}\text{-C}_1\text{-C}_4$ alkyl; provided that the combined total number of aryl and heteroaryl radicals in R^{11} , R^{12} and R^{13} is 0-1;

each R^{18} is independently a hydrogen, $\text{C}_1\text{-C}_4$ alkyl, trifluoromethyl, aryl, heteroaryl, aryl- $\text{C}_1\text{-C}_2$ alkyl or heteroaryl- $\text{C}_1\text{-C}_2$ alkyl radical; wherein the aryl and heteroaryl radicals are optionally substituted by 1-2 radicals of hydroxy, $\text{C}_1\text{-C}_4$ alkoxy, $\text{C}_1\text{-C}_4$ alkylthiol, amino, $\text{C}_1\text{-C}_4$ alkylamino, di($\text{C}_1\text{-C}_4$ alkyl)amino, acetlamino, cyano, halo, azido, $\text{C}_1\text{-C}_4$ alkyl, trifluoromethyl or trifluoromethoxy;

each R^{19} is independently a hydrogen, $\text{C}_1\text{-C}_4$ alkyl, trifluoromethyl, aryl, heteroaryl, aryl- $\text{C}_1\text{-C}_4$ alkyl or heteroaryl- $\text{C}_1\text{-C}_4$ alkyl radical; wherein the aryl and heteroaryl radicals are optionally substituted by 1-2 radicals of hydroxy, methoxy, ethoxy, amino, methylamino, dimethylamino, acetlamino, cyano, halo, methyl, ethyl, trifluoromethyl or trifluoromethoxy;

each R^{21} is independently a hydrogen or methyl radical; and

R^{22} , R^{23} , R^{24} , R^{25} and R^{26} are each independently a radical of hydrogen, $\text{C}_1\text{-C}_4$ alkyl, halo, trifluoromethyl, cyano, azido,

nitro, amidino, R^{18} - Z^{18} - or R^{18} - Z^{18} - C_1 - C_4 alkyl; provided at least one of R^{21} , R^{22} , R^{23} , R^{24} and R^{25} is hydrogen; provided that the combined total number of aryl and heteroaryl radicals in R^{22} , R^{23} , R^{24} , R^{25} and R^{26} is 0-1; each R^{31} is independently a hydrogen, C_1 - C_4 alkyl, trifluoromethyl, aryl, heteroaryl, aryl- C_1 - C_4 alkyl or heteroaryl- C_1 - C_4 alkyl radical; wherein the aryl and heteroaryl radicals are optionally substituted by 1-2 radicals of hydroxy, methoxy, ethoxy, amino, methylamino, dimethylamino, acetylamino, cyano, halo, methyl, ethyl, trifluoromethyl or trifluoromethoxy; U is C- R^{13} or N;

V and W are each independently C- R^{12} or N;

R^{22} R^{23} R^{24} R^{25} and R^{26} are each independently a radical of hydrogen, C_1 - C_4 alkyl, halo, trifluoromethyl, cyano, azido, nitro, amidino, R^{18} - Z^{18} - or R^{18} - Z^{18} - C_1 - C_4 alkyl; provided for each of A), B), C), D) and E) at least one of R^{21} , R^{22} , R^{23} , R^{24} , and R^{25} is hydrogen; and provided that the combined total number of aryl and heteroaryl radicals in R^{22} , R^{23} , R^{24} , R^{25} and R^{26} is 0-1;

each R^{31} is independently a hydrogen, C_1 - C_4 alkyl, trifluoromethyl, aryl, heteroaryl, aryl- C_1 - C_4 alkyl or heteroaryl- C_1 - C_4 alkyl radical; wherein the aryl and heteroaryl radicals are optionally substituted by 1-2 radicals of hydroxy, methoxy, ethoxy, amino, methylamino, dimethylamino, acetylamino, cyano, halo, methyl, ethyl, trifluoromethyl or trifluoromethoxy;

U is N;

V is C- R^{12} or N;

W is N;

each Z^{18} is independently -O-, -S-, -S(O)₂-, -CO₂-, -NR²¹-, -NR²¹-C(O)-, -C(O)-NR²¹-, -NR²¹-S(O)₂- or -S(O)₂-NR²¹-;


each Z^{19} is independently -O-, -S(O)₂-, -CO₂-, -C(O)-, -NR²¹-C(O)-, -C(O)-NR²¹-, -NR²¹-S(O)₂- or -S(O)₂-NR²¹-;

each Z^{31} is independently -O-, -NR²¹-, -NR²¹-C(O)-, -C(O)-NR²¹-, -NR²¹-S(O)₂- or -S(O)₂-NR²¹-; and

wherein aryl is a phenyl, biphenyl or naphthyl radical; and heteroaryl is a monocyclic aromatic heterocyclic ring system having 5-6 ring members per ring,

wherein 1-3 ring members are oxygen, sulfur or nitrogen heteroatoms.

[0027] There is also disclosed compounds of the formula:



or a pharmaceutically acceptable salt thereof, wherein

X is O, S, S(O), S(O)₂ or NR²; preferably, X is O, S or NR²; more preferably, X is O or NR most preferably, X is NR²;

Y is -C(O)-NR³R⁴ or -NR⁴-C(O)-R³;


R¹ is a cycloalkyl, aryl, heterocyclyl or heteroaryl radical which is optionally substituted by 1-4 radicals of alkyl, halo, haloalkyl, cyano, azido, nitro, amidino, R^{18} - Z^{18} - or R^{18} - Z^{18} -alkyl;

preferably, R¹ is a cycloalkyl, aryl, heterocyclyl or heteroaryl radical which is optionally substituted by 1-4 radicals of C_1 - C_6 alkyl, halo, C_1 - C_6 haloalkyl of 1-3 halo radicals, cyano, azido, nitro, amidino, R^{18} - Z^{18} - or R^{18} - Z^{18} - C_1 - C_6 alkyl;


more preferably, R¹ is a cycloalkyl, aryl, heterocyclyl or heteroaryl radical which is optionally substituted by 1-4 radicals of C_1 - C_4 alkyl, halo, C_1 - C_4 haloalkyl of 1-3 halo radicals, cyano, azido, nitro, amidino, R^{18} - Z^{18} - or R^{18} - Z^{18} - C_1 - C_4 alkyl;

provided that the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in R¹ is 1-3, preferably, 1-2, and provided when Y is -NR⁴-C(O)-R³ and X is O or S, R¹ is other than a 2-pyrimidinyl radical;

more preferably, R¹ is a radical of the formula



wherein R^{22} , R^{23} , R^{24} , R^{25} and R^{26} are each independently a radical of hydrogen, C_1 - C_4 alkyl, halo, trifluoromethyl, cyano, azido, nitro, amidino, R^{18} - Z^{18} - or R^{18} - Z^{18} - C_1 - C_4 alkyl; provided at least one of R^{21} , R^{22} , R^{23} , R^{24} and R^{25} is hydrogen; and provided that the combined total number of aryl and heteroaryl radicals in R^{22} , R^{23} , R^{24} , R^{25} and R^{26} is 0-1; R^2 is a hydrogen or alkyl radical; preferably, R^2 is a hydrogen or C_1 - C_4 alkyl radical; more preferably, R^2 is a hydrogen or C_1 - C_2 alkyl radical; more preferably, R^2 is a hydrogen or methyl radical; and most preferably, R^2 is a hydrogen radical; R^3 is an aryl or heteroaryl radical which is optionally substituted by 1-5 radicals of alkyl; halo, haloalkyl, cyano, azido, nitro, amidino, R^{19} - Z^{19} - or R^{19} - Z^{19} -alkyl; preferably, R^3 is an aryl or heteroaryl radical which is optionally substituted by 1-5 radicals of C_1 - C_6 alkyl, halo, C_1 - C_6 haloalkyl of 1-3 halo radicals, cyano, azido, nitro, amidino, R^{19} - Z^{19} - or R^{19} - Z^{19} - C_1 - C_6 alkyl; more preferably, R^3 is an aryl or heteroaryl radical which is optionally substituted by 1-5 radicals of C_1 - C_6 alkyl, halo, C_1 - C_4 haloalkyl of 1-3 halo radicals, cyano, azido, nitro, amidino, R^{19} - Z^{19} - or R^{19} - Z^{19} - C_1 - C_4 alkyl; provided that the total number of aryl and heteroaryl radicals in R^3 is 1-3, preferably, 1-2; and provided when Y is $-C(O)-NR^3R^4$, R^3 is other than a phenyl or naphthyl having an amino, nitro, cyano, carboxy or alkoxycarbonyl substituent bonded to the ring carbon atom adjacent to the ring carbon atom bonded to $-NR^-$; more preferably, R^3 is a radical of the formula



wherein

U is $C-R^{13}$ or N;

V and W are each independently $C-R^{12}$ or N;

R^{11} and R^{13} are each independently a radical of hydrogen, C_1 - C_4 alkyl, halo, trifluoromethyl, cyano, azido, nitro, amidino or R^{19} - Z^{19} -; preferably, R^{11} and R^{13} are each independently a radical of hydrogen, methyl, ethyl, fluoro, chloro, trifluoromethyl, cyano, azido, nitro, amidino, R^{19} -O-, R^{19} - $S(O)_2$ -, R^{19} -O-C(O)-, R^{19} -C(O)-, R^{19} - NR^{21} -C(O)- or R^{19} - NR^{21} - $S(O)_2$ -; each R^{12} is independently a radical of hydrogen, C_1 - C_6 alkyl, halo, C_1 - C_4 haloalkyl of 1-3 halo radicals, R^{31} - Z^{31} - or R^{31} - Z^{31} - C_1 - C_4 alkyl; preferably, each R^{12} is independently a radical of hydrogen, methyl, ethyl, fluoro, chloro, trifluoromethyl, trifluoromethoxy, methoxy, ethoxy, amino, methylamino, dimethylamino, acetylamino, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, aminomethyl, (methylamino)methyl or (dimethylamino)methyl;

provided that the combined total number of aryl and heteroaryl radicals in R^{11} , R^{12} and R^{13} is 0-1;

wherein each R^{31} is independently a hydrogen, C_1 - C_4 alkyl, trifluoromethyl, aryl, heteroaryl, aryl- C_1 - C_4 alkyl or heteroaryl- C_1 - C_4 alkyl radical, wherein the aryl and heteroaryl radicals are optionally substituted by 1-2 radicals of hydroxy, methoxy, ethoxy, amino, methylamino, dimethylamino, acetylamino, cyano, halo, methyl, ethyl, trifluoromethyl or trifluoromethoxy;

each Z^{31} is independently -O-, $-NR^{21}$ -, $-NR^{21}$ -C(O)-, $-C(O)-NR^{21}$ -, $-NR^{21}$ - $S(O)_2$ - or $-S(O)_2-NR^{21}$ -;

R^4 is a hydrogen, alkyl, alkenyl, haloalkyl, haloalkenyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl or R^{20} - Z^{20} -alkyl radical, wherein the aryl and heteroaryl radicals are optionally substituted by 1-3 radicals of hydroxy, alkoxy, alkylthiol, amino, alkylamino, dialkylamino, alkanoylamino, alkylsulfonylamino, alkylsulfinyl, alkylsulfonyl, alkoxycarbonylamino, alkoxycarbonyl, cyano, halo, azido, alkyl, haloalkyl or haloalkoxy;

preferably, R⁴ is a radical of hydrogen, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₁-C₆ haloalkyl of 1-3 halo radicals, C₂-C₆ haloalkenyl of 1-3 halo radicals, aryl, heteroaryl, aryl-C₁-C₄ alkyl, heteroaryl-C₁-C₄ alkyl or R²⁰-Z²⁰-C₁-C₆ alkyl radical, wherein the aryl and heteroaryl radicals are optionally substituted by 1-3 radicals of hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthiol, amino, C₁-C₄ alkylamino, di (C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, C₁-C₄ alkylsulfonylamino, C₁-C₄ alkylsulfinyl, C₁-C₄ alkylsulfonyl, (C₁-C₄ alkoxy)carbonylamino, (C₁-C₄ alkoxy)carbonyl, cyano, halo, azido, C₁-C₄ alkyl, C₁-C₄ haloalkyl of 1-3 halo radicals or C₁-C₄ haloalkoxy of 1-3 halo radicals;

more preferably, R⁴ is a radical of hydrogen, C₁-C₆ alkyl, aryl, heteroaryl, aryl-C₁-C₄ alkyl, heteroaryl-C₁-C₄ alkyl or R²⁰-Z²⁰-C₂-C₄ alkyl radical, wherein the aryl and heteroaryl radicals are optionally substituted by 1-2 radicals of hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthiol, amino, C₁-C₄ alkylamino, di (C₁-C₄ alkyl)amino, acetylamino, halo, C₁-C₄ alkyl, trifluoromethyl or trifluoromethoxy; more preferably, R⁴ is a radical of hydrogen, C₁-C₆ alkyl, aryl, heteroaryl, aryl-C₁-C₄ alkyl, heteroaryl-C₁-C₄ alkyl or R²⁰-Z²⁰-C₂-C₄ alkyl radical, wherein the aryl and heteroaryl radicals are optionally substituted by 1-2 radicals of hydroxy, methoxy, ethoxy, methylthiol, ethylthiol, amino, methylamino, dimethylamino, ethylamino, diethylamino, acetylamino, halo, methyl, ethyl, trifluoromethyl or trifluoromethoxy;

more preferably, R⁴ is a radical of hydrogen, methyl or ethyl radical;

wherein each R¹⁸ is independently a hydrogen, alkyl, haloalkyl, aryl, heteroaryl, arylalkyl or heteroarylalkyl radical, wherein the aryl and heteroaryl radicals are optionally substituted by 1-3 radicals of hydroxy, alkoxy, alkylthiol, amino, alkylamino, dialkylamino, alkanoylamino, alkylsulfonylamino, alkylsulfinyl, alkylsulfonyl, alkoxycarbonylamino, alkoxy-carbonyl, cyano, halo, azido, alkyl, haloalkyl or haloalkoxy;

preferably, each R¹⁸ is independently a hydrogen, C₁-C₄ alkyl, C₁-C₄ haloalkyl of 1-3 halo radicals, aryl, heteroaryl, aryl-C₁-C₄ alkyl or heteroaryl-C₁-C₄ alkyl radical, wherein the aryl and heteroaryl radicals are optionally substituted by 1-3 radicals of hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthiol, amino, C₁-C₄ alkylamino, di(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, C₁-C₄ alkylsulfonylamino, C₁-C₄ alkylsulfinyl, C₁-C₄ alkylsulfonyl, (C₁-C₄ alkoxy)carbonylamino, (C₁-C₄ alkoxy)carbonyl, cyano, halo, azido, C₄-C₄ alkyl, C₁-C₄ haloalkyl of 1-3 halo radicals or C₁-C₄ haloalkoxy of 1-3 halo radicals;

more preferably, each R¹⁸ is independently a hydrogen, C₁-C₄ alkyl, trifluoromethyl, aryl, heteroaryl, aryl-C₁-C₂ alkyl or heteroaryl-C₁-C₂ alkyl radical, wherein the aryl and heteroaryl radicals are optionally substituted by 1-2 radicals of hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthiol, amino, C₁-C₄ alkylamino, di(C₁-C₄ alkyl)amino, acetylamino, cyano, halo, azido, C₁-C₄ alkyl, trifluoromethyl or trifluoromethoxy;

each Z¹⁸ is independently -O-, -S-, -S(O)-, -S(O)₂-, -CO₂-, -C(O)-, -NR²¹-, -NR²¹-C(O)-, -C(O)-NR²¹-, -NR²¹-S(O)₂- or -S(O)₂-NR²¹-; preferably, each Z¹⁸ is independently -O-, -S-, -S(O)₂-, -CO₂-, -NR²¹-, -NR²¹-C(O)-, -C(O)-NR²¹-, -NR²¹-S(O)₂- or -S(O)₂-NR²¹-;

wherein each R¹⁹ is independently a hydrogen, alkyl, haloalkyl, aryl, heteroaryl, arylalkyl or heteroarylalkyl radical, wherein the aryl and heteroaryl radicals are optionally substituted by 1-3 radicals of hydroxy, alkoxy, alkylthiol, amino, alkylamino, dialkylamino, alkanoylamino, alkylsulfonylamino, alkylsulfinyl, alkylsulfonyl, alkoxycarbonylamino, alkoxy-carbonyl, cyano, halo, azido, alkyl, haloalkyl or haloalkoxy;

preferably, each R¹⁹ is independently a hydrogen, C₁-C₄ alkyl, C₁-C₄ haloalkyl of 1-3 halo radicals, aryl, heteroaryl, aryl-C₁-C₄ alkyl or heteroaryl-C₁-C₄ alkyl radical, wherein the aryl and heteroaryl radicals are optionally substituted by 1-3 radicals of hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthiol, amino, C₁-C₄ alkylamino, di(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, C₁-C₄ alkylsulfonylamino, C₁-C₄ alkylsulfinyl, C₁-C₄ alkylsulfonyl, (C₁-C₄ alkoxy)carbonylamino, (C₁-C₄ alkoxy)carbonyl, cyano, halo, azido, C₁-C₄ alkyl, C₁-C₄ haloalkyl of 1-3 halo radicals or C₁-C₄ haloalkoxy of 1-3 halo radicals;

more preferably, each R¹⁹ is independently a hydrogen, C₁-C₄ alkyl, trifluoromethyl, aryl, heteroaryl, aryl-C₁-C₄ alkyl or heteroaryl-C₁-C₄ alkyl radical, wherein the aryl and heteroaryl radicals are optionally substituted by 1-2 radicals of hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthiol, amino, C₁-C₄ alkylamino, di(C₁-C₄ alkyl)amino, acetylamino, cyano, halo, C₁-C₄ alkyl, trifluoromethyl or trifluoromethoxy;

more preferably, each R¹⁹ is independently a hydrogen, C₁-C₄ alkyl, trifluoromethyl, aryl, heteroaryl, aryl-C₁-C₄ alkyl or heteroaryl-C₁-C₄ alkyl radical; wherein the aryl and heteroaryl radicals are optionally substituted by 1-2 radicals of hydroxy, methoxy, ethoxy, amino, methylamino, dimethylamino, acetylamino, cyano, halo, methyl, ethyl, trifluoromethyl or trifluoromethoxy;

more preferably, each R¹⁹ is independently a hydrogen, methyl, ethyl, trifluoromethyl, phenyl, heteroaryl, phenylmethyl or heteroaryl-methyl radical, wherein the phenyl and heteroaryl radicals are optionally substituted by 1-2 radicals of hydroxy, methoxy, ethoxy, amino, methylamino, dimethylamino, acetylamino, cyano, fluoro, chloro, methyl, ethyl, trifluoromethyl or trifluoromethoxy;

each Z¹⁹ is independently -O-, -S-, -S(O)-, -S(O)₂-, -CO₂-, -C(O)-, -NR²¹-, -NR²¹-C(O)-, -C(O)-NR²¹-, -NR²¹-S(O)₂- or -S(O)₂-NR²¹-; preferably, each Z¹⁹ is independently -O-, -S(O)₂-, -CO₂-, -C(O)-, -NR²¹-C(O)-, -C(O)-NR²¹-, -NR²¹-S(O)₂- or -S(O)₂-NR²¹-; more preferably, each Z¹⁹ is independently -O-, -S(O)₂-, -O-C(O)-, -C(O)-, -NR²¹-C(O)- or -NR²¹-S(O)₂-;

wherein each R²⁰ is independently a hydrogen, alkyl, haloalkyl, aryl, heteroaryl, arylalkyl or heteroarylalkyl radical,

wherein the aryl and heteroaryl radicals are optionally substituted by 1-3 radicals of hydroxy, alkoxy, alkylthiol, amino, alkylamino, dialkylamino, alkanoylamino, alkylsulfonylamino, alkylsulfinyl, alkylsulfonyl, alkoxycarbonylamino, alkoxy-carbonyl, cyano, halo, azido, alkyl, haloalkyl or haloalkoxy ;

preferably, each R²⁰ is independently a hydrogen, C₁-C₄ alkyl, C₁-C₄ haloalkyl of 1-3 halo radicals, aryl, heteroaryl, aryl-C₁-C₄ alkyl or heteroaryl-C₁-C₄ alkyl radical, wherein the aryl and heteroaryl radicals are optionally substituted by 1-3 radicals of hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthiol, amino, C₁-C₄ alkylamino, di(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, C₁-C₄ alkylsulfonylamino, C₁-C₄ alkylsulfinyl, C₁-C₄ alkylsulfonyl, (C₁-C₄ alkoxy)carbonylamino, (C₁-C₄ alkoxy)carbonyl, cyano, halo, azido, C₁-C₄ alkyl, C₁-C₄ haloalkyl of 1-3 halo radicals or C₁-C₄ haloalkoxy of 1-3 halo radicals;

more preferably, each R²⁰ is independently a hydrogen, C₁-C₄ alkyl, aryl, heteroaryl, aryl-C₁-C₂ alkyl or heteroaryl-C₁-C₂ alkyl radical, wherein the aryl and heteroaryl radicals are optionally substituted by 1-2 radicals of hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthiol, amino, C₁-C₄ alkylamino, di (C₁-C₄ alkyl)amino, acetylamino, halo, C₁-C₄ alkyl, trifluoromethyl or trifluoromethoxy;

more preferably, each R²⁰ is independently a hydrogen, C₁-C₄ alkyl, aryl, heteroaryl, aryl-C₁-C₂ alkyl or heteroaryl-C₁-C₂ alkyl radical, wherein the aryl and heteroaryl radicals are optionally substituted by 1-2 radicals of hydroxy, methoxy, ethoxy, methylthiol, ethylthiol, amino, methylamino, dimethylamino, ethylamino, diethylamino, acetylamino, halo, methyl, ethyl, trifluoromethyl or trifluoromethoxy;

each Z²⁰ is independently -O-, -S-, -S(O)-, -S(O)₂-, CO₂-, -C(O)-, -NR²¹-, -NR²¹-C(O)-, -C(O)-NR²¹-, -NR²¹-S(O)₂- or -S(O)₂-NR²¹-; preferably, each Z²⁰ is independently -O- or -NR²¹-;

wherein each R²¹ is independently a hydrogen or alkyl radical; preferably, each R²¹ is independently a hydrogen or methyl radical;

R⁵ and R⁶ are each independently a hydrogen, alkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, amino, alkylamino, dialkylamino, alkanoylamino, alkylsulfonylamino, aminosulfonyl, alkylaminosulfonyl, dialkylaminosulfonyl, hydroxy, hydroxyalkyl, thiol, alkylthiol, alkylsulfinyl, alkylsulfonyl, alkoxy, alkoxyalkyl, cyano, azido, nitro, carboxy, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl or dialkylaminocarbonyl radical;

preferably, R⁵ and R⁶ are each independently a hydrogen, C₁-C₄ alkyl, halo, C₁-C₄ haloalkyl of 1-3 halo radicals, C₁-C₄ haloalkoxy of 1-3 halo radicals, C₁-C₄ aminoalkyl, (C₁-C₄ alkyl)amino-C₁-C₄ alkyl, di(C₁-C₄ alkyl)amino-C₁-C₄ alkyl, amino, C₁-C₄ alkylamino, di(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, C₁-C₄ alkylsulfonylamino, aminosulfonyl, C₁-C₄ alkylaminosulfonyl, di(C₁-C₄ alkyl)aminosulfonyl, hydroxy, C₁-C₄ hydroxyalkyl, thiol, C₁-C₄ alkylthiol, C₁-C₄ alkylsulfinyl, C₁-C₄ alkylsulfonyl, C₁-C₄ alkoxy, (C₁-C₄ alkoxy)C₁-C₄ alkyl, cyano, azido, nitro, carboxy, (C₁-C₄ alkoxy)carbonyl, aminocarbonyl, (C₁-C₄ alkyl)aminocarbonyl or di(C₁-C₄ alkyl)aminocarbonyl radical;

more preferably, R⁵ and R⁶ are each independently a hydrogen, C₁-C₄ alkyl, halo, trifluoromethyl, trifluoromethoxy, amino, C₁-C₄ alkylamino, di(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, hydroxy, C₁-C₄ hydroxyalkyl, C₁-C₄ alkoxy, cyano, azido, nitro, carboxy, (C₁-C₄ alkoxy)carbonyl, aminocarbonyl, (C₁-C₄ alkyl)aminocarbonyl or di(C₁-C₄ alkyl)aminocarbonyl radical;

more preferably, R⁵ and R⁶ are each independently a hydrogen, methyl, ethyl, halo, trifluoromethyl, trifluoromethoxy, amino, C₁-C₂ alkylamino, di(C₁-C₂ alkyl)amino, hydroxy, methoxy or ethoxy radical; most preferably, R⁵ and R⁶ are each a hydrogen radical;

R⁷ is a hydrogen, alkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, aminosulfonyl, alkylaminosulfonyl, dialkylaminosulfonyl, hydroxy, hydroxyalkyl, thiol, alkylthiol, alkylsulfinyl, alkylsulfonyl, alkoxy, alkoxyalkyl, cyano, azido, nitro, carboxy, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl or dialkylaminocarbonyl radical;

preferably, R⁷ is a hydrogen, C₁-C₄ alkyl, halo, C₁-C₄ haloalkyl of 1-3 halo radicals, C₁-C₄ haloalkoxy of 1-3 halo radicals, C₁-C₄ aminoalkyl, (C₁-C₄ alkyl)amino-C₁-C₄ alkyl, di(C₁-C₄ alkyl)amino-C₁-C₄ alkyl, aminosulfonyl, C₁-C₄ alkylamino-sulfonyl, di(C₁-C₄ alkyl)aminosulfonyl, hydroxy, C₁-C₄ hydroxyalkyl, thiol, C₁-C₄ alkylthiol, C₁-C₄ alkylsulfinyl, C₁-C₄ alkylsulfonyl, C₁-C₄ alkoxy, (C₁-C₄ alkoxy)C₁-C₄ alkyl, cyano, azido, nitro, carboxy, (C₁-C₄ alkoxy)carbonyl, aminocarbonyl, (C₁-C₄ alkyl)aminocarbonyl or di (C₁-C₄ alkyl)aminocarbonyl radical;

more preferably, R⁷ is a hydrogen, C₁-C₄ alkyl, halo, trifluoromethyl, trifluoromethoxy, hydroxy, C₁-C₄ hydroxyalkyl, C₁-C₄ alkoxy, carboxy, (C₁-C₄ alkoxy)carbonyl, aminocarbonyl, (C₁-C₄ alkyl)aminocarbonyl or di (C₁-C₄ alkyl)aminocarbonyl radical;

more preferably, R⁷ is a hydrogen, methyl, ethyl, halo, trifluoromethyl, trifluoromethoxy, hydroxy, methoxy or ethoxy radical; most preferably, R⁷ is a hydrogen radical.

[0028] The compounds of this invention may have in general several asymmetric centers and are typically depicted in the form of racemic mixtures. This invention is intended to encompass racemic mixtures, partially racemic mixtures and separate enantiomers and diastereomers.

[0029] Compounds of interest include the following:

2-cyclohexyloxy-5-(2-chlorophenylcarbonylamino)pyridine;
2-cyclohexyloxy-5-(2-methylphenylcarbonylamino)pyridine;

2-cyclohexyloxy-5-(2,6-dichlorophenylcarbonylamino) pyridine;
 2-cyclohexyloxy-5-(2,6-dimethylphenylcarbonylamino) pyridine;
 2-(2,4-dimethylphenoxy)-5-(2-chlorophenylcarbonylamino) pyridine;
 2-(2,4-dimethylphenoxy)-5-(2,6-dichlorophenylcarbonyl amino)pyridine;
 2-(2,4-dimethylphenoxy)-5-(2-methylphenylcarbonylamino) pyridine;
 2-(2,6-dimethyl-4-chlorophenoxy)-5-(2,6-dimethylphenyl carbonylamino) pyridine;
 2-(2-methyl-4-fluorophenoxy)-5-(2-methylphenylcarbonyl amino)pyridine;
 2-(2-methyl-4-chlorophenoxy)-5-(2-chlorophenylcarbonyl amino)pyridine;
 2-(2-methyl-4-chlorophenoxy)-5-(2-methylphenylcarbonyl amino)pyridine;
 2-(2-methylphenoxy)-5-(2-chlorophenylcarbonylamino) pyridine;
 2-(2-methylphenoxy)-5-(2,6-dichlorophenyl carbonylamino)pyridine;
 2-(2-methylphenoxy)-5-(2-methylphenylcarbonyl amino)pyridine;
 2-(2-methyl-4-chlorophenoxy)-5-(2,6-dichlorophenyl carbonylamino)pyridine;
 2-(2-methyl-4-chlorophenoxy)-5-(2,6-dimethylphenyl carbonylamino)pyridine;
 2-(4-chlorophenoxy)-5-(2,6-dimethylphenylcarbonylamino) pyridine;
 2-(2-methyl-4-fluorophenoxy)-5-(2,6-dichlorophenyl carbonylamino)pyridine;
 2-(2-methyl-4-fluorophenoxy)-5-(2,6-dimethylphenyl carbonylamino)pyridine;
 2-(2-methylphenoxy)-5-(2,6-dimethylphenyl carbonylamino)pyridine;
 2-(2-methyl-4-fluorophenoxy)-5-(2-fluorophenylcarbonyl amino)pyridine;
 2-(2,4-dimethylphenoxy)-5-(2,6-dimethylphenylcarbonyl amino)pyridine;
 2-(1-naphthylloxy)-5-(2-methylphenylcarbonylamino) pyridine;
 2-(1-naphthylloxy)-5-(2,6-dichlorophenylcarbonylamino) pyridine;
 2-(1-naphthylloxy)-5-(2,6-dimethylphenylcarbonylamino) pyridine;
 2-(2-methyl-3-pyridyloxy)-5-(2,6-dichlorophenylcarbonyl amino)pyridine;
 2-(2-methyl-4-chlorophenoxy)-5-((3,5-dimethyl-4-isoxazolyl)carbonylamino)pyridine;
 2-(2-methyl-4-chlorophenylthiol)-5-(2-methylphenylcarbonyl amino)pyridine;
 2-(2-methyl-4-chlorophenylthiol)-5-(2,6-dimethylphenylcarbonyl amino)pyridine;
 2-cyclohexylamino-5-(2,6-dichlorophenylcarbonylamino) pyridine;
 2-cyclohexylamino-5-(2,6-dimethylphenylcarbonylamino) pyridine;
 2-(2-methylcyclohexylamino)-5-(2,6-dichlorophenylcarbonyl amino)pyridine;
 2-(2-methylcyclohexylamino)-5-(2-methylphenylcarbonyl amino)pyridine;
 2-(2,4-dimethylphenylamino)-5-(2-fluorophenylcarbonyl amino)pyridine;
 2-(2,4-dimethylphenylamino)-5-(2-chlorophenylcarbonyl amino)pyridine;
 2-(2,4-dimethylphenylamino)-5-(2,6-dichlorophenylcarbonyl amino)pyridine;
 2-(2-methyl-4-chlorophenylamino)-5-(2,6-dichlorophenylcarbonylamino)pyridine;
 2-(2,4-dimethylphenylamino)-5-(2-methylphenylcarbonyl amino)pyridine;
 2-(2-methylphenylamino)-5-(2-methylphenylcarbonyl amino)pyridine;
 2-(2-methylphenylamino)-5-(2,6-dichlorophenylcarbonyl amino)pyridine;
 2-(2-methylphenylamino)-5-(2,6-dimethylphenylcarbonyl amino)pyridine;
 2-(2,4-dimethylphenylamino)-5-(2,6-dimethylphenylcarbonyl amino)pyridine;
 2-(2-methyl-4-chlorophenylamino)-5-(2-methylphenyl carbonylamino)pyridine;
 2-(2-methyl-4-chlorophenylamino)-5-(2,6-dimethylphenyl carbonylamino)pyridine; and
 2-(2-methyl-4-chlorophenylamino)-5-(2-methylphenyl aminocarbonyl)pyridine.

[0030] As utilized herein, the following terms shall have the following meanings:

"Alkyl", alone or in combination, means a straight-chain or branched-chain alkyl radical containing preferably 1-15 carbon atoms (C₁-C₁₅), more preferably 1-8 carbon atoms (C₁-C₈), even more preferably 1-6 carbon atoms (C₁-C₆), yet more preferably 1-4 carbon atoms (C₁-C₄), still more preferably 1-3 carbon atoms (C₁-C₃), and most preferably 1-2 carbon atoms (C₁-C₂). Examples of such radicals include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isoamyl, hexyl, octyl and the like.

"Hydroxyalkyl", alone or in combination, means an alkyl radical as defined above wherein at least one hydrogen radical is replaced with a hydroxyl radical, preferably 1-3 hydrogen radicals are replaced by hydroxyl radicals, more preferably 1-2 hydrogen radicals are replaced by hydroxyl radicals, and most preferably one hydrogen radical is replaced by a hydroxyl radical. Examples of such radicals include hydroxymethyl, 1-, 2-hydroxyethyl, 1-, 2-, 3-hydroxypropyl, 1,3-dihydroxy-2-propyl, 1,3-dihydroxybutyl, 1,2,3,4,5,6-hexahydroxy-2-hexyl and the like.

"Alkenyl", alone or in combination, means a straight-chain or branched-chain hydrocarbon radical having one or more double bonds, preferably 1-2 double bonds and more preferably one double bond, and containing preferably 2-15 carbon atoms (C_2-C_{15}), more preferably 2-8 carbon atoms (C_2-C_8), even more preferably 2-6 carbon atoms (C_2-C_6), yet more preferably 2-4 carbon atoms (C_2-C_4), and still more preferably 2-3 carbon atoms, (C_2-C_3). Examples of such alkenyl radicals include ethenyl, propenyl, 2-methylpropenyl, 1,4-butadienyl and the like.

"Alkoxy", alone or in combination, means a radical of the type "R-O-" wherein "R" is an alkyl radical as defined above and "O" is an oxygen atom. Examples of such alkoxy radicals include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, iso-butoxy, sec-butoxy, tert-butoxy and the like.

"Alkoxycarbonyl", alone or in combination, means a radical of the type "R-O-C(O)-" wherein "R-O-" is an alkoxy radical as defined above and "C(O)" is a carbonyl radical.

"Alkoxycarbonylamino", alone or in combination, means a radical of the type "R-O-C(O)-NH-" wherein "R-O-C(O)" is an alkoxycarbonyl radical as defined above, wherein the amino radical may optionally be substituted, such as with alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl and the like.

"Alkylthio", alone or in combination, means a radical of the type "R-S-" wherein "R" is an alkyl radical as defined above and "S" is a sulfur atom. Examples of such alkylthio radicals include methylthio, ethylthio, n-propylthio, isopropylthio, n-butylthio, iso-butylthio, sec-butylthio, tert-butylthio and the like.

"Alkylsulfinyl", alone or in combination, means a radical of the type "R-S(O)-" wherein "R" is an alkyl radical as defined above and "S(O)" is a mono-oxygenated sulfur atom. Examples of such alkylsulfinyl radicals include methylsulfinyl, ethylsulfinyl, n-propylsulfinyl, isopropylsulfinyl, n-butylsulfinyl, iso-butylsulfinyl, sec-butylsulfinyl, tert-butylsulfinyl and the like.

"Alkylsulfonyl", alone or in combination, means a radical of the type "R-S(O)₂-" wherein "R" is an alkyl radical as defined above and "S(O)₂" is a di-oxygenated sulfur atom. Examples of such alkylsulfonyl radicals include methylsulfonyl, ethylsulfonyl, n-propylsulfonyl, isopropylsulfonyl, n-butylsulfonyl, iso-butylsulfonyl, sec-butylsulfonyl, tert-butylsulfonyl and the like.

"Aryl", alone or in combination, means a phenyl or biphenyl radical, which is optionally benzo fused or heterocyclo fused and which is optionally substituted with one or more substituents selected from alkyl, alkoxy, halogen, hydroxy, amino, azido, nitro, cyano, haloalkyl, carboxy, alkoxycarbonyl, cycloalkyl, alkanoylamino, amido, amidino, alkoxy-carbonylamino, N-alkylamidino, alkylamino, dialkylamino, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, N-alkylamido, N,N-dialkylamido, aralkoxycarbonylamino, alkylthio, alkylsulfinyl, alkylsulfonyl, oxo and the like. Examples of aryl radicals are phenyl, o-tolyl, 4-methoxyphenyl, 2-(tert-butoxy)phenyl, 3-methyl-4-methoxyphenyl, 2-CF₃-phenyl, 2-fluorophenyl, 2-chlorophenyl, 3-nitrophenyl, 3-aminophenyl, 3-acetamidophenyl, 2-amino-3-(aminomethyl)phenyl, 6-methyl-3-acetamidophenyl, 6-methyl-2-aminophenyl, 6-methyl-2,3-diaminophenyl, 2-amino-3-methylphenyl, 4,6-dimethyl-2-aminophenyl, 4-hydroxyphenyl, 3-methyl-4-hydroxyphenyl, 4-(2-methoxyphenyl)phenyl, 2-amino-1-naphthyl, 2-naphthyl, 3-amino-2-naphthyl, 1-methyl-3-amino-2-naphthyl, 2,3-diamino-1-naphthyl, 4,8-dimethoxy-2-naphthyl and the like.

"Aralkyl" and "arylalkyl", alone or in combination, means an alkyl radical as defined above in which at least one hydrogen atom, preferably 1-2, is replaced by an aryl radical as defined above, such as benzyl, 1-, 2-phenylethyl, dibenzylmethyl, hydroxyphenylmethyl, methylphenylmethyl, diphenylmethyl, dichlorophenylmethyl, 4-methoxyphenylmethyl and the like.

"Aralkoxy", alone or in combination, means an alkoxy radical as defined above in which at least one hydrogen atom, preferably 1-2, is replaced by an aryl radical as defined above, such as benzyloxy, 1-, 2-phenylethoxy, dibenzylmethoxy, hydroxyphenylmethoxy, methylphenylmethoxy, dichlorophenylmethoxy, 4-methoxyphenylmethoxy and the like.

"Aralkoxycarbonyl", alone or in combination, means a radical of the type "R-O-C(O)-" wherein "R-O-" is an aralkoxy radical as defined above and "-C(O)-" is a carbonyl radical.

"Alkanoyl", alone or in combination, means a radical of the type "R-C(O)-" wherein "R" is an alkyl radical as defined above and "-C(O)-" is a carbonyl radical. Examples of such alkanoyl radicals include acetyl, trifluoroacetyl, hydroxy-

acetyl, propionyl, butyryl, valeryl, 4-methylvaleryl, and the like.

"Alkanoylamino", alone or in combination, means a radical of the type "R-C(O)-NH-" wherein "R-C(O)-" is an alkanoyl radical as defined above, wherein the amino radical may optionally be substituted, such as with alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl and the like.

"Aminocarbonyl", alone or in combination, means an amino substituted carbonyl (carbamoyl) radical, wherein the amino radical may optionally be mono- or di-substituted, such as with alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, alkanoyl, alkoxycarbonyl, aralkoxycarbonyl and the like.

"Aminosulfonyl", alone or in combination, means an amino substituted sulfonyl radical.

"Benzo", alone or in combination, means the divalent radical $C_6H_4=$ derived from benzene. "Benzo fused" forms a ring system in which benzene and a cycloalkyl or aryl group have two carbons in common, for example tetrahydronaphthylene and the like.

"Bicyclic" as used herein is intended to include both fused ring systems, such as naphthyl and β -carbolinyl, and substituted ring systems, such as biphenyl, phenylpyridyl and diphenylpiperazinyl.

"Cycloalkyl", alone or in combination, means a saturated or partially saturated, preferably one double bond, monocyclic, bicyclic or tricyclic carbocyclic alkyl radical, preferably monocyclic, containing preferably 5-12 carbon atoms (C_5-C_{12}), more preferably 5-10 carbon atoms (C_5-C_{10}), even more preferably 5-7 carbon atoms (C_5-C_7), which is optionally benzo fused or heterocyclo fused and which is optionally substituted as defined herein with respect to the definition of aryl. Examples of such cycloalkyl radicals include cyclopentyl, cyclohexyl, dihydroxycyclohexyl, ethylenedioxcyclohexyl, cycloheptyl, octahydronaphthyl, tetrahydronaphthyl, octahydroquinolynyl, dimethoxytetrahydronaphthyl, 2,3-dihydro-1H-indenyl, azabicyclo [3.2.1] octyl and the like.

"Heteroatoms" means nitrogen, oxygen and sulfur heteroatoms.

"Heterocyclo fused" forms a ring system in which a heterocyclyl or heteroaryl group of 5-6 ring members and a cycloalkyl or aryl group have two carbons in common, for example indole, isoquinoline, tetrahydroquinoline, methylenedioxybenzene and the like.

"Heterocyclyl" means a saturated or partially unsaturated, preferably one double bond, monocyclic or bicyclic, preferably monocyclic, heterocycle radical containing at least one, preferably 1 to 4, more preferably 1 to 3, even more preferably 1-2, nitrogen, oxygen or sulfur atom ring member and having preferably 3-8 ring members in each ring, more preferably 5-8 ring members in each ring and even more preferably 5-6 ring members in each ring. "Heterocyclyl" is intended to include sulfone and sulfoxide derivatives of sulfur ring members and N-oxides of tertiary nitrogen ring members, and carbocyclic fused, preferably 3-6 ring carbon atoms and more preferably 5-6 ring carbon atoms, and benzo fused ring systems. "Heterocyclyl" radicals may optionally be substituted on at least one, preferably 1-4, more preferably 1-3, even more preferably 1-2, carbon atoms by halogen, alkyl, alkoxy, hydroxy, oxo, thioxo, aryl, aralkyl, heteroaryl, heteroaralkyl, amidino, N-alkylamidino, alkoxycarbonylamino, alkylsulfonylamino and the like, and/or on a secondary nitrogen atom by hydroxy, alkyl, aralkoxycarbonyl, alkanoyl, alkoxycarbonyl, heteroaralkyl, aryl or aralkyl radicals. More preferably, "heterocyclyl", alone or in combination, is a radical of a monocyclic or bicyclic saturated heterocyclic ring system having 5-8 ring members per ring, wherein 1-3 ring members are oxygen, sulfur or nitrogen heteroatoms, which is optionally partially unsaturated or benzo-fused and optionally substituted by 1-2 oxo or thioxo radicals. Examples of such heterocyclyl radicals include pyrrolidinyl, piperidinyl, piperazinyl, morpholynyl, thiamorpholynyl, 4-benzyl-piperazin-1-yl, pyrimidinyl, tetrahydrofuryl, pyrazolidonyl, pyrazolynyl, pyridazinonyl, pyrrolidonyl, tetrahydrothienyl and its sulfoxide and sulfone derivatives, 2,3-dihydroindolyl, tetrahydroquinolynyl, 1,2,3,4-tetrahydroisoquinolynyl, 1,2,3,4-tetrahydro-1-oxo-isoquinolynyl, 2,3-dihydrobenzofuryl, benzopyranyl, methylenedioxyphenyl, ethylenedioxyphenyl and the like.

"Heteroaryl" means a monocyclic or bicyclic, preferably monocyclic, aromatic heterocycle radical, having at least one, preferably 1 to 4, more preferably 1 to 3, even more preferably 1-2, nitrogen, oxygen or sulfur atom ring members and having preferably 5-6 ring members in each ring, which is optionally saturated carbocyclic fused, preferably 3-4 carbon atoms (C_3-C_4) to form 5-6 ring membered rings and which is optionally substituted as defined above with respect to the definitions of aryl. Examples of such heteroaryl groups include imidazolyl, 1-benzoyloxycarbonylimidazol-4-yl, pyrrolyl, pyrazolyl, pyridyl, 3-(2-methyl)pyridyl, 3-(4-trifluoromethyl)pyridyl, pyrimidinyl, 5-(4-trifluorome-

thyl)pyrimidinyl, pyrazinyl, triazolyl, furyl, thienyl, oxazolyl, thiazolyl, indolyl, quinolinyl, 5,6,7,8-tetrahydroquinolyl, 5,6,7,8-tetrahydroisoquinolinyl, quinoxalyl, benzothiazolyl, benzofuryl, benzimidazolyl, benzoxazolyl and the like.

"Heteroaralkyl" and "heteroarylalkyl," alone or in combination, means an alkyl radical as defined above in which at least one hydrogen atom, preferably 1-2, is replaced by a heteroaryl radical as defined above, such as 3-furylpropyl, 2-pyrrolyl propyl, chloroquinolinylmethyl, 2-thienylethyl, pyridylmethyl, 1-imidazolylethyl and the like.

"Halogen" and "halo", alone or in combination, means fluoro, chloro, bromo or iodo radicals.

"Haloalkyl", alone or in combination, means an alkyl radical as defined above in which at least one hydrogen atom, preferably 1-3, is replaced by a halogen radical, more preferably fluoro or chloro radicals. Examples of such haloalkyl radicals include 1,1,1-trifluoroethyl, chloromethyl, 1-bromoethyl, fluoromethyl, difluoromethyl, trifluoromethyl, bis(trifluoromethyl)methyl and the like.

"Pharmacologically acceptable salt" means a salt prepared by conventional means, and are well known by those skilled in the art. The "pharmacologically acceptable salts" include basic salts of inorganic and organic acids, including but not limited to hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, ethanesulfonic acid, malic acid, acetic acid, oxalic acid, tartaric acid, citric acid, lactic acid, fumaric acid, succinic acid, maleic acid, salicylic acid, benzoic acid, phenylacetic acid, mandelic acid and the like. When compounds of the invention include an acidic function such as a carboxy group, then suitable pharmaceutically acceptable cation pairs for the carboxy group are well known to those skilled in the art and include alkaline, alkaline earth, ammonium, quaternary ammonium cations and the like. For additional examples of "pharmacologically acceptable salts," see *infra* and Berge et al, J. Pharm. Sci. 66, 1 (1977).

"Cytokine" means a secreted protein that affects the functions of other cells, particularly as it relates to the modulation of interactions between cells of the immune system or cells involved in the inflammatory response. Examples of cytokines include but are not limited to interleukin 1 (IL-1), preferably IL-1 β , interleukin 6 (IL-6), interleukin 8 (IL-8) and TNF, preferably TNF- α (tumor necrosis factor- α).

"TNF, IL-1, IL-6, and/or IL-8 mediated disease or disease state" means all disease states wherein TNF, IL-1, IL-6, and/or IL-8 plays a role, either directly as TNF, IL-1, IL-6, and/or IL-8 itself, or by TNF, IL-1, IL-6, and/or IL-8 inducing another cytokine to be released. For example, a disease state in which IL-1 plays a major role, but in which the production of or action of IL-1 is a result of TNF, would be considered mediated by TNF.

"Leaving group" generally refers to groups readily displaceable by a nucleophile, such as an amine, a thiol or an alcohol nucleophile. Such leaving groups are well known in the art. Examples of such leaving groups include, but are not limited to, N-hydroxysuccinimide, N-hydroxybenzotriazole, halides, triflates, tosylates and the like. Preferred leaving groups are indicated herein where appropriate.


"Protecting group" generally refers to groups well known in the art which are used to prevent selected reactive groups, such as carboxy, amino, hydroxy, mercapto and the like, from undergoing undesired reactions, such as nucleophilic, electrophilic, oxidation, reduction and the like. Preferred protecting groups are indicated herein where appropriate. Examples of amino protecting groups include, but are not limited to, aralkyl, substituted aralkyl, cycloalkenylalkyl and substituted cycloalkenyl alkyl, allyl, substituted allyl, acyl, alkoxycarbonyl, aralkoxycarbonyl, silyl and the like. Examples of aralkyl include, but are not limited to, benzyl, ortho-methylbenzyl, trityl and benzhydryl, which can be optionally substituted with halogen, alkyl, alkoxy, hydroxy, nitro, acylamino, acyl and the like, and salts, such as phosphonium and ammonium salts. Examples of aryl groups include phenyl, naphthyl, indanyl, anthracenyl, 9-(9-phenylfluorenyl), phenanthrenyl, durenyl and the like. Examples of cycloalkenylalkyl or substituted cycloalkenylalkyl radicals, preferably have 6-10 carbon atoms, include, but are not limited to, cyclohexenyl methyl and the like. Suitable acyl, alkoxycarbonyl and aralkoxycarbonyl groups include benzyloxycarbonyl, t-butoxycarbonyl, iso-butoxycarbonyl, benzoyl, substituted benzoyl, butyryl, acetyl, tri-fluoroacetyl, tri-chloro acetyl, phthaloyl and the like. A mixture of protecting groups can be used to protect the same amino group, such as a primary amino group can be protected by both an aralkyl group and an aralkoxycarbonyl group. Amino protecting groups can also form a heterocyclic ring with the nitrogen to which they are attached, for example, 1,2-bis(methylene)benzene, phthalimidyl, succinimidyl, maleimidyl and the like and where these heterocyclic groups can further include adjoining aryl and cycloalkyl rings. In addition, the heterocyclic groups can be mono-, di- or tri-substituted, such as nitrophthalimidyl. Amino groups may also be protected against undesired reactions, such as oxidation, through the formation of an addition salt, such as hydrochloride, toluenesulfonic acid, trifluoroacetic acid and the like. Many of the amino

protecting groups are also suitable for protecting carboxy, hydroxy and mercapto groups. For example, aralkyl groups. Alkyl groups are also suitable groups for protecting hydroxy and mercapto groups, such as tert-butyl.

[0031] Silyl protecting groups are silicon atoms optionally substituted by one or more alkyl, aryl and aralkyl groups. Suitable silyl protecting groups include, but are not limited to, trimethylsilyl, triethylsilyl, tri-isopropylsilyl, tertbutyldimethylsilyl, dimethylphenylsilyl, 1,2-bis(dimethylsilyl)benzene, 1,2-bis(dimethylsilyl)ethane and diphenyldimethylsilyl. Silylation of an amino groups provide mono- or di-silylamino groups. Silylation of aminoalcohol compounds can lead to a N,N,O-tri-silyl derivative. Removal of the silyl function from a silyl ether function is readily accomplished by treatment with, for example, a metal hydroxide or ammonium fluoride reagent, either as a discrete reaction step or in situ during a reaction with the alcohol group. Suitable silylating agents are, for example, trimethylsilyl chloride, tert-butyldimethylsilyl chloride, phenyldimethylsilyl chloride, diphenyldimethyl silyl chloride or their combination products with imidazole or DMF. Methods for silylation of amines and removal of silyl protecting groups are well known to those skilled in the art. Methods of preparation of these amine derivatives from corresponding amino acids, amino acid amides or amino acid esters are also well known to those skilled in the art of organic chemistry including amino acid/amino acid ester or aminoalcohol chemistry.

[0032] Protecting groups are removed under conditions which will not affect the remaining portion of the molecule. These methods are well known in the art and include acid hydrolysis, hydrogenolysis and the like. A preferred method involves removal of a protecting group, such as removal of a benzyloxycarbonyl group by hydrogenolysis utilizing palladium on carbon in a suitable solvent system such as an alcohol, acetic acid, and the like or mixtures thereof. A t-butoxycarbonyl protecting group can be removed utilizing an inorganic or organic acid, such as HCl or trifluoroacetic acid, in a suitable solvent system, such as dioxane or methylene chloride. The resulting amino salt can readily be neutralized to yield the free amine. Carboxy protecting group, such as methyl, ethyl, benzyl, tert-butyl, 4-methoxyphenylmethyl and the like, can be removed under hydrolysis and hydrogenolysis conditions well known to those skilled in the art.

[0033] The symbols used above have the following meanings:



[0034] Procedures for preparing the compounds of this invention are set forth below. It should be noted that the general procedures are shown as it relates to preparation of compounds having unspecified stereochemistry. However, such procedures are generally applicable to those compounds of a specific stereochemistry, e.g., where the stereochemistry about a group is (S) or (R). In addition, the compounds having one stereochemistry (e.g., (R)) can often be utilized to produce those having opposite stereochemistry (i.e., (S)) using well-known methods, for example, by inversion.


Preparation of Compounds of Formula I

[0035] The compounds of the present invention represented by Formula I above can be prepared utilizing the following general procedures. Hetero-aromatic Nitrogen Compounds; Pyrroles and Pyridines: Schofield, Kenneth; Plenum Press, New York, NY; (1967) and Advances in Nitrogen Heterocycles: JAI Press, Greenwich, CN; (1995) describe procedures

and references that may be useful in preparing compounds of the present invention.


[0036] 2-Halo-5-nitro-pyridine analogs (2) can be treated with the appropriate amine, alcohol, phenol, or thiol (R^1 -X-H) in the presence of base or Cu(I) in an appropriate solvent, such as THF, DMF, DME, DMSO and the like, at a temperature from -20°C to 120°C to form 2-substituted-5-nitropyridines (3) (Scheme I). Reduction of the nitro group can be performed by treatment of (3) with hydrogen gas in the presence of palladium on carbon or Raney nickel, or alternatively, by treatment with SnCl_2 in an alcoholic solvent and in the presence or absence of HCl to obtain 2-substituted-5-aminopyridines (4). The aminopyridines (4) may be alkylated using alkylhalides and an appropriate base or by reductive alkylation employing the appropriate aldehyde or ketone in the presence of a reducing agent, such as sodium triacetoxy borohydride, borane-THF and the like, to form the substituted aminopyridines (5). Either (4) or (5) may be acylated with an appropriate acid halide (e.g., $R^3\text{C}(\text{O})\text{Cl}$ or $R^3\text{C}(\text{O})\text{Br}$) in the presence of a base, such as pyridine, DMAP and the like, or alternatively may be acylated with an anhydride, either mixed or symmetrical, or alternatively may be acylated by treatment with the appropriate acid ($R^3\text{CO}_2\text{H}$) in the presence of a coupling agent such as a carbodiimide reagent to form the final product (1). Alternatively, substituted 2-bromo-5-nitropyridine analogs may be reduced to, substituted 2-bromo-5-aminopyridine analogs by the action of SnBr_2 in methanolic solvent. Subsequent acylation with an appropriate activated ester (i.e.: $R^3\text{CO}_2\text{H}$ in the presence of diisopropylcarbodiimide in methylene chloride as solvent) produces 2-bromopyridine-5-carboxamide compounds of structure (5a). Coupling of (5a) with an appropriate phenol in the presence of $\text{Cu}(\text{Ac})_2$ and K_2CO_3 in DMF at 140°C provides compounds of formula (1) where $\text{X} = \text{O}$.

SCHEME I



[0037] 6-Substituted-2-halo-5-nitro-pyridine analogs (6) may be prepared from 2,6-dichloro-5-nitropyridine according to the methods outlined in Scheme II. Treatment with one equivalent of an appropriate nucleophile of R^7 or a precursor thereof (such as, HO^- , RO^- , AcS^- , NC^- , RS^- and the like) provides (6). Subsequent reaction to form (7) (treatment with R^1 -X-H in the presence of base or Cu(I) in an appropriate solvent, such as THF, DMF, DME, DMSO and the like, at a temperature from -20°C to 120°C) and (8) (reduction of the nitro group and substitution with R^4) is as described in Scheme I (cf. Colbry, N.L. et al.; J. Heterocyclic Chem., 21: 1521-1525 (1984); Matsumoto, Jun-ichi, et al.; J. Heterocyclic Chem., 21: 673-679 (1984)). (8) may be reacted with an acid halide or an activated

SCHEME II




ester as shown in Scheme I to provide compounds of formula (1). Where $R^7 = CN$, compounds of formula (8) may be hydrolyzed to acids ($R^7 = CO_2H$) of formula (9) using acidic media such as HBr and the like. Utilizing the appropriate N-protecting groups, acids of formula (9) may be transformed into esters, amides and alcohols. Compounds of formula (9) and derivatives described above may be reacted with an acid halide or an activated ester as shown in Scheme I to provide compounds of formula (1). Compounds of formula (8), where $R^7 = -CN$, may be reduced to the primary amine ($R^7 = -CH_2NH_2$) using reagents such as BH_3 or hydrogen gas in the presence of palladium on carbon or Raney nickel. Subsequent manipulation and reaction of the primary amine may be performed in the presence of the pyridine-5-amine substituent due to its greater reactivity. Specifically, compounds of formula (8) where $R^7 = -CH_2NH_2$ may be alkylated by treatment with an appropriate aldehyde or ketone in the presence of a reducing agent, such as sodium triacetoxy borohydride, or may be acylated by treatment with an appropriate activated ester, chloroformate, isocyanate and the like, or may be sulfonylated by treatment with an appropriate sulfonyl halide. Alternatively, substituted 3-aminopyridine intermediates may be prepared from the corresponding nicotinamide compound using Hofmann's reaction.

[0038] When R^6 and/or R^7 is an alkyl group, such as methyl, in compound (7), containing the appropriate protecting groups of or avoiding the presence of base sensitive groups, can be treated with strong base such as $NaNH_2$, $PhLi$, NaH or the like at temperatures from $-78^\circ C$ to $22^\circ C$ then treated with electrophiles, such as alkyl halides, aldehydes, ketones and the like (cf. Fuerst, Feustel; CHEMTECH; 10: 693-699 (1958); Nishigaki, S. et al.; Chem. Pharm. Bull.; 17: 1827-1831 (1969); Kaiser, Edwin M.; Tetrahedron; 39: 2055-2064 (1983)). Alternatively, the alkyl group may be halo-

genated and the haloalkyl group may be reacted with a nucleophile, such as an amino group, alkoxy, alkylthiol and the like.

[0039] 6-Chloronicotinoyl chloride analogs (10) are treated with the appropriate amine (R^3R^4NH) in the presence of base in an appropriate solvent, such as dichloromethane, acetonitrile, DMF, THF and the like, at a temperature from -20°C to 120°C to form nicotinamides (11) as shown in Scheme III. Alternatively, 6-chloronicotinic acid analogs (12) may be coupled with the appropriate amine via an anhydride, either mixed or symmetrical, or alternatively by treatment with the appropriate amine in the presence of a coupling agent such as a carbodiimide reagent to form the amide (11). 6-Chloronicotinamide analogs (11) are treated with the appropriate $R^1\text{-X-H}$ in the presence of absence of base, or Cu(I) in an appropriate solvent, such as pyridine, ethylene glycol, DMF, DME, DMSO and the like, at a temperature from -20°C to 180°C to form the final product (13).

SCHEME III



[0040] Substituted halopyridines may be readily prepared from the corresponding pyridones using phosphorus oxychloride or pentachloride.

[0041] Amines of formula NHR^1R^2 and NHR^3R^4 are commercially available or can be readily prepared by those skilled in the art from commercially available starting materials. For example, an amide, nitro or cyano group can be reduced under reducing conditions, such as in the presence of a reducing agent like lithium aluminum hydride and the like, to form the corresponding amine. Alkylation and acylation of amino groups are well known in the art. Chiral and achiral substituted amines can be prepared from chiral amino acids and amino acid amides (for example, alkyl, aryl, heteroaryl, cycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl and the like) using methods well known in the art, such as H. Brunner, P. Hankofer, U. Holzinger, B. Treitinger and H. Schoenenberger, Eur. J. Med. Chem. 25, 35-44, 1990; M. Freiburger and R. B. Hasbrouck, J. Am. Chem. Soc. 82, 696-698, 1960; Dornow and Fust, Chem. Ber. 87, 984, 1954; M. Kojima and J. Fujita, Bull. Chem. Soc. Jpn. 55, 1454-1459, 1982; W. Wheeler and D. O'Bannon, Journal of Labelled Compounds and Radiopharmaceuticals XXXI, 306, 1992; and S. Davies, N. Garrido, O. Ichihara and I. Walters, J. Chem. Soc., Chem. Commun. 1153, 1993.

[0042] Alkyl sulfonic acids, aryl sulfonic acids, heterocyclyl sulfonic acids, heteroaryl sulfonic acids, alkylmercaptans, arylmercaptans, heterocyclylmercaptans, heteroarylmercaptans, alkylhalides, arylhalides, heterocyclylhalides, heteroarylhalides, and the like are commercially available or can be readily prepared from starting materials commercially available using standard methods well known in the art.

[0043] Thioether derivatives can be converted into the corresponding sulfone or sulfoxide by oxidizing the thioether derivative with a suitable oxidation agent in a suitable solvent. Suitable oxidation agents include, for example, hydrogen peroxide, sodium meta-perborate, oxone (potassium peroxy monosulfate), meta-chloroperoxybenzoic acid, periodic acid and the like, including mixtures thereof. Suitable solvents include acetic acid (for sodium meta-perborate) and, for other peracids, ethers such as THF and dioxane, and acetonitrile, DMF and the like, including mixtures thereof.

[0044] The chemical reactions described above are generally disclosed in terms of their broadest application to the preparation of the compounds of this invention. Occasionally, the reactions may not be applicable as described to each


compound included within the disclosed scope. The compounds for which this occurs will be readily recognized by those skilled in the art. In all such cases, either the reactions can be successfully performed by conventional modifications known to those skilled in the art, e.g., by appropriate protection of interfering groups, by changing to alternative conventional reagents, by routine modification of reaction conditions, and the like, or other reactions disclosed herein or otherwise conventional, will be applicable to the preparation of the corresponding compounds of this invention. In all preparative methods, all starting materials are known or readily prepared from known starting materials.

[0045] Prodrugs of the compounds of this invention are also contemplated by this invention. A prodrug is an active or inactive compound that is modified chemically through in vivo physiological action, such as hydrolysis, metabolism and the like, into a compound of this invention following administration of the prodrug to a patient. The suitability and techniques involved in making and using prodrugs are well known by those skilled in the art. For a general discussion of prodrugs involving esters see Svensson and Tunek Drug Metabolism Reviews 165 (1988) and Bundgaard Design of Prodrugs, Elsevier (1985). Examples of a masked carboxylate anion include a variety of esters, such as alkyl (for example, methyl, ethyl), cycloalkyl (for example, cyclohexyl), aralkyl (for example, benzyl, p-methoxybenzyl), and alkylcarbonyloxyalkyl (for example, pivaloyloxymethyl). Amines have been masked as arylcarbonyloxymethyl substituted derivatives which are cleaved by esterases in vivo releasing the free drug and formaldehyde (Bundgaard J. Med. Chem. 2503 (1989)). Also, drugs containing an acidic NH group, such as imidazole, imide, indole and the like, have been masked with N-acyloxymethyl groups (Bundgaard Design of Prodrugs, Elsevier (1985)). Hydroxy groups have been masked as esters and ethers. EP 039, 051 (Sloan and Little, 4/11/81) discloses Mannich-base hydroxamic acid prodrugs, their preparation and use.

[0046] Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following preferred specific embodiments in accordance with the present invention are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever. The following examples in accordance with the invention illustrate the preparation of compounds of the present invention and intermediates useful in preparing the compounds of the present invention. Subject matter which does not form part of the invention, as claimed, is referred to in the examples for reference purposes only.

Example 1

[0047]



Preparation of 2-(4-Chloro-2-methyl-phenoxy)-5-amino-pyridine

Step A: 2-(4-Chloro-2-methyl-phenoxy)-5-nitropyridine

[0048] 4-Chloro-2-methylphenol (101 mg, 0.71 mmol) was dissolved in tetrahydrofuran (2.1 mL) and the solution was treated with sodium hydride (60% dispersed in mineral oil, 31 mg, 0.78 mmol). After stirring for 30 minutes at 22°C, 2-chloro-5-nitropyridine (101 mg, 0.64 mmol) was added and the reaction mixture was heated to reflux for 1 hour. The solution was cooled to ambient temperature, quenched with saturated aqueous NH_4Cl and concentrated *in vacuo*. The residue was redissolved in ethyl acetate then washed 2x with saturated NaHCO_3 , saturated NaCl , dried over anhydrous Na_2SO_4 and concentrated *in vacuo*.

Step B: 2-(4-Chloro-2-methyl-phenoxy)-5-amino-pyridine

[0049] 2-(4-chloro-2-methyl-phenoxy)-5-nitropyridine (203 mg, 0.77 mmol) was dissolved in 95% ethanol (3 mL) and treated with 20% palladium hydroxide on carbon (50 mg). The reaction mixture was shaken in a hydrogen atmosphere (40 psi) for 1 hour. The solution was filtered through celite and concentrated *in vacuo*. MS (*m/z*): 234/236 ($\text{M}+\text{H}^+$); $\text{C}_{12}\text{H}_{11}\text{N}_2\text{OCl}$ requires 234.7.

Example 2

[0050] The compounds listed in Table 1 were prepared from 2-chloro-5-nitropyridine and the appropriate alcohol,


amine or thiol in the same manner as 2-(4-Chloro-2-methyl-phenoxy)-5-amino-pyridine was prepared.

Table 1

		MS (m/z)
5	2-(4-Chloro-2-methylphenoxy)-5-amino-pyridine	235
	2-(4-Chloro-2,6-dimethylphenoxy)-5-amino-pyridine	249
	2-(2-Methyl-pyridin-3-yloxy)-5-amino-pyridine	201
10	2-(4-Fluoro-2-methylphenoxy)-5-amino-pyridine	218
	2-(2-Isopropylphenoxy)-5-amino-pyridine	228
	2-(1-Naphthyloxy)-5-amino-pyridine	236
	2-(Cyclohexyloxy)-5-amino-pyridine	192
	2-(2-Methylphenoxy)-5-amino-pyridine	200
15	2-(2,4-Dimethylphenoxy)-5-amino-pyridine	214
	2-(4-Chlorophenoxy)-5-amino-pyridine	222
	2-(Phenoxy)-5-amino-pyridine	186
	2-(2-Methylcyclohexylamino)-5-amino-pyridine	205
20	2-(Cyclohexylamino)-5-amino-pyridine	191
	2-(2-Methylanilino)-5-amino-pyridine	199
	2-(4-Chloro-2-methylanilino)-5-amino-pyridine	233
	2-(2,4-Dimethylanilino)-5-amino-pyridine	212
25	2-(4-Chloro-2-methylthiophenoxy)-5-amino-pyridine	251

Example 3

[0051]



Preparation of 2-(4-Chloro-2-methyl-phenoxy)-3-methyl-5-amino-pyridine

Step A: 2-(4-Chloro-2-methyl-phenoxy)-3-methyl-5-nitropyridine

[0052] Sodium hydride (60% in mineral oil, 1.08 g, 27 mmol) was washed 3x with hexanes then a solution of 4-chloro-2-methylphenol (3.50 g, 24.5 mmol) dissolved in tetrahydrofuran (40 mL) was added. The solution was stirred for 20 minutes then 2-chloro-3-methyl-5-nitropyridine (4.02 g, 23.3 mmol) was added and the reaction mixture was heated to reflux for 3 hours. After cooling, the mixture was concentrated *in vacuo* then dissolved in ethyl acetate and washed with water, 3x with saturated NaHCO₃ and saturated NaCl then dried over Na₂SO₄ and concentrated *in vacuo*.

Step B: 2-(4-Chloro-2-methyl-phenoxy)-3-methyl-5-aminopyridine

[0053] 2-(4-chloro-2-methyl-phenoxy)-3-methyl-5-nitropyridine (5.8 g, 20.8 mmol) was dissolved in 95% ethanol (50 mL) and treated with 20% palladium hydroxide on carbon (350 mg). The reaction mixture was shaken in a hydrogen atmosphere (40 psi) for 1 hour. The solution was filtered through celite and concentrated *in vacuo* followed by chromatography on SiO₂ using 1:1 ethyl acetate / hexanes as eluant. MS (m/z): 248/250 (M+H)⁺; C₁₃H₁₃N₂OCl requires 248.7.

Example 4

[0054] The compounds listed in Table 2 were prepared from substituted 2-chloro-5-nitropyridine and 4-chloro-2-meth-


ylphenol in the same manner as 2-(4-Chloro-2-methylphenoxy)-3-methyl-5-amino-pyridine was prepared.

Table 2

	MS (m/z)
2-(4-Chloro-2-methyl-phenoxy)-4-methyl-5-amino-pyridine	249
6-(4-Chloro-2-methyl-phenoxy)-2-methyl-3-amino-pyridine	249
6-(4-Chloro-2-methyl-phenoxy)-2,3-diamino-pyridine	250

Example 5

[0055]



Preparation of N-(2-(4-Chloro-2-methyl-phenoxy)-pyridin-5-yl)-benzamide

[0056] 2-(4-Chloro-2-methyl-phenoxy)-5-aminopyridine (211 mg, 0.90 mmol) was dissolved in methylene chloride (2.7 mL) then treated with triethylamine (0.19 mL, 1.35 mmol) followed by benzoyl chloride (0.13 mL, 1.12 mmol). The reaction mixture was stirred for 3 hours at 22°C then saturated aqueous NaHCO₃ was added and the mixture was stirred for another hour. The organic layer was separated and washed 2x with 6% aqueous NaHCO₃, dried over Na₂SO₄ and concentrated in vacuo. The residue was chromatographed on silica gel using 1:1 ethyl acetate /hexane as eluent. The product was recovered as a white solid. MS (m/z): 338/340 (M+H)⁺; C₁₉H₁₅N₂O₂Cl requires 338.8.

Example 6

[0057] The compounds listed in Table 3 were prepared from substituted 5-aminopyridine compounds and the appropriate acid chloride in the same manner as N-(2-(4-Chloro-2-methyl-phenoxy)-pyridin-5-yl)-benzamide was prepared.

Table 3

	MS (m/z)
2-(4-Chloro-2-methyl-phenoxy)-5-(3-pyridylcarbonylamino)pyridine	340
2-(4-Chloro-2-methyl-phenoxy)-5-((2,6-dichlorophenyl)carbonylamino)pyridine	408
2-(4-Chloro-2-methyl-phenoxy)-5-(4-pyridylcarbonylamino)pyridine	340
2-(4-Chloro-2-methyl-phenoxy)-5-((4-methoxyphenyl)carbonylamino)pyridine	369
2-(4-Chloro-2-methyl-phenoxy)-5-((4-pentylphenyl)carbonylamino)pyridine	409
2-(4-Chloro-2-methyl-phenoxy)-5-(2-naphthylcarbonylamino)pyridine	389
2-(4-Chloro-2-methyl-phenoxy)-5-(2-thienylcarbonylamino)pyridine	345
2-(4-Chloro-2-methyl-phenoxy)-5-((3,5-dimethyl-4-isoxazolyl)carbonylamino)pyridine	358
2-(4-Chloro-2-methyl-phenoxy)-5-((5-benzo[1,3]dioxol-yl)carbonylamino)pyridine	383
2-(4-Chloro-2-methyl-phenoxy)-5-((5-tert-butyl-2-methyl-2H-pyrazol-3-yl)carbonylamino)pyridine	399
2-(4-Chloro-2-methyl-phenoxy)-5-((2-benzo[b]thiophenyl)carbonylamino)pyridine	395
2-(4-Chloro-2-methyl-phenoxy)-5-((2-methoxyphenyl)carbonylamino)pyridine	369
2-(4-Chloro-2-methyl-phenoxy)-5-((3,5-dichlorophenyl)carbonylamino)pyridine	408
2-(4-Chloro-2-methyl-phenoxy)-5-((2,6-dimethylphenyl)carbonylamino)pyridine	367
2-(4-Chloro-2-methyl-phenoxy)-5-((2-methylphenyl)carbonylamino)pyridine	353
2-(4-Chloro-2-methyl-phenoxy)-5-((2-nitrophenyl)carbonylamino)pyridine	384
2-(4-Chloro-2-methyl-phenoxy)-5-((2-acetoxyphenyl)carbonylamino)pyridine	397

EP 1 028 945 B9

(continued)

		MS (m/z)
5	2-(4-chloro-2,6-dimethylphenoxy)-5-((2,6-dichlorophenyl)carbonylamino)pyridine	422
	2-(4-chloro-2,6-dimethylphenoxy)-5-((2,6-dimethylphenyl)carbonylamino)pyridine	381
	2-(2-methyl-pyridin-3-yloxy)-5-((2,6-dichlorophenyl)carbonylamino)pyridine	374
	2-(2-methyl-pyridin-3-yloxy)-5-((2,6-dimethylphenyl)carbonylamino)pyridine	333
	2-(2-methyl-pyridin-3-yloxy)-5-((2-methylphenyl)carbonylamino)pyridine	319
10	2-(4-fluoro-2-methylphenoxy)-5-((2,6-dichlorophenyl)carbonylamino)pyridine	391
	2-(4-fluoro-2-methylphenoxy)-5-((2,6-dimethylphenyl)carbonylamino)pyridine	350
	2-(4-fluoro-2-methylphenoxy)-5-((2-methylphenyl)carbonylamino)pyridine	336
	2-(4-fluoro-2-methylphenoxy)-5-((2-trifluoromethylphenyl)carbonylamino)pyridine	390
15	2-(4-fluoro-2-methylphenoxy)-5-((2-fluorophenyl)carbonylamino)pyridine	340
	2-(2-isopropylphenoxy)-5-((2,6-dichlorophenyl)carbonylamino)pyridine	401
	2-(2-isopropylphenoxy)-5-((2,6-dimethylphenyl)carbonylamino)pyridine	360
	2-(2-isopropylphenoxy)-5-((2-methylphenyl)carbonylamino)pyridine	346
	2-(1-naphthyloxy)-5-((2,6-dichlorophenyl)carbonylamino)pyridine	409
20	2-(1-naphthyloxy)-5-((2,6-dimethylphenyl)carbonylamino)pyridine	368
	2-(1-naphthyloxy)-5-((2-methylphenyl)carbonylamino)pyridine	354
	2-(cyclohexyloxy)-5-((2,6-dichlorophenyl)carbonylamino)pyridine	365
	2-(cyclohexyloxy)-5-((2,6-dimethylphenyl)carbonylamino)pyridine	324
25	2-(cyclohexyloxy)-5-((2-chlorophenyl)carbonylamino)pyridine	331
	2-(cyclohexyloxy)-5-((2-methylphenyl)carbonylamino)pyridine	310
	2-(2-methylphenoxy)-5-((2,6-dichlorophenyl)carbonylamino)pyridine	373
	2-(2-methylphenoxy)-5-((2,6-dimethylphenyl)carbonylamino)pyridine	332
	2-(2-methylphenoxy)-5-((2-chlorophenyl)carbonylamino)pyridine	339
30	2-(2-methylphenoxy)-5-((2-methylphenyl)carbonylamino)pyridine	318
	2-(2,4-dimethylphenoxy)-5-((2,6-dichlorophenyl)carbonylamino)pyridine	387
	2-(2,4-dimethylphenoxy)-5-((2,6-dimethylphenyl)carbonylamino)pyridine	346
	2-(2,4-dimethylphenoxy)-5-((2-chlorophenyl)carbonylamino)pyridine	353
	2-(2,4-dimethylphenoxy)-5-((2-methylphenyl)carbonylamino)pyridine	332
35	2-(4-chlorophenoxy)-5-((2,6-dichlorophenyl)carbonylamino)pyridine	394
	2-(4-chlorophenoxy)-5-((2,6-dimethylphenyl)carbonylamino)pyridine	353
	2-(2-methylcyclohexylamino)-5-((2,6-dichlorophenyl)carbonylamino)pyridine	378
	2-(2-methylcyclohexylamino)-5-((2-methylphenyl)carbonylamino)pyridine	323
40	2-(cyclohexylamino)-5-((2,6-dichlorophenyl)carbonylamino)pyridine	364
	2-(cyclohexylamino)-5-((2,6-dimethylphenyl)carbonylamino)pyridine	323
	2-(cyclohexylamino)-5-((2-methylphenyl)carbonylamino)pyridine	309
	2-(2-methylanilino)-5-((2,6-dichlorophenyl)carbonylamino)pyridine	372
	2-(2-methylanilino)-5-((2,6-dimethylphenyl)carbonylamino)pyridine	331
45	2-(2-methylanilino)-5-((2-methylphenyl)carbonylamino)pyridine	317
	2-(4-chloro-2-methylanilino)-5-((2,6-dichlorophenyl)carbonylamino)pyridine	407
	2-(4-chloro-2-methylanilino)-5-((2,6-dimethylphenyl)carbonylamino)pyridine	366
	2-(4-chloro-2-methylanilino)-5-((2-methylphenyl)carbonylamino)pyridine	352
50	2-(2,4'-dimethylanilino)-5-((2,6-dichlorophenyl)carbonylamino)pyridine	386
	2-(2,4-dimethylanilino)-5-((2,6-dimethylphenyl)carbonylamino)pyridine	345
	2-(2,4-dimethylanilino)-5-((2-methylphenyl)carbonylamino)pyridine	331
	2-(2,4-dimethylanilino)-5-((2-chlorophenyl)carbonylamino)pyridine	352
	2-(2,4-dimethylanilino)-5-((2-fluorophenyl)carbonylamino)pyridine	335
55	2-(4-chloro-2-methyl-thiophenyl)-5-((2,6-dichlorophenyl)carbonylamino)pyridine	424
	2-(4-chloro-2-methyl-thiophenyl)-5-((2,6-dimethylphenyl)carbonylamino)pyridine	383
	2-(4-chloro-2-methyl-thiophenyl)-5-((2-methylphenyl)carbonylamino)pyridine	369

Example 7


[0058] The compounds listed in Table 4 were prepared from substituted 5-aminopyridine compounds and the appropriate acid chloride in the same manner as N-(2-(4-Chloro-2-methyl-phenoxy)-pyridin-5-yl)-benzamide was prepared.

Table 4

	MS (m/z)
2-(4-Chloro-2-methyl-phenoxy)-5-((2,6-dichlorophenyl)carbonylamino)-3-methyl-pyridine	422
2-(4-Chloro-2-methyl-phenoxy)-5-((2-chlorophenyl)carbonylamino)-3-methyl-pyridine	387
2-(4-Chloro-2-methyl-phenoxy)-5-((2-methylphenyl)carbonylamino)-3-methyl-pyridine	367
2-(4-Chloro-2-methyl-phenoxy)-5-((2,6-dimethylphenyl) carbonylamino)-3-methyl-pyridine	332
2-(4-Chloro-2-methyl-phenoxy)-5-((2,6-dichlorophenyl)carbonylamino)-4-methyl-pyridine	422
2-(4-Chloro-2-methyl-phenoxy)-5-((2-fluoro-6-trifluoromethylphenyl)carbonylamino)-4-methylpyridine	439
2-(4-Chloro-2-methyl-phenoxy)-5-((2,4,6-triisopropylphenyl)carbonylamino)-4-methylpyridine	479
2-(4-Chloro-2-methyl-phenoxy)-5-((2-methylphenyl)carbonylamino)-6-methyl-pyridine	367
2-(4-Chloro-2-methyl-phenoxy)-5-((2-chlorophenyl)carbonylamino)-6-methyl-pyridine	387
2-(4-Chloro-2-methyl-phenoxy)-5-((2,6-dichlorophenyl)carbonylamino)-6-methyl-pyridine	422
2-(4-Chloro-2-methyl-phenoxy)-5-((2,6-dichlorophenyl)carbonylamino)-6-amino-pyridine	423
2-(4-Chloro-2-methyl-phenoxy)-5-((2-chlorophenyl)carbonylamino)-6-amino-pyridine	388
2-(4-Chloro-2-methyl-phenoxy)-5-((2,6-dimethylphenyl) carbonylamino)-6-amino-pyridine	382
2-(4-Chloro-2-methyl-phenoxy)-5-((2-methylphenyl)carbonylamino)-6-amino-pyridine	368

Example 8

[0059]




Preparation of 2-Amino-N-(6-(4-chloro-2-methyl-phenoxy)-pyridin-3-yl)-benzamide

[0060] N-(6-(4-chloro-2-methyl-phenoxy)-pyridin-3-yl)-2-nitrobenzamide (301 mg, 0.7 mmol) was dissolved in 95% ethanol (4 mL) and treated with 20% palladium hydroxide on carbon (Pearlman's catalyst, 50 mg) and subjected to a hydrogen atmosphere (40 psi) for 2 hours. The catalyst was removed by filtration and the solvents were removed *in vacuo*. The product was purified by chromatography on SiO₂ using 1:1 ethyl acetate / hexanes as eluent. MS (*m/z*): 353/355 (M+H)⁺; C₁₉H₁₆N₃O₂Cl requires 353.8.


Example 9

[0061]



preparation of N-(6-(4-chloro-2-methyl-phenoxy)-pyridin-3-yl)-2-hydroxy-benzamide

[0062] Acetic acid 2-(6-(4-chloro-2-methyl-phenoxy)-pyridin-3-ylcarbamoyl)-phenyl ester (304 mg, 0.77 mmol) dissolved in tetrahydrofuran (3.8 mL) was treated with an aqueous lithium hydroxide solution (1.0 M, 3.8 mL, 3.8 mmol). The solution was stirred for 30 minutes at 22°C then quenched with aqueous saturated NH_4Cl . The mixture was diluted with ethyl acetate then the organics were washed with water, 2x saturated NaHCO_3 , saturated NaCl , dried over Na_2SO_4 and concentrated in vacuo. MS (m/z): 354/356 ($\text{M}+\text{H}$)⁺; $\text{C}_{19}\text{H}_{15}\text{N}_2\text{O}_3\text{Cl}$ requires 354.8.

Example 10**[0063]**Preparation of 2-(N-Cyclohexyl-N-methylamino)-5-aminopyridineStep A: 2-(Cyclohexylamino)-5-nitro-pyridine

[0064] Sodium hydride (60% dispersion in mineral oil, 1.99 g, 49.8 mmol) was washed 3x with hexanes then a solution of cyclohexylamine (3.8 mL, 33.2 mmol) dissolved in tetrahydrofuran (50 mL) was added. After stirring for 30 minutes at 22°C, 2-chloro-5-nitropyridine (5.00 g, 31.5 mmol) was added and the reaction mixture was heated to reflux for 3 hours. The solution was cooled to ambient temperature, quenched with saturated aqueous NH_4Cl and concentrated *in vacuo*. The residue was redissolved in ethyl acetate then washed 2x with saturated NaHCO_3 , saturated NaCl , dried over anhydrous Na_2SO_4 and concentrated *in vacuo*. The product was recovered as a brown oil.


Step B: 2-(N-Cyclohexyl-N-methylamino)-5-nitro-pyridine

[0065] Sodium hydride (60% dispersion in mineral oil, 0.38 g, 9.48 mmol) was washed 3x with hexanes then a solution of 2-cyclohexylamino-5-nitropyridine (1.88 g, 8.5 mmol) dissolved in dimethylformamide (20 mL) was added. After stirring for 30 minutes at 22°C, the reaction mixture was cooled to 0°C and methyl iodide (0.55 mL, 8.9 mmol) was added. The solution was stirred for 1.5 hours at 0°C followed by quenching with saturated aqueous NH_4Cl . The reaction mixture was diluted with ethyl acetate and extracted 5x with water (200 mL), saturated NaCl , dried over Na_2SO_4 and concentrated *in vacuo* oil was chromatographed on SiO_2 using 2:1 hexanes / ethyl acetate as eluent.

Step C: 2-(N-Cyclohexyl-N-methylamino)-5-amino-pyridine

[0066] Cyclohexyl-methyl-(5-nitro-pyridin-2-yl)-amine (1.72 g, 7.3 mmol) was dissolved in ethanol (80 mL) and treated with 20% palladium hydroxide on carbon (Pearlman's catalyst, 0.5 g) and the mixture was shaken under a hydrogen atmosphere (50 psi) for 6 hours. The catalyst was removed by filtration through celite then the filtrate was concentrated *in vacuo* and the resultant oil was chromatographed on SiO_2 using 1:1 ethyl acetate / hexanes as eluent. MS (m/z): 206 ($\text{M}+\text{H}$)⁺; $\text{C}_{12}\text{H}_{19}\text{N}_3$ requires 205.3.

Example 11**[0067]**




Preparation of 2-(N-(2,4-dimethylphenyl)-N-methylamino)-5-amino-pyridine

[0068] 2-(N-(2,4-dimethylphenyl)-N-methylamino)-5-aminopyridine was prepared from 1-amino-2,4-dimethylbenzene and 2-chloro-5-nitropyridine in the same manner as 2-(N-Cyclohexyl-N-methylamino)-5-amino-pyridine was prepared.

Example 12

[0069]



Preparation of 2,6-Dichloro-N-(2-(N'-cyclohexyl-N'-methylamino)-pyridin-5-yl)-benzamide

[0070] 2-(N-Cyclohexyl-N-methylamino)-5-amino-pyridine (26 mg, 0.13 mmol) dissolved in methylene chloride (0.25 mL) was treated with triethylamine (0.026 mL, 0.18 mmol) followed by a solution of 2,6-dichlorobenzoyl chloride (31 mg, 0.15 mmol) dissolved in methylene chloride (0.15 mL). The reaction mixture was shaken at 22°C for 18 hours followed by quenching with saturated aqueous NH_4Cl and stirring for an additional 5 hours. The organic layer was separated and dried over Na_2SO_4 then concentrated *in vacuo*. The crude product was purified by chromatography on SiO_2 using 1:1 ethyl acetate / hexane as eluent. MS (*m/z*): 378/380 ($\text{M}+\text{H}^+$); $\text{C}_{19}\text{H}_{21}\text{N}_3\text{OCl}_2$ requires 377.

Example 13


[0071] The compounds listed in Table 5 were prepared from substituted 5-aminopyridine compounds and the appropriate acid chloride in the same manner as 2,6-Dichloro-N-(2-(N'-cyclohexyl-N'-methylamino)-pyridin-5-yl)-benzamide was prepared.

Table 5

		MS (<i>m/z</i>)
	2-(N-cyclohexyl-N-methylamino)-5-((2,6-dichlorophenyl)carbonylamino)pyridine	378
	2-(N-cyclohexyl-N-methylamino)-5-((2-chlorophenyl)carbonylamino)pyridine	344
	2-(N-cyclohexyl-N-methylamino)-5-((2-methylphenyl)carbonylamino)pyridine	323
	2-(N-cyclohexyl-N-methylamino)-5-((2,6-dimethylphenyl)carbonylamino)pyridine	337
	2-(2,4-dimethylphenyl)-5-((2,6-dimethylphenyl)carbonylamino)pyridine	359
	2-(2,4-dimethylphenyl)-5-((2-methylphenyl)carbonylamino)pyridine	345
	2-(2,4-dimethylphenyl)-5-((2-chlorophenyl)carbonylamino)pyridine	366
	2-(2,4-dimethylphenyl)-5-((2-fluorophenyl)carbonylamino)pyridine	349
	2-(2,4-dimethylphenyl)-5-((2,6-dichlorophenyl)carbonylamino)pyridine	400

Example 14

[0072]




Preparation of 2-(4-Chloro-2-methyl-phenoxy)-5-(N-methylamino) pyridine

[0073] 2-(4-Chloro-2-methyl-phenoxy)-5-aminopyridine (2.15 g, 9.16 mmol) was combined with powdered sodium hydroxide (1.46 g, 36.6 mmol), potassium carbonate (1.27 g, 9.16 mmol), tetrabutyl ammonium bromide (60 mg, 0.18 mmol) and toluene (10 mL) was stirred for 1 hour at 35°C. A solution of dimethyl sulfate (0.91 mL, 9.6 mmol) dissolved in toluene (5 mL) was added slowly. The mixture was heated at 35°C for 20 hours. After cooling, the solids were removed by filtration and the solvent was concentrated *in vacuo*. The desired material was purified by chromatography on SiO₂ using 30% ethyl acetate / hexanes as eluent. MS (*m/z*): 248/250 (M+H)⁺; C₁₃H₁₃N₂OCl requires 249.

Example 15

[0074]




Preparation of 2,6-Dichloro-N-(6-(4-chloro-2-methylphenoxy)-pyridin-3-yl)-N-methyl-benzamide

[0075] 2-(4-Chloro-2-methyl-phenoxy)-5-(N-methylamino)pyridine (32 mg, 0.13 mmol) dissolved in methylene chloride (0.25 mL) was treated with triethylamine (0.026 mL, 0.18 mmol) followed by a solution of 2,6-dichlorobenzoyl chloride (31 mg, 0.15 mmol) dissolved in methylene chloride (0.15 mL). The reaction mixture was shaken at 22°C for 18 hours followed by quenching with saturated aqueous NH₄Cl and stirring for an additional 5 hours. The organic layer was separated and dried over Na₂SO₄ then concentrated *in vacuo*. The crude product was purified by chromatography on SiO₂ using 1:1 ethyl acetate / hexane as eluent. MS (*m/z*): 422/424 (M+H)⁺; C₂₀H₁₅N₂O₂Cl₃ requires 422.

Example 16

[0076]




Preparation of 2-Chloro-N-(6-(4-chloro-2-methylphenoxy)-pyridin-3-yl)-N-methyl-benzamide

[0077] 2-Chloro-N-(6-(4-chloro-2-methyl-phenoxy)-pyridin-3-yl)-N-methyl-benzamide was prepared from 2-(4-Chloro-2-methyl-phenoxy)-5-(N-methylamino)pyridine and 2-chlorobenzoyl chloride in the same manner as 2,6-Dichloro-N-(6-(4-chloro-2-methyl-phenoxy)-pyridin-3-yl)-N-methyl-benzamide was prepared.

Example 17

[0078]




Preparation of 2-Methyl-N-(6-(4-chloro-2-methylphenoxy)-pyridin-3-yl)-N-methyl-benzamide

[0079] 2-Methyl-N-(6-(4-chloro-2-methylphenoxy)-pyridin-3-yl)-N-methyl-benzamide was prepared from 2-(4-Chloro-2-methyl-phenoxy)-5-(N-methylamino)pyridine and 2-methylbenzoyl chloride in the same manner as 2,6-Dichloro-N-(6-(4-chloro-2-methyl-phenoxy)-pyridin-3-yl)-N-methyl-benzamide was prepared.

Example 18

[0080]



General procedure for the synthesis of 2-substituted-5-acylamino-pyridines

[0081] A solution of the 2-substituted-5-aminopyridine (10 mmol), triethylamine (20 mmol) and an acid chloride (20 mmol) in ethanol free chloroform (250 mL) was shaken for 16 hours. The mixture was then diluted with saturated aqueous sodium hydrogencarbonate (50 mL) and dichloromethane (500 mL), and shaken for 30 min. The mixture was then filtered through anhydrous magnesium sulfate, washing with dichloromethane (250 mL). Concentration of the filtrate under reduced pressure afforded the desired 2-substituted-5-acylamino-pyridines.

[0082] The compounds listed in Table 6 were prepared from substituted 5-aminopyridine compounds and the appropriate acid chloride according to the general procedure above.

Table 6

R ¹ X	R ³	MS (m/z)
4-chloro-2-methylphenoxy	4-biphenyl	415
4-chloro-2-methylphenoxy	3,4-dimethoxyphenyl	319
4-chloro-2-methylphenoxy	2-(trifluoromethyl)phenyl	407
4-chloro-2-methylphenoxy	2,4-difluorophenyl	375
4-chloro-2-methylphenoxy	4-cyanophenyl	364
4-chloro-2-methylphenoxy	3-(trifluoromethyl)phenyl	407
4-chloro-2-methylphenoxy	3-cyanophenyl	364
4-chloro-2-methylphenoxy	2-naphthyl	389
4-chloro-2-methylphenoxy	2-methoxyphenyl	369
4-chloro-2-methylphenoxy	3,4,5-trimethylphenyl	429
4-chloro-2-methylphenoxy	4-nitrophenyl	384
4-chloro-2-methylphenoxy	3,4-dichlorophenyl	408
4-chloro-2-methylphenoxy	5-nitrofuran-2-yl	374

(continued)

	R ¹ X	R ³	MS (m/z)
5	4-chloro-2-methylphenoxy	3-bromophenyl	418
	4-chloro-2-methylphenoxy	3-pyridyl	340
	4-chloro-2-methylphenoxy	2-ethoxynaphth-1-yl	433
	4-chloro-2-methylphenoxy	2,3-dichlorophenyl	408
	4-chloro-2-methylphenoxy	3-nitrophenyl	384
10	4-chloro-2-methylphenoxy	6-chloropyrid-3-yl	374
	4-chloro-2-methylphenoxy	4-(trifluoromethoxy)phenyl	423
	4-chloro-2-methylphenoxy	2-fluoro-4-(trifluoromethyl)phenyl	425
	4-chloro-2-methylphenoxy	2-acetoxyphenyl	397
	4-chloro-2-methylphenoxy	5-methylisoxazol-3-yl	344
15	4-chloro-2-methylphenoxy	2-(phenylthio)pyrid-3-yl	448
	4-chloro-2-methylphenoxy	2-(trifluoromethoxy)phenyl	423
	4-chloro-2-methylphenoxy	1-phenyl-5-propyl-pyrazin-4-yl	447
	4-chloro-2-methylphenoxy	2-ethoxyphenyl	383
	4-chloro-2-methylphenoxy	3-chlorothien-2-yl	379
20	4-chloro-2-methylphenoxy	3-bromothien-2-yl	424
	4-chloro-2-methylphenoxy	1-(2-(2-methyl)propyl)-3-methylpyrazol-5-yl	399
	4-chloro-2-methylphenoxy	3,5-dichlorophenyl	408
	4-chloro-2-methylphenoxy	2-(propylthio)pyridin-3-yl	414
	4-chloro-2-methylphenoxy	2-(ethylthio)pyridin-3-yl	400
25	4-chloro-2-methylphenoxy	3-bromopyridin-5-yl	419
	4-chloro-2-methylphenoxy	4-methyl-1,2,3-thiadiazol-5-yl	361
	4-chloro-2-methylphenoxy	1-methyl-3-(2-(2-methyl)propyl)pyrazol-5-yl	399
	4-chloro-2-methylphenoxy	3-chlorobenzo[b]thiophen-2-yl	429
	4-chloro-2-methylphenoxy	4-chlorophenyl	373
30	4-chloro-2-methylphenoxy	4-methyl-2-phenyl-1,2,3-triazol-5-yl	420
	4-chloro-2-methylphenoxy	benzo[b]thiophen-2-yl	395
	4-chloro-2-methylphenoxy	3,4-dimethylphenyl	367
	4-chloro-2-methylphenoxy	2-(phenoxy)pyridin-3-yl	432
	4-chloro-2-methylphenoxy	2-(methylthio)pyridin-3-yl	386
35	4-chloro-2-methylphenoxy	5-methyl-3-phenylisoxazol-4-yl	420
	4-chloro-2-methylphenoxy	4-chloro-1,3-dimethyl pyrazolo[3,4-b]pyridin-3yl	442
	4-chloro-2-methylphenoxy	2-chloro-6-methylpyridin-4-yl	388
	4-chloro-2-methylphenoxy	3,5-dimethylisoxazol-4-yl	358
	4-chloro-2-methylphenoxy	1-naphthyl	389
40	4-chloro-2-methylphenoxy	2-fluorophenyl	357
	4-chloro-2-methylphenoxy	4-propylphenyl	381
	4-chloro-2-methylphenoxy	4-(trifluoromethyl)phenyl	407
	4-chloro-2-methylphenoxy	3-fluorophenyl	357
	4-chloro-2-methylphenoxy	2,6-difluorophenyl	375
45	4-chloro-2-methylphenoxy	2-chlorophenyl	373
	4-chloro-2-methylphenoxy	3-(chloromethyl)phenyl	387
	4-chloro-2-methylphenoxy	4-(2-(2-methyl)propyl)phenyl	395
	4-chloro-2-methylphenoxy	3-chlorophenyl	373
	4-chloro-2-methylphenoxy	2-nitrophenyl	384
50	4-chloro-2-methylphenoxy	3,5-dimethoxyphenyl	399
	4-chloro-2-methylphenoxy	2,6-dichlorophenyl	408
	4-chloro-2-methylphenoxy	2,4-dichlorophenyl	408
	4-chloro-2-methylphenoxy	4-fluorophenyl	357
	4-chloro-2-methylphenoxy	4-fluorophenyl	357

EP 1 028 945 B9

(continued)

	R ¹ X	R ³	MS (m/z)
5	4-chloro-2-methylphenoxy	4-butylphenyl	395
	4-chloro-2-methylphenoxy	2-methylphenyl	353
	4-chloro-2-methylphenoxy	phenyl	339
	4-chloro-2-methylphenoxy	4-ethylphenyl	367
	4-chloro-2-methylphenoxy	2,3-difluorophenyl	375
10	4-chloro-2-methylphenoxy	2,6-dimethoxyphenyl	399
	4-chloro-2-methylphenoxy	2,5-difluorophenyl	375
	4-chloro-2-methylphenoxy	4-ethoxyphenyl	383
	4-chloro-2-methylphenoxy	2,4,6-trichlorophenyl	442
	4-chloro-2-methylphenoxy	3-methylphenyl	353
15	4-chloro-2-methylphenoxy	2-fluoro-5-(trifluoromethyl)phenyl	425
	4-chloro-2-methylphenoxy	3-methoxyphenyl	369
	4-chloro-2-methylphenoxy	thien-2-yl	345
	4-chloro-2-methylphenoxy	2-bromophenyl	418
	4-chloro-2-methylphenoxy	4-bromophenyl	418
20	4-chloro-2-methylphenoxy	4-fluoro-3-(trifluoromethyl)phenyl	425
	4-chloro-2-methylphenoxy	3-(trifluoromethoxy)phenyl	423
	4-chloro-2-methylphenoxy	9-fluorenon-4-yl	441
	4-chloro-2-methylphenoxy	isoxazol-5-yl	330
	4-chloro-2-methylphenoxy	benzofuroxan-5-yl	397
25	4-chloro-2-methylphenoxy	2-chloropyrid-3-yl	374
	4-chloro-2-methylphenoxy	3,5-difluorophenyl	375
	4-chloro-2-methylphenoxy	2-(4-methylphenoxy)pyridin-3-yl	446
	4-chloro-2-methylphenoxy	pyridin-4-yl	340
	4-chloro-2-methylphenoxy	anthraquinon-2-yl	469
30	4-chloro-2-methylphenoxy	2-iodophenyl	465
	1-naphthoxy	4-biphenyl	416
	1-naphthoxy	3,4-dimethoxyphenyl	400
	1-naphthoxy	2-(trifluoromethyl)phenyl	408
	1-naphthoxy	2,4-difluorophenyl	376
35	1-naphthoxy	4-cyanophenyl	365
	1-naphthoxy	3-(trifluoromethyl)phenyl	408
	1-naphthoxy	3-cyanophenyl	365
	1-naphthoxy	2-naphthyl	390
	1-naphthoxy	2-methoxyphenyl	370
40	1-naphthoxy	3,4,5-trimethylphenyl	430
	1-naphthoxy	4-nitrophenyl	385
	1-naphthoxy	3,4-dichlorophenyl	409
	1-naphthoxy	5-nitrofur-2-yl	375
	1-naphthoxy	3-bromophenyl	419
45	1-naphthoxy	3-pyridyl	341
	1-naphthoxy	2-ethoxynaphth-1-yl	334
	1-naphthoxy	2,3-dichlorophenyl	409
	1-naphthoxy	3-nitrophenyl	385
	1-naphthoxy	6-chloropyrid-3-yl	376
50	1-naphthoxy	4-(trifluoromethoxy)phenyl	424
	1-naphthoxy	2-fluoro-4-(trifluoromethyl)phenyl	426
	1-naphthoxy	3-bromothiophenyl	425
	1-naphthoxy	2-acetoxyphenyl	398
	1-naphthoxy		

EP 1 028 945 B9

(continued)

	R ¹ X	R ³	MS (m/z)
5	1-naphthoxy	5-methylisoxazol-3-yl	345
	1-naphthoxy	2-(phenylthio)pyrid-3-yl	449
	1-naphthoxy	2-(trifluoromethoxy)phenyl	424
	1-naphthoxy	1-phenyl-5-propylpyrazin-4-yl	448
	1-naphthoxy	2-ethoxyphenyl	384
10	1-naphthoxy	3-chlorothien-2-yl	381
	1-naphthoxy	1-(2-(2-methyl)propyl)-3-methylpyrazol-5-yl	400
	1-naphthoxy	3,5-dichlorophenyl	409
	1-naphthoxy	2-(propylthio)pyridin-3-yl	415
	1-naphthoxy	2-(ethylthio)pyridin-3-yl	401
15	1-naphthoxy	3-bromopyridin-5-yl	420
	1-naphthoxy	4-methyl-1,2,3-thiadiazol-5-yl	362
	1-naphthoxy	1-methyl-3-(2-(2-methyl)propyl)pyrazol-5-yl	400
	1-naphthoxy	3-chlorobenzo[b]thiophen-2-yl	431
	1-naphthoxy	4-chlorophenyl	375
20	1-naphthoxy	4-methyl-2-phenyl-1,2,3-triazol-5-yl	421
	1-naphthoxy	benzo[b]thiophen-2-yl	396
	1-naphthoxy	3,4-dimethylphenyl	368
	1-naphthoxy	2-(phenoxy)pyridin-3-yl	433
	1-naphthoxy	2-(methylthio)pyridin-3-yl	387
25	1-naphthoxy	5-methyl-3-phenylisoxazol-4-yl	421
	1-naphthoxy	4-chloro-1,3-dimethylpyrazolo[3,4-b]pyridin-3yl	444
	1-naphthoxy	2-chloro-6-methylpyridin-4-yl	390
	1-naphthoxy	3,5-dimethylisoxazol-4-yl	359
	1-naphthoxy	1-naphthyl	390
30	1-naphthoxy	2-fluorophenyl	358
	1-naphthoxy	4-propylphenyl	382
	1-naphthoxy	4-(trifluoromethyl)phenyl	408
	1-naphthoxy	3-fluorophenyl	358
	1-naphthoxy	2,6-difluorophenyl	376
35	1-naphthoxy	2-chlorophenyl	375
	1-naphthoxy	3-(chloromethyl)phenyl	389
	1-naphthoxy	4-(2-(2-methyl)propyl)phenyl	396
	1-naphthoxy	3-chlorophenyl	375
	1-naphthoxy	2-nitrophenyl	385
40	1-naphthoxy	3,5-dimethoxyphenyl	400
	1-naphthoxy	2,6-dichlorophenyl	409
	1-naphthoxy	2,4-dichlorophenyl	409
	1-naphthoxy	4-fluorophenyl	358
	1-naphthoxy	4-butylphenyl	396
45	1-naphthoxy	2-methylphenyl	354
	1-naphthoxy	phenyl	340
	1-naphthoxy	4-ethylphenyl	368
	1-naphthoxy	2,3-difluorophenyl	376
	1-naphthoxy	2,6-dimethoxyphenyl	400
50	1-naphthoxy	3,4-difluorophenyl	376
	1-naphthoxy	2,5-difluorophenyl	376
	1-naphthoxy	4-ethoxyphenyl	384
	1-naphthoxy	2,4,6-trichlorophenyl	444
	1-naphthoxy		

EP 1 028 945 B9

(continued)

	R ¹ X	R ³	MS (m/z)
5	1-naphthoxy	3-methylphenyl	354
	1-naphthoxy	2-fluoro-5-(trifluoromethyl)phenyl	426
	1-naphthoxy	3-methoxyphenyl	370
	1-naphthoxy	thien-2-yl	346
	1-naphthoxy	2-bromophenyl	419
10	1-naphthoxy	4-bromophenyl	419
	1-naphthoxy	4-fluoro-3-(trifluoromethyl)phenyl	426
	1-naphthoxy	3-(trifluoromethoxy)phenyl	424
	1-naphthoxy	9-fluorenon-4-yl	442
	1-naphthoxy	isoxazol-5-yl	331
15	1-naphthoxy	benzofuroxan-5-yl	398
	1-naphthoxy	2-chloropyrid-3-yl	376
	1-naphthoxy	3,5-difluorophenyl	376
	1-naphthoxy	2-(4-methylphenoxy)pyridin-3-yl	447
	1-naphthoxy	pyridin-4-yl	341
20	1-naphthoxy	anthraquinon-2-yl	470
	1-naphthoxy	2-iodophenyl	466
	2-(2-propyl)phenoxy	4-biphenyl	408
	2-(2-propyl)phenoxy	3,4-dimethoxyphenyl	392
	2-(2-propyl)phenoxy	2-(trifluoromethyl)phenyl	400
25	2-(2-propyl)phenoxy	2,4-difluorophenyl	368
	2-(2-propyl)phenoxy	4-cyanophenyl	357
	2-(2-propyl)phenoxy	3-(trifluoromethyl)phenyl	400
	2-(2-propyl)phenoxy	3-cyanophenyl	357
	2-(2-propyl)phenoxy	2-naphthyl	382
30	2-(2-propyl)phenoxy	2-methoxyphenyl	362
	2-(2-propyl)phenoxy	3,4,5,-trimethylphenyl	422
	2-(2-propyl)phenoxy	4-nitrophenyl	377
	2-(2-propyl)phenoxy	3,4-dichlorophenyl	401
	2-(2-propyl)phenoxy	5-nitrofuran-2-yl	367
35	2-(2-propyl)phenoxy	3-bromophenyl	411
	2-(2-propyl)phenoxy	3-pyridyl	333
	2-(2-propyl)phenoxy	2-ethoxynaphth-1-yl	426
	2-(2-propyl)phenoxy	2,3-dichlorophenyl	401
	2-(2-propyl)phenoxy	3-nitrophenyl	377
40	2-(2-propyl)phenoxy	6-chloropyrid-3-yl	368
	2-(2-propyl)phenoxy	4-(trifluoromethoxy)phenyl	416
	2-(2-propyl)phenoxy	2-fluoro-4-(trifluoromethyl)phenyl	418
	2-(2-propyl)phenoxy	3-bromothiophenyl	417
	2-(2-propyl)phenoxy	2-acetoxyphenyl	390
45	2-(2-propyl)phenoxy	5-methylisoxazol-3-yl	337
	2-(2-propyl)phenoxy	2-(phenylthio)pyrid-3-yl	442
	2-(2-propyl)phenoxy	2-(trifluoromethoxy)phenyl	416
	2-(2-propyl)phenoxy	1-phenyl-5-propylpyrazin-4-yl	441
	2-(2-propyl)phenoxy	2-ethoxyphenyl	376
50	2-(2-propyl)phenoxy	3-chlorothien-2-yl	373
	2-(2-propyl)phenoxy	1-(2-(2-methyl)propyl)-3-methylpyrazol-5-yl	392
	2-(2-propyl)phenoxy	3,5-dichlorophenyl	401
	2-(2-propyl)phenoxy	2-(propylthio)pyridin-3-yl	407
	2-(2-propyl)phenoxy		

EP 1 028 945 B9

	R ¹ X	(continued)	R ³	MS (m/z)
5	2-(2-propyl)phenoxy	2-(ethylthio)pyridin-3-yl		393
	2-(2-propyl)phenoxy	3-bromopyridin-5-yl		412
	2-(2-propyl)phenoxy	4-methyl-1,2,3-thiadiazol-5-yl		354
	2-(2-propyl)phenoxy	1-methyl-3-(2-(2-methyl)propyl)pyrazol-5-yl		392
10	2-(2-propyl)phenoxy	3-chlorobenzo[b]thiophen-2-yl		423
	2-(2-propyl)phenoxy	4-chlorophenyl		367
	2-(2-propyl)phenoxy	4-methyl-2-phenyl-1,2,3-triazol-5-yl		413
	2-(2-propyl)phenoxy	benzo[b]thiophen-2-yl		388
15	2-(2-propyl)phenoxy	3,4-dimethylphenyl		360
	2-(2-propyl)phenoxy	2-(phenoxy)pyridin-3-yl		425
	2-(2-propyl)phenoxy	2-(methylthio)pyridin-3-yl		379
	2-(2-propyl)phenoxy	5-methyl-3-phenylisoxazol-4-yl		413
20	2-(2-propyl)phenoxy	4-chloro-1,3-dimethylpyrazolo[3,4-b]pyridin-3-yl		436
	2-(2-propyl)phenoxy	2-chloro-6-methylpyridin-4-yl		382
	2-(2-propyl)phenoxy	3,5-dimethylisoxazol-4-yl		351
	2-(2-propyl)phenoxy	1-naphthyl		382
25	2-(2-propyl)phenoxy	2-fluorophenyl		350
	2-(2-propyl)phenoxy	4-propylphenyl		374
	2-(2-propyl)phenoxy	4-(trifluoromethyl)phenyl		400
	2-(2-propyl)phenoxy	3-fluorophenyl		350
30	2-(2-propyl)phenoxy	2,6-difluorophenyl		368
	2-(2-propyl)phenoxy	2-chlorophenyl		367
	2-(2-propyl)phenoxy	3-(chloromethyl)phenyl		381
	2-(2-propyl)phenoxy	4-(2-(2-methyl)propyl)phenyl		388
35	2-(2-propyl)phenoxy	3-chlorophenyl		367
	2-(2-propyl)phenoxy	2-nitrophenyl		377
	2-(2-propyl)phenoxy	3,5-dimethoxyphenyl		392
	2-(2-propyl)phenoxy	2,6-dichlorophenyl		401
40	2-(2-propyl)phenoxy	2,4-dichlorophenyl		401
	2-(2-propyl)phenoxy	4-fluorophenyl		
	2-(2-propyl)phenoxy	4-butylphenyl		
	2-(2-propyl)phenoxy	2-methylphenyl		
45	2-(2-propyl)phenoxy	phenyl		
	2-(2-propyl)phenoxy	4-ethylphenyl		
	2-(2-propyl)phenoxy	2,3-difluorophenyl		
	2-(2-propyl)phenoxy	2,6-dimethoxyphenyl		392
50	2-(2-propyl)phenoxy	3,4-difluorophenyl		368
	2-(2-propyl)phenoxy	2,5-difluorophenyl		368
	2-(2-propyl)phenoxy	4-ethoxyphenyl,		376
	2-(2-propyl)phenoxy	2,4,6-trichlorophenyl		436
55	2-(2-propyl)phenoxy	3-methylphenyl		346
	2-(2-propyl)phenoxy	2-fluoro-5-(trifluoromethyl)phenyl		418
	2-(2-propyl)phenoxy	3-methoxyphenyl		362
	2-(2-propyl)phenoxy	thien-2-yl		338
	2-(2-propyl)phenoxy	2-bromophenyl		411
	2-(2-propyl)phenoxy	4-bromophenyl		411
	2-(2-propyl)phenoxy	4-fluoro-3-(trifluoromethyl)phenyl		418
	2-(2-propyl)phenoxy	3-(trifluoromethoxy)phenyl		416
	2-(2-propyl)phenoxy	9-fluorenon-4-yl		434

EP 1 028 945 B9

(continued)

	R ¹ X	R ³	MS (m/z)
5	2-(2-propyl)phenoxy	isoxazol-5-yl	323
	2-(2-propyl)phenoxy	benzofuroxan-5-yl	390
	2-(2-propyl)phenoxy	2-chloropyrid-3-yl	368
	2-(2-propyl)phenoxy	3,5-difluorophenyl	368
10	2-(2-propyl)phenoxy	2-(4-methylphenoxy)pyridin-3-yl	439
	2-(2-propyl)phenoxy	pyridin-4-yl	333
	2-(2-propyl)phenoxy	anthraquinon-2-yl	462
	2-(2-propyl)phenoxy	2-iodophenyl	458
15	3-fluoro-5-methylphenoxy	4-biphenyl	398
	3-fluoro-5-methylphenoxy,	3,4-dimethoxyphenyl	382
	3-fluoro-5-methylphenoxy	2-(trifluoromethyl)phenyl	390
	3-fluoro-5-methylphenoxy	2,4-difluorophenyl	358
20	3-fluoro-5-methylphenoxy	4-cyanophenyl	347
	3-fluoro-5-methylphenoxy	3-(trifluoromethyl)phenyl	390
	3-fluoro-5-methylphenoxy	3-cyanophenyl	347
	3-fluoro-5-methylphenoxy	2-naphthyl	372
25	3-fluoro-5-methylphenoxy	2-methoxyphenyl	352
	3-fluoro-5-methylphenoxy	3,4,5,-trimethylphenyl	412
	3-fluoro-5-methylphenoxy	4-nitrophenyl	367
	3-fluoro-5-methylphenoxy	3,4-dichlorophenyl	391
30	3-fluoro-5-methylphenoxy	5-nitrofur-2-yl	357
	3-fluoro-5-methylphenoxy	3-bromophenyl	401
	3-fluoro-5-methylphenoxy	3-pyridyl	323
	3-fluoro-5-methylphenoxy	2-ethoxynaphth-1-yl	416
35	3-fluoro-5-methylphenoxy	2,3-dichlorophenyl	391
	3-fluoro-5-methylphenoxy	3-nitrophenyl	367
	3-fluoro-5-methylphenoxy	6-chloropyrid-3-yl	358
	3-fluoro-5-methylphenoxy	4-(trifluoromethoxy)phenyl	406
40	3-fluoro-5-methylphenoxy	2-fluoro-4-(trifluoromethyl)phenyl	408
	3-fluoro-5-methylphenoxy	3-bromothieryl	407
	3-fluoro-5-methylphenoxy	2-acetoxyphenyl	380
	3-fluoro-5-methylphenoxy	5-methylisoxazol-3-yl	327
45	3-fluoro-5-methylphenoxy	2-(phenylthio)pyrid-3-yl	431
	3-fluoro-5-methylphenoxy	2-(trifluoromethoxy)phenyl	406
	3-fluoro-5-methylphenoxy	1-phenyl-5-propylpyrazin-4-yl	430
	3-fluoro-5-methylphenoxy	2-ethoxyphenyl	366
50	3-fluoro-5-methylphenoxy	3-chlorothien-2-yl	363
	3-fluoro-5-methylphenoxy	1-(2-(2-methyl)propyl)-3-methylpyrazol-5-yl	382
	3-fluoro-5-methylphenoxy	3,5-dichlorophenyl	391
	3-fluoro-5-methylphenoxy	2-(propylthio)pyridin-3-yl	397
55	3-fluoro-5-methylphenoxy	2-(ethylthio)pyridin-3-yl	383
	3-fluoro-5-methylphenoxy	3-bromopyridin-5-yl	402
	3-fluoro-5-methylphenoxy	4-methyl-1,2,3-thiadiazol-5-yl	344
	3-fluoro-5-methylphenoxy	1-methyl-3-(-2-(2-methyl)propyl)pyrazol-5-yl	382
55	3-fluoro-5-methylphenoxy	3-chlorobenzo[b]thiophen-2-yl	413
	3-fluoro-5-methylphenoxy	4-chlorophenyl	357
	3-fluoro-5-methylphenoxy	4-methyl-2-phenyl-1,2,3-triazol-5-yl	403
	3-fluoro-5-methylphenoxy	benzo[b]thiophen-2-yl	378
	3-fluoro-5-methylphenoxy	3,4-dimethylphenyl	350

EP 1 028 945 B9

(continued)

	R ¹ X	R ³	MS (m/z)
5	3-fluoro-5-methylphenoxy	2-(phenoxy)pyridin-3-yl	415
	3-fluoro-5-methylphenoxy	2-(methylthio)pyridin-3-yl	369
	3-fluoro-5-methylphenoxy	5-methyl-3-phenylisoxazol-4-yl	403
	3-fluoro-5-methylphenoxy	4-chloro-1,3-dimethyl pyrazolo[3,4-b]pyridin-3-yl	426
	3-fluoro-5-methylphenoxy	2-chloro-6-methylpyridin-4-yl	372
10	3-fluoro-5-methylphenoxy	3,5-dimethylisoxazol-4-yl	341
	3-fluoro-5-methylphenoxy	1-naphthyl	372
	3-fluoro-5-methylphenoxy	2-fluorophenyl	340
	3-fluoro-5-methylphenoxy	4-propylphenyl	364
15	3-fluoro-5-methylphenoxy	4-(trifluoromethyl)phenyl	390
	3-fluoro-5-methylphenoxy	3-fluorophenyl	340
	3-fluoro-5-methylphenoxy	2,6-difluorophenyl	358
	3-fluoro-5-methylphenoxy	2-chlorophenyl	357
	3-fluoro-5-methylphenoxy	3-(chloromethyl)phenyl	371
20	3-fluoro-5-methylphenoxy	4-(2-(2-methyl)propyl)phenyl	378
	3-fluoro-5-methylphenoxy	3-chlorophenyl	357
	3-fluoro-5-methylphenoxy	2-nitrophenyl	367
	3-fluoro-5-methylphenoxy	3,5-dimethoxyphenyl	382
	3-fluoro-5-methylphenoxy	2,6-dichlorophenyl	391
25	3-fluoro-5-methylphenoxy	2,4-dichlorophenyl	391
	3-fluoro-5-methylphenoxy	4-fluorophenyl	340
	3-fluoro-5-methylphenoxy	4-butylphenyl	378
	3-fluoro-5-methylphenoxy	2-methylphenyl	336
	3-fluoro-5-methylphenoxy	phenyl	322
30	3-fluoro-5-methylphenoxy	4-ethylphenyl	350
	3-fluoro-5-methylphenoxy	2,3-difluorophenyl	358
	3-fluoro-5-methylphenoxy	2,6-dimethoxyphenyl	382
	3-fluoro-5-methylphenoxy	3,4-difluorophenyl	358
	3-fluoro-5-methylphenoxy	2,5-difluorophenyl	358
35	3-fluoro-5-methylphenoxy	4-ethoxyphenyl	366
	3-fluoro-5-methylphenoxy	2,4,6-trichlorophenyl	426
	3-fluoro-5-methylphenoxy	3-methylphenyl	336
	3-fluoro-5-methylphenoxy	2-fluoro-5-(trifluoromethyl)phenyl	408
	3-fluoro-5-methylphenoxy	3-methoxyphenyl	352
40	3-fluoro-5-methylphenoxy	thien-2-yl	328
	3-fluoro-5-methylphenoxy	2-bromophenyl	401
	3-fluoro-5-methylphenoxy	4-bromophenyl	401
	3-fluoro-5-methylphenoxy	4-fluoro-3-(trifluoromethyl)phenyl	408
	3-fluoro-5-methylphenoxy	3-(trifluoromethoxy)phenyl	406
45	3-fluoro-5-methylphenoxy	9-fluorenon-4-yl	424
	3-fluoro-5-methylphenoxy	isoxazol-5-yl	313
	3-fluoro-5-methylphenoxy	benzofuroxan-5-yl	380
	3-fluoro-5-methylphenoxy	2-chloropyrid-3-yl	358
	3-fluoro-5-methylphenoxy	3,5-difluorophenyl	358
50	3-fluoro-5-methylphenoxy	2-(4-methylphenoxy)pyridin-3-yl	429
	3-fluoro-5-methylphenoxy	pyridin-4-yl	323
	3-fluoro-5-methylphenoxy	anthraquinon-2-yl	452
	3-fluoro-5-methylphenoxy	2-iodophenyl	448
	2-methylpyrid-3-yloxy	4-biphenyl	381

EP 1 028 945 B9

(continued)

	R ¹ X	R ³	MS (m/z)
5	2-methylpyrid-3-yloxy	3,4-dimethoxyphenyl	365
	2-methylpyrid-3-yloxy	2-(trifluoromethyl)phenyl	373
	2-methylpyrid-3-yloxy	2,4-difluorophenyl	341
	2-methylpyrid-3-yloxy	4-cyanophenyl	330
	2-methylpyrid-3-yloxy	3-(trifluoromethyl)phenyl	373
10	2-methylpyrid-3-yloxy	3-cyanophenyl	330
	2-methylpyrid-3-yloxy	2-naphthyl	355
	2-methylpyrid-3-yloxy	2-methoxyphenyl	335
	2-methylpyrid-3-yloxy	3,4,5-trimethylphenyl	395
	2-methylpyrid-3-yloxy	4-nitrophenyl	350
15	2-methylpyrid-3-yloxy	3,4-dichlorophenyl	374
	2-methylpyrid-3-yloxy	5-nitrofuran-2-yl	340
	2-methylpyrid-3-yloxy	3-bromophenyl	384
	2-methylpyrid-3-yloxy	3-pyridyl	306
	2-methylpyrid-3-yloxy	2-ethoxynaphth-1-yl	399
20	2-methylpyrid-3-yloxy	2,3-dichlorophenyl	374
	2-methylpyrid-3-yloxy	3-nitrophenyl	350
	2-methylpyrid-3-yloxy	6-chloropyrid-3-yl	341
	2-methylpyrid-3-yloxy	4-(trifluoromethoxy)phenyl	389
	2-methylpyrid-3-yloxy	2-fluoro-4-(trifluoromethyl)phenyl	391
25	2-methylpyrid-3-yloxy	3-bromothieryl	390
	2-methylpyrid-3-yloxy	2-acetoxyphenyl	363
	2-methylpyrid-3-yloxy	5-methylisoxazol-3-yl	310
	2-methylpyrid-3-yloxy	2-(phenylthio)pyrid-3-yl	414
	2-methylpyrid-3-yloxy	2-(trifluoromethoxy)phenyl	389
30	2-methylpyrid-3-yloxy	1-phenyl-5-propylpyrazin-4-yl	413
	2-methylpyrid-3-yloxy	2-ethoxyphenyl	349
	2-methylpyrid-3-yloxy	3-chlorothieryl	346
	2-methylpyrid-3-yloxy	1-(2-(2-methyl)propyl)-3-methylpyrazol-5-yl	365
	2-methylpyrid-3-yloxy	3,5-dichlorophenyl	374
35	2-methylpyrid-3-yloxy	2-(propylthio)pyridin-3-yl	380
	2-methylpyrid-3-yloxy	2-(ethylthio)pyridin-3-yl	366
	2-methylpyrid-3-yloxy	3-bromopyridin-5-yl	385
	2-methylpyrid-3-yloxy	4-methyl-1,2,3-thiadiazol-5-yl	327
	2-methylpyrid-3-yloxy	1-methyl-3-(2-(2-methyl)propyl)pyrazol-5-yl	365
40	2-methylpyrid-3-yloxy	3-chlorobenzo[b]thiophen-2-yl	396
	2-methylpyrid-3-yloxy	4-chlorophenyl	340
	2-methylpyrid-3-yloxy	4-methyl-2-phenyl-1,2,3-triazol-5-yl	386
	2-methylpyrid-3-yloxy	benzo[b]thiophen-2-yl	361
	2-methylpyrid-3-yloxy	3,4-dimethylphenyl	333
45	2-methylpyrid-3-yloxy	2-(phenoxy)pyridin-3-yl	398
	2-methylpyrid-3-yloxy	2-(methylthio)pyridin-3-yl	352
	2-methylpyrid-3-yloxy	5-methyl-3-phenylisoxazol-4-yl	386
	2-methylpyrid-3-yloxy	4-chloro-1,3-dimethyl pyrazolo[3,4-b]pyridin-3yl	409
	2-methylpyrid-3-yloxy	2-chloro-6-methylpyridin-4-yl	355
50	2-methylpyrid-3-yloxy	3,5-dimethylisoxazol-4-yl	324
	2-methylpyrid-3-yloxy	1-naphthyl	355
	2-methylpyrid-3-yloxy	2-fluorophenyl	323
	2-methylpyrid-3-yloxy	4-propylphenyl	347
	2-methylpyrid-3-yloxy		

(continued)

	R ¹ X	R ³	MS (m/z)
5	2-methylpyrid-3-yloxy	4-(trifluoromethyl)phenyl	373
	2-methylpyrid-3-yloxy	3-fluorophenyl	323
	2-methylpyrid-3-yloxy	2,6-difluorophenyl	341
	2-methylpyrid-3-yloxy	2-chlorophenyl	340
	2-methylpyrid-3-yloxy	3-(chloromethyl)phenyl	354
10	2-methylpyrid-3-yloxy	4-(2-(2-methyl)propyl)phenyl	361
	2-methylpyrid-3-yloxy	3-chlorophenyl	340
	2-methylpyrid-3-yloxy	2-nitrophenyl	350
	2-methylpyrid-3-yloxy	3,5-dimethoxyphenyl	365
	2-methylpyrid-3-yloxy	2,6-dichlorophenyl	374
15	2-methylpyrid-3-yloxy	2,4-dichlorophenyl	374
	2-methylpyrid-3-yloxy	4-fluorophenyl	323
	2-methylpyrid-3-yloxy	4-butylphenyl	361
	2-methylpyrid-3-yloxy	2-methylphenyl	319
	2-methylpyrid-3-yloxy	phenyl	305
20	2-methylpyrid-3-yloxy	4-ethylphenyl	333
	2-methylpyrid-3-yloxy	2,3-difluorophenyl	341
	2-methylpyrid-3-yloxy	2,6-dimethoxyphenyl	365
	2-methylpyrid-3-yloxy	3,4-difluorophenyl	341
	2-methylpyrid-3-yloxy	2,5-difluorophenyl	341
25	2-methylpyrid-3-yloxy	4-ethoxyphenyl	349
	2-methylpyrid-3-yloxy	2,4,6-trichlorophenyl	409
	2-methylpyrid-3-yloxy	3-methylphenyl	319
	2-methylpyrid-3-yloxy	2-fluoro-5-(trifluoromethyl)phenyl	391
	2-methylpyrid-3-yloxy	3-methoxyphenyl	335
30	2-methylpyrid-3-yloxy	thien-2-yl	311
	2-methylpyrid-3-yloxy	2-bromophenyl	384
	2-methylpyrid-3-yloxy	4-bromophenyl	384
	2-methylpyrid-3-yloxy	4-fluoro-3-(trifluoromethyl)phenyl	391
	2-methylpyrid-3-yloxy	3-(trifluoromethoxy)phenyl	389
35	2-methylpyrid-3-yloxy	9-fluorenon-4-yl	407
	2-methylpyrid-3-yloxy	isoxazol-5-yl	296
	2-methylpyrid-3-yloxy	benzofuroxan-5-yl	363
	2-methylpyrid-3-yloxy	2-chloropyrid-3-yl	341
	2-methylpyrid-3-yloxy	3,5-difluorophenyl	341
40	2-methylpyrid-3-yloxy	2-(4-methylphenoxy)-pyridin-3-yl	412
	2-methylpyrid-3-yloxy	pyridin-4-yl	306
	2-methylpyrid-3-yloxy	anthraquinon-2-yl	435
	2-methylpyrid-3-yloxy	2-iodophenyl	431
	4-chloro-2,5-dimethylphenoxy	3,4-dimethoxyphenyl	413
50	4-chloro-2,5-dimethylphenoxy	2-(trifluoromethyl)phenyl	421
	4-chloro-2,5-dimethylphenoxy	2,4-difluorophenyl	389
	4-chloro-2,5-dimethylphenoxy	3-(trifluoromethyl)phenyl	421
	4-chloro-2,5-dimethylphenoxy	2-naphthyl	403
	4-chloro-2,5-dimethylphenoxy	2-methoxyphenyl	484
55	4-chloro-2,5-dimethylphenoxy	3,4,5-trimethylphenyl	443
	4-chloro-2,5-dimethylphenoxy	3,4-dichlorophenyl	422
	4-chloro-2,5-dimethylphenoxy	3-bromophenyl	432
	4-chloro-2,5-dimethylphenoxy	3-pyridyl	354

EP 1 028 945 B9

(continued)

	R ¹ X	R ³	MS (m/z)
5	4-chloro-2,5-dimethylphenoxy	2-ethoxynaphth-1-yl	447
	4-chloro-2,5-dimethylphenoxy	2,3-dichlorophenyl	422
	4-chloro-2,5-dimethylphenoxy	6-chloropyrid-3-yl	388
	4-chloro-2,5-dimethylphenoxy	4-(trifluoromethoxy)phenyl	437
	4-chloro-2,5-dimethylphenoxy	2-fluoro-4-(trifluoromethyl)phenyl	439
10	4-chloro-2,5-dimethylphenoxy	3-bromothieryl	438
	4-chloro-2,5-dimethylphenoxy	2-acetoxyphenyl	411
	4-chloro-2,5-dimethylphenoxy	5-methylisoxazol-3-yl	358
	4-chloro-2,5-dimethylphenoxy	2-(phenylthio)pyrid-3-yl	462
	4-chloro-2,5-dimethylphenoxy	2-(trifluoromethoxy)phenyl	437
15	4-chloro-2,5-dimethylphenoxy	1-phenyl-5-propylpyrazin-4-yl	461
	4-chloro-2,5-dimethylphenoxy	2-ethoxyphenyl	397
	4-chloro-2,5-dimethylphenoxy	3-chlorothieryl-2-yl	393
	4-chloro-2,5-dimethylphenoxy	1-(2-(2-methyl)propyl)-3-methylpyrazol-5-yl	413
	4-chloro-2,5-dimethylphenoxy	3,5-dichlorophenyl	422
20	4-chloro-2,5-dimethylphenoxy	2-(propylthio)pyridin-3-yl	428
	4-chloro-2,5-dimethylphenoxy	2-(ethylthio)pyridin-3-yl	414
	4-chloro-2,5-dimethylphenoxy	3-bromopyridin-5-yl	433
	4-chloro-2,5-dimethylphenoxy	4-methyl-1,2,3-thiadiazol-5-yl	375
	4-chloro-2,5-dimethylphenoxy	1-methyl-3-(2-(2-methyl)propyl)pyrazol-5-yl	413
25	4-chloro-2,5-dimethylphenoxy	3-chlorobenzo[b]thiophen-2-yl	443
	4-chloro-2,5-dimethylphenoxy	4-chlorophenyl	387
	4-chloro-2,5-dimethylphenoxy	4-methyl-2-phenyl-1,2,3-triazol-5-yl	434
	4-chloro-2,5-dimethylphenoxy	benzo[b]thiophen-2-yl	409
	4-chloro-2,5-dimethylphenoxy	3,4-dimethylphenyl	381
30	4-chloro-2,5-dimethylphenoxy	2-(phenoxy)pyridin-3-yl	446
	4-chloro-2,5-dimethylphenoxy	2-(methylthio)pyridin-3-yl	400
	4-chloro-2,5-dimethylphenoxy	5-methyl-3-phenylisoxazol-4-yl	434
	4-chloro-2,5-dimethylphenoxy	4-chloro-1,3-dimethylpyrazolo[3,4-b]pyridin-3-yl	456
	4-chloro-2,5-dimethylphenoxy	2-chloro-6-methylpyridin-4-yl	402
35	4-chloro-2,5-dimethylphenoxy	3,5-dimethylisoxazol-4-yl	372
	4-chloro-2,5-dimethylphenoxy	1-naphthyl	403
	4-chloro-2,5-dimethylphenoxy	2-fluorophenyl,	371
	4-chloro-2,5-dimethylphenoxy	4-propylphenyl	395
	4-chloro-2,5-dimethylphenoxy	3-fluorophenyl	371
40	4-chloro-2,5-dimethylphenoxy	2,6-difluorophenyl	389
	4-chloro-2,5-dimethylphenoxy	2-chlorophenyl	387
	4-chloro-2,5-dimethylphenoxy	3-(chloromethyl)phenyl	401
	4-chloro-2,5-dimethylphenoxy	4-(2-(2-methyl)propyl)phenyl	409
	4-chloro-2,5-dimethylphenoxy	3-chlorophenyl	387
45	4-chloro-2,5-dimethylphenoxy	3,5-dimethoxyphenyl	413
	4-chloro-2,5-dimethylphenoxy	2,6-dichlorophenyl	422
	4-chloro-2,5-dimethylphenoxy	2,4-dichlorophenyl	422
	4-chloro-2,5-dimethylphenoxy	4-fluorophenyl	371
	4-chloro-2,5-dimethylphenoxy	4-butylphenyl	409
50	4-chloro-2,5-dimethylphenoxy	2-methylphenyl	367
	4-chloro-2,5-dimethylphenoxy	phenyl	353
	4-chloro-2,5-dimethylphenoxy	4-ethylphenyl	381
	4-chloro-2,5-dimethylphenoxy	2,3-difluorophenyl	389
	4-chloro-2,5-dimethylphenoxy		

EP 1 028 945 B9

(continued)

	R ¹ X	R ³	MS (m/z)
5	4-chloro-2,5-dimethylphenoxy	2,6-dimethoxyphenyl	413
	4-chloro-2,5-dimethylphenoxy	3,4-difluorophenyl	389
	4-chloro-2,5-dimethylphenoxy	2,5-difluorophenyl	389
	4-chloro-2,5-dimethylphenoxy	4-ethoxyphenyl	397
	4-chloro-2,5-dimethylphenoxy	2,4,6-trichlorophenyl	456
10	4-chloro-2,5-dimethylphenoxy	3-methylphenyl	367
	4-chloro-2,5-dimethylphenoxy	2-fluoro-5-(trifluoromethyl)phenyl	439
	4-chloro-2,5-dimethylphenoxy	3-methoxyphenyl	383
	4-chloro-2,5-dimethylphenoxy	2-bromophenyl	432
15	4-chloro-2,5-dimethylphenoxy	4-bromophenyl	432
	4-chloro-2,5-dimethylphenoxy	4-fluoro-3-(trifluoromethyl)phenyl	439
	4-chloro-2,5-dimethylphenoxy	3-(trifluoromethoxy)phenyl	437
	4-chloro-2,5-dimethylphenoxy	9-fluorenon-4-yl	455
	4-chloro-2,5-dimethylphenoxy	isoxazol-5-yl	344
20	4-chloro-2,5-dimethylphenoxy	benzofuroxan-5-yl	411
	4-chloro-2,5-dimethylphenoxy	2-chloropyrid-3-yl	388
	4-chloro-2,5-dimethylphenoxy	2-(4-methylphenoxy)pyridin-3-yl	460
	4-chloro-2,5-dimethylphenoxy	pyridin-4-yl	354
	4-chloro-2,5-dimethylphenoxy	anthraquinon-2-yl	483
25	4-chloro-2,5-dimethylphenoxy	2-iodophenyl	479
	4-chloro-2,5-dimethylphenoxy	4-pentylphenyl	423
	4-chloro-2,5-dimethylphenoxy	2-(4-chlorophenylthio)pyridin-3-yl	496
	4-chloro-2,5-dimethylphenoxy	2,6-dimethylphenyl	381
	4-chloro-2,5-dimethylphenoxy	2,5-dimethoxyphenyl	413
30	4-chloro-2,5-dimethylphenoxy	2,5-dichloropyridin-3-yl	423
	4-chloro-2,5-dimethylphenoxy	2-chloro-6-methoxypyridin-4-yl	418
	4-chloro-2,5-dimethylphenoxy	2,3-dichloropyridin-5-yl	423
	4-chloro-2,5-dimethylphenoxy	1-naphthyl	417
	4-chloro-2,5-dimethylphenoxy	2,4-dimethoxyphenyl	413
35	4-chloro-2,5-dimethylphenoxy	3,5-bis(trifluoromethyl)phenyl	489
	4-chloro-2,5-dimethylphenoxy	2-(4-chlorophenoxy)pyridin-3-yl	480
	4-chloro-2,5-dimethylphenoxy	pentafluorophenyl	443
	4-methoxyphenoxy	3,4-dimethoxyphenyl	380
	4-methoxyphenoxy	2-(trifluoromethyl)phenyl	388
40	4-methoxyphenoxy	2,4-difluorophenyl	356
	4-methoxyphenoxy	3-(trifluoromethyl)phenyl	388
	4-methoxyphenoxy	2-naphthyl	370
	4-methoxyphenoxy	2-methoxyphenyl	350
	4-methoxyphenoxy	3,4,5-trimethylphenyl	410
45	4-methoxyphenoxy	3,4-dichlorophenyl	389
	4-methoxyphenoxy	3-bromophenyl	399
	4-methoxyphenoxy	3-pyridyl	321
	4-methoxyphenoxy	2-ethoxynaphth-1-yl	414
	4-methoxyphenoxy	2,3-dichlorophenyl	389
50	4-methoxyphenoxy	6-chloropyrid-3-yl	356
	4-methoxyphenoxy	4-(trifluoromethoxy)phenyl	404
	4-methoxyphenoxy	2-fluoro-4-(trifluoromethyl)phenyl	406
	4-methoxyphenoxy	3-bromothieryl	405
	4-methoxyphenoxy	2-acetoxyphenyl	378

EP 1 028 945 B9

(continued)

	R ¹ X	R ³	MS (m/z)
5	4-methoxyphenoxy	5-methylisoxazol-3-yl	325
	4-methoxyphenoxy	2-(phenylthio)pyrid-3-yl	429
	4-methoxyphenoxy	2-(trifluoromethoxy)phenyl	404
	4-methoxyphenoxy	1-phenyl-5-propylpyrazin-4-yl	428
	4-methoxyphenoxy	2-ethoxyphenyl	364
10	4-methoxyphenoxy	3-chlorothien-2-yl	361
	4-methoxyphenoxy	1-(2-(2-methyl)propyl)-3-methylpyrazol-5-yl	380
	4-methoxyphenoxy	3,5-dichlorophenyl	389
	4-methoxyphenoxy	2-(propylthio)pyridin-3-yl	395
	4-methoxyphenoxy	2-(ethylthio)pyridin-3-yl	381
15	4-methoxyphenoxy	3-bromopyridin-5-yl	400
	4-methoxyphenoxy	4-methyl-1,2,3-thiadiazol-5-yl	342
	4-methoxyphenoxy	1-methyl-3-(2-(2-methyl)propyl)pyrazol-5-yl	380
	4-methoxyphenoxy	3-chlorobenzo[b]thiophen-2-yl	411
	4-methoxyphenoxy	4-chlorophenyl	355
20	4-methoxyphenoxy	4-methyl-2-phenyl-1,2,3-triazol-5-yl	401
	4-methoxyphenoxy	benzo[b]thiophen-2-yl	376
	4-methoxyphenoxy	3,4-dimethylphenyl	348
	4-methoxyphenoxy	2-(phenoxy)pyridin-3-yl	413
	4-methoxyphenoxy	2-(methylthio)pyridin-3-yl	367
25	4-methoxyphenoxy	5-methyl-3-phenylisoxazol-4-yl	401
	4-methoxyphenoxy	4-chloro-1,3-dimethylpyrazolo[3,4-b]pyridin-3-yl	424
	4-methoxyphenoxy	2-chloro-6-methylpyridin-4-yl	370
	4-methoxyphenoxy	3,5-dimethylisoxazol-4-yl	339
	4-methoxyphenoxy	1-naphthyl	370
30	4-methoxyphenoxy	2-fluorophenyl	338
	4-methoxyphenoxy	4-propylphenyl	362
	4-methoxyphenoxy	3-fluorophenyl	338
	4-methoxyphenoxy	2,6-difluorophenyl	356
	4-methoxyphenoxy	2-chlorophenyl	355
35	4-methoxyphenoxy	3-(chloromethyl)phenyl	369
	4-methoxyphenoxy	4-(2-(2-methyl)propyl)phenyl	376
	4-methoxyphenoxy	3-chlorophenyl	355
	4-methoxyphenoxy	3,5-dimethoxyphenyl	380
	4-methoxyphenoxy	2,6-dichlorophenyl	389
40	4-methoxyphenoxy	2,4-dichlorophenyl	389
	4-methoxyphenoxy	4-fluorophenyl	338
	4-methoxyphenoxy	4-butylphenyl	376
	4-methoxyphenoxy	2-methylphenyl	334
	4-methoxyphenoxy	phenyl	320
45	4-methoxyphenoxy	4-ethylphenyl	348
	4-methoxyphenoxy	2,3-difluorophenyl	356
	4-methoxyphenoxy	2,6-dimethoxyphenyl	380
	4-methoxyphenoxy	3,4-difluorophenyl	356
	4-methoxyphenoxy	2,5-difluorophenyl	356
50	4-methoxyphenoxy	4-ethoxyphenyl	364
	4-methoxyphenoxy	2,4,6-trichlorophenyl	424
	4-methoxyphenoxy	3-methylphenyl	334
	4-methoxyphenoxy	2-fluoro-5-(trifluoromethyl)phenyl	406
	4-methoxyphenoxy		

EP 1 028 945 B9

	R ¹ X	(continued) R ³	MS (m/z)
5	4-methoxyphenoxy	3-methoxyphenyl	350
	4-methoxyphenoxy	2-bromophenyl	399
	4-methoxyphenoxy	4-bromophenyl	399
	4-methoxyphenoxy	4-fluoro-3-(trifluoromethyl)phenyl	406
10	4-methoxyphenoxy	3-(trifluoromethoxy)phenyl	404
	4-methoxyphenoxy	9-fluorenon-4-yl	422
	4-methoxyphenoxy	isoxazol-5-yl	311
	4-methoxyphenoxy	benzofuroxan-5-yl	378
15	4-methoxyphenoxy	2-chloropyrid-3-yl	356
	4-methoxyphenoxy	2-(4-methylphenoxy)pyridin-3-yl	427
	4-methoxyphenoxy	pyridin-4-yl	321
	4-methoxyphenoxy	anthraquinon-2-yl	450
20	4-methoxyphenoxy	2-iodophenyl	446
	4-methoxyphenoxy	4-pentylphenyl	390
	4-methoxyphenoxy	2-(4-chlorophenylthio)pyridin-3-yl	464
	4-methoxyphenoxy	2,6-dimethylphenyl	348
25	4-methoxyphenoxy	2,5-dimethoxyphenyl	380
	4-methoxyphenoxy	2,5-dichloropyridin-3-yl	390
	4-methoxyphenoxy	2-chloro-6-methoxypyridin-4-yl	386
	4-methoxyphenoxy	2,3-dichloropyridin-5-yl	390
30	4-methoxyphenoxy	1-naphthyl	384
	4-methoxyphenoxy	2,4-dimethoxyphenyl	380
	4-methoxyphenoxy	3,5-bis(trifluoromethyl)phenyl	456
	4-methoxyphenoxy	2-(4-chlorophenoxy)pyridin-3-yl	448
35	4-methoxyphenoxy	pentafluorophenyl	410
	2-(2-propoxy)phenoxy	3,4-dimethoxyphenyl	408
	2-(2-propoxy)phenoxy	2-(trifluoromethyl)phenyl	416
	2-(2-propoxy)phenoxy	2,4-difluorophenyl	384
40	2-(2-propoxy)phenoxy	3-(trifluoromethyl)phenyl	416
	2-(2-propoxy)phenoxy	2-naphthyl	398
	2-(2-propoxy)phenoxy	2-methoxyphenyl	378
	2-(2-propoxy)phenoxy	3,4,5-trimethylphenyl	438
45	2-(2-propoxy)phenoxy	3,4-dichlorophenyl	417
	2-(2-propoxy)phenoxy	3-bromophenyl	427
	2-(2-propoxy)phenoxy	3-pyridyl	349
	2-(2-propoxy)phenoxy	2-ethoxynaphth-1-yl	442
50	2-(2-propoxy)phenoxy	2,3-dichlorophenyl	417
	2-(2-propoxy)phenoxy	6-chloropyrid-3-yl	384
	2-(2-propoxy)phenoxy	4-(trifluoromethoxy)phenyl	432
	2-(2-propoxy)phenoxy	2-fluoro-4-(trifluoromethyl)phenyl	434
55	2-(2-propoxy)phenoxy	3-bromothieryl	433
	2-(2-propoxy)phenoxy	2-acetoxyphenyl	406
	2-(2-propoxy)phenoxy	5-methylisoxazol-3-yl	353
	2-(2-propoxy)phenoxy	2-(phenylthio)pyrid-3-yl	458
	2-(2-propoxy)phenoxy	2-(trifluoromethoxy)phenyl	432
	2-(2-propoxy)phenoxy	1-phenyl-5-propylpyrazin-4-yl	457
	2-(2-propoxy)phenoxy	2-ethoxyphenyl	392
	2-(2-propoxy)phenoxy	3-chlorothien-2-yl	389
	2-(2-propoxy)phenoxy	1-(2-(2-methyl)propyl)-3-methylpyrazol-5-yl	408

EP 1 028 945 B9

(continued)

	R ¹ X	R ³	MS (m/z)
5	2-(2-propoxy)phenoxy	3,5-dichlorophenyl	417
	2-(2-propoxy)phenoxy	2-(propylthio)pyridin-3-yl	423
	2-(2-propoxy)phenoxy	2-(ethylthio)pyridin-3-yl	409
	2-(2-propoxy)phenoxy	3-bromopyridin-5-yl	428
	2-(2-propoxy)phenoxy	4-methyl-1,2,3-thiadiazol-5-yl	370
10	2-(2-propoxy)phenoxy	1-methyl-3-(2-(2-methyl)propyl)pyrazol-5-yl	408
	2-(2-propoxy)phenoxy	3-chlorobenzo[b]thiophen-2-yl	439
	2-(2-propoxy)phenoxy	4-chlorophenyl	383
	2-(2-propoxy)phenoxy	4-methyl-2-phenyl-1,2,3-triazol-5-yl	429
	2-(2-propoxy)phenoxy	benzo[b]thiophen-2-yl	404
15	2-(2-propoxy)phenoxy	3,4-dimethylphenyl	376
	2-(2-propoxy)phenoxy	2-(phenoxy)pyridin-3-yl	441
	2-(2-propoxy)phenoxy	2-(methylthio)pyridin-3-yl	395
	2-(2-propoxy)phenoxy	5-methyl-3-phenylisoxazol-4-yl	429
	2-(2-propoxy)phenoxy	4-chloro-1,3-dimethyl pyrazolo[3,4-b]pyridin-3-yl	452
20	2-(2-propoxy)phenoxy	2-chloro-6-methylpyridin-4-yl	398
	2-(2-propoxy)phenoxy	3,5-dimethylisoxazol-4-yl	367
	2-(2-propoxy)phenoxy	1-naphthyl	398
	2-(2-propoxy)phenoxy	2-fluorophenyl	366
	2-(2-propoxy)phenoxy	4-propylphenyl	390
25	2-(2-propoxy)phenoxy	3-fluorophenyl	366
	2-(2-propoxy)phenoxy	2,6-difluorophenyl	384
	2-(2-propoxy)phenoxy	2-chlorophenyl	383
	2-(2-propoxy)phenoxy	3-(chloromethyl)phenyl	397
	2-(2-propoxy)phenoxy	4-(2-(2-methyl)propyl)phenyl	404
30	2-(2-propoxy)phenoxy	3-chlorophenyl	383
	2-(2-propoxy)phenoxy	3,5-dimethoxyphenyl	408
	2-(2-propoxy)phenoxy	2,6-dichlorophenyl	417
	2-(2-propoxy)phenoxy	2,4-dichlorophenyl	417
	2-(2-propoxy)phenoxy	4-fluorophenyl	366
35	2-(2-propoxy)phenoxy	4-butylphenyl	404
	2-(2-propoxy)phenoxy	2-methylphenyl	362
	2-(2-propoxy)phenoxy	phenyl	348
	2-(2-propoxy)phenoxy	4-ethylphenyl	376
	2-(2-propoxy)phenoxy	2,3-difluorophenyl	384
40	2-(2-propoxy)phenoxy	2,6-dimethoxyphenyl	408
	2-(2-propoxy)phenoxy	3,4-difluorophenyl	384
	2-(2-propoxy)phenoxy	2,5-difluorophenyl	384
	2-(2-propoxy)phenoxy	4-ethoxyphenyl	392
	2-(2-propoxy)phenoxy	2,4,6-trichlorophenyl	452
45	2-(2-propoxy)phenoxy	3-methylphenyl	362
	2-(2-propoxy)phenoxy	2-fluoro-5-(trifluoromethyl)phenyl	434
	2-(2-propoxy)phenoxy	3-methoxyphenyl	378
	2-(2-propoxy)phenoxy	2-bromophenyl	427
	2-(2-propoxy)phenoxy	4-bromophenyl	427
50	2-(2-propoxy)phenoxy	4-fluoro-3-(trifluoromethyl)phenyl	434
	2-(2-propoxy)phenoxy	3-(trifluoromethoxy)phenyl	432
	2-(2-propoxy)phenoxy	9-fluorenon-4-yl	450
	2-(2-propoxy)phenoxy	isoxazol-5-yl	339
	2-(2-propoxy)phenoxy		

EP 1 028 945 B9

(continued)

	R ¹ X	R ³	MS (m/z)
5	2-(2-propoxy)phenoxy	benzofuroxan-5-yl	406
	2-(2-propoxy)phenoxy	2-chloropyrid-3-yl	384
	2-(2-propoxy)phenoxy	2-(4-methylphenoxy)pyridin-3-yl	455
	2-(2-propoxy)phenoxy	pyridin-4-yl	349
	2-(2-propoxy)phenoxy	anthraquinon-2-yl	478
10	2-(2-propoxy)phenoxy	2-iodophenyl	474
	2-(2-propoxy)phenoxy	4-pentylphenyl	419
	2-(2-propoxy)phenoxy	2-(4-chlorophenylthio)pyridin-3-yl	492
	2-(2-propoxy)phenoxy	2,6-dimethylphenyl	376
	2-(2-propoxy)phenoxy	2,5-dimethoxyphenyl	408
15	2-(2-propoxy)phenoxy	2,5-dichloropyridin-3-yl	418
	2-(2-propoxy)phenoxy	2-chloro-6-methoxypyridin-4-yl	414
	2-(2-propoxy)phenoxy	2,3-dichloropyridin-5-yl	418
	2-(2-propoxy)phenoxy	1-naphthyl	412
	2-(2-propoxy)phenoxy	2,4-dimethoxyphenyl	408
20	2-(2-propoxy)phenoxy	3,5-bis(trifluoromethyl)phenyl	484
	2-(2-propoxy)phenoxy	2-(4-chlorophenoxy)pyridin-3-yl	476
	2-(2-propoxy)phenoxy	pentafluorophenyl	438
	4-fluorophenoxy	3,4-dimethoxyphenyl	368
	4-fluorophenoxy	2-(trifluoromethyl)phenyl	376
25	4-fluorophenoxy	2,4-difluorophenyl	344
	4-fluorophenoxy	3-(trifluoromethyl)phenyl	376
	4-fluorophenoxy	2-naphthyl	358
	4-fluorophenoxy	2-methoxyphenyl	338
	4-fluorophenoxy	3,4,5-trimethylphenyl	398
30	4-fluorophenoxy	3,4-dichlorophenyl	377
	4-fluorophenoxy	3-bromophenyl	387
	4-fluorophenoxy	3-pyridyl	309
	4-fluorophenoxy	2-ethoxynaphth-1-yl	402
	4-fluorophenoxy	2,3-dichlorophenyl	377
35	4-fluorophenoxy	6-chloropyrid-3-yl	344
	4-fluorophenoxy	4-(trifluoromethoxy)phenyl	392
	4-fluorophenoxy	2-fluoro-4-(trifluoromethyl)phenyl	394
	4-fluorophenoxy	3-bromothieryl	393
	4-fluorophenoxy	2-acetoxyphenyl	366
40	4-fluorophenoxy	5-methylisoxazol-3-yl	313
	4-fluorophenoxy	2-(phenylthio)pyrid-3-yl	417
	4-fluorophenoxy	2-(trifluoromethoxy)phenyl	392
	4-fluorophenoxy	1-phenyl-5-propylpyrazin-4-yl	416
	4-fluorophenoxy	2-ethoxyphenyl	352
45	4-fluorophenoxy	3-chlorothien-2-yl	349
	4-fluorophenoxy	1-(2-(2-methyl)propyl)-3-methylpyrazol-5-yl	368
	4-fluorophenoxy	3,5-dichlorophenyl	377
	4-fluorophenoxy	2-(propylthio)pyridin-3-yl	383
	4-fluorophenoxy	2-(ethylthio)pyridin-3-yl	369
50	4-fluorophenoxy	3-bromopyridin-5-yl	388
	4-fluorophenoxy	4-methyl-1,2,3-thiadiazol-5-yl	330
	4-fluorophenoxy	1-methyl-3-(2-(2-methyl)propyl)pyrazol-5-yl	368
	4-fluorophenoxy	3-chlorobenzo[b]thiophen-2-yl	399
	4-fluorophenoxy		

EP 1 028 945 B9

(continued)

	R ¹ X	R ³	MS (m/z)
5	4-fluorophenoxy	4-chlorophenyl	343
	4-fluorophenoxy	4-methyl-2-phenyl-1,2,3-triazol-5-yl	389
	4-fluorophenoxy	benzo[b]thiophen-2-yl	364
	4-fluorophenoxy	3,4-dimethylphenyl	336
	4-fluorophenoxy	2-(phenoxy)pyridin-3-yl	401
10	4-fluorophenoxy	2-(methylthio)pyridin-3-yl	355
	4-fluorophenoxy	5-methyl-3-phenylisoxazol-4-yl	389
	4-fluorophenoxy	4-chloro-1,3-dimethyl pyrazolo[3,4-b]pyridin-3yl	412
	4-fluorophenoxy	2-chloro-6-methylpyridin-4-yl	358
	4-fluorophenoxy	3,5-dimethylisoxazol-4-yl	327
15	4-fluorophenoxy	1-naphthyl	358
	4-fluorophenoxy	2-fluorophenyl	326
	4-fluorophenoxy	4-propylphenyl	350
	4-fluorophenoxy	3-fluorophenyl	326
	4-fluorophenoxy	2,6-difluorophenyl	344
20	4-fluorophenoxy	2-chlorophenyl	343
	4-fluorophenoxy	3-(chloromethyl)phenyl	357
	4-fluorophenoxy	4-(2-(2-methyl)propyl)phenyl	364
	4-fluorophenoxy	3-chlorophenyl	343
	4-fluorophenoxy	3,5-dimethoxyphenyl	368
25	4-fluorophenoxy	2,6-dichlorophenyl	377
	4-fluorophenoxy	2,4-dichlorophenyl	377
	4-fluorophenoxy	4-fluorophenyl	326
	4-fluorophenoxy	4-butylphenyl	364
	4-fluorophenoxy	2-methylphenyl	322
30	4-fluorophenoxy	phenyl	308
	4-fluorophenoxy	4-ethylphenyl	336
	4-fluorophenoxy	2,3-difluorophenyl	344
	4-fluorophenoxy	2,6-dimethoxyphenyl	368
	4-fluorophenoxy	3,4-difluorophenyl	344
35	4-fluorophenoxy	2,5-difluorophenyl	344
	4-fluorophenoxy	4-ethoxyphenyl	352
	4-fluorophenoxy	2,4,6-trichlorophenyl	412
	4-fluorophenoxy	3-methylphenyl	322
	4-fluorophenoxy	2-fluoro-5-(trifluoromethyl)phenyl	394
40	4-fluorophenoxy	3-methoxyphenyl	338
	4-fluorophenoxy	2-bromophenyl	387
	4-fluorophenoxy	4-bromophenyl	387
	4-fluorophenoxy	4-fluoro-3-(trifluoromethyl)phenyl	394
	4-fluorophenoxy	3-(trifluoromethoxy)phenyl	392
45	4-fluorophenoxy	9-fluorenon-4-yl	410
	4-fluorophenoxy	isoxazol-5-yl	299
	4-fluorophenoxy	benzofuroxan-5-yl	366
	4-fluorophenoxy	2-chloropyrid-3-yl	344
	4-fluorophenoxy	2-(4-methylphenoxy)pyridin-3-yl	415
50	4-fluorophenoxy	pyridin-4-yl	309
	4-fluorophenoxy	anthraquinon-2-yl	438
	4-fluorophenoxy	2-iodophenyl	434
	4-fluorophenoxy	4-pentylphenyl	378
	4-fluorophenoxy		

EP 1 028 945 B9

(continued)

	R ¹ X	R ³	MS (m/z)
5	4-fluorophenoxy	2-(4-chlorophenylthio)pyridin-3-yl	452
	4-fluorophenoxy	2,6-dimethylphenyl	336
	4-fluorophenoxy	2,5-dimethoxyphenyl	368
	4-fluorophenoxy	2,5-dichloropyridin-3-yl	378
	4-fluorophenoxy	2-chloro-6-methoxypyridin-4-yl	374
10	4-fluorophenoxy	2,3-dichloropyridin-5-yl	378
	4-fluorophenoxy	1-naphthyl	372
	4-fluorophenoxy	2,4-dimethoxyphenyl	368
	4-fluorophenoxy	3,5-bis(trifluoromethyl)phenyl	444
	4-fluorophenoxy	2-(4-chlorophenoxy)pyridin-3-yl	436
15	4-fluorophenoxy	pentafluorophenyl	398
	4-chlorophenoxy	3,4-dimethoxyphenyl	385
	4-chlorophenoxy	2-(trifluoromethyl)phenyl	393
	4-chlorophenoxy	2,4-difluorophenyl	361
	4-chlorophenoxy	3-(trifluoromethyl)phenyl	393
20	4-chlorophenoxy	2-naphthyl	375
	4-chlorophenoxy	2-methoxyphenyl	355
	4-chlorophenoxy.	3,4,5-trimethylphenyl	415
	4-chlorophenoxy	3,4-dichlorophenyl	394
	4-chlorophenoxy.	3-bromophenyl	404
25	4-chlorophenoxy	3-pyridyl	326
	4-chlorophenoxy	2-ethoxynaphth-1-yl	419
	4-chlorophenoxy	2,3-dichlorophenyl	394
	4-chlorophenoxy	6-chloropyrid-3-yl	360
	4-chlorophenoxy	4-(trifluoromethoxy)phenyl	409
30	4-chlorophenoxy	2-fluoro-4-(trifluoromethyl)phenyl	411
	4-chlorophenoxy	3-bromothieryl	410
	4-chlorophenoxy	2-acetoxyphenyl	383
	4-chlorophenoxy	5-methylisoxazol-3-yl	330
	4-chlorophenoxy	2-(phenylthio)pyrid-3-yl	434
35	4-chlorophenoxy	2-(trifluoromethoxy)phenyl	409
	4-chlorophenoxy	1-phenyl-5-propylpyrazin-4-yl	433
	4-chlorophenoxy	2-ethoxyphenyl	369
	4-chlorophenoxy	3-chlorothien-2-yl	365
	4-chlorophenoxy	1-(2-(2-methyl)propyl)-3-methylpyrazol-5-yl	385
40	4-chlorophenoxy	3,5-dichlorophenyl	394
	4-chlorophenoxy	2-(propylthio)pyridin-3-yl	400
	4-chlorophenoxy	2-(ethylthio)pyridin-3-yl	386
	4-chlorophenoxy	3-bromopyridin-5-yl	405
	4-chlorophenoxy	4-methyl-1,2,3-thiadiazol-5-yl	347
45	4-chlorophenoxy	1-methyl-3-(2-(2-methyl)propyl)pyrazol-5-yl	385
	4-chlorophenoxy	3-chlorobenzo[b]thiophen-2-yl	415
	4-chlorophenoxy	4-chlorophenyl	359
	4-chlorophenoxy	4-methyl-2-phenyl-1,2,3-triazol-5-yl	406
	4-chlorophenoxy	benzo[b]thiophen-2-yl	381
50	4-chlorophenoxy	3,4-dimethylphenyl	353
	4-chlorophenoxy	2-(phenoxy)pyridin-3-yl	418
	4-chlorophenoxy	2-(methylthio)pyridin-3-yl	372
	4-chlorophenoxy	5-methyl-3-phenylisoxazol-4-yl	406
	4-chlorophenoxy		

EP 1 028 945 B9

	R ¹ X	(continued)	R ³	MS (m/z)
5	4-chlorophenoxy	4-chloro-1,3-dimethyl pyrazolo[3,4-b]pyridin-3-yl		428
	4-chlorophenoxy	2-chloro-6-methylpyridin-4-yl		374
	4-chlorophenoxy	3,5-dimethylisoxazol-4-yl		344
	4-chlorophenoxy	1-naphthyl		375
	4-chlorophenoxy	2-fluorophenyl		343
10	4-chlorophenoxy	4-propylphenyl		367
	4-chlorophenoxy	3-fluorophenyl		343
	4-chlorophenoxy	2,6-difluorophenyl		361
	4-chlorophenoxy	2-chlorophenyl		359
15	4-chlorophenoxy	3-(chloromethyl)phenyl		373
	4-chlorophenoxy	4-(2-(2-methyl)propyl)phenyl		381
	4-chlorophenoxy	3-chlorophenyl		359
	4-chlorophenoxy	3,5-dimethoxyphenyl		385
	4-chlorophenoxy	2,6-dichlorophenyl		394
20	4-chlorophenoxy	2,4-dichlorophenyl		394
	4-chlorophenoxy	4-fluorophenyl		343
	4-chlorophenoxy	4-butylphenyl		381
	4-chlorophenoxy	2-methylphenyl		339
25	4-chlorophenoxy,	phenyl		325
	4-chlorophenoxy	4-ethylphenyl		353
	4-chlorophenoxy	2,3-difluorophenyl		361
	4-chlorophenoxy	2,6-dimethoxyphenyl		385
	4-chlorophenoxy	3,4-difluorophenyl		361
30	4-chlorophenoxy	2,5-difluorophenyl		361
	4-chlorophenoxy	4-ethoxyphenyl		369
	4-chlorophenoxy	2,4,6-trichlorophenyl		428
	4-chlorophenoxy	3-methylphenyl		339
35	4-chlorophenoxy	2-fluoro-5-(trifluoromethyl)phenyl		411
	4-chlorophenoxy	3-methoxyphenyl		355
	4-chlorophenoxy	2-bromophenyl		404
	4-chlorophenoxy	4-bromophenyl		404
	4-chlorophenoxy	4-fluoro-3-(trifluoromethyl)phenyl		411
40	4-chlorophenoxy	3-(trifluoromethoxy)phenyl		409
	4-chlorophenoxy	9-fluorenon-4-yl		427
	4-chlorophenoxy	isoxazol-5-yl		316
	4-chlorophenoxy	benzofuroxan-5-yl		383
45	4-chlorophenoxy	2-chloropyrid-3-yl		360
	4-chlorophenoxy	2-(4-methylphenoxy)pyridin-3-yl		432
	4-chlorophenoxy ,	pyridin-4-yl		326
	4-chlorophenoxy	anthraquinon-2-yl		455
	4-chlorophenoxy	2-iodophenyl		451
50	4-chlorophenoxy	4-pentylphenyl		395
	4-chlorophenoxy	2-(4-chlorophenylthio)pyridin-3-yl		468
	4-chlorophenoxy	2,6-dimethylphenyl		353
	4-chlorophenoxy	2,5-dimethoxyphenyl		385
	4-chlorophenoxy	2,5-dichloropyridin-3-yl		395
55	4-chlorophenoxy	2-chloro-6-methoxypyridin-4-yl		390
	4-chlorophenoxy	2,3-dichloropyridin-5-yl		395
	4-chlorophenoxy	1-naphthyl		389

EP 1 028 945 B9

(continued)

	R ¹ X	R ³	MS (m/z)
5	4-chlorophenoxy	2,4-dimethoxyphenyl	385
	4-chlorophenoxy	3,5-bis(trifluoromethyl)phenyl	461
	4-chlorophenoxy	2-(4-chlorophenoxy)pyridin-3-yl	452
	4-chlorophenoxy	pentafluorophenyl	415
	2,4-difluorophenoxy	3,4-dimethoxyphenyl	386
10	2,4-difluorophenoxy	2-(trifluoromethyl)phenyl	394
	2,4-difluorophenoxy	2,4-difluorophenyl	362
	2,4-difluorophenoxy	3-(trifluoromethyl)phenyl	394
	2,4-difluorophenoxy	2-naphthyl	376
	2,4-difluorophenoxy	2-methoxyphenyl	356
15	2,4-difluorophenoxy	3,4,5-trimethylphenyl	416
	2,4-difluorophenoxy	3,4-dichlorophenyl	395
	2,4-difluorophenoxy	3-bromophenyl	405
	2,4-difluorophenoxy	3-pyridyl	327
	2,4-difluorophenoxy	2-ethoxynaphth-1-yl	420
20	2,4-difluorophenoxy	2,3-dichlorophenyl	395
	2,4-difluorophenoxy	6-chloropyrid-3-yl	362
	2,4-difluorophenoxy	4-(trifluoromethoxy)phenyl	410
	2,4-difluorophenoxy	2-fluoro-4-(trifluoromethyl)phenyl	412
	2,4-difluorophenoxy	3-bromothieryl	411
25	2,4-difluorophenoxy	2-acetoxyphenyl	384
	2,4-difluorophenoxy	5-methylisoxazol-3-yl	331
	2,4-difluorophenoxy	2-(phenylthio)pyrid-3-yl	435
	2,4-difluorophenoxy	2-(trifluoromethoxy)phenyl	410
	2,4-difluorophenoxy	1-phenyl-5-propylpyrazin-4-yl	434
30	2,4-difluorophenoxy	2-ethoxyphenyl	370
	2,4-difluorophenoxy	3-chlorothieryl-2-yl	367
	2,4-difluorophenoxy	1-(2-(2-methyl)propyl)-3-methylpyrazol-5-yl	386
	2,4-difluorophenoxy	3,5-dichlorophenyl	395
	2,4-difluorophenoxy	2-(propylthio)pyridin-3-yl	401
35	2,4-difluorophenoxy	2-(ethylthio)pyridin-3-yl	387
	2,4-difluorophenoxy	3-bromopyridin-5-yl	406
	2,4-difluorophenoxy	4-methyl-1,2,3-thiadiazol-5-yl	348
	2,4-difluorophenoxy	1-methyl-3-(2-(2-methyl)propyl)pyrazol-5-yl	386
	2,4-difluorophenoxy	3-chlorobenzo[b]thiophen-2-yl	417
40	2,4-difluorophenoxy	4-chlorophenyl	361
	2,4-difluorophenoxy	4-methyl-2-phenyl-1,2,3-triazol-5-yl	407
	2,4-difluorophenoxy	benzo[b]thiophen-2-yl	382
	2,4-difluorophenoxy	3,4-dimethylphenyl	354
	2,4-difluorophenoxy	2-(phenoxy)pyridin-3-yl	409
45	2,4-difluorophenoxy	2-(methylthio)pyridin-3-yl	373
	2,4-difluorophenoxy	5-methyl-3-phenylisoxazol-4-yl	407
	2,4-difluorophenoxy	4-chloro-1,3-dimethyl pyrazolo[3,4-b]pyridin-3yl	430
	2,4-difluorophenoxy	2-chloro-6-methylpyridin-4-yl	376
	2,4-difluorophenoxy	3,5-dimethylisoxazol-4-yl	345
50	2,4-difluorophenoxy	1-naphthyl	376
	2,4-difluorophenoxy	2-fluorophenyl	344
	2,4-difluorophenoxy	4-propylphenyl	368
	2,4-difluorophenoxy	3-fluorophenyl	344
	2,4-difluorophenoxy		

EP 1 028 945 B9

(continued)

	R ¹ X	R ³	MS (m/z)
5	2,4-difluorophenoxy	2,6-difluorophenyl	362
	2,4-difluorophenoxy	2-chlorophenyl	361
	2,4-difluorophenoxy	3-(chloromethyl)phenyl	375
	2,4-difluorophenoxy	4-(2-(2-methyl)propyl)phenyl	382
	2,4-difluorophenoxy	3-chlorophenyl	361
10	2,4-difluorophenoxy	3,5-dimethoxyphenyl	386
	2,4-difluorophenoxy	2,6-dichlorophenyl	395
	2,4-difluorophenoxy	2,4-dichlorophenyl	392
	2,4-difluorophenoxy	4-fluorophenyl	344
	2,4-difluorophenoxy	4-butylphenyl	382
15	2,4-difluorophenoxy	2-methylphenyl	340
	2,4-difluorophenoxy	phenyl	326
	2,4-difluorophenoxy	4-ethylphenyl	354
	2,4-difluorophenoxy	2,3-difluorophenyl	362
	2,4-difluorophenoxy	2,6-dimethoxyphenyl	386
20	2,4-difluorophenoxy	3,4-difluorophenyl	362
	2,4-difluorophenoxy	2,5-difluorophenyl	362
	2,4-difluorophenoxy	4-ethoxyphenyl	370
	2,4-difluorophenoxy	2,4,6-trichlorophenyl	430
	2,4-difluorophenoxy	3-methylphenyl	340
25	2,4-difluorophenoxy	2-fluoro-5-(trifluoromethyl)phenyl	412
	2,4-difluorophenoxy	3-methoxyphenyl	356
	2,4-difluorophenoxy	2-bromophenyl	405
	2,4-difluorophenoxy	4-bromophenyl	405
	2,4-difluorophenoxy	4-fluoro-3-(trifluoromethyl)phenyl	412
30	2,4-difluorophenoxy	3-(trifluoromethoxy)phenyl	410
	2,4-difluorophenoxy	9-fluorenon-4-yl	428
	2,4-difluorophenoxy	isoxazol-5-yl	317
	2,4-difluorophenoxy	benzofuroxan-5-yl	384
	2,4-difluorophenoxy	2-chloropyridin-3-yl	362
35	2,4-difluorophenoxy	2-(4-methylphenoxy)pyridin-3-yl	433
	2,4-difluorophenoxy	pyridin-4-yl	327
	2,4-difluorophenoxy	anthraquinon-2-yl	456
	2,4-difluorophenoxy	2-iodophenyl	452
	2,4-difluorophenoxy	4-pentylphenyl	396
40	2,4-difluorophenoxy	2-(4-chlorophenylthio)pyridin-3-yl	470
	2,4-difluorophenoxy	2,6-dimethylphenyl	354
	2,4-difluorophenoxy	2,5-dimethoxyphenyl	386
	2,4-difluorophenoxy	2,5-dichloropyridin-3-yl	396
	2,4-difluorophenoxy	2-chloro-6-methoxypyridin-4-yl	392
45	2,4-difluorophenoxy	2,3-dichloropyridin-5-yl	396
	2,4-difluorophenoxy.	1-naphthyl	390
	2,4-difluorophenoxy	2,4-dimethoxyphenyl	386
	2,4-difluorophenoxy	3,5-bis(trifluoromethyl)phenyl	462
	2,4-difluorophenoxy	2-(4-chlorophenoxy)pyridin-3-yl	454
50	2,4-difluorophenoxy	pentafluorophenyl	416
	4-thiomethylphenoxy	3,4-dimethoxyphenyl	396
	4-thiomethylphenoxy	2-(trifluoromethyl)phenyl	404
	4-thiomethylphenoxy	2,4-difluorophenyl	372

EP 1 028 945 B9

(continued)

	R ¹ X	R ³	MS (m/z)
5	4-thiomethylphenoxy	3-(trifluoromethyl)phenyl	404
	4-thiomethylphenoxy	2-naphthyl	386
	4-thiomethylphenoxy	2-methoxyphenyl	366
	4-thiomethylphenoxy	3,4,5,-trimethylphenyl	426
10	4-thiomethylphenoxy	3,4-dichlorophenyl	405
	4-thiomethylphenoxy	3-bromophenyl	415
	4-thiomethylphenoxy	3-pyridyl	337
	4-thiomethylphenoxy	2-ethoxynaphth-1-yl	430
15	4-thiomethylphenoxy	2,3-dichlorophenyl	405
	4-thiomethylphenoxy	6-chloropyrid-3-yl	372
	4-thiomethylphenoxy	4-(trifluoromethoxy)phenyl	420
	4-thiomethylphenbxy	2-fluoro-4-(trifluoromethyl)phenyl	422
20	4-thiomethylphenoxy	3-bromothieryl	421
	4-thiomethylphenoxy	2-acetoxyphenyl	394
	4-thiomethylphenoxy	5-methylisoxazol-3-yl	341
	4-thiomethylphenoxy	2-(phenylthio)pyrid-3-yl	446
25	4-thiomethylphenoxy	2-(trifluoromethoxy)phenyl	420
	4-thiomethylphenoxy	1-phenyl-5-propylpyrazin-4-yl	445
	4-thiomethylphenoxy	2-ethoxyphenyl	380
	4-thiomethylphenoxy	3-chlorothien-2-yl	377
30	4-thiomethylphenoxy	1-(2-(2-methyl)propyl)-3-methylpyrazol-5-yl	396
	4-thiomethylphenoxy	3,5-dichlorophenyl	405
	4-thiomethylphenoxy	2-(propylthio)pyridin-3-yl	412
	4-thiomethylphenoxy	2-(ethylthio)pyridin-3-yl	397
35	4-thiomethylphenoxy	3-bromopyridin-5-yl	416
	4-thiomethylphenoxy	4-methyl-1,2,3-thiadiazol-5-yl	358
	4-thiomethylphenoxy	1-methyl-3-(2-(2-methyl)propyl)pyrazol-5-yl	396
	4-thiomethylphenoxy	3-chlorobenzo[b]thiophen--2-yl	427
40	4-thiomethylphenoxy	4-chlorophenyl	371
	4-thiomethylphenoxy	4-methyl-2-phenyl-1,2,3-triazol-5-yl	417
	4-thiomethylphenoxy	benzo[b]thiophen-2-yl	392
	4-thiomethylphenoxy	3,4-dimethylphenyl	364
45	4-thiomethylphenoxy	2-(phenoxy)pyridin-3-yl	429
	4-thiomethylphenoxy	2-(methylthio)pyridin-3-yl	383
	4-thiomethylphenoxy	5-methyl-3-phenylisoxazol-4-yl	417
	4-thiomethylphenoxy	4-chloro-1,3-dimethyl pyrazolo[3,4-b]pyridin-3-yl	440
50	4-thiomethylphenoxy	2-chloro-6-methylpyridin-4-yl	386
	4-thiomethylphenoxy	3,5-dimethylisoxazol-4-yl	355,
	4-thiomethylphenoxy	1-naphthyl	386
	4-thiomethylphenoxy	2-fluorophenyl	354
55	4-thiomethylphenoxy	4-propylphenyl	378
	4-thiomethylphenoxy	3-fluorophenyl	354
	4-thiomethylphenoxy	2,6-difluorophenyl	372
	4-thiomethylphenoxy	2-chlorophenyl	371
	4-thiomethylphenoxy	3-(chloromethyl)phenyl	385
	4-thiomethylphenoxy	4-(2-(2-methyl)propyl)phenyl	392
	4-thiomethylphenoxy	3-chlorophenyl	371
	4-thiomethylphenoxy	3,5-dimethoxyphenyl	396
	4-thiomethylphenoxy	2,6-dichlorophenyl	405

EP 1 028 945 B9

(continued)

	R ¹ X	R ³	MS (m/z)
5	4-thiomethylphenoxy	2,4-dichlorophenyl	405
	4-thiomethylphenoxy	4-fluorophenyl	354
	4-thiomethylphenoxy	4-butylphenyl	392
	4-thiomethylphenoxy	2-methylphenyl	350
	4-thiomethylphenoxy	phenyl	336
10	4-thiomethylphenoxy	4-ethylphenyl	364
	4-thiomethylphenoxy	2,3-difluorophenyl	372
	4-thiomethylphenoxy	2,6-dimethoxyphenyl	396
	4-thiomethylphenoxy	3,4-difluorophenyl	372
	4-thiomethylphenoxy	2,5-difluorophenyl	372
15	4-thiomethylphenoxy	4-ethoxyphenyl	380
	4-thiomethylphenoxy	2,4,6-trichlorophenyl	440
	4-thiomethylphenoxy	3-methylphenyl	350
	4-thiomethylphenoxy	2-fluoro-5-(trifluoromethyl)phenyl	422
	4-thiomethylphenoxy	3-methoxyphenyl	366
20	4-thiomethylphenoxy	2-bromophenyl	415
	4-thiomethylphenoxy	4-bromophenyl	415
	4-thiomethylphenoxy	4-fluoro-3-(trifluoromethyl)phenyl	422
	4-thiomethylphenoxy	3-(trifluoromethoxy)phenyl	420
	4-thiomethylphenoxy	9-fluorenon-4-yl	438
25	4-thiomethylphenoxy	isoxazol-5-yl	327
	4-thiomethylphenoxy	benzofuroxan-5-yl	394
	4-thiomethylphenoxy	2-chloropyrid-3-yl	372
	4-thiomethylphenoxy	2-(4-methylphenoxy)pyridin-3-yl	443
	4-thiomethylphenoxy	pyridin-4-yl	337
30	4-thiomethylphenoxy	anthraquinon-2-yl	466
	4-thiomethylphenoxy	2-iodophenyl	462
	4-thiomethylphenoxy	4-pentylphenyl	407
	4-thiomethylphenoxy	2-(4-chlorophenylthio)pyridin-3-yl	480
	4-thiomethylphenoxy	2,6-dimethylphenyl	364
35	4-thiomethylphenoxy	2,5-dimethoxyphenyl	396
	4-thiomethylphenoxy	2,5-dichloropyridin-3-yl	406
	4-thiomethylphenoxy	2-chloro-6-methoxypyridin-4-yl	402
	4-thiomethylphenoxy	2,3-dichloropyridin-5-yl	406
	4-thiomethylphenoxy	1-naphthyl	400
40	4-thiomethylphenoxy	2,4-dimethoxyphenyl	396
	4-thiomethylphenoxy	3,5-bis(trifluoromethyl)phenyl	372
	4-thiomethylphenoxy	2-(4-chlorophenoxy)pyridin-3-yl	464
	4-thiomethylphenoxy	pentafluorophenyl	426,
	4-(2-(2-methyl)propyl)phenoxy	3,4-dimethoxyphenyl	406
45	4-(2-(2-methyl)propyl)phenoxy	2-(trifluoromethyl)phenyl	414
	4-(2-(2-methyl)propyl)phenoxy	2,4-difluorophenyl	382
	4-(2-(2-methyl)propyl)phenoxy	3-(trifluoromethyl)phenyl	414
	4-(2-(2-methyl)propyl)phenoxy	2-naphthyl	396
	4-(2-(2-methyl)propyl)phenoxy	2-methoxyphenyl	376
50	4-(2-(2-methyl)propyl)phenoxy	3,4,5-trimethylphenyl	436
	4-(2-(2-methyl)propyl)phenoxy	3,4-dichlorophenyl	415
	4-(2-(2-methyl)propyl)phenoxy	3-bromophenyl	425
	4-(2-(2-methyl)propyl)phenoxy	3-pyridyl	347
	4-(2-(2-methyl)propyl)phenoxy		

(continued)

	R ¹ X	R ³	MS (m/z)
5	4-(2-(2-methyl)propyl)phenoxy	2-ethoxynaphth-1-yl	441
	4-(2-(2- 2,3-dichlorophenyl	methyl)propyl)phenoxy	415
	4-(2-(2-methyl)propyl)phenoxy	6-chloropyrid-3-yl	382
	4-(2-(2-methyl)propyl)phenoxy	4-(trifluoromethoxy)phenyl	430
10	4-(2-(2-methyl)propyl)phenoxy	2-fluoro-4-(trifluoromethyl)phenyl	432
	4-(2-(2-methyl)propyl)phenoxy	3-bromothieryl	431
	4-(2-(2-methyl)propyl)phenoxy	2-acetoxyphenyl	404
	4-(2-(2-methyl)propyl)phenoxy	5-methylisoxazol-3-yl	351
15	4-(2-(2-methyl)propyl)phenoxy	2-(phenylthio)pyrid-3-yl	456
	4-(2-(2-methyl)propyl)phenoxy	2-(trifluoromethoxy)phenyl	430
	4-(2-(2-methyl)propyl)phenoxy	1-phenyl-5-propylpyrazin-4-yl	455
	4-(2-(2-methyl)propyl)phenoxy	2-ethoxyphenyl	390
20	4-(2-(2-methyl)propyl)phenoxy	3-chlorothien-2-yl	387
	4-(2-(2-methyl)propyl)phenoxy	1-(2-(2-methyl)propyl)-3-methylpyrazol-5-yl	406
	4-(2-(2-methyl)propyl)phenoxy	3,5-dichlorophenyl	415
	4-(2-(2-methyl)propyl)phenoxy	2-(propylthio)pyridin-3-yl	422
25	4-(2-(2-methyl)propyl)phenoxy	2-(ethylthio)pyridin-3-yl	407
	4-(2-(2-methyl)propyl)phenoxy	3-bromopyridin-5-yl	426
	4-(2-(2-methyl)propyl)phenoxy	4-methyl-1,2,3-thiadiazol-5-yl	368
	4-(2-(2-methyl)propyl)phenoxy	1-methyl-3-(2-(2-methyl)propyl)pyrazol-5-yl	406
30	4-(2-(2-methyl)propyl)phenoxy	3-chlorobenzo[b]thiophen-2-yl	437
	4-(2-(2-methyl)propyl)phenoxy	4-chlorophenyl	381
	4-(2-(2-methyl)propyl)phenoxy	4-methyl-2-phenyl-1,2,3-triazol-5-yl	427
	4-(2-(2-methyl)propyl)phenoxy	benzo[b]thiophen-2-yl	402
35	4-(2-(2-methyl)propyl)phenoxy	3,4-dimethylphenyl	374
	4-(2-(2-methyl)propyl)phenoxy	2-(phenoxy)pyridin-3-yl	439
	4-(2-(2-methyl)propyl)phenoxy	2-(methylthio)pyridin-3-yl	393
	4-(2-(2-methyl)propyl)phenoxy	5-methyl-3-phenylisoxazol-4-yl	427
40	4-(2-(2-methyl)propyl)phenoxy	4-chloro-1,3-dimethyl pyrazolo[3,4-b]pyridin-3-yl	450
	4-(2-(2-methyl)propyl)phenoxy	2-chloro-6-methylpyridin-4-yl	396
	4-(2-(2-methyl)propyl)phenoxy	3,5-dimethylisoxazol-4-yl	365
	4-(2-(2-methyl)propyl)phenoxy	1-naphthyl	396
45	4-(2-(2-methyl)propyl)phenoxy	2-fluorophenyl	364
	4-(2-(2-methyl)propyl)phenoxy	4-propylphenyl	388
	4-(2-(2-methyl)propyl)phenoxy	3-fluorophenyl	364
	4-(2-(2-methyl)propyl)phenoxy	2,6-difluorophenyl	382
50	4-(2-(2-methyl)propyl)phenoxy	2-chlorophenyl	381
	4-(2-(2-methyl)propyl)phenoxy	3-(chloromethyl)phenyl	395
	4-(2-(2-methyl)propyl)phenoxy	4-(2-(2-methyl)propyl)phenyl	402
	4-(2-(2-methyl)propyl)phenoxy	3-chlorophenyl	381
55	4-(2-(2-methyl)propyl)phenoxy	3,5-dimethoxyphenyl	406
	4-(2-(2-methyl)propyl)phenoxy	2,6-dichlorophenyl	415
	4-(2-(2-ethyl)propyl)phenoxy	2,4-dichlorophenyl	415
	4-(2-(2-methyl)propyl)phenoxy	4-fluorophenyl	364
55	4-(2-(2-methyl)propyl)phenoxy	4-butylphenyl	402
	4-(2-(2-methyl)propyl)phenoxy	2-methylphenyl	360
	4-(2-(2-methyl)propyl)phenoxy	phenyl	346
	4-(2-(2-methyl)propyl)phenoxy	4-ethylphenyl	374
	4-(2-(2-methyl)propyl)phenoxy	2,3-difluorophenyl	382

EP 1 028 945 B9

(continued)

	R ¹ X	R ³	MS (m/z)
5	4-(2-(2-methyl)propyl)phenoxy	2,6-dimethoxyphenyl	406
	4-(2-(2-methyl)propyl)phenoxy	3,4-difluorophenyl	382
	4-(2-(2-methyl)propyl)phenoxy	2,5-difluorophenyl	382
	4-(2-(2-methyl)propyl)phenoxy	4-ethoxyphenyl	390
	4-(2-(2-methyl)propyl)phenoxy	2,4,6-trichlorophenyl	450
10	4-(2-(2-methyl)propyl)phenoxy	3-methylphenyl	360
	4-(2-(2-methyl)propyl)phenoxy	2-fluoro-5-(trifluoromethyl)phenyl	432
	4-(2-(2-methyl)propyl)phenoxy	3-methoxyphenyl	376
	4-(2-(2-methyl)propyl)phenoxy	2-bromophenyl	425
	4-(2-(2-methyl)propyl)phenoxy	4-bromophenyl	425
15	4-(2-(2-methyl)propyl)phenoxy	4-fluoro-3-(trifluoromethyl)phenyl	432
	4-(2-(2-methyl)propyl)phenoxy	3-(trifluoromethoxy)phenyl	430
	4-(2-(2-methyl)propyl)phenoxy	9-fluorenon-4-yl	448
	4-(2-(2-methyl)propyl)phenoxy	isoxazol-5-yl	338
	4-(2-(2-methyl)propyl)phenoxy	benzofuroxan-5-yl	404
20	4-(2-(2-methyl)propyl)phenoxy	2-chloropyrid-3-yl	382
	4-(2-(2-methyl)propyl)phenoxy	2-(4-methylphenoxy)pyridin-3-yl	454
	4-(2-(2-methyl)propyl)phenoxy	pyridin-4-yl	347
	4-(2-(2-methyl)propyl)phenoxy	anthraquinon-2-yl	476
	4-(2-(2-methyl)propyl)phenoxy	2-iodophenyl	472
25	4-(2-(2-methyl)propyl)phenoxy	4-pentylphenyl	417
	4-(2-(2-methyl)propyl)phenoxy	2-(4-chlorophenylthio)pyridin-3-yl	490
	4-(2-(2-methyl)propyl)phenoxy	2,6-dimethylphenyl	374
	4-(2-(2-methyl)propyl)phenoxy	2,5-dimethoxyphenyl	406
	4-(2-(2-methyl)propyl)phenoxy	2,5-dichloropyridin-3-yl	416
30	4-(2-(2-methyl)propyl)phenoxy	2-chloro-6-methoxypyridin-4-yl	412
	4-(2-(2-methyl)propyl)phenoxy	2,3-dichloropyridin-5-yl	416
	4-(2-(2-methyl)propyl)phenoxy	1-naphthyl	410
	4-(2-(2-methyl)propyl)phenoxy	2,4-dimethoxyphenyl	406
	4-(2-(2-methyl)propyl)phenoxy	3,5-bis(trifluoromethyl)phenyl	482
35	4-(2-(2-methyl)propyl)phenoxy	2-(4-chlorophenoxy)pyridin-3-yl	474
	4-(2-(2-methyl)propyl)phenoxy	pentafluorophenyl	436
	2,3-dimethylphenoxy	3,4-dimethoxyphenyl	378
	2,3-dimethylphenoxy	2-(trifluoromethyl)phenyl	386
	2,3-dimethylphenoxy	2,4-difluorophenyl	354
40	2,3-dimethylphenoxy	3-(trifluoromethyl)phenyl	386
	2,3-dimethylphenoxy	2-naphthyl	368
	2,3-dimethylphenoxy	2-methoxyphenyl	348
	2,3-dimethylphenoxy	3,4,5-trimethylphenyl	408
	2,3-dimethylphenoxy	3,4-dichlorophenyl	387
45	2,3-dimethylphenoxy	3-bromophenyl	397
	2,3-dimethylphenoxy	3-pyridyl	319
	2,3-dimethylphenoxy	2-ethoxynaphth-1-yl	412
	2,3-dimethylphenoxy	2,3-dichlorophenyl	387
	2,3-dimethylphenoxy	6-chloropyrid-3-yl	354
50	2,3-dimethylphenoxy	4-(trifluoromethoxy)phenyl	402
	2,3-dimethylphenoxy	2-fluoro-4-(trifluoromethyl)phenyl	404
	2,3-dimethylphenoxy	3-bromothieryl	403
	2,3-dimethylphenoxy	2-acetoxyphenyl	376
	2,3-dimethylphenoxy		

EP 1 028 945 B9

(continued)

	R ¹ X	R ³	MS (m/z)
5	2,3-dimethylphenoxy	5-methylisoxazol-3-yl	323
	2,3-dimethylphenoxy	2-(phenylthio)pyrid-3-yl	427
	2,3-dimethylphenoxy	2-(trifluoromethoxy)phenyl	402
	2,3-dimethylphenoxy	1-phenyl-5-propylpyrazin-4-yl	426
	2,3-dimethylphenoxy	2-ethoxyphenyl	362
10	2,3-dimethylphenoxy	3-chlorothien-2-yl	359
	2,3-dimethylphenoxy	1-(2-(2-methyl)propyl)-3-methylpyrazol-5-yl	378
	2,3-dimethylphenoxy	3,5-dichlorophenyl	387
	2,3-dimethylphenoxy	2-(propylthio)pyridin-3-yl	393
	2,3-dimethylphenoxy	2-(ethylthio)pyridin-3-yl	379
15	2,3-dimethylphenoxy	3-bromopyridin-5-yl	398
	2,3-dimethylphenoxy	4-methyl-1,2,3-thiadiazol-5-yl	340
	2,3-dimethylphenoxy	1-methyl-3-(2-(2-methyl)propyl)pyrazol-5-yl	378
	2,3-dimethylphenoxy	3-chlorobenzo[b]thiophen-2-yl	409
	2,3-dimethylphenoxy	4-chlorophenyl	353
20	2,3-dimethylphenoxy	4-methyl-2-phenyl-1,2,3-triazol-5-yl	399
	2,3-dimethylphenoxy	benzo[b]thiophen-2-yl	374
	2,3-dimethylphenoxy	3,4-dimethylphenyl	346
	2,3-dimethylphenoxy	2-(phenoxy)pyridin-3-yl	411
	2,3-dimethylphenoxy	2-(methylthio)pyridin-3-yl	365
25	2,3-dimethylphenoxy	5-methyl-3-phenylisoxazol-4-yl	399
	2,3-dimethylphenoxy	4-chloro-1,3-dimethyl pyrazolo[3,4-b]pyridin-3-yl	422
	2,3-dimethylphenoxy	2-chloro-6-methylpyridin-4-yl	368
	2,3-dimethylphenoxy	3,5-dimethylisoxazol-4-yl	337
	2,3-dimethylphenoxy	1-naphthyl	368
30	2,3-dimethylphenoxy	2-fluorophenyl	336
	2,3-dimethylphenoxy	4-propylphenyl	360
	2,3-dimethylphenoxy	3-fluorophenyl	336
	2,3-dimethylphenoxy	2,6-difluorophenyl	354
	2,3-dimethylphenoxy	2-chlorophenyl	353
35	2,3-dimethylphenoxy	3-(chloromethyl)phenyl	368
	2,3-dimethylphenoxy	4-(2-(2-methyl)propyl)phenyl	374
	2,3-dimethylphenoxy	3-chlorophenyl	353
	2,3-dimethylphenoxy	3,5-dimethoxyphenyl	378
	2,3-dimethylphenoxy	2,6-dichlorophenyl	387
40	2,3-dimethylphenoxy	2,4-dichlorophenyl	387
	2,3-dimethylphenoxy	4-fluorophenyl	336
	2,3-dimethylphenoxy	4-butylphenyl	374
	2,3-dimethylphenoxy	2-methylphenyl	332
	2,3-dimethylphenoxy	phenyl	318
45	2,3-dimethylphenoxy	4-ethylphenyl	346
	2,3-dimethylphenoxy	2,3-difluorophenyl	354
	2,3-dimethylphenoxy	2,6-dimethoxyphenyl	378
	2,3-dimethylphenoxy	3,4-difluorophenyl	354
	2,3-dimethylphenoxy	2,5-difluorophenyl	354
50	2,3-dimethylphenoxy	4-ethoxyphenyl	362
	2,3-dimethylphenoxy	2,4,6-trichlorophenyl	422
	2,3-dimethylphenoxy	3-methylphenyl	332
	2,3-dimethylphenoxy	2-fluoro-5-(trifluoromethyl)phenyl	404
	2,3-dimethylphenoxy		

EP 1 028 945 B9

(continued)

	R ¹ X	R ³	MS (m/z)
5	2,3-dimethylphenoxy	3-methoxyphenyl	348
	2,3-dimethylphenoxy	2-bromophenyl	397
	2,3-dimethylphenoxy	4-bromophenyl	397
	2,3-dimethylphenoxy	4-fluoro-3-(trifluoromethyl)phenyl	404
10	2,3-dimethylphenoxy	3-(trifluoromethoxy)phenyl	402
	2,3-dimethylphenoxy	9-fluorenon-4-yl	420
	2,3-dimethylphenoxy	isoxazol-5-yl	609
	2,3-dimethylphenoxy	benzofuroxan-5-yl	376
15	2,3-dimethylphenoxy	2-chloropyrid-3-yl	354
	2,3-dimethylphenoxy	2-(4-methylphenoxy)pyridin-3-yl	425
	2,3-dimethylphenoxy	pyridin-4-yl	319
	2,3-dimethylphenoxy	anthraquinon-2-yl	448
20	2,3-dimethylphenoxy	2-iodophenyl	444
	2,3-dimethylphenoxy	4-pentylphenyl	388
	2,3-dimethylphenoxy	2-(4-chlorophenylthio)pyridin-3-yl	462
	2,3-dimethylphenoxy	2,6-dimethylphenyl	346
25	2,3-dimethylphenoxy	2,5-dimethoxyphenyl	378
	2,3-dimethylphenoxy	2,5-dichloropyridin-3-yl	388
	2,3-dimethylphenoxy	2-chloro-6-methoxypyridin-4-yl	384
	2,3-dimethylphenoxy	2,3-dichloropyridin-5-yl	388
30	2,3-dimethylphenoxy	1-naphthyl	382
	2,3-dimethylphenoxy	2,4-dimethoxyphenyl	378
	2,3-dimethylphenoxy	3,5-bis(trifluoromethyl)phenyl	454
	2,3-dimethylphenoxy	2-(4-chlorophenoxy)pyridin-3-yl	446
35	2,3-dimethylphenoxy	pentafluorophenyl	408
	3,5-(bis-2-propyl)phenoxy	3,4-dimethoxyphenyl	434
	3,5-(bis-2-propyl)phenoxy	2-(trifluoromethyl)phenyl	442
	3,5-(bis-2-propyl)phenoxy	2,4-difluorophenyl	410
40	3,5-(bis-2-propyl)phenoxy	3-(trifluoromethyl)phenyl	442
	3,5-(bis-2-propyl)phenoxy	2-naphthyl	425
	3,5-(bis-2-propyl)phenoxy	2-methoxyphenyl	404
	3,5-(bis-2-propyl)phenoxy	3,4,5-trimethylphenyl	465
45	3,5-(bis-2-propyl)phenoxy	3,4-dichlorophenyl	443
	3,5-(bis-2-propyl)phenoxy	3-bromophenyl	453
	3,5-(bis-2-propyl)phenoxy	3-pyridyl	375
	3,5-(bis-2-propyl)phenoxy	2-ethoxynaphth-1-yl	469
50	3,5-(bis-2-propyl)phenoxy	2,3-dichlorophenyl	443
	3,5-(bis-2-propyl)phenoxy	6-chloropyrid-3-yl	410
	3,5-(bis-2-propyl)phenoxy	4-(trifluoromethoxy)phenyl	458
	3,5-(bis-2-propyl)phenoxy	2-fluoro-4-(trifluoromethyl)phenyl	460
55	3,5-(bis-2-propyl)phenoxy	3-bromothieryl	459
	3,5-(bis-2-propyl)phenoxy	2-acetoxyphenyl	432
	3,5-(bis-2-propyl)phenoxy	5-methylisoxazol-3-yl	379
	3,5-(bis-2-propyl)phenoxy	2-(phenylthio)pyrid-3-yl	484
	3,5-(bis-2-propyl)phenoxy	2-(trifluoromethoxy)phenyl	458
	3,5-(bis-2-propyl)phenoxy	1-phenyl-5-propylpyrazin-4-yl	483
	3,5-(bis-2-propyl)phenoxy	2-ethoxyphenyl	418
	3,5-(bis-2-propyl)phenoxy	3-chlorothiophen-2-yl	415
	3,5-(bis-2-propyl)phenoxy	1-(2-(2-methyl)propyl)-3-methylpyrazol-5-yl	435

EP 1 028 945 B9

(continued)

	R ¹ X	R ³	MS (m/z)
5	3,5-(bis-2-propyl)phenoxy	3,5-dichlorophenyl	443
	3,5-(bis-2-propyl)phenoxy	2-(propylthio)pyridin-3-yl	450
	3,5-(bis-2-propyl)phenoxy	2-(ethylthio)pyridin-3-yl	436
	3,5-(bis-2-propyl)phenoxy	3-bromopyridin-5-yl	454
	3,5-(bis-2-propyl)phenoxy	4-methyl-1,2,3-thiadiazol-5-yl	396
10	3,5-(bis-2-propyl)phenoxy	1-methyl-3-(2-(2-methyl)propyl)pyrazol-5-yl	435
	3,5-(bis-2-propyl)phenoxy	3-chlorobenzo[b]thiophen-2-yl	465
	3,5-(bis-2-propyl)phenoxy	4-chlorophenyl	409
	3,5-(bis-2-propyl)phenoxy	4-methyl-2-phenyl-1,2,3-triazol-5-yl	456
	3,5-(bis-2-propyl)phenoxy	benzo[b]thiophen-2-yl	431
15	3,5-(bis-2-propyl)phenoxy	3,4-dimethylphenyl	402
	3,5-(bis-2-propyl)phenoxy	2-(phenoxy)pyridin-3-yl	468
	3,5-(bis-2-propyl)phenoxy	2-(methylthio)pyridin-3-yl	422
	3,5-(bis-2-propyl)phenoxy	5-methyl-3-phenylisoxazol-4-yl	456
	3,5-(bis-2-propyl)phenoxy	4-chloro-1,3-dimethyl pyrazolo[3,4-b]pyridin-3-yl	478
20	3,5-(bis-2-propyl)phenoxy	2-chloro-6-methylpyridin-4-yl	424
	3,5-(bis-2-propyl)phenoxy	3,5-dimethylisoxazol-4-yl	393
	3,5-(bis-2-propyl)phenoxy	1-naphthyl	425
	3,5-(bis-2-propyl)phenoxy	2-fluorophenyl	392
	3,5-(bis-2-propyl)phenoxy	4-propylphenyl	417
25	3,5-(bis-2-propyl)phenoxy	3-fluorophenyl	392
	3,5-(bis-2-propyl)phenoxy	2,6-difluorophenyl	410
	3,5-(bis-2-propyl)phenoxy	2-chlorophenyl	409
	3,5-(bis-2-propyl)phenoxy	3-(chloromethyl)phenyl	423
	3,5-(bis-2-propyl)phenoxy	4-(2-(2-methyl)propyl)phenyl	431
30	3,5-(bis-2-propyl)phenoxy	3-chlorophenyl	409
	3,5-(bis-2-propyl)phenoxy	3,5-dimethoxyphenyl	434
	3,5-(bis-2-propyl)phenoxy	2,6-dichlorophenyl	443
	3,5-(bis-2-propyl)phenoxy	2,4-dichlorophenyl	443
	3,5-(bis-2-propyl)phenoxy	4-fluorophenyl	392
35	3,5-(bis-2-propyl)phenoxy	4-butylphenyl	431
	3,5-(bis-2-propyl)phenoxy	2-methylphenyl	388
	3,5-(bis-2-propyl)phenoxy	phenyl	374
	3,5-(bis-2-propyl)phenoxy	4-ethylphenyl	402
	3,5-(bis-2-propyl)phenoxy	2,3-difluorophenyl	410
40	3,5-(bis-2-propyl)phenoxy	2,6-dimethoxyphenyl	434
	3,5-(bis-2-propyl)phenoxy	3,4-difluorophenyl	410
	3,5-(bis-2-propyl)phenoxy	2,5-difluorophenyl	410
	3,5-(bis-2-propyl)phenoxy	4-ethoxyphenyl	418
	3,5-(bis-2-propyl)phenoxy	2,4,6-trichlorophenyl	478
45	3,5-(bis-2-propyl)phenoxy	3-methylphenyl	388
	3,5-(bis-2-propyl)phenoxy	2-fluoro-5-(trifluoromethyl)phenyl	460
	3,5-(bis-2-propyl)phenoxy	3-methoxyphenyl	404
	3,5-(bis-2-propyl)phenoxy	2-bromophenyl	453
	3,5-(bis-2-propyl)phenoxy	4-bromophenyl	453
50	3,5-(bis-2-propyl)phenoxy	4-fluoro-3-(trifluoromethyl)phenyl	460
	3,5-(bis-2-propyl)phenoxy	3-(trifluoromethoxy)phenyl	458
	3,5-(bis-2-propyl)phenoxy	9-fluorenon-4-yl	477
	3,5-(bis-2-propyl)phenoxy	isoxazol-5-yl	365
	3,5-(bis-2-propyl)phenoxy		

EP 1 028 945 B9

(continued)

	R ¹ X	R ³	MS (m/z)
5	3,5-(bis-2-propyl)phenoxy	benzofuroxan-5-yl	432
	3,5-(bis-2-propyl)phenoxy	2-chloropyrid-3-yl	410
	3,5-(bis-2-propyl)phenoxy	2-(4-methylphenoxy)pyridin-3-yl	482
	3,5-(bis-2-propyl)phenoxy	pyridin-4-yl	375
	3,5-(bis-2-propyl)phenoxy	anthraquinon-2-yl	505
10	3,5-(bis-2-propyl)phenoxy	2-iodophenyl	500
	3,5-(bis-2-propyl)phenoxy	4-pentylphenyl	445
	3,5-(bis-2-propyl)phenoxy	2-(4-chlorophenylthio)pyridin-3-yl	518
	3,5-(bis-2-propyl)phenoxy	2,6-dimethylphenyl	402
	3,5-(bis-2-propyl)phenoxy	2,5-dimethoxyphenyl	434
15	3,5-(bis-2-propyl)phenoxy	2,5-dichloropyridin-3-yl	444
	3,5-(bis-2-propyl)phenoxy	2-chloro-6-methoxypyridin-4-yl	440
	3,5-(bis-2-propyl)phenoxy	2,3-dichloropyridin-5-yl	444
	3,5-(bis-2-propyl)phenoxy	1-naphthyl	439
	3,5-(bis-2-propyl)phenoxy	2,4-dimethoxyphenyl	434
20	3,5-(bis-2-propyl)phenoxy	3,5-bis(trifluoromethyl)phenyl	510
	3,5-(bis-2-propyl)phenoxy	2-(4-chlorophenoxy)pyridin-3-yl	502
	3,5-(bis-2-propyl)phenoxy	pentafluorophenyl	464
	3-trifluoromethyl phenoxy	3,4-dimethoxyphenyl	418
	3-trifluoromethyl phenoxy	2-(trifluoromethyl)phenyl	426
25	3-trifluoromethyl phenoxy	2,4-difluorophenyl	394
	3-trifluoromethyl phenoxy	3-(trifluoromethyl)phenyl	426
	3-trifluoromethyl phenoxy	2-naphthyl	408
	3-trifluoromethyl phenoxy	2-methoxyphenyl	388
	3-trifluoromethyl phenoxy	3,4,5-trimethylphenyl	448
30	3-trifluoromethyl phenoxy	3,4-dichlorophenyl	427
	3-trifluoromethyl phenoxy	3-bromophenyl	437
	3-trifluoromethyl phenoxy	3-pyridyl	359
	3-trifluoromethyl phenoxy	2-ethoxynaphth-1-yl	452
	3-trifluoromethyl phenoxy	2,3-dichlorophenyl	427
35	3-trifluoromethyl phenoxy	6-chloropyrid-3-yl	394
	3-trifluoromethyl phenoxy	4-(trifluoromethoxy)phenyl	442
	3-trifluoromethyl phenoxy	2-fluoro-4-(trifluoromethyl)phenyl	444
	3-trifluoromethyl phenoxy	3-bromothieryl	443
	3-trifluoromethyl phenoxy	2-acetoxyphenyl	416
40	3-trifluoromethyl phenoxy	5-methylisoxazol-3-yl	363
	3-trifluoromethyl phenoxy	2-(phenylthio)pyrid-3-yl	467
	3-trifluoromethyl phenoxy	2-(trifluoromethoxy)phenyl	442
	3-trifluoromethyl phenoxy	1-phenyl-5-propylpyrazin-4-yl	466
	3-trifluoromethyl phenoxy	2-ethoxyphenyl	402
45	3-trifluoromethyl phenoxy	3-chlorothien-2-yl	399
	3-trifluoromethyl phenoxy	1-(2-(2-methyl)propyl)-3-methylpyrazol-5-yl	418
	3-trifluoromethyl phenoxy	3,5-dichlorophenyl	427
	3-trifluoromethyl phenoxy	2-(propylthio)pyridin-3-yl	433
	3-trifluoromethyl phenoxy	2-(ethylthio)pyridin-3-yl	419
50	3-trifluoromethyl phenoxy	3-bromopyridin-5-yl	438
	3-trifluoromethyl phenoxy	4-methyl-1,2,3-thiadiazol-5-yl	380
	3-trifluoromethyl phenoxy	1-methyl-3-(2-(2-methyl)propyl)pyrazol-5-yl	418
	3-trifluoromethyl phenoxy	3-chlorobenzo[b]thiophen-2-yl	449
	3-trifluoromethyl phenoxy		

EP 1 028 945 B9

(continued)

	R ¹ X	R ³	MS (m/z)
5	3-trifluoromethyl phenoxy	4-chlorophenyl	393
	3-trifluoromethyl phenoxy	4-methyl-2-phenyl-1,2,3-triazol-5-yl	439
	3-trifluoromethyl phenoxy	benzo[b]thiophen-2-yl	414
	3-trifluoromethyl phenoxy	3,4-dimethylphenyl	386
	3-trifluoromethyl phenoxy	2-(phenoxy)pyridin-3-yl	451
10	3-trifluoromethyl phenoxy	2-(methylthio)pyridin-3-yl	405
	3-trifluoromethyl phenoxy	5-methyl-3-phenylisoxazol-4-yl	439
	3-trifluoromethyl phenoxy	4-chloro-1,3-dimethyl pyrazolo[3,4-b]pyridin-3yl	462
	3-trifluoromethyl phenoxy	2-chloro-6-methylpyridin-4-yl	408
	3-trifluoromethyl phenoxy	3,5-dimethylisoxazol-4-yl	377
15	3-trifluoromethyl phenoxy	1-naphthyl	408
	3-trifluoromethyl phenoxy	2-fluorophenyl	476
	3-trifluoromethyl phenoxy	4-propylphenyl	400
	3-trifluoromethyl phenoxy	3-fluorophenyl	376
	3-trifluoromethyl phenoxy	2,6-difluorophenyl	394
20	3-trifluoromethyl phenoxy	2-chlorophenyl	393
	3-trifluoromethyl phenoxy	3-(chloromethyl)phenyl	407
	3-trifluoromethyl phenoxy	4-(2-(2-methyl)propyl)phenyl	414
	3-trifluoromethyl phenoxy	3-chlorophenyl	393
	3-trifluoromethyl phenoxy	3,5-dimethoxyphenyl	418
25	3-trifluoromethyl phenoxy	2,6-dichlorophenyl	427
	3-trifluoromethyl phenoxy	2,4-dichlorophenyl	427
	3-trifluoromethyl phenoxy	4-fluorophenyl	376
	3-trifluoromethyl phenoxy	4-butylphenyl	414
	3-trifluoromethyl phenoxy	2-methylphenyl	372
30	3-trifluoromethyl phenoxy	phenyl	358
	3-trifluoromethyl phenoxy	4-ethylphenyl	386
	3-trifluoromethyl phenoxy	2,3-difluorophenyl	394
	3-trifluoromethyl phenoxy	2,6-dimethoxyphenyl	418
	3-trifluoromethyl phenoxy	3,4-difluorophenyl	394
35	3-trifluoromethyl phenoxy	2,5-difluorophenyl	394
	3-trifluoromethyl phenoxy	4-ethoxyphenyl	402
	3-trifluoromethyl phenoxy	2,4,6-trichlorophenyl	462
	3-trifluoromethyl phenoxy	3-methylphenyl	372
	3-trifluoromethyl phenoxy	2-fluoro-5-(trifluoromethyl)phenyl	444
40	3-trifluoromethyl phenoxy	3-methoxyphenyl	388
	3-trifluoromethyl phenoxy	2-bromophenyl	437
	3-trifluoromethyl phenoxy	4-bromophenyl	437
	3-trifluoromethyl phenoxy	4-fluoro-3-(trifluoromethyl)phenyl	444
	3-trifluoromethyl phenoxy	3-(trifluoromethoxy)phenyl	442
45	3-trifluoromethyl phenoxy	9-fluorenon-4-yl	460
	3-trifluoromethyl phenoxy	isoxazol-5-yl	349
	3-trifluoromethyl phenoxy	benzofuroxan-5-yl	416
	3-trifluoromethyl phenoxy	2-chloropyrid-3-yl	394
	3-trifluoromethyl phenoxy	2-(4-methylphenoxy)pyridin-3-yl	465
50	3-trifluoromethyl phenoxy	pyridin-4-yl	359
	3-trifluoromethyl phenoxy	anthraquinon-2-yl	488
	3-trifluoromethyl phenoxy	2-iodophenyl	484
	3-trifluoromethyl phenoxy	4-pentylphenyl	428
	3-trifluoromethyl phenoxy		

EP 1 028 945 B9

(continued)

	R ¹ X	R ³	MS (m/z)
5	3-trifluoromethyl phenoxy	2-(4-chlorophenylthio)pyridin-3-yl	502
	3-trifluoromethyl phenoxy	2,6-dimethylphenyl	386
	3-trifluoromethyl phenoxy	2,5-dimethoxyphenyl	418
	3-trifluoromethyl phenoxy	2,5-dichloropyridin-3-yl	428
	3-trifluoromethyl phenoxy	2-chloro-6-methoxypyridin-4-yl	424
10	3-trifluoromethyl phenoxy	2,3-dichloropyridin-5-yl	428
	3-trifluoromethyl phenoxy	1-naphthyl	422
	3-trifluoromethyl phenoxy	2,4-dimethoxyphenyl	418
	3-trifluoromethyl phenoxy	3,5-bis(trifluoromethyl)phenyl	494
15	3-trifluoromethyl phenoxy	2-(4-chlorophenoxy)pyridin-3-yl	486
	3-trifluoromethyl phenoxy	pentafluorophenyl	448
	2,6-dichlorophenoxy	3,4-dimethoxyphenyl	419
	2,6-dichlorophenoxy	2-(trifluoromethyl)phenyl	427
	2,6-dichlorophenoxy	2,4-difluorophenyl	395
20	2,6-dichlorophenoxy	3-(trifluoromethyl)phenyl	427
	2,6-dichlorophenoxy	2-naphthyl	409
	2,6-dichlorophenoxy	2-methoxyphenyl	389
	2,6-dichlorophenoxy	3,4,5-trimethylphenyl	449
25	2,6-dichlorophenoxy	3,4-dichlorophenyl	428
	2,6-dichlorophenoxy	3-bromophenyl	438
	2,6-dichlorophenoxy	3-pyridyl	361
	2,6-dichlorophenoxy	2-ethoxynaphth-1-yl	453
	2,6-dichlorophenoxy	2,3-dichlorophenyl	428
30	2,6-dichlorophenoxy	6-chloropyrid-3-yl	395
	2,6-dichlorophenoxy	4-(trifluoromethoxy)phenyl	443
	2,6-dichlorophenoxy	2-fluoro-4-(trifluoromethyl)phenyl	445
	2,6-dichlorophenoxy	3-bromothieryl	444
	2,6-dichlorophenoxy	2-acetoxyphenyl	417
35	2,6-dichlorophenoxy	5-methylisoxazol-3-yl	364
	2,6-dichlorophenoxy	2-(phenylthio)pyrid-3-yl	468
	2,6-dichlorophenoxy	2-(trifluoromethoxy)phenyl	443
	2,6-dichlorophenoxy	1-phenyl-5-propylpyrazin-4-yl	467
40	2,6-dichlorophenoxy	2-ethoxyphenyl	403
	2,6-dichlorophenoxy	3-chlorothieryl-2-yl	400
	2,6-dichlorophenoxy	1-(2-(2-methyl)propyl)-3-methylpyrazol-5-yl	419
	2,6-dichlorophenoxy	3,5-dichlorophenyl	428
45	2,6-dichlorophenoxy	2-(propylthio)pyridin-3-yl	434
	2,6-dichlorophenoxy	2-(ethylthio)pyridin-3-yl	420
	2,6-dichlorophenoxy	3-bromopyridin-5-yl	439
	2,6-dichlorophenoxy	4-methyl-1,2,3-thiadiazol-5-yl	381
	2,6-dichlorophenoxy	1-methyl-3-(2-(2-methyl)propyl)pyrazol-5-yl	419
50	2,6-dichlorophenoxy	3-chlorobenzo[b]thiophen-2-yl	450
	2,6-dichlorophenoxy	4-chlorophenyl	394
	2,6-dichlorophenoxy	4-methyl-2-phenyl-1,2,3-triazol-5-yl	440
	2,6-dichlorophenoxy	benzo[b]thiophen-2-yl	415
	2,6-dichlorophenoxy	3,4-dimethylphenyl	387
55	2,6-dichlorophenoxy	2-(phenoxy)pyridin-3-yl	452
	2,6-dichlorophenoxy	2-(methylthio)pyridin-3-yl	406
	2,6-dichlorophenoxy	5-methyl-3-phenylisoxazol-4-yl	440

EP 1 028 945 B9

	R ¹ X	(continued)	R ³	MS (m/z)
5	2,6-dichlorophenoxy	4-chloro-1,3-dimethyl pyrazolo[3,4-b]pyridin-3-yl		463
	2,6-dichlorophenoxy	2-chloro-6-methylpyridin-4-yl		409
	2,6-dichlorophenoxy	3,5-dimethylisoxazol-4-yl		378
	2,6-dichlorophenoxy	1-naphthyl		409
	2,6-dichlorophenoxy	2-fluorophenyl		377
10	2,6-dichlorophenoxy	4-propylphenyl		401
	2,6-dichlorophenoxy	3-fluorophenyl		377
	2,6-dichlorophenoxy	2,6-difluorophenyl		395
	2,6-dichlorophenoxy	2-chlorophenyl		394
15	2,6-dichlorophenoxy	3-(chloromethyl)phenyl		408
	2,6-dichlorophenoxy	4-(2-(2-methyl)propyl)phenyl		415
	2,6-dichlorophenoxy	3-chlorophenyl		694
	2,6-dichlorophenoxy	3,5-dimethoxyphenyl		419
	2,6-dichlorophenoxy	2,6-dichlorophenyl		428
20	2,6-dichlorophenoxy	2,4-dichlorophenyl		428
	2,6-dichlorophenoxy	4-fluorophenyl		377
	2,6-dichlorophenoxy	4-butylphenyl		415
	2,6-dichlorophenoxy	2-methylphenyl		373
25	2,6-dichlorophenoxy	phenyl		359
	2,6-dichlorophenoxy	4-ethylphenyl		387
	2,6-dichlorophenoxy	2,3-difluorophenyl		395
	2,6-dichlorophenoxy	2,6-dimethoxyphenyl		419
	2,6-dichlorophenoxy	3,4-difluorophenyl		395
30	2,6-dichlorophenoxy	2,5-difluorophenyl		395
	2,6-dichlorophenoxy	4-ethoxyphenyl		403
	2,6-dichlorophenoxy	2,4,6-trichlorophenyl		463
	2,6-dichlorophenoxy	3-methylphenyl		373
35	2,6-dichlorophenoxy	2-fluoro-5-(trifluoromethyl)phenyl		445
	2,6-dichlorophenoxy	3-methoxyphenyl		389
	2,6-dichlorophenoxy	2-bromophenyl		438
	2,6-dichlorophenoxy	4-bromophenyl		438
	2,6-dichlorophenoxy	4-fluoro-3-(trifluoromethyl)phenyl		445
40	2,6-dichlorophenoxy	3-(trifluoromethoxy)phenyl		443
	2,6-dichlorophenoxy	9-fluorenon-4-yl		461
	2,6-dichlorophenoxy	isoxazol-5-yl		350
	2,6-dichlorophenoxy	benzofuroxan-5-yl		417
45	2,6-dichlorophenoxy	2-chloropyrid-3-yl		395
	2,6-dichlorophenoxy	2-(4-methylphenoxy)pyridin-3-yl		466
	2,6-dichlorophenoxy	pyridin-4-yl		360
	2,6-dichlorophenoxy	anthraquinon-2-yl		489
	2,6-dichlorophenoxy	2-iodophenyl		485
50	2,6-dichlorophenoxy	4-pentylphenyl		429
	2,6-dichlorophenoxy	2-(4-chlorophenylthio)pyridin-3-yl		503
	2,6-dichlorophenoxy	2,6-dimethylphenyl		387
	2,6-dichlorophenoxy	2,5-dimethoxyphenyl		419
	2,6-dichlorophenoxy	2,5-dichloropyridin-3-yl		429
55	2,6-dichlorophenoxy	2-chloro-6-methoxypyridin-4-yl		425
	2,6-dichlorophenoxy	2,3-dichloropyridin-5-yl		429
	2,6-dichlorophenoxy	1-naphthyl		413

EP 1 028 945 B9

(continued)

	R ¹ X	R ³	MS (m/z)
5	2,6-dichlorophenoxy	2,4-dimethoxyphenyl	419
	2,6-dichlorophenoxy	3,5-bis(trifluoromethyl)phenyl	495
	2,6-dichlorophenoxy	2-(4-chlorophenoxy)pyridin-3-yl	487
	2,6-dichlorophenoxy	pentafluorophenyl	449
	2,4-dichlorophenoxy	3,4-dimethoxyphenyl	419
10	2,4-dichlorophenoxy	2-(trifluoromethyl)phenyl	427
	2,4-dichlorophenoxy	2,4-difluorophenyl	395
	2,4-dichlorophenoxy	3-(trifluoromethyl)phenyl	427
	2,4-dichlorophenoxy	2-naphthyl	409
	2,4-dichlorophenoxy	2-methoxyphenyl	389
15	2,4-dichlorophenoxy	3,4,5-trimethylphenyl	449
	2,4-dichlorophenoxy	3,4-dichlorophenyl	428
	2,4-dichlorophenoxy	3-bromophenyl	438
	2,4-dichlorophenoxy	3-pyridyl	361
	2,4-dichlorophenoxy	2-ethoxynaphth-1-yl	453
20	2,4-dichlorophenoxy	2,3-dichlorophenyl	428
	2,4-dichlorophenoxy	6-chloropyrid-3-yl	395
	2,4-dichlorophenoxy	4-(trifluoromethoxy)phenyl	443
	2,4-dichlorophenoxy	2-fluoro-4-(trifluoromethyl)phenyl	445
	2,4-dichlorophenoxy	3-bromothienyl	444
25	2,4-dichlorophenoxy	2-acetoxyphenyl	417
	2,4-dichlorophenoxy	5-methylisoxazol-3-yl	364
	2,4-dichlorophenoxy	2-(phenylthio)pyrid-3-yl	468
	2,4-dichlorophenoxy	2-(trifluoromethoxy)phenyl	443
	2,4-dichlorophenoxy	1-phenyl-5-propylpyrazin-4-yl	467
30	2,4-dichlorophenoxy	2-ethoxyphenyl	403
	2,4-dichlorophenoxy	3-chlorothien-2-yl	400
	2,4-dichlorophenoxy	1-(2-(2-methyl)propyl)-3-methylpyrazol-5-yl	419
	2,4-dichlorophenoxy	3,5-dichlorophenyl	428
	2,4-dichlorophenoxy	2-(propylthio)pyridin-3-yl	434
35	2,4-dichlorophenoxy	2-(ethylthio)pyridin-3-yl	420
	2,4-dichlorophenoxy	3-bromopyridin-5-yl	439
	2,4-dichlorophenoxy	4-methyl-1,2,3-thiadiazol-5-yl	381
	2,4-dichlorophenoxy	1-methyl-3-(2-(2-methyl)propyl)pyrazol-5-yl	419
	2,4-dichlorophenoxy	3-chlorobenzo[b]thiophen-2-yl	450
40	2,4-dichlorophenoxy	4-chlorophenyl	394
	2,4-dichlorophenoxy	4-methyl-2-phenyl-1,2,3-triazol-5-yl	440
	2,4-dichlorophenoxy	benzo[b]thiophen-2-yl	415
	2,4-dichlorophenoxy	3,4-dimethylphenyl	387
	2,4-dichlorophenoxy	2-(phenoxy)pyridin-3-yl	452
45	2,4-dichlorophenoxy	2-(methylthio)pyridin-3-yl	406
	2,4-dichlorophenoxy	5-methyl-3-phenylisoxazol-4-yl	440
	2,4-dichlorophenoxy	4-chloro-1,3-dimethyl pyrazolo[3,4-b]pyridin-3yl	463
	2,4-dichlorophenoxy	2-chloro-6-methylpyridin-4-yl	409
	2,4-dichlorophenoxy	3,5-dimethylisoxazol-4-yl	378
50	2,4-dichlorophenoxy	1-naphthyl	409
	2,4-dichlorophenoxy	2-fluorophenyl	377
	2,4-dichlorophenoxy	4-propylphenyl	401
	2,4-dichlorophenoxy	3-fluorophenyl	377
	2,4-dichlorophenoxy		

EP 1 028 945 B9

(continued)

	R ¹ X	R ³	MS (m/z)
5	2,4-dichlorophenoxy	2,6-difluorophenyl	395
	2,4-dichlorophenoxy	2-chlorophenyl	394
	2,4-dichlorophenoxy	3-(chloromethyl)phenyl	408
	2,4-dichlorophenoxy	4-(2-(2-methyl)propyl)phenyl	415
	2,4-dichlorophenoxy	3-chlorophenyl	694
10	2,4-dichlorophenoxy	3,5-dimethoxyphenyl	419
	2,4-dichlorophenoxy	2,6-dichlorophenyl	428
	2,4-dichlorophenoxy	2,4-dichlorophenyl	428
	2,4-dichlorophenoxy	4-fluorophenyl	377
	2,4-dichlorophenoxy	4-butylphenyl	415
15	2,4-dichlorophenoxy	2-methylphenyl	373
	2,4-dichlorophenoxy	phenyl	359
	2,4-dichlorophenoxy	4-ethylphenyl	387
	2,4-dichlorophenoxy	2,3-difluorophenyl	395
	2,4-dichlorophenoxy	2,6-dimethoxyphenyl	419
20	2,4-dichlorophenoxy	3,4-difluorophenyl	395
	2,4-dichlorophenoxy	2,5-difluorophenyl	395
	2,4-dichlorophenoxy	4-ethoxyphenyl	403
	2,4-dichlorophenoxy	2,4,6-trichlorophenyl	463
	2,4-dichlorophenoxy	3-methylphenyl	373
25	2,4-dichlorophenoxy	2-fluoro-5-(trifluoromethyl)phenyl	445
	2,4-dichlorophenoxy	3-methoxyphenyl	389
	2,4-dichlorophenoxy	2-bromophenyl	438
	2,4-dichlorophenoxy	4-bromophenyl	438
	2,4-dichlorophenoxy	4-fluoro-3-(trifluoromethyl)phenyl	445
30	2,4-dichlorophenoxy	3-(trifluoromethoxy)phenyl	443
	2,4-dichlorophenoxy	9-fluorenon-4-yl	461
	2,4-dichlorophenoxy	isoxazol-5-yl	350
	2,4-dichlorophenoxy	benzofuroxan-5-yl	417
	2,4-dichlorophenoxy	2-chloropyridin-3-yl	395
35	2,4-dichlorophenoxy	2-(4-methylphenoxy)pyridin-3-yl	466
	2,4-dichlorophenoxy	pyridin-4-yl	360
	2,4-dichlorophenoxy	anthraquinon-2-yl	489
	2,4-dichlorophenoxy	2-iodophenyl	485
	2,4-dichlorophenoxy	4-pentylphenyl	429
40	2,4-dichlorophenoxy	2-(4-chlorophenylthio)pyridin-3-yl	503
	2,4-dichlorophenoxy	2,6-dimethylphenyl	387
	2,4-dichlorophenoxy	2,5-dimethoxyphenyl	419
	2,4-dichlorophenoxy	2,5-dichloropyridin-3-yl	429
	2,4-dichlorophenoxy	2-chloro-6-methoxypyridin-4-yl	425
45	2,4-dichlorophenoxy	2,3-dichloropyridin-5-yl	429
	2,4-dichlorophenoxy	1-naphthyl	413
	2,4-dichlorophenoxy	2,4-dimethoxyphenyl	419
	2,4-dichlorophenoxy	3,5-bis(trifluoromethyl)phenyl	495
	2,4-dichlorophenoxy	2-(4-chlorophenoxy)pyridin-3-yl	487
50	2,4-dichlorophenoxy	pentafluorophenyl	449
	4-chloro-3-methylphenoxy	3,4-dimethoxyphenyl	319
	4-chloro-3-methylphenoxy	2-(trifluoromethyl)phenyl	407
	4-chloro-3-methylphenoxy	2,4-difluorophenyl	375

EP 1 028 945 B9

(continued)

	R ¹ X	R ³	MS (m/z)
5	4-chloro-3-methylphenoxy	3-(trifluoromethyl)phenyl	407
	4-chloro-3-methylphenoxy	2-naphthyl	389
	4-chloro-3-methylphenoxy	2-methoxyphenyl	369
	4-chloro-3-methylphenoxy	3,4,5-trimethylphenyl	429
10	4-chloro-3-methylphenoxy	3,4-dichlorophenyl	408
	4-chloro-3-methylphenoxy	3-bromophenyl	418
	4-chloro-3-methylphenoxy	3-pyridyl	340
	4-chloro-3-methylphenoxy	2-ethoxynaphth-1-yl	433
15	4-chloro-3-methylphenoxy	2,3-dichlorophenyl	408
	4-chloro-3-methylphenoxy	6-chloropyrid-3-yl	374
	4-chloro-3-methylphenoxy	4-(trifluoromethoxy)phenyl	423
	4-chloro-3-methylphenoxy	2-fluoro-4-(trifluoromethyl)phenyl	425
20	4-chloro-3-methylphenoxy	3-bromothieryl	424
	4-chloro-3-methylphenoxy	2-acetoxyphenyl	397
	4-chloro-3-methylphenoxy	5-methylisoxazol-3-yl	344
	4-chloro-3-methylphenoxy	2-(phenylthio)pyrid-3-yl	448
25	4-chloro-3-methylphenoxy	2-(trifluoromethoxy)phenyl	423
	4-chloro-3-methylphenoxy	1-phenyl-5-propylpyrazin-4-yl	447
	4-chloro-3-methylphenoxy	2-ethoxyphenyl	383
	4-chloro-3-methylphenoxy	3-chlorothien-2-yl	379
30	4-chloro-3-methylphenoxy	1-(2-(2-methyl)propyl)-3-ethylpyrazol-5-yl	399
	4-chloro-3-methylphenoxy	3,5-dichlorophenyl	408
	4-chloro-3-methylphenoxy	2-(propylthio)pyridin-3-yl	414
	4-chloro-3-methylphenoxy	2-(ethylthio)pyridin-3-yl	400
35	4-chloro-3-methylphenoxy	3-bromopyridin-5-yl	419
	4-chloro-3-methylphenoxy	4-methyl-1,2,3-thiadiazol-5-yl	361
	4-chloro-3-methylphenoxy	1-methyl-3-(2-(2-methyl)propyl)pyrazol-5-yl	399
	4-chloro-3-methylphenoxy	3-chlorobenzo[b]thiophen-2-yl	429
40	4-chloro-3-methylphenoxy	4-chlorophenyl	373
	4-chloro-3-methylphenoxy	4-methyl-2-phenyl-1,2,3-triazol-5-yl	420
	4-chloro-3-methylphenoxy	benzo[b]thiophen-2-yl	395
	4-chloro-3-methylphenoxy	3,4-dimethylphenyl	367
45	4-chloro-3-methylphenoxy	2-(phenoxy)pyridin-3-yl	432
	4-chloro-3-methylphenoxy	2-(methylthio)pyridin-3-yl	386
	4-chloro-3-methylphenoxy	5-methyl-3-phenylisoxazol-4-yl	420
	4-chloro-3-methylphenoxy	4-chloro-1,3-dimethyl pyrazolo[3,4-b]pyridin-3-yl	442
50	4-chloro-3-methylphenoxy	2-chloro-6-methylpyridin-4-yl	388
	4-chloro-3-methylphenoxy	3,5-dimethylisoxazol-4-yl	358
	4-chloro-3-methylphenoxy	1-naphthyl	389
	4-chloro-3-methylphenoxy	2-fluorophenyl	357
55	4-chloro-3-methylphenoxy	4-propylphenyl	381
	4-chloro-3-methylphenoxy	4-(trifluoromethyl)phenyl	407
	4-chloro-3-methylphenoxy	3-fluorophenyl	357
	4-chloro-3-methylphenoxy	2,6-difluorophenyl	375
	4-chloro-3-methylphenoxy	2-chlorophenyl	373
	4-chloro-3-methylphenoxy	3-(chloromethyl)phenyl	387
	4-chloro-3-methylphenoxy	4-(2-(2-methyl)propyl)phenyl	395
	4-chloro-3-methylphenoxy	3-chlorophenyl	373
	4-chloro-3-methylphenoxy	3,5-dimethoxyphenyl	399

EP 1 028 945 B9

(continued)

	R ¹ X	R ³	MS (m/z)
5	4-chloro-3-methylphenoxy	2,6-dichlorophenyl	408
	4-chloro-3-methylphenoxy	2,4-dichlorophenyl	408
	4-chloro-3-methylphenoxy	4-fluorophenyl	357
	4-chloro-3-methylphenoxy	4-butylphenyl	395
	4-chloro-3-methylphenoxy	2-methylphenyl	353
10	4-chloro-3-methylphenoxy	phenyl	339
	4-chloro-3-methylphenoxy	4-ethylphenyl	367
	4-chloro-3-methylphenoxy	2,3-difluorophenyl	375
	4-chloro-3-methylphenoxy	2,6-dimethoxyphenyl	399
	4-chloro-3-methylphenoxy	3,4-difluorophenyl	375
15	4-chloro-3-methylphenoxy	2,5-difluorophenyl	375
	4-chloro-3-methylphenoxy	4-ethoxyphenyl	383
	4-chloro-3-methylphenoxy	2,4,6-trichlorophenyl	442
	4-chloro-3-methylphenoxy	3-methylphenyl	353
	4-chloro-3-methylphenoxy	2-fluoro-5-(trifluoromethyl)phenyl	425
20	4-chloro-3-methylphenoxy	3-methoxyphenyl	369
	4-chloro-3-methylphenoxy	2-bromophenyl	418
	4-chloro-3-methylphenoxy	4-bromophenyl	418
	4-chloro-3-methylphenoxy	4-fluoro-3-(trifluoromethyl)phenyl	425
	4-chloro-3-methylphenoxy	3-(trifluoromethoxy)phenyl	423
25	4-chloro-3-methylphenoxy	9-fluorenon-4-yl	441
	4-chloro-3-methylphenoxy	isoxazol-5-yl	330
	4-chloro-3-methylphenoxy	benzofuroxan-5-yl	397
	4-chloro-3-methylphenoxy	2-chloropyrid-3-yl	374
	4-chloro-3-methylphenoxy	2-(4-methylphenoxy)pyridin-3-yl	446
30	4-chloro-3-methylphenoxy	pyridin-4-yl	340
	4-chloro-3-methylphenoxy	anthraquinon-2-yl	469
	4-chloro-3-methylphenoxy	2-iodophenyl	465
	4-chloro-3-methylphenoxy	4-pentylphenyl	409
	4-chloro-3-methylphenoxy	2-(4-chlorophenylthio)pyridin-3-yl	482
35	4-chloro-3-methylphenoxy	2,6-dimethylphenyl	367
	4-chloro-3-methylphenoxy	2,5-dimethoxyphenyl	399
	4-chloro-3-methylphenoxy	2,5-dichloropyridin-3-yl	409
	4-chloro-3-methylphenoxy	2-chloro-6-methoxypyridin-4-yl	404
	4-chloro-3-methylphenoxy	2,3-dichloropyridin-5-yl	409
40	4-chloro-3-methylphenoxy	1-naphthyl	403
	4-chloro-3-methylphenoxy	2,4-dimethoxyphenyl	399
	4-chloro-3-methylphenoxy	3,5-bis(trifluoromethyl)phenyl	475
	4-chloro-3-methylphenoxy	2-(4-chlorophenoxy)pyridin-3-yl	466
	4-chloro-3-methylphenoxy	pentafluorophenyl	429
45	4-chloro-2-cyclohexylphenoxy	3,4-dimethoxyphenyl	467
	4-chloro-2-cyclohexylphenoxy	2-(trifluoromethyl)phenyl	475
	4-chloro-2-cyclohexylphenoxy	2,4-difluorophenyl	443
	4-chloro-2-cyclohexylphenoxy	3-(trifluoromethyl)phenyl	475
	4-chloro-2-cyclohexylphenoxy	2-naphthyl	457
50	4-chloro-2-cyclohexylphenoxy	2-methoxyphenyl	437
	4-chloro-2-cyclohexylphenoxy	3,4,5-trimethylphenyl	497
	4-chloro-2-cyclohexylphenoxy	3,4-dichlorophenyl	176
	4-chloro-2-cyclohexylphenoxy	3-bromophenyl	486
	4-chloro-2-cyclohexylphenoxy		

(continued)

	R ¹ X	R ³	MS (m/z)
5	4-chloro-2-cyclohexylphenoxy	3-pyridyl	408
	4-chloro-2-cyclohexylphenoxy	2-ethoxynaphth-1-yl	501
	4-chloro-2-cyclohexylphenoxy	2,3-dichlorophenyl	476
	4-chloro-2-cyclohexylphenoxy	6-chloropyrid-3-yl	442
	4-chloro-2-cyclohexylphenoxy	4-(trifluoromethoxy)phenyl	491
10	4-chloro-2-cyclohexylphenoxy	2-fluoro-4-(trifluoromethyl)phenyl	493
	4-chloro-2-cyclohexylphenoxy	3-bromothieryl	492
	4-chloro-2-cyclohexylphenoxy	2-acetoxyphenyl	465
	4-chloro-2-cyclohexylphenoxy	5-methylisoxazol-3-yl	412
15	4-chloro-2-cyclohexylphenoxy	2-(phenylthio)pyrid-3-yl	516
	4-chloro-2-cyclohexylphenoxy	2-(trifluoromethoxy)phenyl	491
	4-chloro-2-cyclohexylphenoxy	1-phenyl-5-propylpyrazin-4-yl	515
	4-chloro-2-cyclohexylphenoxy	2-ethoxyphenyl	451
	4-chloro-2-cyclohexylphenoxy	3-chlorothien-2-yl	447
20	4-chloro-2-cyclohexylphenoxy	1-(2-(2-methyl)propyl)-3-methylpyrazol-5-yl	467
	4-chloro-2-cyclohexylphenoxy	3,5-dichlorophenyl	476
	4-chloro-2-cyclohexylphenoxy	2-(propylthio)pyridin-3-yl	482
	4-chloro-2-cyclohexylphenoxy	2-(ethylthio)pyridin-3-yl	468
25	4-chloro-2-cyclohexylphenoxy	3-bromopyridin-5-yl	487
	4-chloro-2-cyclohexylphenoxy	4-methyl-1,2,3-thiadiazol-5-yl	429
	4-chloro-2-cyclohexylphenoxy	1-methyl-3-(2-(2-ethyl)propyl)pyrazol-5-yl	467
	4-chloro-2-cyclohexylphenoxy	3-chlorobenzo[b]thiophen-5-yl	497
	4-chloro-2-cyclohexylphenoxy	4-chlorophenyl	441
30	4-chloro-2-cyclohexylphenoxy	4-methyl-2-phenyl-1,2,3-triazol-5-yl	488
	4-chloro-2-cyclohexylphenoxy	benzo[b]thiophen-2-yl	463
	4-chloro-2-cyclohexylphenoxy	3,4-dimethylphenyl	435
	4-chloro-2-cyclohexylphenoxy	2-(phenoxy)pyridin-3-yl	500
35	4-chloro-2-cyclohexylphenoxy	2-(methylthio)pyridin-3-yl	454
	4-chloro-2-cyclohexylphenoxy	5-methyl-3-phenylisoxazol-4-yl	488
	4-chloro-2-cyclohexylphenoxy	4-chloro-1,3-dimethylpyrazolo[3,4-b]pyridin-3-yl	510
	4-chloro-2-cyclohexylphenoxy	2-chloro-6-methylpyridin-4-yl	456
	4-chloro-2-cyclohexylphenoxy	3,5-dimethylisoxazol-4-yl	426
40	4-chloro-2-cyclohexylphenoxy	1-naphthyl	457
	4-chloro-2-cyclohexylphenoxy	2-fluorophenyl	425
	4-chloro-2-cyclohexylphenoxy	4-propylphenyl	449
	4-chloro-2-cyclohexylphenoxy	3-fluorophenyl	425
45	4-chloro-2-cyclohexylphenoxy	2,6-difluorophenyl	443
	4-chloro-2-cyclohexylphenoxy	2-chlorophenyl	441
	4-chloro-2-cyclohexylphenoxy	3-(chloromethyl)phenyl	455
	4-chloro-2-cyclohexylphenoxy	4-(2-(2-methyl)propyl)phenyl	463
	4-chloro-2-cyclohexylphenoxy	3-chlorophenyl	441
50	4-chloro-2-cyclohexylphenoxy	3,5-dimethoxyphenyl	467
	4-chloro-2-cyclohexylphenoxy	2,6-dichlorophenyl	476
	4-chloro-2-cyclohexylphenoxy	2,4-dichlorophenyl	476
	4-chloro-2-cyclohexylphenoxy	4-fluorophenyl	425
	4-chloro-2-cyclohexylphenoxy	4-butylphenyl	463
55	4-chloro-2-cyclohexylphenoxy	2-methylphenyl	421
	4-chloro-2-cyclohexylphenoxy	phenyl	407
	4-chloro-2-cyclohexylphenoxy	4-ethylphenyl	435

(continued)

	R ¹ X	R ³	MS (m/z)
5	4-chloro-2-cyclohexylphenoxy	2,3-difluorophenyl	443
	4-chloro-2-cyclohexylphenoxy	2,6-dimethoxyphenyl	467
	4-chloro-2-cyclohexylphenoxy	3,4-difluorophenyl	443
	4-chloro-2-cyclohexylphenoxy	2,5-difluorophenyl	443
	4-chloro-2-cyclohexylphenoxy	4-ethoxyphenyl	451
10	4-chloro-2-cyclohexylphenoxy	2,4,6-trichlorophenyl	510
	4-chloro-2-cyclohexylphenoxy	3-methylphenyl	421
	4-chloro-2-cyclohexylphenoxy	2-fluoro-5-(trifluoromethyl)phenyl	493
	4-chloro-2-cyclohexylphenoxy	3-methoxyphenyl	437
	4-chloro-2-cyclohexylphenoxy	2-bromophenyl	486
15	4-chloro-2-cyclohexylphenoxy	4-bromophenyl	486
	4-chloro-2-cyclohexylphenoxy	4-fluoro-3-(trifluoromethyl)phenyl	493
	4-chloro-2-cyclohexylphenoxy	3'-(trifluoromethoxy)phenyl	491
	4-chloro-2-cyclohexylphenoxy	9-fluorenon-4-yl	503
	4-chloro-2-cyclohexylphenoxy	isoxazol-5-yl	398
20	4-chloro-2-cyclohexylphenoxy	benzofuroxan-5-yl	465
	4-chloro-2-cyclohexylphenoxy	2-chloropyrid-3-yl	442
	4-chloro-2-cyclohexylphenoxy	2-(4-methylphenoxy)pyridin-3-yl	514
	4-chloro-2-cyclohexylphenoxy	pyridin-4-yl	408
	4-chloro-2-cyclohexylphenoxy	anthraquinon-2-yl	537
25	4-chloro-2-cyclohexylphenoxy	2-iodophenyl	533
	4-chloro-2-cyclohexylphenoxy	4-pentylphenyl	477
	4-chloro-2-cyclohexylphenoxy	2-(4-chlorophenylthio)pyridin-3-yl	550
	4-chloro-2-cyclohexylphenoxy	2,6-dimethylphenyl	435
	4-chloro-2-cyclohexylphenoxy	2,5-dimethoxyphenyl	467
30	4-chloro-2-cyclohexylphenoxy	2,5-dichloropyridin-3-yl	477
	4-chloro-2-cyclohexylphenoxy	2-chloro-6-methoxypyridin-4-yl	472
	4-chloro-2-cyclohexylphenoxy	2,3-dichloropyridin-5-yl	477
	4-chloro-2-cyclohexylphenoxy	1-naphthyl	471
	4-chloro-2-cyclohexylphenoxy	2,4-dimethoxyphenyl	467
35	4-chloro-2-cyclohexylphenoxy	3,5-bis(trifluoromethyl)phenyl	546
	4-chloro-2-cyclohexylphenoxy	2-(4-chlorophenoxy)pyridin-3-yl	534
	4-chloro-2-cyclohexylphenoxy	pentafluorophenyl	497
	4-chloro-3,5-dimethylphenoxy	3,4-dimethoxyphenyl	413
	4-chloro-3,5-dimethylphenoxy	2-(trifluoromethyl)phenyl	421
40	4-chloro-3,5-dimethylphenoxy	2,4-difluorophenyl	389
	4-chloro-3,5-dimethylphenoxy	3-(trifluoromethyl)phenyl	421
	4-chloro-3,5-dimethylphenoxy	2-naphthyl	403
	4-chloro-3,5-dimethylphenoxy	2-methoxyphenyl	484
	4-chloro-3,5-dimethylphenoxy	3,4,5-trimethylphenyl	443
45	4-chloro-3,5-dimethylphenoxy	3,4-dichlorophenyl	422
	4-chloro-3,5-dimethylphenoxy	3-bromophenyl	432
	4-chloro-3,5-dimethylphenoxy	3-pyridyl	354
	4-chloro-3,5-dimethylphenoxy	2-ethoxynaphth-1-yl	447
	4-chloro-3,5-dimethylphenoxy	2,3-dichlorophenyl	422
50	4-chloro-3,5-dimethylphenoxy	6-chloropyrid-3-yl	388
	4-chloro-3,5-dimethylphenoxy	4-(trifluoromethoxy)phenyl	437
	4-chloro-3,5-dimethylphenoxy	2-fluoro-4-(trifluoromethyl)phenyl	439
	4-chloro-3,5-dimethylphenoxy	3-bromothieryl	438

EP 1 028 945 B9

(continued)

	R ¹ X	R ³	MS (m/z)
5	4-chloro-3,5-dimethylphenoxy	2-acetoxyphenyl	411
	4-chloro-3,5-dimethylphenoxy	5-methylisoxazol-3-yl	358
	4-chloro-3,5-dimethylphenoxy	2-(phenylthio)pyrid-3-yl	462
	4-chloro-3,5-dimethylphenoxy	2-(trifluoromethoxy)phenyl	437
	4-chloro-3,5-dimethylphenoxy	1-phenyl-5-propylpyrazin-4-yl	461
10	4-chloro-3,5-dimethylphenoxy	2-ethoxyphenyl	397
	4-chloro-3,5-dimethylphenoxy	3-chlorothien-2-yl	393
	4-chloro-3,5-dimethylphenoxy	1-(2-(2-methyl)propyl)-3-methylpyrazol-5-yl	413
	4-chloro-3,5-dimethylphenoxy	3,5-dichlorophenyl	422
	4-chloro-3,5-dimethylphenoxy	2-(propylthio)pyridin-3-yl	428
15	4-chloro-3,5-dimethylphenoxy	2-(ethylthio)pyridin-3-yl	414
	4-chloro-3,5-dimethylphenoxy	3-bromopyridin-5-yl	433
	4-chloro-3,5-dimethylphenoxy	4-methyl-1,2,3-thiadiazol-5-yl	375
	4-chloro-3,5-dimethylphenoxy	1-methyl-3-(2-(2-methyl)propyl)pyrazol-5-yl	413
	4-chloro-3,5-dimethylphenoxy	3-chlorobenzo[b]thiophen-2-yl	443
20	4-chloro-3,5-dimethylphenoxy	4-chlorophenyl	387
	4-chloro-3,5-dimethylphenoxy	4-methyl-2-phenyl-1,2,3-triazol-5-yl	434
	4-chloro-3,5-dimethylphenoxy	benzo[b]thiophen-2-yl	409
	4-chloro-3,5-dimethylphenoxy	3,4-dimethylphenyl	381
	4-chloro-3,5-dimethylphenoxy	2-(phenoxy)pyridin-3-yl	446
25	4-chloro-3,5-dimethylphenoxy	2-(methylthio)pyridin-3-yl	400
	4-chloro-3,5-dimethylphenoxy	5-methyl-3-phenylisoxazol-4-yl	434
	4-chloro-3,5-dimethylphenoxy	4-chloro-1,3-dimethyl pyrazolo[3,4-b]pyridin-3-yl	456
	4-chloro-3,5-dimethylphenoxy	2-chloro-6-methylpyridin-4-yl	402
	4-chloro-3,5-dimethylphenoxy	3,5-dimethylisoxazol-4-yl	372
30	4-chloro-3,5-dimethylphenoxy	1-naphthyl	403
	4-chloro-3,5-dimethylphenoxy	2-fluorophenyl	371
	4-chloro-3,5-dimethylphenoxy	4-propylphenyl	395
	4-chloro-3,5-dimethylphenoxy	3-fluorophenyl	371
	4-chloro-3,5-dimethylphenoxy	2,6-difluorophenyl	389
35	4-chloro-3,5-dimethylphenoxy	2-chlorophenyl	387
	4-chloro-3,5-dimethylphenoxy	3-(chloromethyl)phenyl	401
	4-chloro-3,5-dimethylphenoxy	4-(2-(2-methyl)propyl)phenyl	409
	4-chloro-3,5-dimethylphenoxy	3-chlorophenyl	387
	4-chloro-3,5-dimethylphenoxy	3,5-dimethoxyphenyl	413
40	4-chloro-3,5-dimethylphenoxy	2,6-dichlorophenyl	422
	4-chloro-3,5-dimethylphenoxy	2,4-dichlorophenyl	422
	4-chloro-3,5-dimethylphenoxy	4-fluorophenyl	371
	4-chloro-3,5-dimethylphenoxy	4-butylphenyl	409
	4-chloro-3,5-dimethylphenoxy	2-methylphenyl	367
45	4-chloro-3,5-dimethylphenoxy	phenyl	353
	4-chloro-3,5-dimethylphenoxy	4-ethylphenyl	381
	4-chloro-3,5-dimethylphenoxy	2,3-difluorophenyl	389
	4-chloro-3,5-dimethylphenoxy	2,6-dimethoxyphenyl	413
	4-chloro-3,5-dimethylphenoxy	3,4-difluorophenyl	389
50	4-chloro-3,5-dimethylphenoxy	2,5-difluorophenyl	389
	4-chloro-3,5-dimethylphenoxy	4-ethoxyphenyl	397
	4-chloro-3,5-dimethylphenoxy	2,4,6-trichlorophenyl	456
	4-chloro-3,5-dimethylphenoxy	3-methylphenyl	367
	4-chloro-3,5-dimethylphenoxy		

EP 1 028 945 B9

(continued)

	R ¹ X	R ³	MS (m/z)
5	4-chloro-3,5-dimethylphenoxy	2-fluoro-5-(trifluoromethyl)phenyl	439
	4-chloro-3,5-dimethylphenoxy	3-methoxyphenyl	383
	4-chloro-3,5-dimethylphenoxy	2-bromophenyl	432
	4-chloro-3,5-dimethylphenoxy	4-bromophenyl	432
	4-chloro-3,5-dimethylphenoxy	4-fluoro-3-(trifluoromethyl)phenyl	439
10	4-chloro-3,5-dimethylphenoxy	3-(trifluoromethoxy)phenyl	437
	4-chloro-3,5-dimethylphenoxy	9-fluorenon-4-yl	455
	4-chloro-3,5-dimethylphenoxy	isoxazol-5-yl	344
	4-chloro-3,5-dimethylphenoxy	benzofuroxan-5-yl	411
	4-chloro-3,5-dimethylphenoxy	2-chloropyrid-3-yl	388
15	4-chloro-3,5-dimethylphenoxy	2-(4-methylphenoxy)pyridin-3-yl	460
	4-chloro-3,5-dimethylphenoxy	pyridin-4-yl	354
	4-chloro-3,5-dimethylphenoxy	anthraquinon-2-yl	483
	4-chloro-3,5-dimethylphenoxy	2-iodophenyl	479
	4-chloro-3,5-dimethylphenoxy	4-pentylphenyl	423
20	4-chloro-3,5-dimethylphenoxy	2-(4-chlorophenylthio)pyridin-3-yl	496
	4-chloro-3,5-dimethylphenoxy	2,6-dimethylphenyl	381
	4-chloro-3,5-dimethylphenoxy	2,5-dimethoxyphenyl	413
	4-chloro-3,5-dimethylphenoxy	2,5-dichloropyridin-3-yl	423
	4-chloro-3,5-dimethylphenoxy	2-chloro-6-methoxypyridin-4-yl	418
25	4-chloro-3,5-dimethylphenoxy	2,3-dichloropyridin-5-yl	423
	4-chloro-3,5-dimethylphenoxy	1-naphthyl	417
	4-chloro-3,5-dimethylphenoxy	2,4-dimethoxyphenyl	413
	4-chloro-3,5-dimethylphenoxy	3,5-bis(trifluoromethyl)phenyl	489
	4-chloro-3,5-dimethylphenoxy	2-(4-chlorophenoxy)pyridin-3-yl	480
30	4-chloro-3,5-dimethylphenoxy	pentafluorophenyl	443
	pyrid-3-yloxy	3,4-dimethoxyphenyl	351
	pyrid-3-yloxy	2-(trifluoromethyl)phenyl	359
	pyrid-3-yloxy	2,4-difluorophenyl	327
	pyrid-3-yloxy	3-(trifluoromethyl)phenyl	359
35	pyrid-3-yloxy	2-naphthyl	341
	pyrid-3-yloxy	2-methoxyphenyl	321
	pyrid-3-yloxy	3,4,5-trimethylphenyl	381
	pyrid-3-yloxy	3,4-dichlorophenyl	360
	pyrid-3-yloxy	3-bromophenyl	370
40	pyrid-3-yloxy	3-pyridyl	292
	pyrid-3-yloxy	2-ethoxynaphth-1-yl	385
	pyrid-3-yloxy	2,3-dichlorophenyl	360
	pyrid-3-yloxy	6-chloropyrid-3-yl	327
	pyrid-3-yloxy	4-(trifluoromethoxy)phenyl	375
45	pyrid-3-yloxy	2-fluoro-4-(trifluoromethyl)phenyl	377
	pyrid-3-yloxy	3-bromothieryl	376
	pyrid-3-yloxy	2-acetoxyphenyl	349
	pyrid-3-yloxy	5-methylisoxazol-3-yl	296
	pyrid-3-yloxy	2-(phenylthio)pyrid-3-yl	400
50	pyrid-3-yloxy	2-(trifluoromethoxy)phenyl	375
	pyrid-3-yloxy	1-phenyl-5-propylpyrazin-4-yl	399
	pyrid-3-yloxy	2-ethoxyphenyl	335
	pyrid-3-yloxy	3-chlorothien-2-yl	332

EP 1 028 945 B9

(continued)

	R ¹ X	R ³	MS (m/z)
5	pyrid-3-yloxy	1-(2-(2-methyl)propyl)-3-methylpyrazol-5-yl	351
	pyrid-3-yloxy	3,5-dichlorophenyl	360
	pyrid-3-yloxy	2-(propylthio)pyridin-3-yl	366
	pyrid-3-yloxy	2-(ethylthio)pyridin-3-yl	352
	pyrid-3-yloxy	3-bromopyridin-5-yl	371
10	pyrid-3-yloxy	4-methyl-1,2,3-thiadiazol-5-yl	313
	pyrid-3-yloxy	1-methyl-3-(2-(2-methyl)propyl)pyrazol-5-yl	351
	pyrid-3-yloxy	3-chlorobenzo[b]thiophen-2-yl	382
	pyrid-3-yloxy	4-chlorophenyl	326
	pyrid-3-yloxy	4-methyl-2-phenyl-1,2,3-triazol-5-yl	372
15	pyrid-3-yloxy	benzo[b]thiophen-2-yl	347
	pyrid-3-yloxy	3,4-dimethylphenyl	319
	pyrid-3-yloxy	2-(phenoxy)pyridin-3-yl	384
	pyrid-3-yloxy	2-(methylthio)pyridin-3-yl	338
	pyrid-3-yloxy	5-methyl-3-phenylisoxazol-4-yl	372
20	pyrid-3-yloxy	4-chloro-1,3-dimethyl pyrazolo[3,4-b]pyridin-3-yl	395
	pyrid-3-yloxy	2-chloro-6-methylpyridin-4-yl	341
	pyrid-3-yloxy	3,5-dimethylisoxazol-4-yl	310
	pyrid-3-yloxy	1-naphthyl	341
	pyrid-3-yloxy	2-fluorophenyl	309
25	pyrid-3-yloxy	4-propylphenyl	333
	pyrid-3-yloxy	3-fluorophenyl	309
	pyrid-3-yloxy	2,6-difluorophenyl	327
	pyrid-3-yloxy	2-chlorophenyl	326
	pyrid-3-yloxy	3-(chloromethyl)phenyl	340
30	pyrid-3-yloxy	4-(2-(2-methyl)propyl)phenyl	347.
	pyrid-3-yloxy	3-chlorophenyl	326
	pyrid-3-yloxy	3,5-dimethoxyphenyl	351
	pyrid-3-yloxy	2,6-dichlorophenyl	360
	pyrid-3-yloxy	2,4-dichlorophenyl	360
35	pyrid-3-yloxy	4-fluorophenyl	309
	pyrid-3-yloxy	4-butylphenyl	347
	pyrid-3-yloxy	2-methylphenyl	305
	pyrid-3-yloxy	phenyl	291
	pyrid-3-yloxy	4-ethylphenyl	319
40	pyrid-3-yloxy	2,3-difluorophenyl	327
	pyrid-3-yloxy	2,6-dimethoxyphenyl	351
	pyrid-3-yloxy	3,4-difluorophenyl	327
	pyrid-3-yloxy	2,5-difluorophenyl	327
	pyrid-3-yloxy	4-ethoxyphenyl	335
45	pyrid-3-yloxy	2,4,6-trichlorophenyl	395
	pyrid-3-yloxy	3-methylphenyl	305
	pyrid-3-yloxy	2-fluoro-5-(trifluoromethyl)phenyl	377
	pyrid-3-yloxy	3-methoxyphenyl	321
	pyrid-3-yloxy	2-bromophenyl	370
50	pyrid-3-yloxy	4-bromophenyl	370
	pyrid-3-yloxy	4-fluoro-3-(trifluoromethyl)phenyl	377
	pyrid-3-yloxy	3-(trifluoromethoxy)phenyl	375
	pyrid-3-yloxy	9-fluorenon-4-yl	393
	pyrid-3-yloxy		

EP 1 028 945 B9

(continued)

	R ¹ X	R ³	MS (m/z)
5	pyrid-3-yloxy	isoxazol-5-yl	282
	pyrid-3-yloxy	benzofuroxan-5-yl	349
	pyrid-3-yloxy	2-chloropyrid-3-yl	327
	pyrid-3-yloxy	2-(4-methylphenoxy)pyridin-3-yl	398
10	pyrid-3-yloxy	pyridin-4-yl	292
	pyrid-3-yloxy	anthraquinon-2-yl	421
	pyrid-3-yloxy	2-iodophenyl	417
	pyrid-3-yloxy	4-pentylphenyl	361
15	pyrid-3-yloxy	2-(4-chlorophenylthio)pyridin-3-yl	435
	pyrid-3-yloxy	2,6-dimethylphenyl	319
	pyrid-3-yloxy	2,5-dimethoxyphenyl	354
	pyrid-3-yloxy	2,5-dichloropyridin-3-yl	361
20	pyrid-3-yloxy	2-chloro-6-methoxypyridin-4-yl	357
	pyrid-3-yloxy	2,3-dichloropyridin-5-yl	361
	pyrid-3-yloxy	1-naphthyl	355
	pyrid-3-yloxy	2,4-dimethoxyphenyl	351
25	pyrid-3-yloxy	3,5-bis(trifluoromethyl)phenyl	427
	pyrid-3-yloxy	2-(4-chlorophenoxy)pyridin-3-yl	419
	pyrid-3-yloxy	pentafluorophenyl	381
	4-bromophenoxy	3,4-dimethoxyphenyl	429
30	4-bromophenoxy	2-(trifluoromethyl)phenyl	437
	4-bromophenoxy	2,4-difluorophenyl	405
	4-bromophenoxy	3-(trifluoromethyl)phenyl	437
	4-bromophenoxy	2-naphthyl	419
35	4-bromophenoxy	2-methoxyphenyl	399
	4-bromophenoxy	3,4,5-trimethylphenyl	459
	4-bromophenoxy	3,4-dichlorophenyl	438
	4-bromophenoxy	3-bromophenyl	448
40	4-bromophenoxy	3-pyridyl	370
	4-bromophenoxy	2-ethoxynaphth-1-yl	463
	4-bromophenoxy	2,3-dichlorophenyl	438
	4-bromophenoxy	6-chloropyrid-3-yl	405
45	4-bromophenoxy	4-(trifluoromethoxy)phenyl	453
	4-bromophenoxy	2-fluoro-4-(trifluoromethyl)phenyl	455
	4-bromophenoxy	3-bromothieryl	454
	4-bromophenoxy	2-acetoxyphenyl	427
50	4-bromophenoxy	5-methylisoxazol-3-yl	374
	4-bromophenoxy	2-(phenylthio)pyrid-3-yl	478
	4-bromophenoxy	2-(trifluoromethoxy)phenyl	453
	4-bromophenoxy	1-phenyl-5-propylpyrazin-4-yl	477
55	4-bromophenoxy	2-ethoxyphenyl	413
	4-bromophenoxy	3-chlorothien-2-yl	410
	4-bromophenoxy	1-(2-(2-methyl)propyl)-3-methylpyrazol-5-yl	429
	4-bromophenoxy	3,5-dichlorophenyl	438
55	4-bromophenoxy	2-(propylthio)pyridin-3-yl	444
	4-bromophenoxy	2-(ethylthio)pyridin-3-yl	430
	4-bromophenoxy	3-bromopyridin-5-yl	449
	4-bromophenoxy	4-methyl-1,2,3-thiadiazol-5-yl	391
	4-bromophenoxy	1-methyl-3-(2-(2-methyl)propyl)pyrazol-5-yl	429

EP 1 028 945 B9

(continued)

	R ¹ X	R ³	MS (m/z)
5	4-bromophenoxy	3-chlorobenzo[b]thiophen-2-yl	460
	4-bromophenoxy	4-chlorophenyl	404
	4-bromophenoxy	4-methyl-2-phenyl-1,2,3-triazol-5-yl	450
	4-bromophenoxy	benzo[b]thiophen-2-yl	425
	4-bromophenoxy	3,4-dimethylphenyl	397
10	4-bromophenoxy	2-(phenoxy)pyridin-3-yl	462
	4-bromophenoxy	2-(methylthio)pyridin-3-yl	416
	4-bromophenoxy	5-methyl-3-phenylisoxazol-4-yl	450
	4-bromophenoxy	4-chloro-1,3-dimethyl pyrazolo[3,4-b]pyridin-3-yl	473
	4-bromophenoxy	2-chloro-6-methylpyridin-4-yl	419
15	4-bromophenoxy	3,5-dimethylisoxazol-4-yl	388
	4-bromophenoxy	1-naphthyl	419
	4-bromophenoxy	2-fluorophenyl	387
	4-bromophenoxy	4-propylphenyl	411
	4-bromophenoxy	3-fluorophenyl	387
20	4-bromophenoxy	2,6-difluorophenyl	405
	4-bromophenoxy	2-chlorophenyl	414
	4-bromophenoxy	3-(chloromethyl)phenyl	418
	4-bromophenoxy	4-(2-(2-methyl)propyl)phenyl	425
	4-bromophenoxy	3-chlorophenyl	404
25	4-bromophenoxy	3,5-dimethoxyphenyl	429
	4-bromophenoxy	2,6-dichlorophenyl	438
	4-bromophenoxy	2,4-dichlorophenyl	438
	4-bromophenoxy	4-fluorophenyl	387
	4-bromophenoxy	4-butylphenyl	425
30	4-bromophenoxy	2-methylphenyl	383
	4-bromophenoxy	phenyl	369
	4-bromophenoxy	4-ethylphenyl	397
	4-bromophenoxy	2,3-difluorophenyl	405
	4-bromophenoxy	2,6-dimethoxyphenyl	429
35	4-bromophenoxy	3,4-difluorophenyl	405
	4-bromophenoxy	2,5-difluorophenyl	405
	4-bromophenoxy	4-ethoxyphenyl	413
	4-bromophenoxy	2,4,6-trichlorophenyl	473
	4-bromophenoxy	3-methylphenyl	383
40	4-bromophenoxy	2-fluoro-5-(trifluoromethyl)phenyl	455
	4-bromophenoxy	3-methoxyphenyl	399
	4-bromophenoxy	2-bromophenyl	448
	4-bromophenoxy	4-bromophenyl	448
	4-bromophenoxy	4-fluoro-3-(trifluoromethyl)phenyl	455
45	4-bromophenoxy	3-(trifluoromethoxy)phenyl	453
	4-bromophenoxy	9-fluorenon-4-yl	471
	4-bromophenoxy	isoxazol-5-yl	360
	4-bromophenoxy	benzofuroxan-5-yl	427
	4-bromophenoxy	2-chloropyrid-3-yl	360
50	4-bromophenoxy	2-(4-methylphenoxy)pyridin-3-yl	476
	4-bromophenoxy	pyridin-4-yl	370
	4-bromophenoxy	anthraquinon-2-yl	499
	4-bromophenoxy	2-iodophenyl	495
	4-bromophenoxy		

EP 1 028 945 B9

(continued)

	R ¹ X	R ³	MS (m/z)
5	4-bromophenoxy	4-pentylphenyl	439
	4-bromophenoxy	2-(4-chlorophenylthio)pyridin-3-yl	513
	4-bromophenoxy	2,6-dimethylphenyl	397
	4-bromophenoxy	2,5-dimethoxyphenyl	429
	4-bromophenoxy	2,5-dichloropyridin-3-yl	439
10	4-bromophenoxy	2-chloro-6-methoxypyridin-4-yl	435
	4-bromophenoxy	2,3-dichloropyridin-5-yl	439
	4-bromophenoxy	1-naphthyl	433
	4-bromophenoxy	2,4-dimethoxyphenyl	429
	4-bromophenoxy	3,5-bis(trifluoromethyl)phenyl	505
15	4-bromophenoxy	2-(4-chlorophenoxy)pyridin-3-yl	497
	4-bromophenoxy	pentafluorophenyl	459
	4-chloro-2-methylphenylthio	4-biphenyl	431
	4-chloro-2-methylphenylthio	3,4-dimethoxyphenyl	415
	4-chloro-2-methylphenylthio	2-(trifluoromethyl)phenyl	423
20	4-chloro-2-methylphenylthio	2,4-difluorophenyl	391
	4-chloro-2-methylphenylthio	4-cyanophenyl	380
	4-chloro-2-methylphenylthio	3-(trifluoromethyl)phenyl	423
	4-chloro-2-methylphenylthio	3-cyanophenyl	380
	4-chloro-2-methylphenylthio	2-naphthyl	405
25	4-chloro-2-methylphenylthio	2-methoxyphenyl	385
	4-chloro-2-methylphenylthio	3,4,5-trimethylphenyl	445
	4-chloro-2-methylphenylthio	4-nitrophenyl	400
	4-chloro-2-methylphenylthio	3,4-dichlorophenyl	424
	4-chloro-2-methylphenylthio	5-nitrofuran-2-yl	390
30	4-chloro-2-methylphenylthio	3-bromophenyl	434
	4-chloro-2-methylphenylthio	3-pyridyl	356
	4-chloro-2-methylphenylthio	2-ethoxynaphth-1-yl	449
	4-chloro-2-methylphenylthio	2,3-dichlorophenyl	424
	4-chloro-2-methylphenylthio	3-nitrophenyl	400
35	4-chloro-2-methylphenylthio	6-chloropyrid-3-yl	390
	4-chloro-2-methylphenylthio	4-(trifluoromethoxy)phenyl	439
	4-chloro-2-methylphenylthio	2-fluoro-4-(trifluoromethyl)phenyl	441
	4-chloro-2-methylphenylthio	3-bromothieryl	440
	4-chloro-2-methylphenylthio	2-acetoxyphenyl	413
40	4-chloro-2-methylphenylthio	5-methylisoxazol-3-yl	360
	4-chloro-2-methylphenylthio	2-(phenylthio)pyrid-3-yl	464
	4-chloro-2-methylphenylthio	2-(trifluoromethoxy)phenyl	439
	4-chloro-2-methylphenylthio	1-phenyl-5-propylpyrazin-4-yl	463
	4-chloro-2-methylphenylthio	2-ethoxyphenyl	399
45	4-chloro-2-methylphenylthio	3-chlorothien-2-yl	395
	4-chloro-2-methylphenylthio	1-(2-(2-methyl)propyl)-3-methylpyrazol-5-yl	415
	4-chloro-2-methylphenylthio	3,5-dichlorophenyl	424
	4-chloro-2-methylphenylthio	2-(propylthio)pyridin-3-yl	430
	4-chloro-2-methylphenylthio	2-(ethylthio)pyridin-3-yl	416
50	4-chloro-2-methylphenylthio	3-bromopyridin-5-yl	435
	4-chloro-2-methylphenylthio	4-methyl-1,2,3-thiadiazol-5-yl	377
	4-chloro-2-methylphenylthio	1-methyl-3-(2-(2-methyl)propyl)pyrazol-5-yl	415
	4-chloro-2-methylphenylthio	3-chlorobenzo[b]thiophen-2-yl	445
	4-chloro-2-methylphenylthio		

EP 1 028 945 B9

(continued)

	R ¹ X	R ³	MS (m/z)
5	4-chloro-2-methylphenylthio	4-chlorophenyl	389
	4-chloro-2-methylphenylthio	4-methyl-2-phenyl-1,2,3-triazol-5-yl	436
	4-chloro-2-methylphenylthio	benzo[b]thiophen-2-yl	411
	4-chloro-2-methylphenylthio	3,4-dimethylphenyl	383
	4-chloro-2-methylphenylthio	2-(phenoxy)pyridin-3-yl	448
10	4-chloro-2-methylphenylthio	2-(methylthio)pyridin-3-yl	402
	4-chloro-2-methylphenylthio	5-methyl-3-phenylisoxazol-4-yl	436
	4-chloro-2-methylphenylthio	4-chloro-1,3-dimethyl pyrazolo[3,4-b]pyridin-3yl	458
	4-chloro-2-methylphenylthio	2-chloro-6-methylpyridin-4-yl	404
	4-chloro-2-methylphenylthio	3,5-dimethylisoxazol-4-yl	374
15	4-chloro-2-methylphenylthio	1-naphthyl	405
	4-chloro-2-methylphenylthio	2-fluorophenyl	373
	4-chloro-2-methylphenylthio	4-propylphenyl	397
	4-chloro-2-methylphenylthio	4-(trifluoromethyl)phenyl	423
	4-chloro-2-methylphenylthio	3-fluorophenyl	373
20	4-chloro-2-methylphenylthio	2,6-difluorophenyl	391
	4-chloro-2-methylphenylthio	2-chlorophenyl	389
	4-chloro-2-methylphenylthio	3-(chloromethyl)phenyl	403
	4-chloro-2-methylphenylthio	4-(2-(2-methyl)propyl)phenyl	411
	4-chloro-2-methylphenylthio	3-chlorophenyl	389
25	4-chloro-2-methylphenylthio	2-nitrophenyl	400
	4-chloro-2-methylphenylthio	3,5-dimethoxyphenyl	415
	4-chloro-2-methylphenylthio	2,6-dichlorophenyl	424
	4-chloro-2-methylphenylthio	2,4-dichlorophenyl	424
	4-chloro-2-methylphenylthio	4-fluorophenyl	373
30	4-chloro-2-methylphenylthio	4-butylphenyl	41,1
	4-chloro-2-methylphenylthio	2-methylphenyl	369
	4-chloro-2-methylphenylthio	phenyl	355
	4-chloro-2-methylphenylthio	4-ethylphenyl	383
	4-chloro-2-methylphenylthio	2,3-difluorophenyl	391
35	4-chloro-2-methylphenylthio	2,6-dimethoxyphenyl	415
	4-chloro-2-methylphenylthio	3,4-difluorophenyl	391
	4-chloro-2-methylphenylthio	2,5-difluorophenyl	391
	4-chloro-2-methylphenylthio	4-ethoxyphenyl	399
	4-chloro-2-methylphenylthio	2,4,6-trichlorophenyl	458
40	4-chloro-2-methylphenylthio	3-methylphenyl	369
	4-chloro-2-methylphenylthio	2-fluoro-5-(trifluoromethyl)phenyl	441
	4-chloro-2-methylphenylthio	3-methoxyphenyl	385
	4-chloro-2-methylphenylthio	thien-2-yl	361
	4-chloro-2-methylphenylthio	2-bromophenyl	434
45	4-chloro-2-methylphenylthio	4-bromophenyl	434
	4-chloro-2-methylphenylthio	4-fluoro-3-(trifluoromethyl)phenyl	441
	4-chloro-2-methylphenylthio	3-(trifluoromethoxy)phenyl	439
	4-chloro-2-methylphenylthio	9-fluorenon-4-yl	457
	4-chloro-2-methylphenylthio	isoxazol-5-yl	346
50	4-chloro-2-methylphenylthio	benzofuroxan-5-yl	413
	4-chloro-2-methylphenylthio	2-chloropyrid-3-yl	390
	4-chloro-2-methylphenylthio	3,5-difluorophenyl	391
	4-chloro-2-methylphenylthio	2-(4-methylphenoxy)pyridin-3-yl	462
	4-chloro-2-methylphenylthio		

(continued)

	R ¹ X	R ³	MS (m/z)
5	4-chloro-2-methylphenylthio	pyridin-4-yl	356
	4-chloro-2-methylphenylthio	anthraquinon-2-yl	485
	4-chloro-2-methylphenylthio	2-iodophenyl	481
	4-chloro-2-methylanilino	4-biphenyl	414
10	4-chloro-2-methylanilino	3,4-dimethoxyphenyl	398
	4-chloro-2-methylanilino	2-(trifluoromethyl)phenyl	406
	4-chloro-2-methylanilino	2,4-difluorophenyl	374
	4-chloro-2-methylanilino	4-cyanophenyl	363
15	4-chloro-2-methylanilino	3-(trifluoromethyl)phenyl	406
	4-chloro-2-methylanilino	3-cyanophenyl	363
	4-chloro-2-methylanilino	2-naphthyl	388
	4-chloro-2-methylanilino	2-methoxyphenyl	368
20	4-chloro-2-methylanilino	3,4,5-trimethylphenyl	428
	4-chloro-2-methylanilino	4-nitrophenyl	383
	4-chloro-2-methylanilino	3,4-dichlorophenyl	407
	4-chloro-2-methylanilino	5-nitrofur-2-yl	373
25	4-chloro-2-methylanilino	3-bromophenyl	417
	4-chloro-2-methylanilino	3-pyridyl	339
	4-chloro-2-methylanilino	2-ethoxynaphth-1-yl	432
	4-chloro-2-methylanilino	2,3-dichlorophenyl	407
30	4-chloro-2-methylanilino	3-nitrophenyl	383
	4-chloro-2-methylanilino	6-chloropyrid-3-yl	373
	4-chloro-2-methylanilino	4-(trifluoromethoxy)phenyl	422
	4-chloro-2-methylanilino	2-fluoro-4-trifluoromethyl)phenyl	424
35	4-chloro-2-methylanilino	3-bromothieryl	423
	4-chloro-2-methylanilino	2-acetoxyphenyl	396
	4-chloro-2-methylanilino	5-methylisoxazol-3-yl	343
	4-chloro-2-methylanilino	2-(phenylthio)pyrid-3-yl	447
40	4-chloro-2-methylanilino	2-(trifluoromethoxy)phenyl	422
	4-chloro-2-methylanilino	1-phenyl-5-propylpyrazin-4-yl	446
	4-chloro-2-methylanilino	2-ethoxyphenyl	382
	4-chloro-2-methylanilino	3-chlorothieryl-2-yl	378
45	4-chloro-2-methylanilino	1-(2-(2-methyl)propyl)-3-methylpyrazol-5-yl	398
	4-chloro-2-methylanilino	3,5-dichlorophenyl	407
	4-chloro-2-methylanilino	2-(propylthio)pyridin-3-yl	413
	4-chloro-2-methylanilino	2-(ethylthio)pyridin-3-yl	399
50	4-chloro-2-methylanilino	3-bromopyridin-5-yl	418
	4-chloro-2-methylanilino	4-inethyl-1,2,3-thiadiazol-5-yl	360
	4-chloro-2-methylanilino	1-methyl-3-(2-(2-methyl)propyl)pyrazol-5-yl	398
	4-chloro-2-methylanilino	3-chlorobenzo[b]thiophen-2-yl	428
55	4-chloro-2-methylanilino	4-chlorophenyl	372
	4-chloro-2-methylanilino	4-methyl-2-phenyl-1,2,3-thiazol-5-yl	419
	4-chloro-2-methylanilino	benzo[b]thiophen-2-yl	394
	4-chloro-2-methylanilino	3,4-dimethylphenyl	366
55	4-chloro-2-methylanilino	2-(phenoxy)pyridin-3-yl	431
	4-chloro-2-methylanilino	2-(methylthio)pyridin-3-yl	385
	4-chloro-2-methylanilino	5-methyl-3-phenylisoxazol-4-yl	419
	4-chloro-2-methylanilino	4-chloro-1,3-dimethyl pyrazolo[3,4-b]pyridin-3-yl	441
	4-chloro-2-methylanilino	2-chloro-6-methylpyridin-4-yl	387

	R ¹ X	(continued)	R ³	MS (m/z)
5	4-chloro-2-methylanilino	3,5-dimethylisoxazol-4-yl		357
	4-chloro-2-methylanilino	1-naphthyl		388
	4-chloro-2-methylanilino	2-fluorophenyl		356
	4-chloro-2-methylanilino	4-propylphenyl		380
	4-chloro-2-methylanilino	4-(trifluoromethyl)phenyl		406
10	4-chloro-2-methylanilino	3-fluorophenyl		356
	4-chloro-2-methylanilino	2,6-difluorophenyl		374
	4-chloro-2-methylanilino	2-chlorophenyl		372
	4-chloro-2-methylanilino	3-(chloromethyl)phenyl		386
	4-chloro-2-methylanilino	4-(2-(2-methyl)propyl)phenyl		394
15	4-chloro-2-methylanilino	3-chlorophenyl		372
	4-chloro-2-methylanilino	2-nitrophenyl		383
	4-chloro-2-methylanilino	3,5-dimethoxyphenyl		398
	4-chloro-2-methylanilino	2,6-dichlorophenyl		407
20	4-chloro-2-methylanilino	2,4-dichlorophenyl		407
	4-chloro-2-methylanilino	4-fluorophenyl		356
	4-chloro-2-methylanilino	4-butylphenyl		394
	4-chloro-2-methylanilino	2-methylphenyl		352
	4-chloro-2-methylanilino	phenyl		338
25	4-chloro-2-methylanilino	4-ethylphenyl		366
	4-chloro-2-methylanilino	2,3-difluorophenyl		374
	4-chloro-2-methylanilino	2,6-dimethoxyphenyl		398
	4-chloro-2-methylanilino	3,4-difluorophenyl		374
30	4-chloro-2-methylanilino	2,5-difluorophenyl		374
	4-chloro-2-methylanilino	4-ethoxyphenyl		382
	4-chloro-2-methylanilino	2,4,6-trichlorophenyl		441
	4-chloro-2-methylanilino	3-methylphenyl		352
	4-chloro-2-methylanilino	2-fluoro-5-(trifluoromethyl)phenyl		424
35	4-chloro-2-methylanilino	3-methoxyphenyl		368
	4-chloro-2-methylanilino	thien-2-yl		344
	4-chloro-2-methylanilino	2-bromophenyl		417
	4-chloro-2-methylanilino	4-bromophenyl		417
40	4-chloro-2-methylanilino	4-fluoro-3-(trifluoromethyl)phenyl		424
	4-chloro-2-methylanilino	3-(trifluoromethoxy)phenyl		422
	4-chloro-2-methylanilino	9-fluorenon-4-yl		440
	4-chloro-2-methylanilino	isoxazol-5-yl		329
45	4-chloro-2-methylanilino	benzofuroxan-5-yl		396
	4-chloro-2-methylanilino	2-chloropyrid-3-yl		373
	4-chloro-2-methylanilino	3,5-difluorophenyl		374
	4-chloro-2-methylanilino	2-(4-methylphenoxy)pyridin-3-yl		445
	4-chloro-2-methylanilino	pyridin-4-yl		339
50	4-chloro-2-methylanilino	anthraquinon-2-yl		468
	4-chloro-2-methylanilino	2-iodophenyl		464

[0083] The compounds listed in Table 7 can be prepared from substituted 5-aminopyridine compounds and the appropriate acid chloride according to the general procedure above.

Table 7

	R ¹ X	R ³
5	4-chloro-2-methylphenoxy	3,4-difluorophenyl
	4-chloro-2-methylphenoxy	4-pentylphenyl
	4-chloro-2-methylphenoxy	2-(4-chlorophenylthio)pyridin-3-yl
	4-chloro-2-methylphenoxy	2,6-dimethylphenyl
	4-chloro-2-methylphenoxy	2,5-dimethoxyphenyl
10	4-chloro-2-methylphenoxy	2,5-dichloropyridin-3-yl
	4-chloro-2-methylphenoxy	2-chloro-6-methoxypyridin-4-yl
	4-chloro-2-methylphenoxy	2,3-dichloropyridin-5-yl
	4-chloro-2-methylphenoxy	1-naphthyl
	4-chloro-2-methylphenoxy	2,4-dimethoxyphenyl
15	4-chloro-2-methylphenoxy	3,5-bis(trifluoromethyl)phenyl
	4-chloro-2-methylphenoxy	2-(4-chlorophenoxy)pyridin-3-yl
	4-chloro-2-methylphenoxy	pentafluorophenyl
	1-naphthoxy	4-pentylphenyl
	1-naphthoxy	2-(4-chlorophenylthio)pyridin-3-yl
20	1-naphthoxy	2,6-dimethylphenyl
	1-naphthoxy	2,5-dimethoxyphenyl
	1-naphthoxy	2,5-dichloropyridin-3-yl
	1-naphthoxy	2-chloro-6-methoxypyridin-4-yl
	1-naphthoxy	2,3-dichloropyridin-5-yl
25	1-naphthoxy	1-naphthyl
	1-naphthoxy	2,4-dimethoxyphenyl
	1-naphthoxy	3,5-bis(trifluoromethyl)phenyl
	1-naphthoxy	2-(4-chlorophenoxy)pyridin-3-yl
	1-naphthoxy	pentafluorophenyl
30	2-(2-propyl)phenoxy	4-pentylphenyl
	2-(2-propyl)phenoxy	2-(4-chlorophenylthio)pyridin-3-yl
	2-(2-propyl)phenoxy	2,6-dimethylphenyl
	2-(2-propyl)phenoxy	2,5-dimethoxyphenyl
	2-(2-propyl)phenoxy	2,5-dichloropyridin-3-yl
35	2-(2-propyl)phenoxy	2-chloro-6-methoxypyridin-4-yl
	2-(2-propyl)phenoxy	2,3-dichloropyridin-5-yl
	2-(2-propyl)phenoxy	1-naphthyl
	2-(2-propyl)phenoxy	2,4-dimethoxyphenyl
	2-(2-propyl)phenoxy	3,5-bis(trifluoromethyl)phenyl
40	2-(2-propyl)phenoxy	2-(4-chlorophenoxy)pyridin-3-yl
	2-(2-propyl)phenoxy	pentafluorophenyl
	3-fluoro-5-methylphenoxy	4-pentylphenyl
	3-fluoro-5-methylphenoxy	2-(4-chlorophenylthio)pyridin-3-yl
	3-fluoro-5-methylphenoxy	2,6-dimethylphenyl
45	3-fluoro-5-methylphenoxy	2,5-dimethoxyphenyl
	3-fluoro-5-methylphenoxy	2,5-dichloropyridin-3-yl
	3-fluoro-5-methylphenoxy	2-chloro-6-methoxypyridin-4-yl
	3-fluoro-5-methylphenoxy	2,3-dichloropyridin-5-yl
	3-fluoro-5-methylphenoxy	1-naphthyl
50	3-fluoro-5-methylphenoxy	2,4-dimethoxyphenyl
	3-fluoro-5-methylphenoxy	3,5-bis(trifluoromethyl)phenyl
	3-fluoro-5-methylphenoxy	2-(4-chlorophenoxy)pyridin-3-yl
	3-fluoro-5-methylphenoxy	pentafluorophenyl
	3-fluoro-5-methylphenoxy	4-pentylphenyl
55	2-methylpyrid-3-yloxy	4-pentylphenyl

(continued)

	R ¹ X	R ³
5	2-methylpyrid-3-yloxy	2-(4-chlorophenylthio)pyridin-3-yl
	2-methylpyrid-3-yloxy	2,6-dimethylphenyl
	2-methylpyrid-3-yloxy	2,5-dimethoxyphenyl
	2-methylpyrid-3-yloxy	2,5-dichloropyridin-3-yl
	2-methylpyrid-3-yloxy	2-chloro-6-methoxypyridin-4-yl
10	2-methylpyrid-3-yloxy	2,3-dichloropyridin-5-yl
	2-methylpyrid-3-yloxy	1-naphthyl
	2-methylpyrid-3-yloxy	2,4-dimethoxyphenyl
	2-methylpyrid-3-yloxy	3,5-bis(trifluoromethyl)phenyl
	2-methylpyrid-3-yloxy	2-(4-chlorophenoxy)pyridin-3-yl
15	2-methylpyrid-3-yloxy	pentafluorophenyl
	4-methoxyphenoxy	4-biphenyl
	4-methoxyphenoxy	4-cyanophenyl
	4-methoxyphenoxy	3-cyanophenyl
	4-methoxyphenoxy	4-nitrophenyl
20	4-methoxyphenoxy	5-nitrofuran-2-yl
	4-methoxyphenoxy	3-nitrophenyl
	4-methoxyphenoxy	4-(trifluoromethyl)phenyl
	4-methoxyphenoxy	2-nitrophenyl
	4-methoxyphenoxy	thien-2-yl
25	2-(2-propoxy)phenoxy	4-biphenyl
	2-(2-propoxy)phenoxy	4-cyanophenyl
	2-(2-propoxy)phenoxy	3-cyanophenyl
	2-(2-propoxy)phenoxy	4-nitrophenyl
	2-(2-propoxy)phenoxy	5-nitrofuran-2-yl
30	2-(2-propoxy)phenoxy	3-nitrophenyl
	2-(2-propoxy)phenoxy	2-nitrophenyl
	2-(2-propoxy)phenoxy	thien-2-yl
	2-(2-propoxy)phenoxy	3,5-difluorophenyl
	4-fluorophenoxy	4-biphenyl
35	4-fluorophenoxy	4-cyanophenyl
	4-fluorophenoxy	3-cyanophenyl
	4-fluorophenoxy	4-nitrophenyl
	4-fluorophenoxy	5-nitrofuran-2-yl
	4-fluorophenoxy	3-nitrophenyl
40	4-fluorophenoxy	2-nitrophenyl
	4-fluorophenoxy	4-(trifluoromethyl)phenyl
	4-fluorophenoxy	thien-2-yl
	4-fluorophenoxy	3,5-difluorophenyl
	4-chlorophenoxy	4-biphenyl
45	4-chlorophenoxy	4-cyanophenyl
	4-chlorophenoxy	3-cyanophenyl
	4-chlorophenoxy	4-nitrophenyl
	4-chlorophenoxy	5-nitrofuran-2-yl
	4-chlorophenoxy	3-nitrophenyl
50	4-chlorophenoxy	2-nitrophenyl
	4-chlorophenoxy	4-(trifluoromethyl)phenyl
	4-chlorophenoxy	thien-2-yl
	4-chlorophenoxy	3,5-difluorophenyl
	2,4-difluorophenoxy	4-biphenyl
55		

(continued)

	R ¹ X	R ³
5	2,4-difluorophenoxy	4-cyanophenyl
	2,4-difluorophenoxy	3-cyanophenyl
	2,4-difluorophenoxy	4-nitrophenyl
	2,4-difluorophenoxy	5-nitrofuran-2-yl
	2,4-difluorophenoxy	3-nitrophenyl
10	2,4-difluorophenoxy	4-(trifluoromethyl)phenyl
	2,4-difluorophenoxy	2-nitrophenyl
	4-chloro-2,5- dimethylphenoxy	4-biphenyl
	4-chloro-2,5- dimethylphenoxy	4-cyanophenyl
	4-chloro-2,5- dimethylphenoxy	3-cyanophenyl
15	4-chloro-2,5- dimethylphenoxy	4-nitrophenyl
	4-chloro-2,5- dimethylphenoxy	5-nitrofuran-2-yl
	4-chloro-2,5-dimethylphenoxy	3-nitrophenyl
	4-chloro-2,5-dimethylphenoxy	4-(trifluoromethyl)phenyl
	4-chloro-2,5-dimethylphenoxy	2-nitrophenyl
20	4-chloro-2,5-dimethylphenoxy	thien-2-yl
	4-chloro-2,5-dimethylphenoxy	3,5-difluorophenyl
	4-methoxyphenoxy	3,5-difluorophenyl
	2-(2-propoxy)phenoxy	4-(trifluoromethyl)phenyl
	2,4-difluorophenoxy	thien-2-yl
25	2,4-difluorophenoxy	3,5-difluorophenyl
	4-thiomethylphenoxy	4-biphenyl
	4-thiomethylphenoxy	4-cyanophenyl
	4-thiomethylphenoxy	3-cyanophenyl
	4-thiomethylphenoxy	4-nitrophenyl
30	4-thiomethylphenoxy	5-nitrofuran-2-yl
	4-thiomethylphenoxy	3-nitrophenyl
	4-thiomethylphenoxy	4-(trifluoromethyl)phenyl
	4-thiomethylphenoxy	2-nitrophenyl
	4-thiomethylphenoxy	thien-2-yl
35	4-thiomethylphenoxy	3,5-difluorophenyl
	4-(2-(2-methyl)propyl) phenoxy	4-biphenyl
	4-(2-(2-methyl)propyl) phenoxy	4-cyanophenyl
	4-(2-(2-methyl)propyl) phenoxy	3-cyanophenyl
	4-(2-(2-methyl)propyl) phenoxy	4-nitrophenyl
40	4-(2-(2-methyl)propyl) phenoxy	5-nitrofuran-2-yl
	4-(2-(2-methyl)propyl) phenoxy	3-nitrophenyl
	4-(2-(2-methyl)propyl) phenoxy	4-(trifluoromethyl)phenyl
	4-(2-(2-methyl)propyl) phenoxy	2-nitrophenyl
	4-(2-(2-methyl)propyl) phenoxy	thien-2-yl
45	4-(2-(2-methyl)propyl) phenoxy	3,5-difluorophenyl
	2,3-dimethylphenoxy	4-biphenyl
	2,3-dimethylphenoxy	4-cyanophenyl
	2,3-dimethylphenoxy	3-cyanophenyl
	2,3-dimethylphenoxy	4-nitrophenyl
50	2,3-dimethylphenoxy	5-nitrofuran-2-yl
	2,3-dimethylphenoxy	3-nitrophenyl
	2,3-dimethylphenoxy	4-(trifluoromethyl)phenyl
	2,3-dimethylphenoxy	2-nitrophenyl
	2,3-dimethylphenoxy	thien-2-yl
55	2,3-dimethylphenoxy	3,5-difluorophenyl
	2,3-dimethylphenoxy	4-biphenyl
	2,3-dimethylphenoxy	4-cyanophenyl
	2,3-dimethylphenoxy	3-cyanophenyl
	2,3-dimethylphenoxy	4-nitrophenyl

(continued)


	R ¹ X	R ³
5	2,3-dimethylphenoxy	3,5-difluorophenyl
	3,5-(bis-2-propyl)phenoxy	4-biphenyl
	3,5-(bis-2-propyl)phenoxy	4-cyanophenyl
	3,5-(bis-2-propyl)phenoxy	3-cyanophenyl
	3,5-(bis-2-propyl)phenoxy	4-nitrophenyl
10	3,5-(bis-2-propyl)phenoxy	5-nitrofuranyl
	3,5-(bis-2-propyl)phenoxy	3-nitrophenyl
	3,5-(bis-2-propyl)phenoxy	4-(trifluoromethyl)phenyl
	3,5-(bis-2-propyl)phenoxy	2-nitrophenyl
	3,5-(bis-2-propyl)phenoxy	thien-2-yl
15	3,5-(bis-2-propyl)phenoxy	3,5-difluorophenyl
	3-trifluoromethyl phenoxy	4-biphenyl
	3-trifluoromethyl phenoxy	4-cyanophenyl
	3-trifluoromethyl phenoxy	3-cyanophenyl
	3-trifluoromethyl phenoxy	4-nitrophenyl
20	3-trifluoromethyl phenoxy	5-nitrofuranyl
	3-trifluoromethyl phenoxy	3-nitrophenyl
	3-trifluoromethyl phenoxy	4-(trifluoromethyl)phenyl
	3-trifluoromethyl phenoxy	2-nitrophenyl
	3-trifluoromethyl phenoxy	thien-2-yl
25	3-trifluoromethyl phenoxy	3,5-difluorophenyl
	2,6-dichlorophenoxy	4-biphenyl
	2,6-dichlorophenoxy	4-cyanophenyl
	2,6-dichlorophenoxy	3-cyanophenyl
	2,6-dichlorophenoxy	4-nitrophenyl
30	2,6-dichlorophenoxy	5-nitrofuranyl
	2,6-dichlorophenoxy	3-nitrophenyl
	2,6-dichlorophenoxy	4-(trifluoromethyl)phenyl
	2,6-dichlorophenoxy	2-nitrophenyl
	2,6-dichlorophenoxy	thien-2-yl
35	2,6-dichlorophenoxy	3,5-difluorophenyl
	2,4-dichlorophenoxy	4-biphenyl
	2,4-dichlorophenoxy	4-cyanophenyl
	2,4-dichlorophenoxy	3-cyanophenyl
	2,4-dichlorophenoxy	4-nitrophenyl
40	2,4-dichlorophenoxy	5-nitrofuranyl
	2,4-dichlorophenoxy	3-nitrophenyl
	2,4-dichlorophenoxy	4-(trifluoromethyl)phenyl
	2,4-dichlorophenoxy	2-nitrophenyl
	2,4-dichlorophenoxy	thien-2-yl
45	2,4-dichlorophenoxy	3,5-difluorophenyl
	4-chloro-3-methylphenoxy	4-biphenyl
	4-chloro-3-methylphenoxy	4-cyanophenyl
	4-chloro-3-methylphenoxy	3-cyanophenyl
	4-chloro-3-methylphenoxy	4-nitrophenyl
50	4-chloro-3-methylphenoxy	5-nitrofuranyl
	4-chloro-3-methylphenoxy	3-nitrophenyl
	4-chloro-3-methylphenoxy	2-nitrophenyl
	4-chloro-3-methylphenoxy	thien-2-yl
	4-chloro-3-methylphenoxy	3,5-difluorophenyl
55	4-chloro-3-methylphenoxy	4-biphenyl
	4-chloro-3-methylphenoxy	4-cyanophenyl
	4-chloro-3-methylphenoxy	3-cyanophenyl
	4-chloro-3-methylphenoxy	4-nitrophenyl
	4-chloro-3-methylphenoxy	5-nitrofuranyl

(continued)

	R ¹ X	R ³
5	4-chloro-2-cyclohexylphenoxy	4-biphenyl
	4-chloro-2-cyclohexylphenoxy	4-cyanophenyl
	4-chloro-2-cyclohexylphenoxy	3-cyanophenyl
	4-chloro-2-cyclohexylphenoxy	4-nitrophenyl
	4-chloro-2-cyclohexylphenoxy	5-nitrofuran-2-yl
10	4-chloro-2-cyclohexylphenoxy	3-nitrophenyl
	4-chloro-2-cyclohexylphenoxy	4-(trifluoromethyl)phenyl
	4-chloro-2-cyclohexylphenoxy	2-nitrophenyl
	4-chloro-2-cyclohexylphenoxy	thien-2-yl
	4-chloro-2-cyclohexylphenoxy	3,5-difluorophenyl
15	4-chloro-3,5-dimethylphenoxy	4-biphenyl
	4-chloro-3,5-dimethylphenoxy	4-cyanophenyl
	4-chloro-3,5-dimethylphenoxy	3-cyanophenyl
	4-chloro-3,5-dimethylphenoxy	4-nitrophenyl
	4-chloro-3,5-dimethylphenoxy	5-nitrofuran-2-yl
20	4-chloro-3,5-dimethylphenoxy	3-nitrophenyl
	4-chloro-3,5-dimethylphenoxy	4-(trifluoromethyl)phenyl
	4-chloro-3,5-dimethylphenoxy	2-nitrophenyl
	4-chloro-3,5-dimethylphenoxy	thien-2-yl
	4-chloro-3,5-dimethylphenoxy	3,5-difluorophenyl
25	pyrid-3-yloxy	4-biphenyl
	pyrid-3-yloxy	4-cyanophenyl
	pyrid-3-yloxy	3-cyanophenyl
	pyrid-3-yloxy	4-nitrophenyl
	pyrid-3-yloxy	5-nitrofuran-2-yl
30	pyrid-3-yloxy	3-nitrophenyl
	pyrid-3-yloxy	4-(trifluoromethyl)phenyl
	pyrid-3-yloxy	2-nitrophenyl
	pyrid-3-yloxy	thien-2-yl
	pyrid-3-yloxy	3,5-difluorophenyl
35	4-bromophenoxy	4-biphenyl
	4-bromophenoxy	4-cyanophenyl
	4-bromophenoxy	3-cyanophenyl
	4-bromophenoxy	4-nitrophenyl
	4-bromophenoxy	5-nitrofuran-2-yl
40	4-bromophenoxy	3-nitrophenyl
	4-bromophenoxy	4-(trifluoromethyl)phenyl
	4-bromophenoxy	2-nitrophenyl
	4-bromophenoxy	thien-2-yl
	4-bromophenoxy	3,5-difluorophenyl
45	4-bromophenoxy	4-pentylphenyl
	4-chloro-2-methylphenylthio	2-(4-chlorophenylthio)pyridin-3-yl
	4-chloro-2-methylphenylthio	2,6-dimethylphenyl
	4-chloro-2-methylphenylthio	2,5-dimethoxyphenyl
	4-chloro-2-methylphenylthio	2,5-dichloropyridin-3-yl
50	4-chloro-2-methylphenylthio	2-chloro-6-methoxypyridin-4-yl
	4-chloro-2-methylphenylthio	2,3-dichloropyridin-5-yl
	4-chloro-2-methylphenylthio	1-naphthyl
	4-chloro-2-methylphenylthio	2,4-dimethoxyphenyl
	4-chloro-2-methylphenylthio	3,5-bis(trifluoromethyl)phenyl

(continued)

	R ¹ X	R ³
5	4-chloro-2-methylphenylthio	2-(4-chlorophenoxy)pyridin-3-yl
	4-chloro-2-methylphenylthio	pentafluorophenyl
	4-chloro-2-methylanilino	4-pentylphenyl
	4-chloro-2-methylanilino	2-(4-chlorophenylthio)
		pyridin-3-yl
10	4-chloro-2-methylanilino	2,6-dimethylphenyl
	4-chloro-2-methylanilino	2,5-dimethoxyphenyl
	4-chloro-2-methylanilino	2,5-dichloropyridin-3-yl
	4-chloro-2-methylanilino	2-chloro-6-methoxypyridin-4-yl
	4-chloro-2-methylanilino	2,3-dichloropyridin-5-yl
15	4-chloro-2-methylanilino	1-naphthyl
	4-chloro-2-methylanilino	2,4-dimethoxyphenyl
	4-chloro-2-methylanilino	3,5-bis(trifluoromethyl)phenyl
	4-chloro-2-methylanilino	2-(4-chlorophenoxy)pyridin-3-yl
20	4-chloro-2-methylanilino	pentafluorophenyl

Example 19**[0084]**General procedure for the synthesis of 6-(substituted-amino)-N-substituted nicotinamidesStep A. General procedure for the preparation of 6-chloro-N-substituted nicotinamide:

[0085] To a suspension of 6-chloronicotinoyl chloride (1.76 g, 10.0 mmol) in dry dichloromethane (10 mL) was added the amine (R³R⁴NH) (10.0 mmol) followed by the dropwise addition of triethylamine (1.7 mL, 12.2 mmol). After stirring for 40 min. at room temperature, the mixture was diluted with dichloromethane, washed with aqueous 1 M hydrochloric acid, saturated aqueous sodium hydrogencarbonate and water, dried over sodium sulfate and concentrated to dryness under reduce pressure to afford the desired nicotinamide.

[0086] The following compounds were prepared according to this procedure using the appropriate substituted amine:


- 6-Chloro-N-o-tolynicotinamide: MS (*m/z*) : 247/249 (M+H)⁺; C₁₃H₁₁Cl₁N₂O₁ requires 246.5.
 6-Chloro-N-(2-fluorophenyl)nicotinamide: MS (*m/z*): 251/253 (M+H)⁺; C₁₂H₈Cl₁F₁N₂O₁ requires 250.7.
 6-Chloro-N-(2,6-dimethylphenyl)nicotinamide: MS (*m/z*): 261/263 (M+H)⁺; C₁₄H₁₃Cl₁N₂O₁ requires 260.7.
 6-Chloro-N-(2-phenoxyphenyl)nicotinamide: MS (*m/z*): 325/327 (M+H)⁺; C₁₈H₁₃Cl₁N₂O₁ requires 324.8.
 6-Chloro-N-phenylnicotinamide: MS (*m/z*): 233/235 (M+H)⁺; C₁₂H₈Cl₁N₂O₁ requires 232.7.
 6-Chloro-N-(2,4-difluorophenyl)nicotinamide: MS (*m/z*): 269/271 (M+H)⁺; C₁₂H₇Cl₁F₂N₂O₁ requires 268.6.
 6-Chloro-N-(2,6-diisopropylphenyl)nicotinamide: MS (*m/z*): 317/319 (M+H)⁺; C₁₈H₂₁Cl₁N₂O₁ requires 316.8.
 6-Chloro-N-(4-chlorophenyl)-N-methylnicotinamide: MS (*m/z*) : 281/283 (M+H)⁺; C₁₃H₁₀Cl₂N₂O₁ requires 281.1.
 6-Chloro-N-(2,4-dimethoxyphenyl)nicotinamide: MS (*m/z*): 293/295 (M+H)⁺; C₁₄H₁₃Cl₁N₂O₃ requires 292.7.
 6-Chloro-N-(3-methoxyphenyl)nicotinamide: MS (*m/z*): 263/265 (M+H)⁺; C₁₃H₁₁Cl₁N₂O₂ requires 262.7.
 6-Chloro-N-(4-methoxyphenyl)nicotinamide: MS (*m/z*): 263/265 (M+H)⁺; C₁₃H₁₁Cl₁N₂O₂ requires 262.7.
 6-Chloro-N-(2-methoxyphenyl)nicotinamide: MS (*m/z*): 263/265 (M+H)⁺; C₁₃H₁₁Cl₁N₂O₂ requires 262.7.
 6-Chloro-N-methyl-N-phenylnicotinamide: MS (*m/z*): 247/249 (M+H)⁺; C₁₃H₁₁Cl₁N₂O₁ requires 246.7.
 N-Benzyl-6-chloronicotinamide: MS (*m/z*): 247/249 (M+H)⁺; C₁₃H₁₁Cl₁N₂O₁ requires 246.7.

Step B. General procedure for the preparation of 6-(substituted-amino)-N-substituted nicotinamides

[0087] A mixture of the 6-chloro-N-substituted nicotinamide (12.5 mmol) and amine (R^1NH_2 or R^1NHCH_3) (20 mmol) in ethylene glycol (50 mL) or pyridine (alkylamines) (50 mL) was heated to 140°C for 20 hours. After cooling to room temperature, the mixture was diluted with dichloromethane/methanol (9:1, 250 mL) and filtered through a plug of silica gel, washing with additional dichloromethane/methanol (9:1, 250 mL). Concentration under reduced pressure afforded the desired 6-(substituted-amino)-N-substituted nicotinamide.

[0088] The compounds listed in Tables 8-11 were prepared from 6-chloro-N-substituted nicotinamides compounds and the appropriate amine according to the general procedure above.

Table 8



R^3	R^1	MS (m/z)
o-tolyl	phenyl	303
o-tolyl	o-tolyl	317
o-tolyl	4-chloro-2-methylphenyl	352
o-tolyl	2-fluorophenyl	321
o-tolyl	3-fluorophenyl	321
o-tolyl	4-fluorophenyl	321
o-tolyl	2,4-difluorophenyl	339
o-tolyl	2-methoxyphenyl	333
o-tolyl	3-methoxyphenyl	333
o-tolyl	4-methoxyphenyl	333
o-tolyl	2,4-dimethoxyphenyl	363
o-tolyl	2-phenoxyphenyl	395
o-tolyl	3-phenoxyphenyl	395
o-tolyl	4-phenoxyphenyl	395
o-tolyl	4-biphenyl	379
o-tolyl	4-benzylphenyl	393
o-tolyl	4-(trifluoromethoxy)phenyl	387
o-tolyl	cyclohexyl	309
o-tolyl	2-methylcyclohexyl	323
o-tolyl	cycloheptyl	323
o-tolyl	indan-1-yl	343
o-tolyl	2-dicyclohexyl	492
2-fluorophenyl	phenyl	307
2-fluorophenyl	o-tolyl	321
2-fluorophenyl	4-chloro-2-methylphenyl	356
2-fluorophenyl	2-fluorophenyl	325
2-fluorophenyl	3-fluorophenyl	325
2-fluorophenyl	4-fluorophenyl	325
2-fluorophenyl	2,4-difluorophenyl	343
2-fluorophenyl	2-methoxyphenyl	337
2-fluorophenyl	3-methoxyphenyl	337
2-fluorophenyl	4-methoxyphenyl	337

EP 1 028 945 B9

(continued)

	R ³	R ¹	MS (m/z)
5	2-fluorophenyl	2,4-dimethoxyphenyl	367
	2-fluorophenyl	2-phenoxyphenyl	399
	2-fluorophenyl	3-phenoxyphenyl	399
	2-fluorophenyl	4-phenoxyphenyl	399
	2-fluorophenyl	4-biphenyl	383
10	2-fluorophenyl	4-benzylphenyl	397
	2-fluorophenyl	4-(trifluoromethoxy)phenyl	391
	2-fluorophenyl	cyclohexyl	313
	2-fluorophenyl	2-methylcyclohexyl	327
	2-fluorophenyl	cycloheptyl	327
15	2-fluorophenyl	indan-1-yl	347
	2-fluorophenyl	2-dicyclohexyl	395
	2,6-dimethylphenyl	phenyl	317
	2,6-dimethylphenyl	o-tolyl	331
	2,6-dimethylphenyl	4-chloro-2-methylphenyl	366
20	2,6-dimethylphenyl	2-fluorophenyl	335
	2,6-dimethylphenyl	3-fluorophenyl	335
	2,6-dimethylphenyl	4-fluorophenyl	335
	2,6-dimethylphenyl	2,4-difluorophenyl	353
	2,6-dimethylphenyl	2-methoxyphenyl	347
25	2,6-dimethylphenyl	3-methoxyphenyl	347
	2,6-dimethylphenyl	4-methoxyphenyl	347
	2,6-dimethylphenyl	2,4-dimethoxyphenyl	377
	2,6-dimethylphenyl	2-phenoxyphenyl	409
	2,6-dimethylphenyl	3-phenoxyphenyl	409
30	2,6-dimethylphenyl	4-phenoxyphenyl	409
	2,6-dimethylphenyl	4-biphenyl	393
	2,6-dimethylphenyl	4-benzylphenyl	407
	2,6-dimethylphenyl	4-(trifluoromethoxy)phenyl	401
	2,6-dimethylphenyl	cyclohexyl	323
35	2,6-dimethylphenyl	2-methylcyclohexyl	337
	2,6-dimethylphenyl	cycloheptyl	667
	2,6-dimethylphenyl	indan-1-yl	357
	2,6-dimethylphenyl	2-dicyclohexyl	406
	2-phenoxyphenyl	phenyl	381
40	2-phenoxyphenyl	o-tolyl	395
	2-phenoxyphenyl	4-chloro-2-methylphenyl	430
	2-phenoxyphenyl	2-fluorophenyl	399
	2-phenoxyphenyl	3-fluorophenyl	399
	2-phenoxyphenyl	4-fluorophenyl	399
45	2-phenoxyphenyl	2,4-difluorophenyl	417
	2-phenoxyphenyl	2-methoxyphenyl	411
	2-phenoxyphenyl	3-methoxyphenyl	411
	2-phenoxyphenyl	4-methoxyphenyl	411
	2-phenoxyphenyl	2,4-dimethoxyphenyl	441
50	2-phenoxyphenyl	2-phenoxyphenyl	473
	2-phenoxyphenyl	3-phenoxyphenyl	473
	2-phenoxyphenyl	4-phenoxyphenyl	473
	2-phenoxyphenyl	4-biphenyl	457
	2-phenoxyphenyl		

EP 1 028 945 B9

(continued)

	R ³	R ¹	MS (m/z)
5	2-phenoxyphenyl	4-benzylphenyl	472
	2-phenoxyphenyl	4-(trifluoromethoxy)phenyl	465
	2-phenoxyphenyl	cyclohexyl	387
	2-phenoxyphenyl	2-methylcyclohexyl	401
10	2-phenoxyphenyl	cycloheptyl	401
	2-phenoxyphenyl	indan-1-yl	421
	2-phenoxyphenyl	2-dicyclohexyl	470
	phenyl	phenyl	289
15	phenyl	o-tolyl	303
	phenyl	4-chloro-2-methylphenyl	338
	phenyl	2-fluorophenyl	307
	phenyl	3-fluorophenyl	307
20	phenyl	4-fluorophenyl	307
	phenyl	2,4-difluorophenyl	325
	phenyl	2-methoxyphenyl	319
	phenyl	3-methoxyphenyl	319
25	phenyl	4-methoxyphenyl	319
	phenyl	2,4-dimethoxyphenyl	349
	phenyl	2-phenoxyphenyl	381
	phenyl	3-phenoxyphenyl	381
30	phenyl	4-phenoxyphenyl	381
	phenyl	4-biphenyl	365
	phenyl	4-benzylphenyl	379
	phenyl	4-(trifluoromethoxy)phenyl	373
35	phenyl	cyclohexyl	295
	phenyl	2-methylcyclohexyl	309
	phenyl	cycloheptyl	309
	phenyl	indan-1-yl	329
40	phenyl	2-dicyclohexyl	377
	2,4-difluorophenyl	phenyl	325
	2,4-difluorophenyl	o-tolyl	339
	2,4-difluorophenyl	4-chloro-2-methylphenyl	374
45	2,4-difluorophenyl	2-fluorophenyl	343
	2,4-difluorophenyl	3-fluorophenyl	343
	2,4-difluorophenyl	4-fluorophenyl	343
	2,4-difluorophenyl	2,4-difluorophenyl	361
50	2,4-difluorophenyl	2-methoxyphenyl	355
	2,4-difluorophenyl	3-methoxyphenyl	355
	2,4-difluorophenyl	4-methoxyphenyl	355
	2,4-difluorophenyl	2,4-dimethoxyphenyl	385
55	2,4-difluorophenyl	2-phenoxyphenyl	417
	2,4-difluorophenyl	3-phenoxyphenyl	417
	2,4-difluorophenyl	4-phenoxyphenyl	417
	2,4-difluorophenyl	4-biphenyl	401
55	2,4-difluorophenyl	4-benzylphenyl	415
	2,4-difluorophenyl	4-(trifluoromethoxy)phenyl	409
	2,4-difluorophenyl	cyclohexyl	331
	2,4-difluorophenyl	2-methylcyclohexyl	345
	2,4-difluorophenyl	cycloheptyl	345

EP 1 028 945 B9

(continued)

	R ³	R ¹	MS (m/z)
5	2,4-difluorophenyl	indan-1-yl	365
	2,4-difluorophenyl	2-dicyclohexyl	413
	2,6-diisopropylphenyl	phenyl	373
	2,6-diisopropylphenyl	o-tolyl	387
10	2,6-diisopropylphenyl	4-chloro-2-methylphenyl	422
	2,6-diisopropylphenyl	2-fluorophenyl	391
	2,6-diisopropylphenyl	3-fluorophenyl	391
	2,6-diisopropylphenyl	4-fluorophenyl	391
15	2,6-diisopropylphenyl	2,4-difluorophenyl	409
	2,6-diisopropylphenyl	2-methoxyphenyl	403
	2,6-diisopropylphenyl	3-methoxyphenyl	403
	2,6-diisopropylphenyl	4-methoxyphenyl	403
20	2,6-diisopropylphenyl	2,4-dimethoxyphenyl	434
	2,6-diisopropylphenyl	2-phenoxyphenyl	466
	2,6-diisopropylphenyl	3-phenoxyphenyl	466
	2,6-diisopropylphenyl	4-phenoxyphenyl	466
25	2,6-diisopropylphenyl	4-biphenyl	450
	2,6-diisopropylphenyl	4-benzylphenyl	464
	2,6-diisopropylphenyl	4-(trifluoromethoxy)phenyl	457
	2,6-diisopropylphenyl	cyclohexyl	380
30	2,6-diisopropylphenyl	2-methylcyclohexyl	394
	2,6-diisopropylphenyl	cycloheptyl	394
	2,6-diisopropylphenyl	indan-1-yl	414
	2,6-diisopropylphenyl	2-dicyclohexyl	462
35	2,4-dimethoxyphenyl	phenyl	349
	2,4-dimethoxyphenyl	o-tolyl	363
	2,4-dimethoxyphenyl	4-chloro-2-methylphenyl	398
	2,4-dimethoxyphenyl	2-fluorophenyl	367
40	2,4-dimethoxyphenyl	3-fluorophenyl	367
	2,4-dimethoxyphenyl	4-fluorophenyl	367
	2,4-dimethoxyphenyl	2,4-difluorophenyl	385
	2,4-dimethoxyphenyl	2-methoxyphenyl	379
45	2,4-dimethoxyphenyl	3-methoxyphenyl	379
	2,4-dimethoxyphenyl	4-methoxyphenyl	379
	2,4-dimethoxyphenyl	2,4-dimethoxyphenyl	409
	2,4-dimethoxyphenyl	2-phenoxyphenyl	441
50	2,4-dimethoxyphenyl	3-phenoxyphenyl	441
	2,4-dimethoxyphenyl	4-phenoxyphenyl	441
	2,4-dimethoxyphenyl	4-biphenyl	425
	2,4-dimethoxyphenyl	4-benzylphenyl	439
55	2,4-dimethoxyphenyl	4-(trifluoromethoxy)phenyl	433
	2,4-dimethoxyphenyl	3-trifluoromethylphenyl	417
	2,4-dimethoxyphenyl	cyclohexyl	355
	2,4-dimethoxyphenyl	2-methylcyclohexyl	369
55	3-methoxyphenyl	phenyl	319
	3-methoxyphenyl	o-tolyl	333
	3-methoxyphenyl	4-chloro-2-methylphenyl	368
	3-methoxyphenyl	2-fluorophenyl	337
	3-methoxyphenyl	3-fluorophenyl	337

EP 1 028 945 B9


(continued)

	R ³	R ¹	MS (m/z)
5	3-methoxyphenyl	4-fluorophenyl	337
	3-methoxyphenyl	2,4-difluorophenyl	355
	3-methoxyphenyl	2-methoxyphenyl	349
	3-methoxyphenyl	3-methoxyphenyl	349
10	3-methoxyphenyl	4-methoxyphenyl	349
	3-methoxyphenyl	2,4-dimethoxyphenyl	379
	3-methoxyphenyl	2-phenoxyphenyl	411
	3-methoxyphenyl	3-phenoxyphenyl	411
15	3-methoxyphenyl	4-phenoxyphenyl	411
	3-methoxyphenyl	4-biphenyl	395
	3-methoxyphenyl	4-benzylphenyl	409
	3-methoxyphenyl	4-(trifluoromethoxy)phenyl	403
20	3-methoxyphenyl	3-trifluoromethylphenyl	387
	3-methoxyphenyl	cyclohexyl	625
	3-methoxyphenyl	2-methylcyclohexyl	339
	4-methoxyphenyl	phenyl	319
25	4-methoxyphenyl	o-tolyl	333
	4-methoxyphenyl	4-chloro-2-methylphenyl	368
	4-methoxyphenyl	2-fluorophenyl	337
	4-methoxyphenyl	3-fluorophenyl	337
30	4-methoxyphenyl	4-fluorophenyl	337
	4-methoxyphenyl	2,4-difluorophenyl	355
	4-methoxyphenyl	2-methoxyphenyl	349
	4-methoxyphenyl	3-methoxyphenyl	349
35	4-methoxyphenyl	4-methoxyphenyl	349
	4-methoxyphenyl	2,4-dimethoxyphenyl	379
	4-methoxyphenyl	2-phenoxyphenyl	411
	4-methoxyphenyl	3-phenoxyphenyl	411
40	4-methoxyphenyl	4-phenoxyphenyl	411
	4-methoxyphenyl	4-biphenyl	395
	4-methoxyphenyl	4-benzylphenyl	409
	4-methoxyphenyl	4-(trifluoromethoxy)phenyl	403
45	4-methoxyphenyl	3-trifluoromethylphenyl	387
	4-methoxyphenyl	cyclohexyl	625
	4-methoxyphenyl	2-methylcyclohexyl	339
	2-methoxyphenyl	phenyl	319
50	2-methoxyphenyl	o-tolyl	333
	2-methoxyphenyl	4-chloro-2-methylphenyl	368
	2-methoxyphenyl	2-fluorophenyl	337
	2-methoxyphenyl	3-fluorophenyl	337
55	2-methoxyphenyl	4-fluorophenyl	337
	2-methoxyphenyl	2,4-difluorophenyl	355
	2-methoxyphenyl	2-methoxyphenyl	349
	2-methoxyphenyl	3-methoxyphenyl	349
	2-methoxyphenyl	4-methoxyphenyl	349
	2-methoxyphenyl	2,4-dimethoxyphenyl	379
	2-methoxyphenyl	2-phenoxyphenyl	411
	2-methoxyphenyl	3-phenoxyphenyl	411
	2-methoxyphenyl	4-phenoxyphenyl	411

(continued)

	R ³	R ¹	MS (m/z)
5	2-methoxyphenyl	4-biphenyl	395
	2-methoxyphenyl	4-benzylphenyl	409
	2-methoxyphenyl	4-(trifluoromethoxy)phenyl	403
	2-methoxyphenyl -	3-trifluoromethylphenyl	387
10	2-methoxyphenyl	cyclohexyl	625
	2-methoxyphenyl	2-methylcyclohexyl	339

Table 9




	R ³	R ¹	MS (m/z)
25	4-chlorophenyl	phenyl	338
	4-chlorophenyl	o-tolyl	352
	4-chlorophenyl	4-chloro-2-methylphenyl	386
	4-chlorophenyl	2-fluorophenyl	356
	4-chlorophenyl	3-fluorophenyl	356
30	4-chlorophenyl	4-fluorophenyl	356
	4-chlorophenyl	2,4-difluorophenyl	374
	4-chlorophenyl	2-methoxyphenyl	368
	4-chlorophenyl	3-methoxyphenyl	368
	4-chlorophenyl	4-methoxyphenyl	368
35	4-chlorophenyl	2,4-dimethoxyphenyl	398
	4-chlorophenyl	2-phenoxyphenyl	430
	4-chlorophenyl	3-phenoxyphenyl	430
	4-chlorophenyl	4-phenoxyphenyl	430
40	4-chlorophenyl	4-biphenyl	414
	4-chlorophenyl	4-benzylphenyl	428
	4-chlorophenyl	4-(trifluoromethoxy)phenyl	422
	4-chlorophenyl	cyclohexyl	344
	4-chlorophenyl	2-methylcyclohexyl	358
45	phenyl	phenyl	303
	phenyl	o-tolyl	317
	phenyl	4-chloro-2-methylphenyl	352
	phenyl	2-fluorophenyl	321
50	phenyl	3-fluorophenyl	321
	phenyl	4-fluorophenyl	321
	phenyl	2,4-difluorophenyl	339
	phenyl	2-methoxyphenyl	333
	phenyl	3-methoxyphenyl	333
55	phenyl	4-methoxyphenyl	333
	phenyl	2,4-dimethoxyphenyl	363

(continued)

	R ³	R ¹	MS (m/z)
5	phenyl	2-phenoxyphenyl	395
	phenyl	3-phenoxyphenyl	395
	phenyl	4-phenoxyphenyl	395
	phenyl	4-biphenyl	379
	phenyl	4-benzylphenyl	393
10	phenyl	4-(trifluoromethoxy)phenyl	387
	phenyl	3-trifluoromethylphenyl	371
	phenyl	cyclohexyl	309
	phenyl	2-methylcyclohexyl	323

Table 10




	R ³	R ¹	MS (m/z)
	o-tolyl	N-methylphenyl	317
30	o-tolyl	4-chloro-N-methylphenyl	352
	o-tolyl	N-methylcyclohexyl	323
	2-fluorophenyl	N-methylphenyl	321
	2-fluorophenyl	4-chloro-N-methylphenyl	356
	2-fluorophenyl	N-methylcyclohexyl	327
35	2,6-dimethylphenyl	N-methylphenyl	331
	2,6-dimethylphenyl	4-chloro-N-methylphenyl	366
	2,6-dimethylphenyl	N-methylcyclohexyl	337
	2-phenoxyphenyl	N-methylphenyl	395
40	2-phenoxyphenyl	4-chloro-N-methylphenyl	430
	2-phenoxyphenyl	N-methylcyclohexyl	401
	phenyl	N-methylphenyl	303
	phenyl	4-chloro-N-methylphenyl	338
	phenyl	N-methylcyclohexyl	309
45	2,4-difluorophenyl	N-methylphenyl	339
	2,4-difluorophenyl	4-chloro-N-methylphenyl	374
	2,4-difluorophenyl	N-methylcyclohexyl	345
	2,6-diisopropylphenyl	N-methylphenyl	387
50	2,6-diisopropylphenyl	4-chloro-N-methylphenyl	422
	2,6-diisopropylphenyl	N-methylcyclohexyl	394
	2,4-dimethoxyphenyl	N-methylphenyl	363
	2,4-dimethoxyphenyl	4-chloro-N-methylphenyl	398
	2,4-dimethoxyphenyl	N-methylcyclohexyl	369
55	3-methoxyphenyl	N-methylphenyl	333
	3-methoxyphenyl	4-chloro-N-methylphenyl	368

(continued)

	R ³	R ¹	MS (m/z)
5	3-methoxyphenyl	N-methylcyclohexyl	339
	4-methoxyphenyl	N-methylphenyl	333
	4-methoxyphenyl	4-chloro-N-methylphenyl	368
	4-methoxyphenyl	N-methylcyclohexyl	339
10	2-methoxyphenyl	N-methylphenyl	333
	2-methoxyphenyl	4-chloro-N-methylphenyl	368
	2-methoxyphenyl	N-methylcyclohexyl	339


Table 11



	R ³	R ¹	MS (m/z)
25	4-chlorophenyl	phenyl	352
	4-chlorophenyl	4-chlorophenyl	386
	4-chlorophenyl	cyclohexyl	358
30	phenyl	phenyl	317
	phenyl	4-chlorophenyl	352
	phenyl	cyclohexyl	323

[0089] The compounds listed in Tables 12-13 can be prepared from 6-chloro-N-substituted nicotinamides compounds and the appropriate amine according to the general procedure above.

Table 12




	R ¹ X	R ³
45	o-tolyl	3-trifluoromethylphenyl
	2-fluorophenyl	3-trifluoromethylphenyl
	2,6-dimethylphenyl	3-trifluoromethylphenyl
50	2-phenoxyphenyl	3-trifluoromethylphenyl
	phenyl	3-trifluoromethylphenyl
	2,4-difluorophenyl	3-trifluoromethylphenyl
	2,6-diisopropylphenyl	3-trifluoromethylphenyl
55	2,4-dimethoxyphenyl	cycloheptyl
	2,4-dimethoxyphenyl	indan-1-yl
	2,4-dimethoxyphenyl	2-dicyclohexyl

(continued)

	R ¹ X	R ³
5	3-methoxyphenyl	cycloheptyl
	3-methoxyphenyl	indan-1-yl
	3-methoxyphenyl	2-dicyclohexyl
	4-methoxyphenyl	cycloheptyl
	4-methoxyphenyl	indan-1-yl
10	4-methoxyphenyl	2-dicyclohexyl
	2-methoxyphenyl	cycloheptyl
	2-methoxyphenyl	indan-1-yl
	2-methoxyphenyl	2-dicyclohexyl

Table 13



	R ¹ X	R ³
25	4-chlorophenyl	3-trifluoromethylphenyl
	4-chlorophenyl	cycloheptyl
	4-chlorophenyl	indan-1-yl
	4-chlorophenyl	2-dicyclohexyl
30	phenyl	cycloheptyl
	phenyl	indam-1-yl
	phenyl	2-dicyclohexyl

Example 20

[0090] The following assays were used to characterize the ability of compounds of the invention to inhibit the production of TNF- α and IL-1- β . The second assay measured the inhibition of TNF- α and/or IL-1- β in mice after oral administration of the test compounds. The third assay, a glucagon binding inhibition in vitro assay, can be used to characterize the ability of compounds of the invention to inhibit glucagon binding. The fourth assay, a Cyclooxygenase enzyme (COX-1 and COX-2) inhibition activity in vitro assay, can be used to characterize the ability of compounds of the invention to inhibit COX-1 and/or COX-2. The fifth assay, a Raf-kinase inhibition assay, can be used to characterize the compounds of the invention to inhibit phosphorylation of MEK by activated Raf-kinase.

Lipopolysaccharide-activated monocyte TNF production assayIsolation of monocytes

[0091] Test compounds were evaluated *in vitro* for the ability to inhibit the production of tumor necrosis factor (TNF) by monocytes activated with bacterial lipopolysaccharide (LPS). Fresh residual source leukocytes (a byproduct of platelet-pheresis) were obtained from a local blood bank, and peripheral blood mononuclear cells (PBMCs) were isolated by density gradient centrifugation on Ficoll-Paque Plus (Pharmacia). PBMCs were suspended at 2×10^6 /ml in DMEM supplemented to contain 2% FCS, 10 mM, 0.3 mg/ml glutamate, 100 U/ml penicillin G and 100 mg/ml streptomycin sulfate (complete media). Cells were plated into Falcon flat bottom, 96 well culture plates (200 μ l/well) and cultured overnight at 37°C and 6% CO₂. Non-adherent cells were removed by washing with 200 μ l/well of fresh medium. Wells containing adherent cells (~70% monocytes) were replenished with 100 μ l of fresh medium.

Preparation of test compound stock solutions

[0092] Test compounds were dissolved in DMSO. Compound stock solutions were prepared to an initial concentration of 10 - 50 μ M. Stocks were diluted initially to 20 - 200 μ M in complete media. Nine twofold serial dilutions of each compound were then prepared in complete medium.

Treatment of cells with test compounds and activation of TNF production with lipopolysaccharide

[0093] One hundred microliters of each test compound dilution were added to microtiter wells containing adherent monocytes and 100 μ l complete medium. Monocytes were cultured with test compounds for 60 min at which time 25 μ l of complete medium containing 30 ng/ml lipopolysaccharide from E. coli K532 were added to each well. Cells were cultured an additional 4 hrs. Culture supernatants were then removed and TNF presence in the supernatants was quantified using an ELISA.

TNF ELISA

[0094] Flat bottom, 96 well Corning High Binding ELISA plates were coated overnight (4°C) with 150 μ L/well of 3 μ g/ml murine anti-human TNF- α MAb (R&D Systems #MAB210). Wells were then blocked for 1 hr at room temperature with 200 μ L/well of CaCl₂-free ELISA buffer supplemented to contain 20 mg/ml BSA (standard ELISA buffer: 20 mM, 150 mM NaCl, 2 mM CaCl₂, 0.15 mM thimerosal, pH 7.4). Plates were washed and replenished with 100 μ l of test supernatants (diluted 1:3) or standards. Standards consisted of eleven 1.5-fold serial dilutions from a stock of 1 ng/ml recombinant human TNF (R&D Systems). Plates were incubated at room temperature for 1 hr on orbital shaker (300 rpm), washed and replenished with 100 μ l/well of 0.5 μ g/ml goat anti-human TNF- α (R&D systems #AB-210-NA) biotinylated at a 4:1 ratio. Plates were incubated for 40 min, washed and replenished with 100 μ l/well of alkaline phosphatase-conjugated streptavidin (Jackson ImmunoResearch #016-050-084) at 0.02 μ g/ml. Plates were incubated 30 min, washed and replenished with 200 μ l/well of 1 mg/ml of p-nitrophenyl phosphate. After 30 min, plates were read at 405 nm on a V_{max} plate reader.

Data analysis

[0095] Standard curve data were fit to a second order polynomial and unknown TNF- α concentrations determined from their OD by solving this equation for concentration. TNF concentrations were then plotted vs. test compound concentration using a second order polynomial. This equation was then used to calculate the concentration of test compounds causing a 50% reduction in TNF production.

[0096] The following compounds had an IC₅₀ of less than 15 μ M:

2-cyclohexyloxy-5-(2-chlorophenylcarbonylamino)pyridine;
 2-cyclohexyloxy-5-(2-methylphenylcarbonylamino)pyridine;
 2-cyclohexyloxy-5-(2,6-dichlorophenylcarbonylamino) pyridine;
 2-cyclohexyloxy-5-(2,6-dimethylphenylcarbonylamino) pyridine;
 2-(2,4-dimethylphenoxy)-5-(2-methylphenylcarbonylamino) pyridine;
 2-(2-methyl-4-fluorophenoxy)-5-(2-methylphenylcarbonyl amino)pyridine;
 2-(2-methyl-4-chlorophenoxy)-5-(2-chlorophenylcarbonyl amino)pyridine;
 2-(2-methyl-4-chlorophenoxy)-5-(2,6-dichlorophenyl carbonylamino)pyridine;
 2-(2-methyl-4-chlorophenoxy)-5-(2,6-dimethylphenyl carbonylamino)pyridine;
 2-(4-chlorophenoxy)-5-(2,6-dimethylphenylcarbonylamino) pyridine;
 2-(2-methyl-4-fluorophenoxy)-5-(2,6-dichlorophenyl carbonylamino)pyridine;
 2-(2-methyl-4-fluorophenoxy)-5-(2,6-dimethylphenyl carbonylamino)pyridine;
 2-(2-methyl-4-fluorophenoxy)-5-(2-fluorophenylcarbonyl amino)pyridine;
 2-(2,4-dimethylphenoxy)-5-(2,6-dimethylphenylcarbonyl amino)pyridine;
 2-(1-naphthyl)-5-(2-methylphenylcarbonylamino) pyridine;
 2-(1-naphthyl)-5-(2,6-dichlorophenylcarbonylamino) pyridine;
 2-(2-methyl-3-pyridyloxy)-5-(2,6-dichlorophenylcarbonyl amino)pyridine;
 2-(2-methyl-4-chlorophenoxy)-5-(2,6-dimethyl-4-isoxazolyl)carbonylamino)pyridine;
 2-cyclohexylamino-5-(2,6-dichlorophenylcarbonylamino) pyridine;
 2-cyclohexylamino-5-(2,6-dimethylphenylcarbonylamino) pyridine;
 2-(2-methylcyclohexylamino)-5-(2,6-dichlorophenylcarbonyl amino)pyridine;
 2-(2-methylcyclohexylamino)-5-(2-methylphenylcarbonyl amino)pyridine;

2-(2-methylphenylamino)-5-(2-methylphenylcarbonyl amino)pyridine;
 2-(2-methylphenylamino)-5-(2,6-dimethylphenylcarbonyl amino)pyridine;
 2-(2-methyl-4-chlorophenylamino)-5-(2-methylphenyl carbonylamino)pyridine; and
 2-(2-methyl-4-chlorophenylamino)-5-(2-methylphenyl aminocarbonyl)pyridine.

[0097] Compounds of the invention can also be shown to inhibit LPS-induced release of IL-1 β , IL-6 and/or IL-8 from monocytes by measuring concentrations of IL-1 β , IL-6 and/or IL-8 by methods well known to those skilled in the art. In a similar manner to the above described assay involving the LPS induced release of TNF- α from monocytes, compounds of this invention can also be shown to inhibit LPS induced release of IL-1 β , IL-6 and/or IL-8 from monocytes by measuring concentrations of IL-1 β , IL-6 and/or IL-8 by methods well known to those skilled in the art. Thus, the compounds of the invention may lower elevated levels of TNF- α , IL-1, IL-6, and IL-8 levels. Reducing elevated levels of these inflammatory cytokines to basal levels or below is favorable in controlling, slowing progression, and alleviating many disease states. All of the compounds are useful in the methods of treating disease states in which TNF- α , IL-1 β , IL-6, and IL-8 play a role to the full extent of the definition of TNF- α -mediated diseases described herein.

Inhibition of LPS-Induced TNF- α production in mice

[0098] Male DBA/1LACJ mice are dosed with vehicle or test compounds in a vehicle (the vehicle consisting of 0.5% tragacanth in 0.03 N HCl) 30 minutes prior to lipopolysaccharide (2 mg/kg, I.V.) injection. Ninety minutes after LPS injection, blood are collected and the serum is analyzed by ELISA for TNF levels.

[0099] Selected compounds from the class have shown in vivo activity in a LPS mouse model in which serum levels of TNF- α were reduced in the presence of compounds of this invention.

[0100] Compounds of the invention may be shown to have anti-inflammatory properties in animal models of inflammation, including carageenan paw edema, collagen induced arthritis and adjuvant arthritis, such as the carageenan paw edema model (C. A. Winter et al Proc. Soc. Exp. Biol. Med. (1962) vol 111, p 544; K. F. Swingle, in R. A. Scherrer and M. W. Whitehouse, Eds., Antiinflammatory Agents, Chemistry and Pharmacology, Vol. 13-II, Academic, New York, 1974, p. 33) and collagen induced arthritis (D. E. Trentham et al J. Exp. Med. (1977) vol. 146, p 857; J. S. Courtenay, Nature (New Biol.) (1980), Vol 283, p 666).

¹²⁵I-Glucagon Binding Screen with CHO/hGLUR Cells

[0101] The assay is described in WO 97/16442, which is incorporated herein by reference in its entirety.

Reagents

[0102] The reagents can be prepared as follows: (a) prepare fresh 1M o-Phenanthroline (Aldrich) (198.2 mg/ml ethanol); (b) prepare fresh 0.5M DTT (Sigma); (c) Protease Inhibitor Mix (1000X): 5 mg leupeptin, 10 mg benzamidine, 40 mg bacitracin and 5 mg soybean trypsin inhibitor per ml DMSO and store aliquots at -20°C; (d) 250 μ M human glucagon (Peninsula): solubilize 0.5 mg vial in 575 μ l 0.1N acetic acid (1 μ l yields 1 μ M final concentration in assay for non-specific binding) and store in aliquots at -20°C; (e) Assay Buffer: 20mM Tris (pH 7.8), 1 mM DTT and 3 mM o-phenanthroline; (f) Assay Buffer with 0.1% BSA (for dilution of label only; 0.01% final in assay): 10 μ l 10% BSA (heat-inactivated) and 990 μ l Assay Buffer; (g) ¹²⁵I-Glucagon (NEN, receptor-grade, 2200 Ci/mmol): dilute to 50,000 cpm/25 μ l in assay buffer with BSA (about 50pM final concentration in assay).

Harvesting of CHO/hGLUR Cells for Assay

[0103]

1. Remove media from confluent flask then rinse once each with PBS (Ca, Mg-free) and Enzyme-free Dissociation Fluid (Specialty Media, Inc.).
2. Add 10 ml Enzyme-free Dissoc. Fluid and hold for about 4 min. at 37°C.
3. Gently tap cells free, triturate, take aliquot for counting and centrifuge remainder for 5 min. at 1000 rpm.
4. Resuspend pellet in Assay Buffer at 75000 cells per 100 μ l.

[0104] Membrane preparations of CHO/hGLUR cells can be used in place of whole cells at the same assay volume. Final protein concentration of a membrane preparation is determined on a per batch basis.

Assay

[0105] The determination of inhibition of glucagon binding can be carried out by measuring the reduction of [¹²⁵I]-glucagon binding in the presence of compounds of Formula I. The reagents are combined in 120 μ L of assay buffer as follows:

	Compound/ Vehicle	250 μ M Glucagon	¹²⁵ I-Glucagon	CHO/hGLUR Cells
Total Binding	-- / 5 μ L	--	25 μ L	100 μ L
+ Compound	5 μ L/--	--	25 μ L	100 μ L
Nonspecific Binding	--/5 μ L	1 μ L	25 μ L	100 μ L

The mixture is incubated for 60 min. at 22°C on a shaker at 275 rpm. The mixture is filtered over pre-soaked (0.5% polyethylimine (PEI)) GF/C filtermat using an Innotech Harvester or Tomtec Harvester with four washes of ice-cold 20mM Tris buffer (pH 7.8). The radioactivity in the filters is determined by a gamma-scintillation counter.

[0106] Thus, compounds of the invention may also be shown to inhibit the binding of glucagon to glucagon receptors.

Cyclooxygenase Enzyme Activity Assay

[0107] The human monocytic leukemia cell line, THP-1, differentiated by exposure to phorbol esters expresses only COX-1; the human osteosarcoma cell line 143B expresses predominantly COX-2. THP-1 cells are routinely cultured in RPMI complete media supplemented with 10% FBS and human osteosarcoma cells (HOSC) are cultured in minimal essential media supplemented with 10% fetal bovine serum (MEM-10%FBS); all cell incubations are at 37°C in a humidified environment containing 5% CO₂.

COX-1 Assay

[0108] In preparation for the COX-1 assay, THP-1 cells are grown to confluency, split 1:3 into RPMI containing 2% FBS and 10 mM phorbol 12-myristate 13-acetate (TPA), and incubated for 48 hours on a shaker to prevent attachment. Cells are pelleted and resuspended in Hank's Buffered Saline (HBS) at a concentration of 2.5×10^6 cells/mL and plated in 96-well culture plates at a density of 5×10^5 cells/mL. Test compounds are diluted in HBS and added to the desired final concentration and the cells are incubated for an additional 4 hours. Arachidonic acid is added to a final concentration of 30 mM, the cells incubated for 20 minutes at 37°C, and enzyme activity determined as described below.

COX-2 Assay

[0109] For the COX-2-assay, subconfluent HOSC are trypsinized and resuspended at 3×10^6 cells/mL in MEM-FBS containing 1 ng human IL-1b/mL, plated in 96-well tissue culture plates at a density of 3×10^4 cells per well, incubated on a shaker for 1 hour to evenly distribute cells, followed by an additional 2 hour static incubation to allow attachment. The media is then replaced with MEM containing 2% FBS (MEM-2%FBS) and 1 ng human IL-1b/mL, and the cells incubated for 18-22 hours. Following replacement of media with 190 mL MEM, 10 mL of test compound diluted in HBS is added to achieve the desired concentration and the cells incubated for 4 hours. The supernatants are removed and replaced with MEM containing 30 mM arachidonic acid, the cells incubated for 20 minutes at 37°C, and enzyme activity determined as described below.

COX Activity Determined

[0110] After incubation with arachidonic acid, the reactions are stopped by the addition of 1 N HCl, followed by neutralization with 1 N NaOH and centrifugation to pellet cell debris. Cyclooxygenase enzyme activity in both HOSC and THP-1 cell supernatants is determined by measuring the concentration of PGE₂ using a commercially available ELISA (Neogen #404110). A standard curve of PGE₂ is used for calibration, and commercially available COX-1 and COX-2 inhibitors are included as standard controls.

[0111] The following compound exhibits activities in the Cyclooxygenase assay with IC₅₀ values of 10 μ M or less: 2-(2,4-dimethylphenylamino)-5-(2,6-dichlorophenylcarbonyl amino)pyridine.

Raf Kinase assay

[0112] *In vitro* Raf kinase activity is measured by the extent of phosphorylation of the substrate MEK (Map kinase/ERK

kinase) by activated Raf kinase. Phosphorylated MEK is trapped on a filter and incorporation of radiolabeled phosphate is quantified by scintillation counting.

MATERIALS:

[0113]

Activated Raf is produced by triple transfection of Sf9 cells with baculoviruses expressing "Glu-Glu"-epitope tagged Raf, val¹²-H-Ras, and Lck. The "Glu-Glu"-epitope, Glu-Tyr-Met-Pro-Met-Glu, was fused to the carboxy-terminus of full length c-Raf.

Catalytically inactive MEK (K97A mutation) is produced in Sf9 cells transfected with a baculovirus expressing c-terminus "Glu-Glu" epitope-tagged K97A MEK1.

Anti "Glu-Glu" antibody was purified from cells grown as described in: Grussenmeyer, et al., Proceedings of the National Academy of Science, U.S.A. pp 7952-7954, 1985.

Column buffer: 20 mM Tris pH=8, 100 mM NaCl, 1 mM EDTA, 2.5 mM EGTA, 10 mM MgCl₂, 2 mM DTT, 0.4 mM AEBSF, 0.1% n-octylglucopyranoside, 1 nM okadaic acid, and 10 µg/mL each of benzamidine, leupeptin, pepstatin, and aprotinin.

5x Reaction buffer: 125 mM HEPES pH=8, 25 mM MgCl₂, 5 mM EDTA, 5 mM Na₃VO₄, 100 µg/mL BSA.

Enzyme dilution buffer: 25 mM HEPES pH=8, 1 mM EDTA, 1 mM Na₃VO₄, 400 µg/mL BSA.

Stop solution: 100 mM EDTA, 80 mM sodium pyrophosphate.

Filter plates: Milipore multiscreen # SE3MO78E3, Immobilon-P (PVDF).

METHODS:

[0114] Protein purification: Sf9 cells were infected with baculovirus and grown as described in Williams, et al., Proceedings of the National Academy of Science, U.S.A. pp 2922-2926, 1992. All subsequent steps were performed, on ice or at 4 °C. Cells were pelleted and lysed by sonication in column buffer. Lysates were spun at 17,000xg for 20 min, followed by 0.22 µm filtration. Epitope tagged proteins were purified by chromatography over GammaBind Plus affinity column to which the "Glu-Glu" antibody was coupled. Proteins were loaded on the column followed by sequential washes with two column volumes of column buffer, and eluted with 50 µg/mL Glu-Tyr-Met-Pro-Met-Glu in column buffer.

[0115] Raf kinase assay: Test compounds were evaluated using ten 3-fold serial dilutions starting at 10 - 100 µM. 10 µL of the test inhibitor or control, dissolved in 10% DMSO, was added to the assay plate followed by the addition of 30 µL of a mixture containing 10 µL 5x reaction buffer, 1mM ³³P-γ-ATP (20 µCi/mL), 0.5 µL MEK (2.5 mg/mL), 1 µL 50 mM β-mercaptoethanol. The reaction was started by the addition of 10 µL of enzyme dilution buffer containing 1 mM DTT and an amount of activated Raf that produces linear kinetics over the reaction time course. The reaction was mixed and incubated at room temperature for 90 min. and stopped by the addition of 50 µL stop solution. 90 µL aliquots of this stopped solution were transferred onto GFP-30 cellulose microtiter filter plates (Polyfiltronics), the filter plates washed in four well volumes of 5% phosphoric acid, allowed to dry, and then replenished with 25 µL scintillation cocktail. The plates were counted for ³³P gamma emission using a TopCount Scintillation Reader.

[0116] Accordingly, the compounds of the invention or a pharmaceutical composition thereof are useful for prophylaxis and treatment of rheumatoid arthritis; Pagets disease; osteophorosis; multiple myeloma; uveitis; acute and chronic myelogenous leukemia; pancreatic β cell destruction; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; adult respiratory distress syndrome (ARDS); psoriasis; Crohn's disease; allergic rhinitis; ulcerative colitis; anaphylaxis; contact dermatitis; asthma; muscle degeneration; cachexia; Reiter's syndrome; type I and type II diabetes; bone resorption diseases; graft vs. host reaction; ischemia reperfusion injury; atherosclerosis; brain trauma; Alzheimer's disease; stroke; myocardial infarction; multiple sclerosis; cerebral malaria; sepsis; septic shock; toxic shock syndrome; fever, and myalgias due to infection. HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses (including HSV-1, HSV-2), and herpes zoster, all of which are sensitive to TNF-α and/or IL-1 inhibition or glucagon antagonism, will also be positively effected by the compounds and methods of the invention.

[0117] The compounds of the present invention may also possess oncolytic characteristics and may be useful for the treatment of cancer. The compounds of the present invention may also block signal transduction by extracellular mitogenic stimuli and oncoproteins through inhibition of Raf kinase.

[0118] The compounds of the present invention also may possess analgesic properties and may be useful for the treatment of pain disorders, such as hyperalgesia due to excessive IL-1. The compounds of the present invention may also prevent the production of prostaglandins by inhibition of enzymes in the human arachidonic acid/prostaglandin pathway, including cyclooxygenase (WO 96/03387, incorporated herein by reference in its entirety).

[0119] Because of their ability to lower TNF-α and IL-1 concentrations or inhibit glucagon binding to its receptor, the compounds of the invention are also useful research tools for studying the physiology associated with blocking these

effects.

[0120] The methods of the invention comprise administering an effective dose of a compound of the invention, a pharmaceutical salt thereof, or a pharmaceutical composition of either, to a subject (i.e., an animal, preferably a mammal, most preferably a human) in need of a reduction in the level of TNF- α , IL-1, IL-6, and/or IL-8 levels and/or reduction in plasma glucose levels and/or which subject may be suffering from rheumatoid arthritis; Paget's disease; osteoporosis; multiple myeloma; uveitis; acute and chronic myelogenous leukemia; pancreatic β cell destruction; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; adult respiratory distress syndrome (ARDS); psoriasis; Crohn's disease; allergic rhinitis; ulcerative colitis; anaphylaxis; contact dermatitis; asthma; muscle degeneration; cachexia; Reiter's syndrome; type I and type II diabetes; cancer; bone resorption diseases; graft vs. host reaction; Alzheimer's disease; stroke; myocardial infarction; ischemia reperfusion injury; atherosclerosis; brain trauma; multiple sclerosis; cerebral malaria; sepsis; septic shock; toxic shock syndrome; fever, and myalgias due to infection, or which subject is infected by HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses (including HSV-1, HSV-2), or herpes zoster.

[0121] In another aspect, this invention comprises the use of a compound of the invention, or pharmaceutically acceptable salts thereof, in the manufacture of a medicament for the treatment either acutely or chronically of a TNF- α , IL-1 β , IL-6, and/or IL-8 mediated disease state, including those described previously. The compounds of the present invention are also useful in the manufacture of an anti-cancer medicament. The compounds of the present invention are also useful in the manufacture of a medicament to attenuate or prevent signal transduction by extracellular mitogenic stimuli and oncoproteins through inhibition of Raf kinase. Also, the compounds of this invention are useful in the manufacture of an analgesic medicament and a medicament for treating pain disorders, such as hyperalgesia. The compounds of the present invention also are useful in the manufacture of a medicament to prevent the production of prostaglandins by inhibition of enzymes in the human arachidonic acid/prostaglandin pathway.

[0122] In still another aspect, this invention provides a pharmaceutical composition comprising an effective TNF- α , IL-1 β , IL-6, and/or IL-8 lowering amount and/or effective plasma glucose level lowering amount, and/or effective tumor suppressing amount of a compound of the invention and a pharmaceutically acceptable carrier or diluent, and if desired other active ingredients. The compounds of the invention are administered by any suitable route, preferably in the form of a pharmaceutical composition adapted to such a route, and in a dose effective for the treatment intended. Therapeutically effective doses of the compounds of the present invention required to arrest the progress or prevent tissue damage associated with the disease are readily ascertained by one of ordinary skill in the art using standard methods.

[0123] For the treatment of TNF- α , IL-1 β , IL-6, and IL-8 mediated diseases, cancer, and/or hyperglycemia, the compounds of the present invention may be administered orally, parentally, by inhalation spray, rectally, or topically in dosage unit formulations containing conventional pharmaceutically acceptable carriers, adjuvants, and vehicles. The term parenteral as used herein includes, subcutaneous, intravenous, intramuscular, intrasternal, infusion techniques or intraperitoneally.

[0124] The dosage regimen for treating a TNF- α , IL-1, IL-6, and IL-8 mediated diseases, cancer, and/or hyperglycemia with the compounds of this invention and/or compositions of this invention is based on a variety of factors, including the type of disease, the age, weight, sex, medical condition of the patient, the severity of the condition, the route of administration, and the particular compound employed. Thus, the dosage regimen may vary widely, but can be determined routinely using standard methods. Dosage levels of the order from about 0.01 mg to 30 mg per kilogram of body weight per day, preferably from about 0.1 mg to 10 mg/kg, more preferably from about 0.25 mg to 1 mg/kg are useful for all methods of use disclosed herein.

[0125] The pharmaceutically active compounds of this invention can be processed in accordance with conventional methods of pharmacy to produce medicinal agents for administration to patients, including humans and other mammals.

[0126] For oral administration, the pharmaceutical composition may be in the form of, for example, a capsule, a tablet, a suspension, or liquid. The pharmaceutical composition is preferably made in the form of a dosage unit containing a given amount of the active ingredient. For example, these may contain an amount of active ingredient from about 1 to 2000 mg, preferably from about 1 to 500 mg, more preferably from about 5 to 150 mg. A suitable daily dose for a human or other mammal may vary widely depending on the condition of the patient and other factors, but, once again, can be determined using routine methods.

[0127] The active ingredient may also be administered by injection as a composition with suitable carriers including saline, dextrose, or water. The daily parenteral dosage regimen will be from about 0.1 to about 30 mg/kg of total body weight, preferably from about 0.1 to about 10 mg/kg, and more preferably from about 0.25 mg to 1 mg/kg.

[0128] Injectable preparations, such as sterile injectable aqueous or oleaginous suspensions, may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed, including synthetic

mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.

[0129] Suppositories for rectal administration of the drug can be prepared by mixing the drug with a suitable nonirritating excipient such as cocoa butter and polyethylene glycols that are solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum and release the drug.

[0130] A suitable topical dose of active ingredient of a compound of the invention is 0.1 mg to 150 mg administered one to four, preferably one or two times daily. For topical administration, the active ingredient may comprise from 0.001% to 10% w/w, e.g., from 1% to 2% by weight of the formulation, although it may comprise as much as 10% w/w, but preferably not more than 5% w/w, and more preferably from 0.1% to 1% of the formulation.

[0131] Formulations suitable for topical administration include liquid or semi-liquid preparations suitable for penetration through the skin (e.g., liniments, lotions, ointments, creams, or pastes) and drops suitable for administration to the eye, ear, or nose.

[0132] For administration, the compounds of this invention are ordinarily combined with one or more adjuvants appropriate for the indicated route of administration. The compounds may be admixed with lactose, sucrose, starch powder, cellulose esters of alkanolic acids, stearic acid, talc, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulphuric acids, acacia, gelatin, sodium alginate, polyvinylpyrrolidone, and/or polyvinyl alcohol, and tableted or encapsulated for conventional administration. Alternatively, the compounds of this invention may be dissolved in saline, water, polyethylene glycol, propylene glycol, ethanol, corn oil, peanut oil, cottonseed oil, sesame oil, tragacanth gum, and/or various buffers. Other adjuvants and modes of administration are well known in the pharmaceutical art. The carrier or diluent may include time delay material, such as glyceryl monostearate or glyceryl distearate alone or with a wax, or other materials well known in the art.

[0133] The pharmaceutical compositions may be made up in a solid form (including granules, powders or suppositories) or in a liquid form (e.g., solutions, suspensions, or emulsions). The pharmaceutical compositions may be subjected to conventional pharmaceutical operations such as sterilization and/or may contain conventional adjuvants, such as preservatives, stabilizers, wetting agents, emulsifiers, buffers etc.

[0134] Solid dosage forms for oral administration may include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound may be admixed with at least one inert diluent such as sucrose, lactose, or starch. Such dosage forms may also comprise, as in normal practice, additional substances other than inert diluents, e.g., lubricating agents such as magnesium stearate. In the case of capsules, tablets, and pills, the dosage forms may also comprise buffering agents. Tablets and pills can additionally be prepared with enteric coatings.

[0135] Liquid dosage forms for oral administration may include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs containing inert diluents commonly used in the art, such as water. Such compositions may also comprise adjuvants, such as wetting, sweetening, flavoring, and perfuming agents.

[0136] Compounds of the present invention can possess one or more asymmetric carbon atoms and are thus capable of existing in the form of optical isomers as well as in the form of racemic or non-racemic mixtures thereof. The optical isomers can be obtained by resolution of the racemic mixtures according to conventional processes, e.g., by formation of diastereoisomeric salts, by treatment with an optically active acid or base. Examples of appropriate acids are tartaric, diacetyltartaric, dibenzoyltartaric, ditoluoyltartaric, and camphorsulfonic acid and then separation of the mixture of diastereoisomers by crystallization followed by liberation of the optically active bases from these salts. A different process for separation of optical isomers involves the use of a chiral chromatography column optimally chosen to maximize the separation of the enantiomers. Still another available method involves synthesis of covalent diastereoisomeric molecules by reacting compounds of the invention with an optically pure acid in an activated form or an optically pure isocyanate. The synthesized diastereoisomers can be separated by conventional means such as chromatography, distillation, crystallization or sublimation, and then hydrolyzed to deliver the enantiomerically pure compound. The optically active compounds of the invention can likewise be obtained by using active starting materials. These isomers may be in the form of a free acid, a free base, an ester or a salt.

[0137] The compounds of the present invention can be used in the form of salts derived from inorganic or organic acids. The salts include, but are not limited to, the following: acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, cyclopentanepropionate, dodecylsulfate, ethanesulfonate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxy-ethanesulfonate, lactate, maleate, methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, palmoate, pectinate, persulfate, 2-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, mesylate, and undecanoate. Also, the basic nitrogen-containing groups can be quaternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl, and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides like benzyl and phenethyl bromides, and others. Water or oil-soluble or dispersible products are thereby obtained.

[0138] Examples of acids that may be employed to form pharmaceutically acceptable acid addition salts include such inorganic acids as hydrochloric acid, sulphuric acid and phosphoric acid and such organic acids as oxalic acid, maleic

acid, succinic acid and citric acid. Other examples include salts with alkali metals or alkaline earth metals, such as sodium, potassium, calcium or magnesium or with organic bases.


[0139] While the compounds of the invention can be administered as the sole active pharmaceutical agent, they can also be used in combination with one or more compounds of the invention or other agents. When administered as a combination; the therapeutic agents can be formulated as separate compositions that are given at the same time or different times, or the therapeutic agents can be given as a single composition.

[0140] The foregoing is merely illustrative of the invention and is not intended to limit the invention to the disclosed compounds. Variations and changes which are obvious to one skilled in the art are intended to be within the scope and nature of the invention which are defined in the appended claims.

[0141] From the foregoing description, one skilled in the art can easily ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions.

Claims

1. A compound of the formula




or a pharmaceutically acceptable salt thereof, wherein

X is NR^2 ;


Y is $-\text{NR}^4-\text{C}(\text{O})-\text{R}^3$;

R^1 is a radical of the formula



R^2 is a hydrogen or methyl radical;

R^3 is a radical of the formula



R⁴ is a radical of hydrogen, methyl or ethyl radical;

R⁵, R⁶ and R⁷ are each independently a hydrogen radical;

R¹¹ and R¹³ are each independently a radical of hydrogen, C₁-C₄ alkyl, halo, trifluoromethyl, cyano, azido, nitro, amidino or R¹⁹-Z¹⁹-;

each R¹² is independently a radical of hydrogen, C₁-C₆ alkyl, halo, C₁-C₄ haloalkyl of 1-3 halo radicals, R³¹-Z³¹- or R³¹-Z³¹-C₁-C₄ alkyl; provided that the combined total number of aryl and heteroaryl radicals in R¹¹, R¹² and R¹³ is 0-1;

each R¹⁸ is independently a hydrogen, C₁-C₄ alkyl, trifluoromethyl, aryl, heteroaryl, aryl-C₁-C₂ alkyl or heteroaryl-C₁-C₂ alkyl radical; wherein the aryl and heteroaryl radicals are optionally substituted by 1-2 radicals of hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthiol, amino, C₁-C₄ alkylamino, di(C₁-C₄ alkyl)amino, acetamino, cyano, halo, azido, C₁-C₄ alkyl, trifluoromethyl or trifluoromethoxy,

each R¹⁹ is independently a hydrogen, C₁-C₄ alkyl, trifluoromethyl, aryl, heteroaryl, aryl-C₁-C₄ alkyl or heteroaryl-C₁-C₄ alkyl radical; wherein the aryl and heteroaryl radicals are optionally substituted by 1-2 radicals of hydroxy, methoxy, ethoxy, amino, methylamino, dimethylamino, acetamino, cyano, halo, methyl, ethyl, trifluoromethyl or trifluoromethoxy;

each R²¹ is independently a hydrogen or methyl radical ;

either


each Z¹⁸ is independently -O-, -S-, -S(O)₂-, -CO₂-, -NR²¹-, -NR²¹-C(O)-, -C(O)-NR²¹-, NR²¹-S(O)₂- or -S(O)₂-NR²¹-;

each Z¹⁹ is independently -O-, -S(O)₂-, -CO₂-, -C(O)-, -NR²¹-C(O)-, -C(O)-NR²¹-, -NR²¹-S(O)₂- or -S(O)₂-NR²¹-;

each Z³¹ is independently -O-, -NR²¹-, -NR²¹-C(O)-, -C(O)-NR²¹-, -NR²¹-S(O)₂- or -S(O)₂-NR²¹-; and

wherein aryl is a phenyl, biphenyl or naphthyl radical; and heteroaryl is a monocyclic aromatic heterocyclic ring system having 5-6 ring members per ring, wherein 1-3 ring members are oxygen, sulfur or nitrogen heteroatoms.

2. A compound of the formula




or a pharmaceutically acceptable salt thereof, wherein

X is NR²;


Y is -NR⁴-C(O)-R³;

R¹ is a radical of the formula



15 R^2 is a hydrogen or methyl radical;

R^3 is a radical of the formula



30 R^4 is a radical of hydrogen, methyl or ethyl radical;

R^5 , R^6 and R^7 are each independently a hydrogen radical;

R^{11} and R^{13} are each independently a radical of hydrogen, C_1 - C_4 alkyl, halo, trifluoromethyl, cyano, azido, nitro, amidino or R^{19} - Z^{19} ;

each R^{12} is independently a radical of hydrogen, C_1 - C_6 alkyl, halo, C_1 - C_4 haloalkyl of 1-3 halo radicals, R^{31} - Z^{31} - or R^{31} - Z^{31} - C_1 - C_4 alkyl; provided that the combined total number of aryl and heteroaryl radicals in R^{11} , R^{12} and R^{13} is 0-1;

each R^{18} is independently a hydrogen, C_1 - C_4 alkyl, trifluoromethyl, aryl, heteroaryl, aryl- C_1 - C_2 alkyl or heteroaryl- C_1 - C_2 alkyl radical; wherein the aryl and heteroaryl radicals are optionally substituted by 1-2 radicals of hydroxy, C_1 - C_4 alkoxy, C_1 - C_4 alkylthiol, amino, C_1 - C_4 alkylamino, di(C_1 - C_4 alkyl)amino, acetylamino, cyano, halo, azido, C_1 - C_4 alkyl, trifluoromethyl or trifluoromethoxy;

each R^{19} is independently a hydrogen, C_1 - C_4 alkyl, trifluoromethyl, aryl, heteroaryl, aryl- C_1 - C_4 alkyl or heteroaryl- C_1 - C_4 alkyl radical; wherein the aryl and heteroaryl radicals are optionally substituted by 1-2 radicals of hydroxy, methoxy, ethoxy, amino, methylamino, dimethylamino, acetylamino, cyano, halo, methyl, ethyl, trifluoromethyl or trifluoromethoxy;

each R^{21} is independently a hydrogen or methyl radical;

R^{22} , R^{23} , R^{24} , R^{25} and R^{26} are each independently a radical of hydrogen, C_1 - C_4 alkyl, halo, trifluoromethyl, cyano, azido, nitro, amidino, R^{18} - Z^{18} - or R^{18} - Z^{18} - C_1 - C_4 alkyl; provided at least one of R^{21} , R^{22} , R^{23} , R^{24} and R^{25} is hydrogen; and provided that the combined total number of aryl and heteroaryl radicals in R^{22} , R^{23} , R^{24} , R^{25} and R^{26} is 0-1;

each R^{31} is independently a hydrogen, C_1 - C_4 alkyl, trifluoromethyl, aryl, heteroaryl, aryl- C_1 - C_4 alkyl or heteroaryl- C_1 - C_4 alkyl radical; wherein the aryl and heteroaryl radicals are optionally substituted by 1-2 radicals of hydroxy, methoxy, ethoxy, amino, methylamino, dimethylamino, acetylamino, cyano, halo, methyl, ethyl, trifluoromethyl or trifluoromethoxy;

U is C - R^{13} or N;

V is N;

W is C - R^{12} or N;


each Z^{18} is independently -O-, -S-, -S(O)₂-, -CO₂-, -NR²¹-, -NR²¹-C(O)-, -C(O)-NR²¹-, -NR²¹-S(O)₂- or -S(O)₂-NR²¹-;

each Z^{19} is independently -O-, -S(O)₂-, -CO₂-, -C(O)-, -NR²¹-C(O)-, -C(O)-NR²¹-, -NR²¹-S(O)₂- or -S(O)₂-NR²¹-;

each Z^{31} is independently -O-, -NR²¹-, -NR²¹-C(O)-, -C(O)-NR²¹-, -NR²¹-S(O)₂- or -S(O)₂-NR²¹-; and

wherein aryl is a phenyl, biphenyl or naphthyl radical; and heteroaryl is a monocyclic aromatic heterocyclic ring system having 5-6 ring members per ring, wherein 1-3 ring members are oxygen, sulfur or nitrogen heteroatoms.

3. A compound of the formula




or a pharmaceutically acceptable salt thereof, wherein

X is NR²;


Y is -NR⁴-C(O)-R³;

R¹ is a radical of the formula



R² is a hydrogen or methyl radical;

R³ is a radical of the formula



R⁴ is a radical of hydrogen, methyl or ethyl radical;

R⁵, R⁶ and R⁷ are each independently a hydrogen radical;

R¹¹ and R¹³ are each independently a radical of hydrogen, C₁-C₄ alkyl, halo, trifluoromethyl, cyano, azido, nitro, amidino or R¹⁹-Z¹⁹;

each R¹² is independently a radical of hydrogen, C₁-C₆ alkyl, halo, C₁-C₄ haloalkyl of 1-3 halo radicals, R³¹-Z³¹- or R³¹-Z³¹-C₁-C₄ alkyl; provided that the combined total number of aryl and heteroaryl radicals in R¹¹, R¹² and R¹³ is 0-1;

each R¹⁸ is independently a hydrogen, C₁-C₄ alkyl, trifluoromethyl, aryl, heteroaryl, aryl-C₁-C₂ alkyl or heteroaryl-C₁-C₂ alkyl radical; wherein the aryl and heteroaryl radicals are optionally substituted by 1-2 radicals of hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthiol, amino, C₁-C₄ alkylamino, di(C₁-C₄ alkyl)amino, acetylamino, cyano, halo, azido,

C₁-C₄ alkyl, trifluoromethyl or trifluoromethoxy;

each R¹⁹ is independently a hydrogen, C₁-C₄ alkyl, trifluoromethyl, aryl, heteroaryl, aryl-C₁-C₄ alkyl or heteroaryl-C₁-C₄ alkyl radical; wherein the aryl and heteroaryl radicals are optionally substituted by 1-2 radicals of hydroxy, methoxy, ethoxy, amino, methylamino, dimethylamino, acetylamino, cyano, halo, methyl, ethyl, trifluoromethyl or trifluoromethoxy;

each R²¹ is independently a hydrogen or methyl radical;

R²², R²³, R²⁴, R²⁵ and R²⁶ are each independently a radical of hydrogen, C₁-C₄ alkyl, halo, trifluoromethyl, cyano, azido, nitro, amidino, R¹⁸-Z¹⁸- or R¹⁸-Z¹⁸-C₁-C₄ alkyl; provided at least one of R²¹, R²², R²³, R²⁴ and R²⁵ is hydrogen; and

provided that the combined total number of aryl and heteroaryl radicals in R²², R²³, R²⁴, R²⁵ and R²⁶ is 0-1;

each R³¹ is independently a hydrogen, C₁-C₄ alkyl, trifluoromethyl, aryl, heteroaryl, aryl-C₁-C₄ alkyl or heteroaryl-C₁-C₄ alkyl radical; wherein the aryl and heteroaryl radicals are optionally substituted by 1-2 radicals of hydroxy, methoxy, ethoxy, amino, methylamino, dimethylamino, acetylamino, cyano, halo, methyl, ethyl, trifluoromethyl or trifluoromethoxy;

U is N;

V is C-R¹² or N;

W is N;

each Z¹⁸ is independently -O-, -S-, -S(O)₂-, -CO₂-, -NR²¹-, -NR²¹-C(O)-, -C(O)-NR²¹-, -NR²¹-S(O)₂- or -S(O)₂-NR²¹-;

each Z¹⁹ is independently -O-, -S(O)₂-, -CO₂-, -C(O)-, -NR²¹-C(O)-, -C(O)-NR²¹-, -NR²¹-S(O)₂- or -S(O)₂-NR²¹-;

each Z³¹ is independently -O-, -NR²¹-, -NR²¹-C(O)-, -C(O)-NR²¹-, -NR²¹-S(O)₂- or -S(O)₂-NR²¹-; and

wherein aryl is a phenyl, biphenyl or naphthyl radical; and heteroaryl is a monocyclic aromatic heterocyclic ring system having 5-6 ring members per ring, wherein 1-3 ring members are oxygen, sulfur or nitrogen heteroatoms.

4. A compound selected from: .

2-cyclohexyloxy-5-(2-chlorophenylcarbonylamino)pyridine;

2-cyclohexyloxy-5-(2-methylphenylcarbonylamino)pyridine;

2-cyclohexyloxy-5-(2,6-dichlorophenylcarbonylamino) pyridine;

2-cyclohexyloxy-5-(2,6-dimethylphenylcarbonylamino) pyridine;

2-(2,4-dimethylphenoxy)-5-(2-chlorophenylcarbonylamino) pyridine;

2-(2,4-dimethylphenoxy)-5-(2,6-dichlorophenylcarbonyl amino)pyridine;

2-(2,4-dimethylphenoxy)-5-(2-methylphenylcarbonylamino) pyridine;

2-(2,6-dimethyl-4-chlorophenoxy)-5-(2,6-dimethylphenyl carbonylamino) pyridine;

2-(2-methyl-4-fluorophenoxy)-5-(2-methylphenylcarbonyl amino)pyridine;

2-(2-methyl-4-chlorophenoxy)-5-(2-chlorophenylcarbonyl amino)pyridine ;

2-(2-methyl-4-chlorophenoxy)-5-(2-methylphenylcarbonyl amino)pyridine;

2-(2-methylphenoxy)-5-(2-chlorophenylcarbonylamino) pyridine;

2-(2-methylphenoxy)-5-(2,6-dichlorophenyl carbonylamino)pyridine;

2-(2-methylphenoxy)-5-(2-methylphenylcarbonyl amino)pyridine ;

2-(2-methyl-4-chlorophenoxy)-5-(2,6-dichlorophenyl carbonylamino)pyridine ;

2-(2-methyl-4-chlorophenoxy)-5-(2,6-dimethylphenyl carbonylamino)pyridine ;

2-(4-chlorophenoxy)-5-(2,6-dimethylphenylcarbonylamino) pyridine;

2-(2-methyl-4-fluorophenoxy)-5-(2,6-dichlorophenyl carbonylamino)pyridine;

2-(2-methyl-4-fluorophenoxy)-5-(2,6-dimethylphenyl carbonylamino)pyridine;

2-(2-methylphenoxy)-5-(2,6-dimethylphenyl carbonylamino)pyridine;

2-(2-methyl-4-fluorophenoxy)-5-(2-fluorophenylcarbonyl amino)pyridine;

2-(2,4-dimethylphenoxy)-5-(2,6-dimethylphenylcarbonyl amino)pyridine;

2-(1-naphthyloxy)-5-(2-methylphenylcarbonylamino) pyridine;

2-(1-naphthyloxy)-5-(2,6-dichlorophenylcarbonylamino) pyridine;

2-(1-naphthyloxy)-5-(2,6-dimethylphenylcarbonylamino) pyridine;

2-(2-methyl-3-pyridyloxy)-5-(2,6-dichlorophenylcarbonyl amino)pyridine;

2-(2-methyl-4-chlorophenoxy)-5-((3,5-dimethyl-4-isoxazolyl)carbonylamino)pyridine;

2-(2-methyl-4-chlorophenylthiol)-5-(2-methylphenylcarbonyl amino)pyridine;

2-(2-methyl-4-chlorophenylthiol)-S-(2,6-dimethylphenylcarbonyl amino)pyridine;

2-cyclohexylamino-5-(2,6-dichlorophenylcarbonylamino) pyridine;

2-cyclohexylamino-5-(2,6-dimethylphenylcarbonylamino) pyridine;

2-(2-methylcyclohexylamino)-5-(2,6-dichlorophenylcarbonyl amino)pyridine;

2-(2-methylcyclohexylamino)-5-(2-methylphenylcarbonyl amino)pyridine;


2-(2,4-dimethylphenylamino)-5-(2-fluorophenylcarbonyl amino)pyridine;
 2-(2,4-dimethylphenylamino)-5-(2-chlorophenylcarbonyl amino)pyridine;
 2-(2,4-dimethylphenylamino)-5-(2,6-dichlorophenylcarbonyl amino)pyridine;
 2-(2-methyl-4-chlorophenylamino)-5-(2,6-dichlorophenylcarbonylamino)pyridine;
 2-(2,4-dimethylphenylamino)-5-(2-methylphenylcarbonyl amino)pyridine;
 2-(2-methylphenylamino)-5-(2-methylphenylcarbonyl amino)pyridine;
 2-(2-methylphenylamino)-5-(2,6-dichlorophenylcarbonyl amino)pyridine;
 2-(2-methylphenylamino)-5-(2,6-dimethylphenylcarbonyl amino)pyridine;
 2-(2,4-dimethylphenylamino)-5-(2,6-dimethylphenylcarbonyl amino)pyridine;
 2-(2-methyl-4-chlorophenylamino)-5-(2-methylphenyl carbonylamino)pyridine;
 2-(2-methyl-4-chlorophenylamino)-5-(2,6-dimethylphenyl carbonylamino)pyridine; and
 2-(2-methyl-4-chlorophenylamino)-5-(2-methylphenyl aminocarbonyl)pyridine,

or a pharmaceutically acceptable salt thereof.


5. A pharmaceutical composition comprising a compound according to any preceding claim and a pharmaceutically acceptable carrier.
6. A compound according to any one of Claims 1 to 4 or a pharmaceutical composition according to Claim 5, for use in the prophylaxis or treatment of diseases.
7. A compound or composition according to Claim 6, for use in the prophylaxis or treatment of inflammation.
8. A compound or composition according to Claim 6, for use in the prophylaxis or treatment of cancer.
9. A compound or composition according to Claim 6, for use in the prophylaxis or treatment of rheumatoid arthritis, Pagets disease, osteoporosis, multiple myeloma, uveitis, acute or chronic myelogenous leukemia, pancreatic β cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs. host reaction, Alzheimer's disease, stroke, myocardial infarction, ischemia reperfusion injury, atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever, myalgias due to HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the , herpes viruses or herpes zoster infection in a mammal comprising administering an effective amount of a compound of Claim 1.
10. A compound or composition according to Claim 6 for use in the prophylaxis or treatment of pain.
11. Use of a compound according to any one of Claims 1 to 4 or a pharmaceutical composition according to Claim 5 for the manufacture of a medicament for the prophylaxis or treatment of inflammation.
12. Use of a compound according to any one of Claims 1 to 4 or a pharmaceutical composition according to Claim 5 for the manufacture of a medicament for the prophylaxis or treatment of cancer.
13. Use of a compound according to any one of Claims 1 to 4 or a pharmaceutical composition according to Claim 5 for the manufacture of a medicament for the prophylaxis or treatment of rheumatoid arthritis, Pagets disease, osteoporosis, multiple myeloma, uveitis, acute or chronic myelogenous leukemia, pancreatic β cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs. host reaction, Alzheimer's disease, stroke, myocardial infarction, ischemia reperfusion injury, atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever, myalgias due to HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses or herpes zoster infection in a mammal comprising administering an effective amount of a compound of Claim 1.
14. Use of a compound according to any one of Claims 1 to 4 or a pharmaceutical composition according to Claim 5 for the manufacture of a medicament for the prophylaxis or treatment of pain.

Patentansprüche


1. Verbindung der Formel



oder ein pharmazeutisch annehmbares Salz davon, wobei
 X NR² ist;
 Y -NR⁴-C(O)-R³ ist;
 R¹ ein Rest der Formel



ist;
 R² ein Wasserstoff- oder Methylrest ist;
 R³ ein Rest der Formel



ist;
 R⁴ ein Wasserstoff-, Methyl- oder Ethylrest ist;
 R⁵, R⁶ und R⁷ jeweils unabhängig ein Wasserstoffrest sind;
 R¹¹ und R¹³ jeweils unabhängig ein Wasserstoff-, C₁-C₄-Alkyl-, Halo-, Trifluormethyl-, Cyano-, Azido-, Nitro-, Amino-, oder R¹⁹-Z¹⁹-Rest sind;
 R¹² jeweils unabhängig ein Wasserstoff-, C₁-C₈-Alkyl-, Halo-, C₁-C₄-Haloalkyl- mit 1-3 Haloresten, R³¹-Z³¹- oder R³¹-Z³¹-C₁-C₄-Alkylrest ist; vorausgesetzt, daß die kombinierte Gesamtzahl von Aryl- und Heteroarylresten in R¹¹, R¹² und R¹³ 0-1 ist;
 R¹⁸ jeweils unabhängig ein Wasserstoff-, C₁-C₄-Alkyl-, Trifluormethyl-, Aryl-, Heteroaryl-, Aryl-C₁-C₂-alkyl- oder Heteroaryl-C₁-C₂-alkylrest ist; wobei die Aryl- und Heteroarylreste fakultativ mit 1-2 Hydroxy-, C₁-C₄-Alkoxy-, C₁-C₄-Alkylthiol-, Amino-, C₁-C₄-Alkylamino-, Di(C₁-C₄-alkyl)amino-, Acetylamino-, Cyano-, Halo-, Azido-, C₁-C₄-Alkyl-, Trifluormethyl- oder Trifluormethoxyresten substituiert sind;

R¹⁹ jeweils unabhängig ein Wasserstoff-, C₁-C₄-Alkyl-, Trifluormethyl-, Aryl-, Heteroaryl-, Aryl-C₁-C₄-alkyl- oder Heteroaryl-C₁-C₄-alkylrest ist; wobei die Aryl- und Heteroarylreste fakultativ mit 1-2 Hydroxy-, Methoxy-, Ethoxy-, Amino-, Methylamino-, Dimethylamino-, Acetylamino-, Cyano-, Halo-, Methyl-, Ethyl-, Trifluormethyl- oder Trifluor-

methoxyresten substituiert sind;
 5 R²¹ jeweils unabhängig ein Wasserstoff- oder Methylrest ist;
 entweder

A)

R²² ein C₁-C₄-Alkyl-, Halo-, Trifluormethyl-, Cyano-, Azido-, Nitro-, Amidino-, R¹⁸-Z¹⁸- oder R¹⁸-Z¹⁸-C₁-C₄-Al-

10 kylrest ist;
 R²³ ein Wasserstoff-, C₁-C₄-Alkyl-, Halo-, Trifluormethyl-, Cyano-, Azido-, Nitro-, Amidino-, R¹⁸-Z¹⁸- oder R¹⁸-Z¹⁸-C₁-C₄-Alkylrest ist;

R²⁴ ein Wasserstoff-, C₁-C₄-Alkyl-, Halo-, Trifluormethyl-, Cyano-, Azido-, Nitro-, Amidino-, R¹⁸-Z¹⁸- oder R¹⁸-Z¹⁸-C₁-C₄-Alkylrest ist;

15 R²⁵ ein Wasserstoff-, C₁-C₄-Alkyl-, Halo-, Trifluormethyl-, Cyano-, Azido-, Nitro-, Amidino-, R¹⁸-Z¹⁸- oder R¹⁸-Z¹⁸-C₁-C₄-Alkylrest ist;

R²⁶ ein Wasserstoff-, C₁-C₄-Alkyl-, Halo-, Trifluormethyl-, Cyano-, Azido-, Nitro-, Amidino-, R¹⁸-Z¹⁸- oder R¹⁸-Z¹⁸-C₁-C₄-Alkylrest ist;

oder

B)

R²² ein Wasserstoff-, C₁-C₄-Alkyl-, Halo-, Trifluormethyl-, Cyano-, Azido-, Nitro-, Amidino-, R¹⁸-Z¹⁸- oder R¹⁸-Z¹⁸-C₁-C₄-Alkylrest ist;

R²³ ein C₁-C₄-Alkyl-, Halo-, Trifluormethyl-, Cyano-, Azido-, Nitro-, Amidino-, R¹⁸-Z¹⁸- oder R¹⁸-Z¹⁸-C₁-C₄-Al-

25 kylrest ist;
 R²⁴ ein Wasserstoff-, C₁-C₄-Alkyl-, Halo-, Trifluormethyl-, Cyano-, Azido-, Nitro-, Amidino-, R¹⁸-Z¹⁸- oder R¹⁸-Z¹⁸-C₁-C₄-Alkylrest ist;

R²⁵ ein Wasserstoff-, C₁-C₄-Alkyl-, Halo-, Trifluormethyl-, Cyano-, Azido-, Nitro-, Amidino-, R¹⁸-Z¹⁸- oder R¹⁸-Z¹⁸-C₁-C₄-Alkylrest ist;

R²⁶ ein Wasserstoff-, C₁-C₄-Alkyl-, Halo-, Trifluormethyl-, Cyano-, Azido-, Nitro-, Amidino-, R¹⁸-Z¹⁸- oder R¹⁸-Z¹⁸-C₁-C₄-Alkylrest ist;

oder

C)

R²² ein Wasserstoff-, C₁-C₄-Alkyl-, Halo-, Trifluormethyl-, Cyano-, Azido-, Nitro-, Amidino-, R¹⁸-Z¹⁸- oder R¹⁸-Z¹⁸-C₁-C₄-Alkylrest ist;

35 R²³ ein Wasserstoff-, C₁-C₄-Alkyl-, Halo-, Trifluormethyl-, Cyano-, Azido-, Nitro-, Amidino-, R¹⁸-Z¹⁸- oder R¹⁸-Z¹⁸-C₁-C₄-Alkylrest ist;

R²⁴ ein C₁-C₄-Alkyl-, Halo-, Trifluormethyl-, Cyano-, Azido-, Nitro-, Amidino-, R¹⁸-Z¹⁸- oder R¹⁸-Z¹⁸-C₁-C₄-Al-

40 kylrest ist;
 R²⁵ ein Wasserstoff-, C₁-C₄-Alkyl-, Halo-, Trifluormethyl-, Cyano-, Azido-, Nitro-, Amidino-, R¹⁸-Z¹⁸- oder R¹⁸-Z¹⁸-C₁-C₄-Alkylrest ist;

R²⁶ ein Wasserstoff-, C₁-C₄-Alkyl-, Halo-, Trifluormethyl-, Cyano-, Azido-, Nitro-, Amidino-, R¹⁸-Z¹⁸- oder R¹⁸-Z¹⁸-C₁-C₄-Alkylrest ist;

oder

D)

45 R²² ein Wasserstoff-, C₁-C₄-Alkyl-, Halo-, Trifluormethyl-, Cyano-, Azido-, Nitro-, Amidino-, R¹⁸-Z¹⁸- oder R¹⁸-Z¹⁸-C₁-C₄-Alkylrest ist ;

R²³ ein Wasserstoff-, C₁-C₄-Alkyl-, Halo-, Trifluormethyl-, Cyano-, Azido-, Nitro-, Amidino-, R¹⁸-Z¹⁸- oder R¹⁸-Z¹⁸-C₁-C₄-Alkylrest ist;

50 R²⁴ ein Wasserstoff-, C₁-C₄-Alkyl-, Halo-, Trifluormethyl-, Cyano-, Azido-, Nitro-, Amidino-, R¹⁸-Z¹⁸- oder R¹⁸-Z¹⁸-C₁-C₄-Alkylrest ist;

R²⁵ ein C₁-C₄-Alkyl-, Halo-, Trifluormethyl-, Cyano-, Azido-, Nitro-, Amidino-, R¹⁸-Z¹⁸- oder R¹⁸-Z¹⁸-C₁-C₄-Al-

kylrest ist;
 R²⁶ ein Wasserstoff-, C₁-C₄-Alkyl-, Halo-, Trifluormethyl-, Cyano-, Azido-, Nitro-, Amidino-, R¹⁸-Z¹⁸- oder R¹⁸-Z¹⁸-C₁-C₄-Alkylrest ist;

oder

E)

R²² ein Wasserstoff-, C₁-C₄-Alkyl-, Halo-, Trifluormethyl-, Cyano-, Azido-, Nitro-, Amidino-, R¹⁸-Z¹⁸- oder R¹⁸-Z¹⁸-C₁-C₄-Alkylrest ist;

R²³ ein Wasserstoff-, C₁-C₄-Alkyl-, Halo-, Trifluormethyl-, Cyano-, Azido-, Nitro-, Amidino-, R¹⁸-Z¹⁸- oder R¹⁸-Z¹⁸-C₁-C₄-Alkylrest ist;

R²⁴ ein Wasserstoff-, C₁-C₄-Alkyl-, Halo-, Trifluormethyl-, Cyano-, Azido-, Nitro-, Amidino-, R¹⁸-Z¹⁸- oder R¹⁸-Z¹⁸-C₁-C₄-Alkylrest ist;

R²⁵ ein Wasserstoff-, C₁-C₄-Alkyl-, Halo-, Trifluormethyl-, Cyano-, Azido-, Nitro-, Amidino-, R¹⁸-Z¹⁸ oder R¹⁸-Z¹⁸-C₁-C₄-Alkylrest ist;

R²⁶ ein C₁-C₄-Alkyl-, Halo-, Trifluormethyl-, Cyano-, Azido-, Nitro-, Amidino-, R¹⁸-Z¹⁸- oder R¹⁸-Z¹⁸-C₁-C₄-Alkylrest ist;

vorausgesetzt, daß für jedes von A), B), C), D) und E) wenigstens eines von R²², R²³, R²⁴, R²⁵ und R²⁶ Wasserstoff ist; und vorausgesetzt, daß die kombinierte Gesamtzahl von Aryl- und Heteroarylresten in R²², R²³, R²⁴, R²⁵ und R²⁶ 0-1 ist;

R³¹ jeweils unabhängig ein Wasserstoff-, C₁-C₄-Alkyl-, Trifluormethyl-, Aryl-, Heteroaryl, Aryl-C₁-C₄-alkyl- oder Heteroaryl-C₁-C₄-alkylrest ist; wobei die Aryl- und Heteroarylreste fakultativ mit 1-2 Hydroxy-, Methoxy-, Ethoxy-, Amino-, Methylamino-, Dimethylamino-, Acetylamino-, Cyano-, Halo-, Methyl-, Ethyl-, Trifluormethyl- oder Trifluor-methoxyresten substituiert sind;

U C-R¹³ oder N ist;

V und W jeweils unabhängig C-R¹² oder N sind;


R¹⁸ jeweils unabhängig -O-, -S-, -S(O)₂-, -CO₂-, -NR²¹- C(O)-, -C(O)-NR²¹-, -NR²¹-S(O)₂- oder -S(O)₂-NR²¹- ist;

R¹⁹ jeweils unabhängig -O-, -S(O)₂-, -CO₂-, -C(O)-, -NR²¹-C(O)-, -C(O)-NR²¹-, -NR²¹-S(O)₂- oder -S(O)₂-NR²¹- ist;

R³¹ jeweils unabhängig -O-, -NR²¹-, -NR²¹-C(O)-, -C(O)-NR²¹-, -NR²¹-S(O)₂- oder -S(O)₂-NR²¹- ist; und

wobei Aryl ein Phenyl-, Biphenyl- oder Naphthylrest ist; und Heteroaryl ein monocyclisches aromatisches hetero-cyclisches Ringsystem mit 5-6 Ringgliedern pro Ring ist, wobei 1-3 Ringglieder Sauerstoff-, Schwefel- oder Stickstoff-Heteroatome sind.

2. Verbindung der Formel




oder ein pharmazeutisch annehmbares Salz davon, wobei

X NR² ist;

Y -NR⁴-C(O)-R³ ist;


R¹ ein Rest der Formel



ist;

R² ein Wasserstoff- oder Methylrest ist;

R³ ein Rest der Formel



ist;

R⁴ ein Wasserstoff-, Methyl- oder Ethylrest ist;

R⁵, R⁶ und R⁷ jeweils unabhängig ein Wasserstoffrest sind;

R¹¹ und R¹³ jeweils unabhängig ein Wasserstoff-, C₁-C₄-Alkyl-, Halo-, Trifluormethyl-, Cyano-, Azido-, Nitro-, Amidino- oder R¹⁹-Z¹⁹-Rest sind;

R¹² jeweils unabhängig ein Wasserstoff-, C₁-C₆-Alkyl-, Halo-, C₁-C₄-Haloalkyl- mit 1-3 Haloresten, R³¹-Z³¹- oder R³¹-Z³¹-C₁-C₄-Alkylrest ist; vorausgesetzt, daß die kombinierte Gesamtzahl von Aryl- und Heteroarylresten in R¹¹, R¹² und R¹³ 0-1 ist;

R¹⁸ jeweils unabhängig ein Wasserstoff-, C₁-C₄-Alkyl-, Trifluormethyl-, Aryl-, Heteroaryl-, Aryl-C₁-C₂-alkyl- oder Heteroaryl-C₁-C₂-alkylrest ist; wobei die Aryl- und Heteroarylreste fakultativ mit 1-2 Hydroxy-, C₁-C₄-Alkoxy-, C₁-C₄-Alkylthiol-, Amino-, C₁-C₄-Alkylamino-, Di(C₁-C₄-alkyl)amino-, Acetylamino-, Cyano-, Halo-, Azido-, C₁-C₄-Alkyl-, Trifluormethyl- oder Trifluormethoxyresten substituiert sind;

R¹⁹ jeweils unabhängig ein Wasserstoff-, C₁-C₄-Alkyl-, Trifluormethyl-, Aryl-, Heteroaryl-, Aryl-C₁-C₄-alkyl- oder Heteroaryl-C₁-C₄-alkylrest ist; wobei die Aryl- und Heteroarylreste fakultativ mit 1-2 Hydroxy-, Methoxy-, Ethoxy-, Amino-, Methylamino-, Dimethylamino-, Acetylamino-, Cyano-, Halo-, Methyl-, Ethyl-, Trifluormethyl- oder Trifluormethoxyresten substituiert sind;

R²¹ jeweils unabhängig ein Wasserstoff- oder Methylrest ist;

R²², R²³, R²⁴, R²⁵ und R²⁶ jeweils unabhängig ein Wasserstoff-, C₁-C₄-Alkyl-, Halo-, Trifluormethyl-, Cyano-, Azido-, Nitro-, Amidino-, R¹⁸-Z¹⁸- oder R¹⁸-Z¹⁸-C₁-C₄-Alkylrest sind; vorausgesetzt, daß wenigstens eines von R²¹, R²², R²³, R²⁴ und R²⁵ Wasserstoff ist; und vorausgesetzt, daß die kombinierte Gesamtzahl von Aryl- und Heteroarylresten in R²², R²³, R²⁴, R²⁵ und R²⁶ 0-1 ist;

R³¹ jeweils unabhängig ein Wasserstoff-, C₁-C₄-Alkyl-, Trifluormethyl-, Aryl-, Heteroaryl-, Aryl-C₁-C₄-alkyl- oder Heteroaryl-C₁-C₄-alkylrest ist; wobei die Aryl- und Heteroarylreste fakultativ mit 1-2 Hydroxy-, Methoxy-, Ethoxy-, Amino-, Methylamino-, Dimethylamino-, Acetylamino-, Cyano-, Halo-, Methyl-, Ethyl-, Trifluormethyl- oder Trifluormethoxyresten substituiert sind;

U C-R¹³ oder N ist;

V N ist;

W C-R¹² oder N ist;


R¹⁸ jeweils unabhängig -O-, -S-, -S(O)₂-, -CO₂-, -NR²¹-, -NR²¹-C(O)-, -C(O)-NR²¹-, NR²¹-S(O)₂- oder -S(O)₂-NR²¹- ist;

R¹⁹ jeweils unabhängig -O-, -S(O)₂-, -CO₂-, -C(O)-, -NR²¹-C(O)-, -C(O)-NR²¹-, -NR²¹-S(O)₂- oder -S(O)₂-NR²¹- ist;

R³¹ jeweils unabhängig -O-, -NR²¹-, -NR²¹-C(O)-, -C(O)-NR²¹-, -NR²¹-S(O)₂- oder -S(O)₂-NR²¹- ist; und

wobei Aryl ein Phenyl-, Biphenyl- oder Naphthylrest ist; und Heteroaryl ein monocyclisches aromatisches heterocyclisches Ringsystem mit 5-6 Ringgliedern pro Ring ist, wobei 1-3 Ringglieder Sauerstoff-, Schwefel- oder Stickstoff Heteroatome sind.

3. Verbindung der Formel




oder ein pharmazeutisch annehmbares Salz davon, wobei

X NR² ist;

Y -NR⁴-C(O)-R³ ist;


R¹ ein Rest der Formel



ist;

R² ein Wasserstoff- oder Methylrest ist;

R³ ein Rest der Formel



ist,

R⁴ ein Wasserstoff-, Methyl- oder Ethylrest ist;

R⁵, R⁶ und R⁷ jeweils unabhängig ein Wasserstoffrest sind;

R¹¹ und R¹³ jeweils unabhängig ein Wasserstoff-, C₁-C₄-Alkyl-, Halo-, Trifluormethyl-, Cyano-, Azido-, Nitro-, Amidino- oder R¹⁹-Z¹⁹-Rest sind;

R¹² jeweils unabhängig ein Wasserstoff-, C₁-C₆-Alkyl-, Halo-, C₁-C₄-Haloalkyl- mit 1-3 Haloresten, R³¹-Z³¹- oder R³¹-Z³¹-C₁-C₄-Alkylrest ist; vorausgesetzt, daß die kombinierte Gesamtzahl von Aryl- und Heteroarylresten in R¹¹, R¹² und R¹³ 0-1 ist;

R¹⁸ jeweils unabhängig ein Wasserstoff-, C₁-C₄-Alkyl-, Trifluormethyl-, Aryl-, Heteroaryl-, Aryl-C₁-C₂-alkyl- oder Heteroaryl-C₁-C₂-alkylrest ist; wobei die Aryl- und Heteroarylreste fakultativ mit 1-2 Hydroxy-, C₁-C₄-Alkoxy-, C₁-C₄-Alkylthiol-, Amino-, C₁-C₄-Alkylamino-, Di(C₁-C₄-alkyl)amino-, Acetylamino-, Cyano-, Halo-, Azido-, C₁-C₄-Alkyl-, Trifluormethyl- oder Trifluormethoxyresten substituiert sind;

R¹⁹ jeweils unabhängig ein Wasserstoff-, C₁-C₄-Alkyl-, Trifluormethyl-, Aryl-, Heteroaryl-, Aryl-C₁-C₄-alkyl- oder Heteroaryl-C₁-C₄-alkylrest ist; wobei die Aryl- und Heteroarylreste fakultativ mit 1-2 Hydroxy-, Methoxy-, Ethoxy-, Amino-, Methylamino-, Dimethylamino-, Acetylamino-, Cyano-, Halo-, Methyl-, Ethyl-, Trifluornethyl- oder Trifluormethoxyresten substituiert sind;

R²¹ jeweils unabhängig ein Wasserstoff- oder Methylrest ist;

R¹², R²³, R²⁴, R²⁵ und R²⁶ jeweils unabhängig ein Wasserstoff-, C₁-C₄-Alkyl-, Halo-, Trifluormethyl-, Cyano-, Azido-, Nitro-, Amidino-, R¹⁸-Z¹⁸- oder R¹⁸-Z¹⁸-C₁-C₄-Alkylrest sind; vorausgesetzt, daß wenigstens eines von R²¹, R²², R²³, R²⁴ und R²⁵ Wasserstoff ist; und vorausgesetzt, daß die kombinierte Gesamtzahl von Aryl- und Heteroarylresten in R²², R²³, R²⁴, R²⁵ und R²⁶ 0-1 ist;

R³¹ jeweils unabhängig ein Wasserstoff-, C₁-C₄-Alkyl-, Trifluormethyl-, Aryl-, Heteroaryl-, Aryl-C₁-C₄-alkyl- oder Heteroaryl-C₁-C₄-alkylrest ist; wobei die Aryl- und Heteroarylreste fakultativ mit 1-2 Hydroxy-, Methoxy-, Ethoxy-, Amino-, Methylamino-, Dimethylamino-, Acetylamino-, Cyano-, Halo-, Methyl-, Ethyl-, Trifluormethyl- oder Trifluormethoxyresten substituiert sind,

UN ist;

V C-R¹² oder N ist;

W N ist;

R¹⁸ jeweils unabhängig -O-, -S-, -S(O)₂-, -CO₂-, -NR²¹-, -NR²¹-C(O)-, -C(O)-NR²¹-, -NR²¹-S(O)₂- oder -S(O)₂-NR²¹- ist;

R¹⁹ jeweils unabhängig -O-, -S(O)₂-, -CO₂-, -C(O)-, -NR²¹-C(O)-, -C(O)-NR²¹-, -NR²¹-S(O)₂- oder -S(O)₂-NR²¹- ist ;

R³¹ jeweils unabhängig -O-, -NR²¹-, -NR²¹-C(O)-, -C(O)-NR²¹-, -NR²¹-S(O)₂- oder -S(O)₂-NR²¹- ist; und wobei Aryl ein Phenyl-, Biphenyl- oder Naphthylrest ist; und Heteroaryl ein monocyclisches aromatisches heterocyclisches Ringsystem mit 5-6 Ringgliedern pro Ring ist, wobei 1-3 Ringglieder Sauerstoff-, Schwefel- oder Stickstoff-Heteroatome sind.

4. Verbindung, ausgewählt aus:


2-Cyclohexyloxy-5-(2-chlorphenylcarbonylamino)pyridin;
 2-Cyclohexyloxy-5-(2-methylphenylcarbonylamino)pyridin;
 2-Cyclohexyloxy-5-(2,6-dichlorphenylcarbonylamino)pyridin;
 2-Cyclohexyloxy-5-(2,6-dimethylphenylcarbonylamino)pyridin ;
 2-(2,4-Dimethylphenoxy)-5-(2-chlorphenylcarbonylamino)pyridin ;
 2-(2,4-Dimethylphenoxy)-5-(2,6-dichlorphenylcarbonylamino)pyridin ;
 2-(2,4-Dimethylphenoxy)-5-(2-methylphenylcarbonylamino)pyridin ;
 2-(2,6-Dimethyl-4-chlorphenoxy)-5-(2,6-dimethylphenylcarbonylamino)pyridin ;
 2-(2-Methyl-4-fluorphenoxy)-5-(2-methylphenylcarbonylamino)pyridin ;
 2-(2-Methyl-4-chlorphenoxy)-5-(2-chlorphenylcarbonylamino)pyridin;
 2-(2-Methyl-4-chlorphenoxy)-5-(2-methylphenylcarbonylamino)pyridin;
 2-(2-Methylphenoxy)-5-(2-chlorphenylcarbonylamino)pyridin;
 2-(2-Methylphenoxy)-5-(2,6-dichlorphenylcarbonylamino)pyridin;
 2-(2-Methylphenoxy)-5-(2-methylphenylcarbonylamino)pyridin;
 2-(2-Methyl-4-chlorphenoxy)-5-(2,6-dichlorphenylamino)pyridin;
 2-(2-Methyl-4-chlorphenoxy)-5-(2,6-dimethylphenylcarbonylamino)pyridin;
 2-(4-Chlorphenoxy)-5-(2,6-dimethylphenylcarbonylamino)pyridin;
 2-(2-Methyl-4-fluorphenoxy)-5-(2,6-dichlorphenylcarbonylamino)pyridin;
 2-(2-Methyl-4-fluorphenoxy)-5-(2,6-dimethylphenylcarbonylamino)pyridin;
 2-(2-Methylphenoxy)-5-(2,6-dimethylphenylcarbonylamino)pyridin;
 2-(2-Methyl-4-fluorphenoxy)-5-(2-fluorphenylcarbonylamino)pyridin;
 2-(2,4-Dimethylphenoxy)-5-(2,6-dimethylphenylcarbonylamino)pyridin;
 2-(1-Naphthyloxy)-5-(2-methylphenylcarbonylamino)pyridin;
 2-(1-Naphthyloxy)-5-(2,6-dichlorphenylcarbonylamino)pyridin;
 2-(1-Naphthyloxy)-5-(2,6-dimethylphenylcarbonylamino)pyridin;
 2-(2-Methyl-3-pyridyloxy)-5-(2,6-dichlorphenylcarbonylamino)pyridin;
 2-(2-Methyl-4-chlorphenoxy)-5-(3,5-dimethyl-4-isoxazolyl)carbonylamino)pyridin;
 2-(2-Methyl-4-chlorphenylthiol)-5-(2-methylphenylcarbonylamino)pyridin;
 2-(2-Methyl-4-chlorphenylthiol)-5-(2,6-dimethylphenylcarbonylamino)pyridin;
 2-Cyclohexylamino-5-(2,6-dichlorphenylcarbonylamino)pyridin;
 2-Cyclohexylomino-5-(2,6-dimethylphenylcarbonylamino)pyridin;
 2-(2-Methylcyclohexylamino)-5-(2,6-dichlorphenylcarbonylamino)pyridin ;
 2-(2-Methylcyclohexylamino)-5-(2-methylphenylcarbonylamino)pyridin ;
 2-(2,4-Dimethylphenylamino)-5-(2-fluorphenylcarbonylamino)pyridin ;
 2-(2,4-Dimethylphenylamino)-5-(2-chlorphenylcarbonylamino)pyridin ;
 2-(2,4-Dimethylphenylamino)-5-(2,6-dichlorphenylcarbonylamino)pyridin,
 2-(2-Methyl-4-chlorphenylamino)-5-(2,6-dichlorphenylcarbonylamino)pyridin ;
 2-(2,4-Dimethylphenylamino)-5-(2-methylphenylcarbonylamino)pyridin ;
 2-(2-Methylphenylamino)-5-(2-methylphenylcarbonylamino)pyridin ;
 2-(2-Methylphenylamino)-5-(2,6-dichlorphenylcarbonylamino)pyridin ;
 2-(2-Methylphenylamino)-5-(2,6-dimethylphenylcarbonylamino)pyridin;
 2-(2,4-Dimethylphenylamino)-5-(2,6-dimethylphenylcarbonylamino)pyridin;
 2-(2-Methyl-4-chlorphenylamino)-5-(2-methylphenylcarbonylamino)pyridin;
 2-(2-Methyl-4-chlorphenylamino)-5-(2,6-dimethylphenylcarbonylamino)pyridin; und
 2-(2-Methyl-4-chlorphenylamino)-5-(2-methylphenylaminocarbonyl)pyridin

oder ein pharmazeutisch annehmbares Salz davon.

5. Pharmazeutische Zusammensetzung, die eine Verbindung nach einem vorangehenden Anspruch und einen pharmazeutisch annehmbaren Trägerstoff umfaßt.
6. Verbindung nach einem der Ansprüche 1 bis 4 oder pharmazeutische Zusammensetzung nach Anspruch 5 zur Verwendung in der Prophylaxe oder Behandlung von Erkrankungen.
7. Verbindung oder Zusammensetzung nach Anspruch 6 zur Verwendung in der Prophylaxe oder Behandlung von Entzündung.
8. Verbindung oder Zusammensetzung nach Anspruch 6 zur Verwendung in der Prophylaxe oder Behandlung von Krebs.
9. Verbindung oder Zusammensetzung nach Anspruch 6 zur Verwendung in der Prophylaxe oder Behandlung von rheumatoider Arthritis, Paget-Krankheit, Osteoporose, multiplem Myelom, Uveitis, akuter oder chronischer myelogener Leukämie, Pancreas-β-Zellzerstörung, Osteoarthritis, rheumatoider Spondylitis, Gichtarthritis, entzündlicher Darmerkrankung, adultem respiratorischen Distress-Syndrom (ARDS), Psoriasis, Crohn-Krankheit, allergischer Rhinitis, Colitis ulcerosa, Anaphylaxie, Kontaktdermatitis, Asthma, Muskeldegeneration, Kachexie, Reiter-Syndrom, Diabetes Typ I, Diabetes Typ II, Knochenresorptionserkrankungen, Graft-versus-Host-Reaktion, Alzheimer-Krankheit, Schlaganfall, Myokardinfarkt, Ischämieperfusionsschädigung, Atherosklerose, Hirntrauma, multipler Sklerose, Zerebralmalaria, Sepsis, septischem Schock, toxischem Schocksyndrom, Fieber, Myalgien aufgrund von HIV-1, HIV-2, HIV-3, Cytomegalovirus (CMV), Influenza, Adenovirus, den Herpesviren oder Herpes-zoster-Infektion in einem Säuger, welche die Verabreichung einer wirksamen Menge einer Verbindung von Anspruch 1 umfaßt.
10. Verbindung oder Zusammensetzung nach Anspruch 6 zur Verwendung in der Prophylaxe oder Behandlung von Schmerz.
11. Verwendung einer Verbindung nach einem der Ansprüche 1 bis 4 oder einer pharmazeutischen Zusammensetzung nach Anspruch 5 zur Herstellung eines Arzneimittels zur Prophylaxe oder Behandlung von Entzündung.
12. Verwendung einer Verbindung nach einem der Ansprüche 1 bis 4 oder einer pharmazeutischen Zusammensetzung nach Anspruch 5 zur Herstellung eines Arzneimittels zur Prophylaxe oder Behandlung von Krebs.
13. Verwendung einer Verbindung nach einem der Ansprüche 1 bis 4 oder einer pharmazeutischen Zusammensetzung nach Anspruch 5 zur Prophylaxe oder Behandlung von Arthritis, Paget-Krankheit, Osteoporose, multiplem Myelom, Uveitis, akuter oder chronischer myelogener Leukämie, Pancreas-β-Zellzerstörung, Osteoarthritis, rheumatoider Spondylitis, Gichtarthritis, entzündlicher Darmerkrankung, adultem respiratorischen Distress-Syndrom (ARDS), Psoriasis, Crohn-Krankheit, allergischer Rhinitis, Colitis ulcerosa, Anaphylaxie, Kontaktdermatitis, Asthma, Muskeldegeneration, Kachexie, Reiter-Syndrom, Diabetes Typ I, Diabetes Typ II, Knochenresorptionserkrankungen, Graft-versus-Host-Reaktion, Alzheimer-Krankheit, Schlaganfall, Myokardinfarkt, Ischämieperfusionsschädigung, Atherosklerose, Hirntrauma, multipler Sklerose, Zerebralmalaria, Sepsis, septischem Schock, toxischem Schocksyndrom, Fieber, Myalgien aufgrund von HIV-1, HIV-2, HIV-3, Cytomegalovirus (CMV), Influenza, Adenovirus, den Herpesviren oder Herpes-zoster-Infektion in einem Säuger, welche die Verabreichung einer wirksamen Menge einer Verbindung von Anspruch 1 umfaßt.
14. Verwendung einer Verbindung nach einem der Ansprüche 1 bis 4 oder einer pharmazeutischen Zusammensetzung nach Anspruch 5 zur Herstellung eines Arzneimittels zur Prophylaxe oder Behandlung von Schmerz.

Revendications

1. Composé de formule




ou un sel pharmaceutiquement acceptable de celui-ci, dans lequel

X est NR²;


Y est -NR⁴-C(O)-R³;

R¹ est un radical de formule



R² est un radical hydrogène ou méthyle ;

R³ est un radical de formule



R⁴ est un radical d'hydrogène, un radical méthyle ou éthyle;

R⁵, R⁶ et R⁷ sont chacun indépendamment un radical hydrogène ;

R¹¹ et R¹³ sont chacun indépendamment un radical d'hydrogène, C₁-C₄alkyle, halo, trifluorométhyle, cyano, azido, nitro, amidino ou R¹⁹-Z¹⁹;

chaque R¹² est indépendamment un radical d'hydrogène, C₁-C₆alkyle, halo, C₁-C₄haloalkyle de 1 à 3 radicaux halo, R³¹-Z³¹ ou R³¹-Z³¹-C₁-C₄alkyle; à condition que le nombre total combiné de radicaux aryle et hétéroaryle dans R¹¹, R¹² et R¹³ soit de 0 ou 1;

chaque R¹⁸ est indépendamment un radical hydrogène, C₁-C₄alkyle, trifluorométhyle, aryle, hétéroaryle, aryl-C₁-C₂alkyle ou hétéroaryl-C₁-C₂alkyle ; dans lequel les radicaux aryle et hétéroaryle sont éventuellement substitués par 1 ou 2 radicaux d'hydroxy, C₁-C₄alkoxy, C₁-C₄alkylthiol, amino, C₁-C₄alkylamino, di(C₁-C₆alkyl)amino, acétylamino, cyano, halo, azido, C₁-C₄alkyle, trifluorométhyle ou trifluorométhoxy ;

chaque R¹⁹ est indépendamment un radical hydrogène, C₁-C₄alkyle, trifluorométhyle, aryle, hétéroaryle, aryl-C₁-C₄alkyle ou hétéroaryl-C₁-C₄alkyle; dans lequel les radicaux aryle et hétéroaryle sont éventuellement substitués par 1 ou 2 radicaux d'hydroxy, méthoxy, éthoxy, amino, méthylamino, diméthylamino, acétylamino, cyano, halo, méthyle, éthyle, trifluorométhyle ou trifluorométhoxy;

chaque R²¹ est indépendamment un radical hydrogène ou méthyle;

R^{18} - Z^{18} - C_1 - C_4 alkyle;

R^{26} est un radical de C_1 - C_4 alkyle, halo, trifluorométhyle, cyano, azido, nitro, amidino, R^{18} - Z^{18} - ou R^{18} - Z^{18} - C_1 - C_4 alkyle;

à condition que pour chacun de A), B), C), D) et E) au moins un de R^{22} , R^{23} , R^{24} , R^{25} et R^{26} soit un hydrogène ;
et à condition que le nombre total combiné de radicaux aryle et hétéroaryle dans R^{22} , R^{23} , R^{24} , R^{25} et R^{26} soit de 0 ou 1 ;

chaque R^{31} est indépendamment un radical hydrogène, C_1 - C_4 alkyle, trifluorométhyle, aryle, hétéroaryle, aryl- C_1 - C_4 alkyle ou hétéroaryl- C_1 - C_4 alkyle ; dans lequel les radicaux aryle et hétéroaryle sont éventuellement substitués par 1 ou 2 radicaux d'hydroxy, méthoxy, éthoxy, amino, méthylamino, diméthylamino, acétylamino, cyano, halo, méthyle, éthyle, trifluorométhyle ou trifluorométhoxy;

U est C- R^{13} ou N ;


V et W sont chacun indépendamment C- R^{12} ou N;

chaque Z^{18} est indépendamment -O-, -S-, -S(O)₂-, -CO₂-, -NR²¹-, -NR²¹-C(O)-, -C(O)-NR²¹-, -NR²¹-S(O)₂- ou -S(O)₂-NR²¹- ;

chaque Z^{19} est indépendamment -O-, -S(O)₂-, -CO₂-, -C(O)-, -NR²¹-C(O)-, -C(O)-NR²¹-, -NR²¹-S(O)₂- ou -S(O)₂-NR²¹- ;

chaque Z^{31} est indépendamment -O-, -NR²¹-, -NR²¹-C(O)-, -C(O)-NR²¹-, -NR²¹-S(O)₂- ou -S(O)₂-NR²¹- ; et dans lequel l'aryle est un radical phényle, biphenyle ou naphthyle et l'hétéroaryle est un noyau hétérocyclique aromatique monocyclique ayant 5 ou 6 chaînons par cycle, dans lequel 1 à 3 chaînons sont des hétéroatomes d'oxygène, de soufre ou d'azote.

2. Composé de formule




ou un sel pharmaceutiquement acceptable de celui-ci, dans lequel

X est NR²;


Y est -NR⁴-C(O)-R³;

R¹ est un radical de formule



R² est un radical hydrogène ou méthyle;

R³ est un radical de formule



R⁴ est un radical d'hydrogène, un radical méthyle ou éthyle ;

R⁶, R⁶ et R⁷ sont chacun indépendamment un radical hydrogène ;

R¹¹ et R¹³ sont chacun indépendamment un radical d'hydrogène, C₁-C₄alkyle, halo, trifluorométhyle, cyano, azido, nitro, amidino ou R¹⁹-Z¹⁹ ;

chaque R¹² est indépendamment un radical d'hydrogène, C₁-C₆alkyle, halo, C₁-C₄haloalkyle de 1 à 3 radicaux halo, R³¹-Z³¹ ou R³¹-Z³¹-C₁-C₄alkyle ; à condition que le nombre total combiné de radicaux aryle et hétéroaryle dans R¹¹, R¹² et R¹³ soit de 0 ou 1 ;

chaque R¹⁸ est indépendamment un radical hydrogène, C₁-C₄alkyle, trifluorométhyle, aryle, hétéroaryle, aryl-C₁-C₂alkyle ou hétéroaryl-C₁-C₂alkyle dans lequel les radicaux aryle et hétéroaryle sont éventuellement substitués par 1 ou 2 radicaux d'hydroxy, C₁-C₄alkoxy, C₁-C₄alkylthiol, amino, C₁-C₄alkylamino, di(C₁-C₄alkyl)amino, acétylamino, cyano, halo, azido, C₁-C₄alkyle, trifluorométhyle ou trifluorométhoxy ;

chaque R¹⁹ est indépendamment un radical hydrogène, C₁-C₄alkyle, trifluorométhyle, aryle, hétéroaryle, aryl-C₁-C₄alkyle ou hétéroaryl-C₁-C₄alkyle ; dans lequel les radicaux aryle et hétéroaryle sont éventuellement substitués par 1 ou 2 radicaux d'hydroxy, méthoxy, éthoxy, amino, méthylamino, diméthylamino, acétylamino, cyano, halo, méthyle, éthyle, trifluorométhyle ou trifluorométhoxy ;

chaque R²¹ est indépendamment un radical hydrogène ou méthyle ;

R²², R²³, R²⁴, R²⁵ et R²⁶ sont chacun indépendamment un radical d'hydrogène, C₁-C₄alkyle, halo, trifluorométhyle, cyano, azido, nitro, amidino, R¹⁸-Z¹⁸ ou R¹⁸-Z¹⁸-C₁-C₄alkyle ; à condition qu'au moins un de R²¹, R²², R²³, R²⁴ et R²⁵ soit un hydrogène ; et à condition que le nombre total combiné de radicaux aryle et hétéroaryle dans R²², R²³, R²⁴, R²⁵ et R²⁶ soit

de 0 ou 1 ;

chaque R³¹ est indépendamment un radical hydrogène, C₁-C₄alkyle, trifluorométhyle, aryle, hétéroaryle, aryl-C₁-C₄alkyle ou hétéroaryl-C₁-C₄alkyle ; dans lequel les radicaux aryle et hétéroaryle sont éventuellement substitués par 1 ou 2 radicaux d'hydroxy, méthoxy, éthoxy, amino, méthylamino, diméthylamino, acétylamino, cyano, halo, méthyle, éthyle, trifluorométhyle ou trifluorométhoxy ;

U est C-R¹³ ou N ;

V est N ;


W est C-R¹² ou N ;

chaque Z¹⁸ est indépendamment -O-, -S-, -S(O)₂-, -CO₂-, -NR²¹-, -NR²¹-C(O)-, -C(O)-NR²¹-, -NR²¹-S(O)₂- ou -S(O)₂-NR²¹ ;

chaque Z¹⁹ est indépendamment -O-, -S(O)₂-, -CO₂-, -C(O)-, -NR²¹-C(O)-, -C(O)-NR²¹-, -NR²¹-S(O)₂- ou -S(O)₂-NR²¹ ;

chaque Z³¹ est indépendamment -O-, -NR²¹-, -NR²¹-C(O)-, -C(O)-NR²¹-, -NR²¹-S(O)₂- ou -S(O)₂-NR²¹ ; et dans lequel l'aryle est un radical phényle, biphenyle ou naphthyle ; et l'hétéroaryle est un noyau hétérocyclique aromatique monocyclique ayant 5 ou 6 chaînons par cycle, dans lequel 1 à 3 chaînons sont des hétéroatomes d'oxygène, de soufre ou d'azote.

3. Composé de formule




ou un sel pharmaceutiquement acceptable de celui-ci, dans lequel

X est NR²;


Y est NR⁴-C(O)-R³;

R¹ est un radical de formule



R² est un radical hydrogène ou méthyle ;

R³ est un radical de formule



R⁴ est un radical d'hydrogène, un radical méthyle ou éthyle

R⁵, R⁶ et R⁷ sont chacun indépendamment un radical hydrogène :

R¹¹ et R¹³ sont chacun indépendamment un radical d'hydrogène, C₁-C₄alkyle, halo, trifluorométhyle, cyano, azido, nitro, amidino ou R¹⁹-Z¹⁹;

chaque R¹² est indépendamment un radical d'hydrogène, C₁-Coalkyle, halo, C₁-C₄haloalkyle de 1 à 3 radicaux halo, R³¹-Z³¹ ou R³¹-Z³¹-C₁-C₄alkyle; à condition que le nombre total combiné de radicaux aryle et hétéroaryle dans R¹¹, R¹² et R¹³ soit de 0 ou 1;

chaque R¹⁸ est indépendamment un radical hydrogène, C₁-C₄alkyle, trifluorométhyle, aryle, hétéroaryle, aryl-C₁-C₂alkyle ou hétéroaryl-C₁-C₂alkyle ; dans lequel les radicaux aryle et hétéroaryle sont éventuellement substitués par 1 ou 2 radicaux d'hydroxy, C₁-C₄alkoxy, C₁-C₄alkylthiol, amino, C₁-C₄alkylamino, di(C₁-C₄alkyl)amino, acétylamino, cyano, halo, azido, C₁-C₄alkyle, trifluorométhyle ou trifluorométhoxy;

chaque R¹⁹ est indépendamment un radical hydrogène, C₁-C₄alkyle, trifluorométhyle, aryle, hétéroaryle, aryl-C₁-C₄alkyle ou hétéroaryl-C₁-C₄alkyle; dans lequel les radicaux aryle et hétéroaryle sont éventuellement substitués par 1 ou 2 radicaux d'hydroxy, méthoxy, éthoxy, amino, méthylamino, diméthylamino, acétylamino, cyano, halo, méthyle, éthyle, trifluorométhyle ou trifluorométhoxy;

chaque R²¹ est indépendamment un radical hydrogène ou méthyle;

R²², R²³, R²⁴, R²⁵ et R²⁶ sont chacun indépendamment un radical d'hydrogène, C₁-C₄alkyle, halo, trifluorométhyle,

cyano, azido, nitro, amidino, R^{18} -Z¹⁸- ou R^{18} -Z¹⁸-C₁-C₄alkyle ; à condition qu'au moins un de R²¹, R²², R²³, R²⁴ et R²⁵ soit un hydrogène ; et à condition que le nombre total combiné de radicaux aryle et hétéroaryle dans R²², R²³, R²⁴, R²⁵ et R²⁶ soit de 0 ou 1 ;

chaque R³ est indépendamment un radical hydrogène C₁-C₄alkyle, trifluorométhyle, aryle, hétéroaryle, aryl-C₁-C₄alkyle ou hétéroaryl-C₁-C₄alkyle ; dans lequel les radicaux aryle et hétéroaryle sont éventuellement substitués par 1 ou 2 radicaux d'hydroxy, méthoxy, éthoxy, amino, méthylamino, diméthylamino, acétylamino, cyano, halo, méthyle, éthyle, trifluorométhyle ou trifluorométhoxy ;

U est N ;

V est C-R¹² ou N ;

WestN ;

chaque Z¹⁸ est indépendamment -O-, -S-, -S(O)₂-, -CO₂-, -NR²¹-, -NR²¹-C(O)-, -C(O)-NR²¹-, -NR²¹-S(O)₂- ou -S(O)₂-NR²¹- ;

chaque Z¹⁹ est indépendamment -O-, -S(O)₂-, -CO₂-, -C(O)-, -NR²¹-C(O)-, -C(O)-NR²¹-, -NR²¹-S(O)₂- ou -S(O)₂-NR²¹- ;

chaque Z³¹ est indépendamment -O-, -NR²¹-, -NR²¹-C(O)-, -C(O)-NR²¹-, -NR²¹-S(O)₂- ou -S(O)₂-NR²¹- ; et dans lequel l'aryle est un radical phényle, biphenyle ou naphtyle ; et l'hétéroaryle est un noyau hétérocyclique aromatique monocyclique ayant 5 ou 6 chaînons par cycle, dans lequel 1 à 3 chaînons sont des hétéroatomes d'oxygène, de soufre ou d'azote.

4. Composé choisi parmi :

2-cyclohexyloxy-5-(2-chlorophénylcarbonylamino)pyridine ;
 2-cyclohexyloxy-5-(2-méthylphénylcarbonylamino)pyridine ;
 2-cyclohexyloxy-5-(2,6-dichlorophénylcarbonylamino)pyridine ;
 2-cyclohexyloxy-5-(2,6-diméthylphénylcarbonylamino)pyridine ;
 2-(2,4-diméthylphénoxy)-5-(2-chlorophénylcarbonylamino)pyridine ;
 2-(2,4-diméthylphénoxy)-5-(2,6-dichlorophénylcarbonylamino)pyridine ;
 2-(2,4-diméthylphénoxy)-5-(2-méthylphénylcarbonylamino)pyridine ;
 2-(2,6-diméthyl-4-chlorophénoxy)-5-(2,6-diméthylphénylcarbonylamino)pyridine ;
 2-(2-méthyl-4-fluorophénoxy)-5-(2-méthylphénylcarbonylamino)pyridine ;
 2-(2-méthyl-4-chlorophénoxy)-5-(2-chlorophénylcarbonylamino)pyridine ;
 2-(2-méthyl-4-chlorophénoxy)-5-(2-méthylphénylcarbonylamino)pyridine ;
 2-(2-méthylphénoxy)-5-(2-chlorophénylcarbonylamino)pyridine ;
 2-(2-méthylphénoxy)-5-(2,6-dichlorophénylcarbonylamino)pyridine ;
 2-(2-méthylphénoxy)-5-(2-méthylphénylcarbonylamino)pyridine ;
 2-(2-méthyl-4-chlorophénoxy)-5-(2,6-dichlorophénylcarbonylamino)pyridine ;
 2-(2-méthyl-4-chlorophénoxy)-5-(2,6-diméthylphénylcarbonylamino)pyridine ;
 2-(4-chlorophénoxy)-5-(2,6-diméthylphénylcarbonylamino)pyridine ;
 2-(2-méthyl-4-fluorophénoxy)-5-(2,6-dichlorophénylcarbonylamino)pyridine ;
 2-(2-méthyl-4-fluorophénoxy)-5-(2,6-diméthylphénylcarbonylamino)pyridine ;
 2-(2-méthylphénoxy)-5-(2,6-diméthylphénylcarbonylamino)pyridine ;
 2-(2-méthyl-4-fluorophénoxy)-5-(2-fluorophénylcarbonylamino)pyridine ;
 2-(2,4-diméthylphénoxy)-5-(2,6-diméthylphénylcarbonylamino)pyridine ;
 2-(1-naphtyloxy)-5-(2-méthylphénylcarbonylamino)pyridine ;
 2-(1-naphtyloxy)-5-(2,6-dichlorophénylcarbonylamino)pyridine ;
 2-(1-naphtyloxy)-5-(2,6-diméthylphénylcarbonylamino)pyridine ;
 2-(2-méthyl-3-pyridyloxy)-5-(2,6-dichlorophénylcarbonylamino)pyridine ;
 2-(2-méthyl-4-chlorophénoxy)-5-((3,5-diméthyl-4-isoxazolyl)carbonylamino)pyridine ;
 2-(2-méthyl-4-chlorophénylthiol)-5-(2-méthylphénylcarbonylamino)pyridine ;
 2-(2-méthyl-4-chlorophénylthiol)-5-(2,6-diméthylphénylcarbonylamino)pyridine ;
 2-cyclohexylamino-5-(2,6-dichlorophénylcarbonylamino)pyridine ;
 2-cyclohexylamino-5-(2,6-diméthylphénylcarbonylamino)pyridine ;
 2-(2-méthylcyclohexylamino)-5-(2,6-dichlorophénylcarbonylamino)pyridine ;
 2-(2-méthylcyclohexylamino)-5-(2-méthylphénylcarbonylamino)pyridine ;
 2-(2,4-diméthylphénylamino)-5-(2-fluorophénylcarbonylamino)pyridine ;
 2-(2,4-diméthylphénylamino)-5-(2-chlorophénylcarbonylamino)pyridine ;
 2-(2,4-diméthylphénylamino)-5-(2,6-dichlorophénylcarbonylamino)pyridine ;
 2-(2-méthyl-4-chlorophénylamino)-5-(2,6-dichlorophénylcarbonylamino)pyridine ;

2-(2,4-diméthylphénylamino)-5-(2-méthylphénylcarbonylamino)pyridine ;
 2-(2-méthylphénylamino)-5-(2-méthylphénylcarbonylamino)pyridine ;
 2-(2-méthylphénylamino)-5-(2,6-dichlorophénylcarbonylamino)pyridine ;
 2-(2-méthylphénylamino)-5-(2,6-diméthylphénylcarbonylamino)pyridine ;
 2-(2,4-diméthylphénylamino)-5-(2,6-diméthylphénylcarbonylamino)pyridine ;
 2-(2-méthyl-4-chlorophénylamino)-5-(2-méthylphénylcarbonylamino)pyridine ;
 2-(2-méthyl-4-chlorophénylamino)-5-(2,6-diméthylphénylcarbonylamino)pyridine ;
 et
 2-(2-méthyl-4-chlorophénylamino)-5-(2-méthylphénylaminocarbonyl)pyridine,

ou un sel pharmaceutiquement acceptable de celui-ci,

5. Composition pharmaceutique comprenant un composé selon l'une quelconque des revendications précédentes et un support pharmaceutiquement acceptable.
6. Composé selon l'une quelconque des revendications 1 à 4 ou composition pharmaceutique selon la revendication 5 pour une utilisation dans la prophylaxie ou le traitement de maladies.
7. Composé ou composition selon la revendication 6 pour une utilisation dans la prophylaxie ou le traitement de l'inflammation.
8. Composé ou composition selon la revendication 6 pour une utilisation dans la prophylaxie ou le traitement du cancer.
9. Composé ou composition selon la revendication 6 pour une utilisation dans la prophylaxie ou le traitement de la polyarthrite rhumatoïde, la maladie de Paget, l'ostéoporose, le myélome multiple, l'uvéïte, la leucémie myélogène aiguë ou chronique, la destruction des cellules pancréatiques β , l'arthrose, la spondylite rhumatoïde, l'arthrite goutteuse, la maladie inflammatoire des intestins, le syndrome de détresse respiratoire de l'adulte (SDRA), le psoriasis, la maladie de Crohn, la rhinite allergique, la rectocolite hémorragique, l'anaphylaxie, la dermite de contact, l'asthme, la dégénérescence musculaire, la cachexie, le syndrome de Reiter, le diabète de type I et de type II, les maladies de résorption osseuse, la réaction du greffon contre l'hôte, la maladie d'Alzheimer, l'apoplexie, l'infarctus du myocarde, la lésion de reperfusion d'ischémie, l'athérosclérose, le traumatisme cérébral, la sclérose en plaques, le paludisme cérébral, la septicémie, le choc septique, le syndrome de choc toxique, la fièvre, les myalgies dues à une infection de VIH-1, VIH-2, VIH-3, de cytomégalo virus (CMV), de grippe, d'adénovirus, des virus de l'herpes ou du zona chez un mammifère consistant à administrer une quantité efficace d'un composé de la revendication 1.
10. Composé ou composition selon la revendication 6 pour une utilisation dans la prophylaxie ou le traitement de la douleur.
11. Utilisation d'un composé selon l'une quelconque des revendications 1 à 4 ou d'une composition pharmaceutique selon la revendication 5 pour la fabrication d'un médicament destiné à la prophylaxie ou au traitement de l'inflammation.
12. Utilisation d'un composé selon l'une quelconque des revendications 1 à 4 ou d'une composition pharmaceutique selon la revendication 5 pour la fabrication d'un médicament destiné à la prophylaxie ou au traitement du cancer.
13. Utilisation d'un composé selon l'une quelconque des revendications 1 à 4 ou d'une composition pharmaceutique selon la revendication 5 pour la fabrication d'un médicament destiné à la prophylaxie ou au traitement de la polyarthrite rhumatoïde, la maladie de Paget, l'ostéoporose, le myélome multiple, l'uvéïte, la leucémie myélogène aiguë ou chronique, la destruction des cellules pancréatiques β , l'arthrose, la spondylite rhumatoïde, l'arthrite goutteuse, la maladie inflammatoire des intestins, le syndrome de détresse respiratoire de l'adulte (SDRA), le psoriasis, la maladie de Crohn, la rhinite allergique, la rectocolite hémorragique, l'anaphylaxie, la dermite de contact, l'asthme, la dégénérescence musculaire, la cachexie, le syndrome de Reiter, le diabète de type I et de type II, les maladies de résorption osseuse, la réaction du greffon contre l'hôte, la maladie d'Alzheimer, l'apoplexie, l'infarctus du myocarde, la lésion de reperfusion d'ischémie, l'athérosclérose, le traumatisme cérébral, la sclérose en plaques, le paludisme cérébral, la septicémie, le choc septique, le syndrome de choc toxique, la fièvre, les myalgies dues à une infection de VIH-1, VIH-2, VIH-3, de cytomégalo virus (CMV), de grippe, d'adénovirus, des virus de l'herpes ou du zona chez un mammifère consistant à administrer une quantité efficace d'un composé de la revendication 1.

- 14.** Utilisation d'un composé selon l'une quelconque des revendications 1 à 4 ou d'une composition pharmaceutique selon la revendication 5 pour la fabrication d'un médicament destiné à la prophylaxie ou au traitement de la douleur.

5

10

15

20

25

30

35

40

45

50

55

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- WO 9716442 A [0008] [0015] [0101]
- US 5593992 A [0015]
- WO 9314081 A [0015]
- WO 9718626 A [0015]
- WO 9621452 A [0015]
- WO 9621654 A [0015]
- WO 9640143 A [0015]
- WO 9705878 A [0015] [0015] [0015]
- US 3929807 A [0015]
- WO 9705877 A [0015]
- WO 9716426 A [0015]
- WO 9716441 A [0015]
- WO 9618616 A [0016]
- WO 9618617 A [0016]
- WO 9624584 A [0017]
- US 5596008 A [0017]
- US 3980652 A [0018]
- US 3991057 A [0018]
- US 4002629 A [0018]
- JP 6135934 B [0019]
- GB 1189188 A [0019]
- EP 0424848 A [0020]
- EP 039051 A, Sloan and Little [0045]
- EP 41181 A [0045]
- WO 9603387 A [0118]

Non-patent literature cited in the description

- **SHOHAMI et al.** *J. Cereb. Blood Flow Metab*, 1994, vol. 14, 615 [0004]
- **FEURSTEIN et al.** *Neurosci. Lett*, 1993, vol. 164, 125 [0004]
- **FEURSTEIN.** *Stroke*, 1994, vol. 25, 1481 [0004]
- *Endocrinol*, 1994, vol. 130, 43-52 [0004]
- *Endocrinol*, 1995, vol. 136, 1474-1481 [0004]
- **CLOUSE et al.** *J. Immunol*, 1989, vol. 142, 431 [0005]
- **LAHDEVIRTA et al.** *Am. J. Med*, 1988, vol. 85, 289 [0005]
- **CHANDRASEKHAR et al.** *Clinical Immunol Immunopathol*, 1990, vol. 55, 382 [0009]
- **FIRESTEIN.** *Am. J. Pathol*, 1992, vol. 140, 1309 [0009]
- **DINARELLO.** *Eur. Cytokine Netw*, 1994, vol. 5, 517-531 [0009]
- **FOLKS et al.** *J. Immunol*, 1986, vol. 136, 40 [0010]
- **BEUTLER et al.** *J. Immunol.*, 1985, vol. 135, 3969 [0010]
- **BARACOS et al.** *New Eng. J. Med*, 1983, vol. 308, 553 [0010]
- **BRAHN et al.** *Lymphokine Cytokine Res*, 1992, vol. 11, 253 [0011]
- **COOPER.** *Clin. Exp. Immunol*, 1992, vol. 898, 244 [0011]
- **FELDMANN et al.** *Immunological Reviews*, 1995, 195-223 [0013]
- **BERGE et al.** *J. Pharm. Sci*, 1977, vol. 66, 1 [0030]
- Hetero-aromatic Nitrogen Compounds; Pyrroles and Pyridines. Plenum Press, 1967 [0035]
- Advances in Nitrogen Heterocycles. JAI Press, 1995 [0035]
- **COLBRY, N.L et al.** *J. Heterocyclic Chem*, 1984, vol. 21, 1521-1525 [0037]
- **MATSUMOTO, JUN-ICHI et al.** *J. Heterocyclic Chem*, 1984, vol. 21, 673-679 [0037]
- **FUERST ; FEUSTEL.** *CHEMTECH*, 1958, vol. 10, 693-699 [0038]
- **NISHIGAKI, S et al.** *Chem. Pharm. Bull*, 1969, vol. 17, 1827-1831 [0038]
- **KAISER ; EDWIN M.** *Tetrahedron*, 1983, vol. 39, 2055-2064 [0038]
- **H. BRUNNER ; P. HANKOFER ; U. HOLZINGER ; B. TREITTINGER ; H. SCHOENENBERGER.** *Eur. J. Med. Chem.*, 1990, vol. 25, 35-44 [0041]
- **M. FREIBERGER ; R. B. HASBROUCK.** *J. Am. Chem. Soc.*, 1960, vol. 82, 696-698 [0041]
- **DORNOW ; FUST.** *Chem. Ber.*, 1954, vol. 87, 984 [0041]
- **M. KOJIMA ; J. FUJITA.** *Bull. Chem. Soc. Jpn.*, 1982, vol. 55, 1454-1459 [0041]
- **W. WHEELER ; D. O'BANNON.** *Journal of Labelled Compounds and Radiopharmaceuticals XXXI*, 1992, 306 [0041]
- **S. DAVIES ; N. GARRIDO ; O. ICHIHARA ; I. WALTERS.** *J. Chem. Soc. Chem. Commun.*, 1993, 1153 [0041]
- **SVENSSON ; TUNEK.** *Drug Metabolism Reviews*, 1988, 165 [0045]
- Bundgaard Design of Prodrugs. Elsevier, 1985 [0045] [0045]
- **BUNGAARD.** *J. Med. Chem.*, 1989, 2503 [0045]

EP 1 028 945 B9 (W2B1)

- **C. A. WINTER et al.** *Proc. Soc. Exp. Biol. Med.*, 1962, vol. 111, 544 **[0100]**
- **K. F. SWINGLE.** *Antiinflammatory Agents, Chemistry and Pharmacology.* 1974, vol. 13-II, 33 **[0100]**
- **D. E. TRENTHAM et al.** *J. Exp. Med.*, 1977, vol. 146, 857 **[0100]**
- **J. S. COURTENAY.** *Nature*, 1980, vol. 283, 666 **[0100]**
- **GRUSSENMEYER et al.** *Proceedings of the National Academy of Science, U.S.A.*, 1985, 7952-7954 **[0113]**
- **WILLIAMS et al.** *Proceedings of the National Academy of Science, U.S.A.*, 1992, 2922-2926 **[0114]**